0001564590-21-015256.txt : 20210325 0001564590-21-015256.hdr.sgml : 20210325 20210325064049 ACCESSION NUMBER: 0001564590-21-015256 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 94 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210325 DATE AS OF CHANGE: 20210325 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SYNLOGIC, INC. CENTRAL INDEX KEY: 0001527599 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261824804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37566 FILM NUMBER: 21770075 BUSINESS ADDRESS: STREET 1: 301 BINNEY STREET STREET 2: SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-401-9975 MAIL ADDRESS: STREET 1: 301 BINNEY STREET STREET 2: SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Mirna Therapeutics, Inc. DATE OF NAME CHANGE: 20110809 10-K 1 sybx-10k_20201231.htm 10-K sybx-10k_20201231.htm
false FY 0001527599 --12-31 true true true true true true true true true true greater than 50% true true P10Y P8Y8M12D P8Y4M24D P8Y4M24D P7Y8M12D P7Y2M12D P8Y2M12D 0001527599 2020-01-01 2020-12-31 xbrli:shares 0001527599 2021-03-18 iso4217:USD 0001527599 2020-06-30 0001527599 2020-12-31 0001527599 2019-12-31 iso4217:USD xbrli:shares 0001527599 2019-01-01 2019-12-31 0001527599 us-gaap:CommonStockMember 2018-12-31 0001527599 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001527599 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001527599 us-gaap:RetainedEarningsMember 2018-12-31 0001527599 2018-12-31 0001527599 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001527599 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001527599 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001527599 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001527599 us-gaap:CommonStockMember 2019-12-31 0001527599 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001527599 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001527599 us-gaap:RetainedEarningsMember 2019-12-31 0001527599 us-gaap:CommonStockMember sybx:AtTheMarketOfferingMember 2020-01-01 2020-12-31 0001527599 us-gaap:AdditionalPaidInCapitalMember sybx:AtTheMarketOfferingMember 2020-01-01 2020-12-31 0001527599 sybx:AtTheMarketOfferingMember 2020-01-01 2020-12-31 0001527599 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001527599 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001527599 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001527599 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001527599 us-gaap:CommonStockMember 2020-12-31 0001527599 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001527599 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001527599 us-gaap:RetainedEarningsMember 2020-12-31 0001527599 sybx:LongTermIncentivePlan2015And2017Member 2020-01-01 2020-12-31 0001527599 us-gaap:LetterOfCreditMember 2020-12-31 0001527599 us-gaap:LetterOfCreditMember 2019-12-31 0001527599 sybx:ComputerAndOfficeEquipmentMember 2020-01-01 2020-12-31 0001527599 us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-12-31 0001527599 us-gaap:EquipmentMember 2020-01-01 2020-12-31 0001527599 us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-12-31 sybx:Segment 0001527599 us-gaap:AccountingStandardsUpdate201912Member 2020-12-31 0001527599 us-gaap:AccountingStandardsUpdate201813Member 2020-12-31 0001527599 us-gaap:AccountingStandardsUpdate201815Member 2020-12-31 0001527599 us-gaap:AccountingStandardsUpdate201818Member 2020-12-31 0001527599 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001527599 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:FairValueMeasurementsRecurringMember sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember 2020-12-31 0001527599 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001527599 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:FairValueMeasurementsRecurringMember sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember 2019-12-31 0001527599 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:CommercialPaperMember 2020-12-31 0001527599 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001527599 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001527599 us-gaap:CommercialPaperMember 2019-12-31 0001527599 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001527599 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 sybx:Investment sybx:Security 0001527599 us-gaap:EquipmentMember 2020-12-31 0001527599 us-gaap:EquipmentMember 2019-12-31 0001527599 sybx:ComputerAndOfficeEquipmentMember 2020-12-31 0001527599 sybx:ComputerAndOfficeEquipmentMember 2019-12-31 0001527599 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001527599 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001527599 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001527599 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001527599 us-gaap:ConstructionInProgressMember 2020-12-31 0001527599 us-gaap:ConstructionInProgressMember 2019-12-31 sybx:Vote 0001527599 2007-12-01 2020-12-31 0001527599 sybx:GinkgoBioworksIncMember us-gaap:CommonStockMember 2019-06-01 2019-06-30 0001527599 sybx:GinkgoBioworksIncMember 2019-06-30 0001527599 sybx:GinkgoBioworksIncMember sybx:PreFundedWarrantsMember srt:MaximumMember 2019-06-30 0001527599 sybx:GinkgoBioworksIncMember sybx:PreFundedWarrantsMember 2019-06-30 0001527599 sybx:GinkgoBioworksIncMember 2019-06-01 2019-06-30 0001527599 sybx:GinkgoBioworksIncMember sybx:PreFundedWarrantsMember 2019-06-01 2019-06-30 0001527599 sybx:GinkgoBioworksIncMember sybx:PreFundedWarrantsMember 2020-12-31 xbrli:pure 0001527599 sybx:GinkgoBioworksIncMember sybx:PreFundedWarrantsMember srt:MaximumMember 2019-06-01 2019-06-30 0001527599 sybx:AtTheMarketMember sybx:CowenAndCompanyLLCMember 2020-01-01 2020-12-31 0001527599 sybx:AtTheMarketMember sybx:CowenAndCompanyLLCMember srt:MaximumMember 2020-01-01 2020-12-31 0001527599 sybx:AtTheMarketMember sybx:CowenAndCompanyLLCMember us-gaap:SubsequentEventMember 2021-01-01 2021-03-25 0001527599 sybx:PreFundedWarrantsMember 2020-12-31 0001527599 us-gaap:EmployeeStockOptionMember 2020-12-31 0001527599 us-gaap:EmployeeStockMember 2020-12-31 0001527599 sybx:LongTermIncentivePlan2015Member 2019-01-01 2019-12-31 0001527599 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001527599 us-gaap:EmployeeStockMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001527599 sybx:EmployeesAndNonemployeesMember sybx:LongTermIncentivePlan2015And2017Member 2020-01-01 2020-12-31 0001527599 sybx:EmployeesAndNonemployeesMember sybx:LongTermIncentivePlan2015And2017Member 2019-01-01 2019-12-31 0001527599 sybx:LongTermIncentivePlan2015And2017Member 2019-12-31 0001527599 sybx:LongTermIncentivePlan2015And2017Member 2020-12-31 0001527599 sybx:LongTermIncentivePlan2015And2017Member 2019-01-01 2019-12-31 0001527599 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001527599 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001527599 us-gaap:RestrictedStockMember 2019-12-31 0001527599 us-gaap:RestrictedStockMember 2020-12-31 0001527599 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0001527599 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001527599 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001527599 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001527599 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001527599 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001527599 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001527599 sybx:GinkgoBioworksIncMember us-gaap:CommonStockMember 2019-06-01 2019-06-30 0001527599 sybx:GinkgoBioworksIncMember sybx:PreFundedWarrantsMember 2019-06-30 0001527599 sybx:GinkgoBioworksIncMember 2019-06-30 0001527599 sybx:GinkgoBioworksIncMember 2019-06-01 2019-06-30 0001527599 sybx:AbbVieAgreementMember sybx:IbdcoMember 2020-01-01 2020-12-31 0001527599 sybx:AbbVieAgreementMember 2020-01-01 2020-12-31 0001527599 sybx:AbbVieAgreementMember 2019-01-01 2019-12-31 0001527599 sybx:AbbVieAgreementMember 2020-12-31 0001527599 sybx:UnvestedRestrictedStockAwardsMember 2020-01-01 2020-12-31 0001527599 sybx:UnvestedRestrictedStockAwardsMember 2019-01-01 2019-12-31 0001527599 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001527599 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001527599 us-gaap:StockCompensationPlanMember 2020-01-01 2020-12-31 0001527599 us-gaap:InternalRevenueServiceIRSMember 2020-12-31 0001527599 us-gaap:InternalRevenueServiceIRSMember 2019-12-31 0001527599 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001527599 us-gaap:StateAndLocalJurisdictionMember 2018-12-31 0001527599 us-gaap:InternalRevenueServiceIRSMember 2020-01-01 2020-12-31 0001527599 us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-12-31 0001527599 us-gaap:ResearchMember us-gaap:InternalRevenueServiceIRSMember 2020-12-31 0001527599 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2020-12-31 utr:sqft 0001527599 2017-07-01 2017-07-31 0001527599 2017-07-31 0001527599 srt:MaximumMember 2017-07-31 0001527599 sybx:MasterContractServicesAgreementMember sybx:AzzurGroupLimitedLiabilityCompanyMember 2018-01-01 2018-12-31 0001527599 2018-01-01 2018-12-31 0001527599 sybx:GinkgoBioworksIncMember 2020-12-31 0001527599 sybx:GinkgoBioworksIncMember 2020-01-01 2020-12-31 0001527599 2020-01-01 2020-03-31 0001527599 2020-04-01 2020-06-30 0001527599 2020-07-01 2020-09-30 0001527599 2020-10-01 2020-12-31 0001527599 2019-01-01 2019-03-31 0001527599 2019-04-01 2019-06-30 0001527599 2019-07-01 2019-09-30 0001527599 2019-10-01 2019-12-31

t

f

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2020

OR

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO                     

Commission File Number 001-37566

 

SYNLOGIC, INC.

(Exact name of Registrant as specified in its Charter)

 

 

Delaware

26-1824804

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

 

 

301 Binney St., Suite 402

Cambridge, MA

02142

(Address of principal executive offices)

(Zip Code)

(617) 401-9975

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol

Name of exchange on which registered

Common Stock, par value $0.001 per share

SYBX

The Nasdaq Capital Market

 

 

Securities registered pursuant to Section 12(g) of The Act:

None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐    No  ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    Yes  ☐    No  ☒

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

☐

  

Accelerated filer

 

☐

Non-accelerated filer

 

☒ 

  

Small reporting company

 

☒

Emerging growth company

 

☐

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    YES  ☐    NO  ☒

The aggregate market value of common stock held by non-affiliates of the registrant as of June 30, 2020, the last business day of the registrant’s most recently completed second quarter, was $38.0 million, computed based on the closing price of $2.03 per share on June 30, 2020.    

As of March 18, 2021 there were 39,657,841 shares of the registrant’s common stock, par value $0.001 per share, outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the registrant’s definitive proxy statement for the 2021 annual meeting of stockholders to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2020.

 

 

 

 

Table of Contents

 

 

 

Page

PART I

 

 

Item 1.

Business

2

Item 1A.

Risk Factors

34

Item 1B.

Unresolved Staff Comments

63

Item 2.

Properties

63

Item 3.

Legal Proceedings

63

Item 4.

Mine Safety Disclosures

63

 

 

 

PART II

 

 

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

64

Item 6.

Selected Financial Data

64

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

65

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

77

Item 8.

Financial Statements and Supplementary Data

77

Item 9.

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

77

Item 9A.

Controls and Procedures

77

Item 9B.

Other Information

78

 

 

 

PART III

 

 

Item 10.

Directors, Executive Officers and Corporate Governance

79

Item 11.

Executive Compensation

79

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

79

Item 13.

Certain Relationships and Related Transactions, and Director Independence

79

Item 14.

Principal Accounting Fees and Services

79

 

 

 

PART IV

 

 

Item 15.

Exhibits, Financial Statement Schedules

80

Item 16.

Form 10-K Summary

82

 

 

 

i

 

 

FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained herein are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

 

•

the success of our research and development efforts;

 

•

the initiation, progress, timing, costs and results of clinical trials for our product candidates;

 

•

the time and costs involved in obtaining regulatory approvals for our product candidates;

 

•

the success of our collaborations with third parties;

 

•

the progress, timing and costs involved in developing manufacturing processes and in manufacturing products, as well as agreements with third-party manufacturers;

 

•

the rate of progress and cost of our commercialization activities;

 

•

the expenses we incur in marketing and selling our product candidates;

 

•

the revenue generated by sales of our product candidates;

 

•

the emergence of competing or complementary technological developments;

 

•

the terms and timing of any additional collaborative, licensing or other arrangements that we may establish;

 

•

the acquisition of businesses, products and technologies;

 

•

our need to implement additional infrastructure and internal systems;

 

•

our need to add personnel and financial and management information systems to support our product development and potential future commercialization efforts, and to enable us to operate as a public company; and

 

•

other risks and uncertainties, including those listed under Part I, Item 1A. “Risk Factors”.

 

Any forward-looking statements in this Annual Report on Form 10-K reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part I, Item 1A. “Risk Factors” and elsewhere in this Annual Report on Form 10-K. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.

1

 

PART I

Item 1. Business.

Overview

We are a clinical-stage biopharmaceutical company focused on the discovery and development of Synthetic Biotic™ medicines. Synthetic Biotic medicines are generated from Synlogic’s proprietary drug discovery and development platform, using Synthetic Biology and leveraging a reproducible, modular approach to develop beneficial microbes that perform or deliver critical therapeutic functions. Synthetic Biotic medicines are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Our goal is to discover, develop, and ultimately commercialize Synthetic Biotic medicines. Synlogic’s proprietary pipeline includes Synthetic Biotic medicines for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria. We are also building a portfolio of partner-able assets in immunology and oncology.

We are supported by our Board of Directors and our scientific advisory board, each of which offers complementary experience in drug discovery and development, as well as expertise in building public companies, management, and business development. Our founding science came from the laboratories of Professors James Collins and Timothy Lu from the Massachusetts Institute of Technology (MIT), who remain highly engaged in guiding development and application of our platform.

Product Pipeline: Metabolic Disease

Phenylketonuria

Our most advanced product candidate is SYNB1618, an oral therapy intended for the treatment of PKU, a rare metabolic disease in which an amino acid known as phenylalanine (Phe) accumulates in the body as a result of genetic defects. Elevated levels of Phe are toxic to the brain and can lead to neurological dysfunction. SYNB1618 is designed to function in the gut of patients to reduce excess Phe, with the goal of lowering levels in the blood and other tissues. SYNB1618 has received both Fast Track designation and orphan drug designation for PKU from the U.S. Food and Drug Administration (FDA).

We initiated a Phase 2 clinical trial with SYNB1618 in the third quarter of 2020. The Phase 2 trial, referred to as the SynPheny-1 Study, is designed to evaluate safety and tolerability of a solid formulation of SYNB1618 as well as its potential to lower blood Phe levels in adult PKU patients. The SynPheny-1 Study is designed to be flexible, with subjects physically coming to the clinic or participating from the patient's home utilizing home healthcare services.

We completed a Phase 1/2a clinical trial of an early liquid formulation of SYNB1618 and announced top-line data from healthy volunteers evaluated in this study in September 2018. In July 2019, we announced data that demonstrated that SYNB1618 was safe and well-tolerated and achieved proof-of-mechanism of strain activity in both healthy volunteers and patients with PKU. Following the study using the liquid formulation, we developed a lyophilized formulation of SYNB1618. We have evaluated this lyophilized formulation in a bridging study in healthy volunteers. The study of this more patient- and commercialization-appropriate presentation of SYNB1618 demonstrated activity and improved tolerability over the early liquid formulation.

SYNB1618 is a member of a family of SYNB strains that consume Phe. We have additional Phe consuming strains for PKU in preclinical development, including SYNB1934.

Enteric Hyperoxaluria

Enteric Hyperoxaluria is an acquired metabolic disorder. Enteric Hyperoxaluria is caused by increased absorption of dietary oxalate, which is present in many healthy foods such as leafy greens, nuts, and chocolate, making it difficult to control with dietary interventions. Enteric hyperoxaluria often occurs as a result of a primary insult to the bowel, such as inflammatory bowel disease, short bowel syndrome, or surgical procedures such as Roux-en-Y bariatric weight-loss surgery. The disorder may cause dangerously high levels of urinary oxalate and progressive kidney damage, kidney stone formation, and nephrocalcinosis. There are no approved treatments.

In May 2020, we announced the nomination of a clinical candidate for Enteric Hyperoxaluria, SYNB8802. We initiated a Phase 1 clinical trial of SYNB8802 in the fourth quarter of 2020. This study will assess the safety, tolerability and kinetics of SYNB8802 as well as the effect SYNB8802 has on changes in plasma and urine biomarkers of strain activity, and the potential to reduce urinary oxalate. The study has two parts: Part A is a multiple ascending dose study in healthy volunteers in whom we will induce temporary hyperoxaluria via diet; Part B is a placebo controlled, cross-over design study in patients with Enteric Hyperoxaluria following Roux-n-Y gastric bypass surgery.

2

 

Other Metabolic Programs

We are advancing a portfolio of investigational Synthetic Biotic medicines for rare, niche, and common metabolic disorders which, similar to PKU and enteric hyperoxaluria, have a toxic metabolite found in the GI tract. We will disclose additional details on such programs as they move through preclinical development.

Maple Syrup Urine Disease (MSUD) is an inherited, rare metabolic disease characterized by a deficiency of enzymes required to break down certain amino acids. We have been conducting studies to advance a pre-clinical candidate for MSUD.  Prototype strains did not meet pre-specified criteria for candidate declaration. Therefore, we discontinued efforts in MSUD in the third quarter of 2020 to prioritize other metabolic disorders.

Product Pipeline: Immunomodulation

Oncology

We have also developed a portfolio of Synthetic Biotic medicines to treat certain cancers that are designed to modify the tumor microenvironment, activate the immune system and result in tumor reduction. These Synthetic Biotic medicines could be used in combination with other cancer therapies such as checkpoint inhibitors. Our first Synthetic Biotic clinical immuno-oncology (IO) candidate is SYNB1891, an intratumorally administered Synthetic Biotic medicine engineered to act as a dual innate and adaptive immune activator. SYNB1891 has been designed to activate the immune response in tumors via the E.coli Nissle chassis and production of cyclic di-AMP, an activator of the Stimulator of Interferon Genes, also referred to as the STING pathway. The STING pathway plays a critical role in the initiation of an anti-tumor immune response. In January 2020, we treated the first subject in a Phase 1 clinical trial of SYNB1891 in patients with advanced solid tumors and lymphoma.  The clinical trial is designed to identify a maximum tolerated dose (MTD) of SYNB1891 delivered as a monotherapy.  Once an MTD is identified, we will evaluate treatment of patients with a combination of SYNB1891 and the checkpoint inhibitor atezolizumab (Tecentriq), provided through a supply agreement with Roche. Despite the COVID-19 pandemic, the Phase 1 clinical trial has remained open to both currently enrolled patients and for new patient enrollment. We released interim data from the ongoing monotherapy arm of this trial in December of 2020, which demonstrated target engagement and the production of biomarkers consistent with STING activation. In December of 2020, we also initiated the combination arm of the Phase 1 clinical trial. Additional data on this study may be shared at future medical meetings.

ImmunologyWe also leverage our proprietary technology platform to develop Synthetic Biotic medicines to treat a broader range of human diseases. To achieve this goal, we collaborate with key disease experts who have developed robust models of relevant diseases and inform our translational medicine strategy. These collaborators bring complementary expertise in preclinical development, clinical development and commercialization. Inflammatory bowel disease (IBD) is an attractive target for our technology as Synthetic Biotic medicines can be designed to locally deliver combinations of complementary therapeutics to potentially address the unmet medical need for maintenance of disease remissions. In May 2020, we announced the termination of our collaboration with AbbVie S.à.r.l. (AbbVie) to develop Synthetic Biotic medicines for the treatment of types of inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis.  Upon termination, we regained all rights to develop these and new IBD Synthetic Biotic medicines for all effectors targeting IBD. This allows us to fully leverage our expertise in strain engineering, quantitative biology, regulatory, and manufacturing to expand our wholly owned GI-based program portfolio to include IBD. We further regained the rights to partner these IBD programs. We may enter into additional strategic partnerships in the future to maximize the value of our programs and our Synthetic Biotic platform.

3

 

Our pipeline of our programs is shown below.

 

 

As we advance our lead programs, we continue to learn and improve our Synthetic Biotic platform, which will inform all future portfolio programs. Consequently, we believe we have a robust engine for building a sustainable pipeline of novel, Synthetic Biotic medicines across a range of diseases. Through the strength of our internal team and network of partners, we believe we can deliver on the promise of Synthetic Biotic medicines to improve the lives of patients with significant unmet medical needs.

Our Strategy

To achieve our goal, we are pursuing the following key strategies:

Advance an internal portfolio of investigational Synthetic Biotic medicines that address rare or niche metabolic diseases by metabolizing toxic substances in the GI tract.

Advance Clinical Development of SYNB1618 for PKU. We initiated a Phase 2 clinical trial with SYNB1618 in the third quarter of 2020.  The Phase 2 trial, referred to as the SynPheny-1 Study, is designed to evaluate safety and tolerability of a solid formulation of SYNB1618 as well as its potential to lower blood Phe levels in adult PKU patients.

We completed a Phase 1/2a clinical trial of an early liquid formulation of SYNB1618 and announced top-line data from healthy volunteers evaluated in this study in September 2018. In July 2019, we announced data that demonstrated that SYNB1618 was safe and well-tolerated and achieved proof-of-mechanism of strain activity in both healthy volunteers and patients with PKU. In September 2019, we presented data from a Phase 1/2a clinical trial that demonstrated that an early liquid formulation of SYNB1618 was safe in healthy volunteers and patients with PKU and achieved proof-of-mechanism demonstrating that SYNB1618 is consuming Phe in the GI tract. In the second half of 2019, we initiated a bridging study in healthy volunteers to evaluate a new solid lyophilized formulation which provides a more commercially appropriate presentation of SYNB1618. The bridging study demonstrated improved tolerability of the lyophilized SYNB1618 over the early liquid formulation and enabled us to determine an MTD to take forward to test in patients.  

Advance Clinical Development of SYNB8802 for Enteric Hyperoxaluria. In May 2020, we announced the nomination of a clinical candidate for Enteric Hyperoxaluria, SYNB8802. We initiated a Phase 1 clinical trial of SYNB8802 in the fourth quarter of 2020.

SYNB8802 will be assessed for safety and tolerability, strain kinetics, changes in plasma and urine biomarkers of strain activity, and the potential to reduce urinary oxalate in the Phase 1 clinical study. The study has two parts: Part A is a multiple ascending dose study in healthy volunteers in whom we will induce temporary hyperoxaluria via diet; Part B is a placebo controlled, cross-over design study in patients with Enteric Hyperoxaluria following Roux-n-Y gastric bypass surgery.

4

 

Create a portfolio of investigational Synthetic Biotic medicines that modulate the immune system, which we can then partner with third parties for further development.

Advance Clinical Development of our First Immuno-Oncology program, SYNB1891. We initiated a Phase 1 clinical trial of our first IO program, SYNB1891, in patients with advanced solid tumors and lymphoma and in January 2020 announced that we had treated the first subject. The first arm of the study is designed to evaluate SYNB1891 as a monotherapy and to establish an MTD which will inform dosing in the second arm in which SYNB1891 will be evaluated in combination with atezolizumab. We released interim data from the ongoing monotherapy arm of this trial in December of 2020 that demonstrated target engagement and the production of biomarkers consistent with STING activation. In December of 2020 we also initiated the combination arm of the Phase 1 clinical trial.

Maximize the Value of the Synthetic Biotic Platform by Leveraging Strategic Collaborations. We expect to continue to explore strategic partnerships that would leverage the complementary capabilities of our partners to develop Synthetic Biotic medicines and maximize the value of our Synthetic Biotic platform.

 

Expand our Synthetic Biotic platform capabilities including expertise in synthetic biology, microbial and disease biology, process development and manufacturing, clinical and regulatory development.

 

Support Clinical Pipeline Progress with Expanded Manufacturing and Formulation Capability. We have established internal manufacturing capabilities to produce both liquid and solid oral formulations of clinical trial material for mid-stage studies through entry into an agreement to lease good manufacturing practice (GMP) clean-room space in Waltham, Massachusetts. The clean-room facility provides an affordable and flexible option that maximizes control over our processes and timelines enabling us to move efficiently through clinical development. We continue to evaluate additional formulation and presentation options for later stage clinical studies and eventual commercialization of our Synthetic Biotic medicines.

Enhance our Synthetic Biotic Platform Capabilities to Expand our Pipeline of Synthetic Biotic Medicines. As a leader in the development of engineered non-pathogenic bacteria for therapeutic use, we intend to advance the field of Synthetic Biotic medicines by continuing to innovate and broaden the potential of our platform to deliver clinically meaningful benefits for patients. We intend to build on our expertise in design, optimization, and manufacturing to further develop the Synthetic Biotic platform as a reproducible and scalable engine for generating a pipeline of innovative product candidates that address a broad range of diseases. We established a technology collaboration with Ginkgo Bioworks, Inc. (Ginkgo) to enable the rapid optimization of Synthetic Biotic candidates. We will collaborate with other groups as appropriate to further develop our platform capabilities.

Protect and Leverage Our Intellectual Property Portfolio and Patents. We believe that we have a broad intellectual property portfolio that includes patents and patent applications relevant to the engineering, development, manufacturing and formulation of human therapeutic products based on synthetic biology and the metabolic engineering of non-pathogenic bacteria. We intend to continue to protect and leverage our intellectual property assets by maintenance and expansion of our worldwide portfolio of intellectual property, including the pursuit of composition of matter and other intellectual property focused on our Synthetic Biotic programs and our technology platform.

 

Our Focus: Synthetic Biotic Medicines

Our novel, proprietary Synthetic Biotic discovery and development platform combines synthetic biology and metabolic engineering to re-design the genetic circuitry of beneficial non-pathogenic microbes. Synthetic Biotic medicines are designed to perform metabolic transformations to compensate for missing or defective pathways in a patient or to produce therapeutically beneficial molecules. Synthetic Biotic medicines have unique advantages as potential therapeutics. Engineered microbes can be programmed to carry out functions that cannot be performed by conventional drug treatments, such as small molecules or antibodies. A Synthetic Biotic medicine can function catalytically, since a single living cell can carry out multiple cycles of the intended therapeutic activity during its time in the patient.

5

 

Leveraging Synthetic Biology and Metabolic Engineering of Non-Pathogenic Bacteria to Produce Synthetic Biotic Medicines

Non-Pathogenic Bacteria. Bacteria have been isolated from the human microbiota and widely used as supplements (probiotics) that are believed to provide health benefits. Bacteria have evolved over millions of years to adapt, survive, and actively metabolize to consume or produce metabolites in the human body. They are also amenable to genetic manipulation. To confer a therapeutic effect, we use basic biological properties of bacteria and the tools of synthetic biology to develop Synthetic Biotic medicines from non-pathogenic microbes, focusing initially on a single strain of the bacteria E. coli Nissle.

Using Synthetic Biology to Generate Synthetic Biotic Medicines. Our scientists genetically engineer this non-pathogenic bacterium with “wiring” or biological circuits to direct cellular biological processes in a manner analogous to designing electrical circuits. The critical parts of an engineered Synthetic Biotic medicine include (1) the “chassis,” or non-pathogenic bacterium, (2) the effector module, which is a gene or pathway encoding the core biological activity that provides the therapeutic function, and (3) tunable switches to precisely determine the circumstances under which the effector module will be active, as well as the potency, performance and output of the effectors themselves. We aim to precisely and appropriately control the amount, location and activity of our Synthetic Biotic medicines to address specific diseases.

 

Schematic of the Synthetic Biotic Platform Components: Chassis, Effector Module, Switch

 

 

(1) The Chassis: Our Synthetic Biotic platform starts with a well-characterized bacteria used as probiotic to serve as the chassis upon which we build our living medicines. Our initial programs use E.coli Nissle, which is one of many non-pathogenic strains isolated from the human microbiota. E. coli Nissle is non-colonizing and has been used as a probiotic bacterial supplement for many years to promote gut health.  Clinical studies have demonstrated that E.coli Nissle is rapidly cleared from most individuals with no significant safety issues (Clin. Transl. Sci. (2017) 00, 1—8). We also observed similar rates of clearance from subjects in our recent Phase 1 clinical trial of SYNB1020 in healthy volunteers (Sci. Transl. Med. 2019: Vol. 11, Issue 475, eaau7975). We believe E. coli Nissle’s widespread use as a probiotic is evidence of its utility as a safe background chassis to apply synthetic biology to confer a therapeutic benefit.  There are a number of additional features of E.coli Nissle organism that makes it an attractive chassis for our platform:

 

•

E. coli Nissle’s genetic and metabolic machinery are well understood and provide a robust cellular context into which genetic information can be introduced with high efficiency and little or no damage to the fitness of the bacterium.

 

•

The advanced nature of the synthetic biology toolkit available for E. coli Nissle enables rapid iterative design, assembly, and testing of prototype product candidates and remains unique among other bacterial and cellular engineering approaches.

 

•

E.coli is relatively easy to manufacture at large scale compared to other bacteria.

6

 

 

 

•

As a Gram-negative bacterium, with a protective outer wall, E.coli Nissle survives well in the human GI tract.

(2) Building the Effector Module or Circuit: Synthetic Biotic medicines have the advantage that they can be designed with multiple pathway components. We have developed proprietary integration systems to direct stable insertion of multiple genetic circuits and pathways into optimal chromosomal locations, or “landing pads,” of E.coli Nissle. This enables efficient and stable expression of multiple genes encoding enzymes and other proteins. These activities may be further improved for therapeutic effect when combined or when under the control of tunable switches that determine when the mechanisms should be activated. Our Synthetic Biotic platform allows us to engineer two types of mechanistic activities into our Synthetic Biotic medicines: 1) we can engineer Synthetic Biotics capable of metabolic transformations that can substitute or compensate for missing or defective pathways in a patient, and 2) we can engineer Synthetic Biotics to produce therapeutically beneficial molecules. The enzymatic pathways needed to produce or consume molecules are protected from the harsh GI environment by their location within the cell cytoplasm of E. coli Nissle, allowing them the potential to function throughout the GI tract.  We have leveraged proprietary tools, know-how and intellectual property to build multiple Synthetic Biotic lead strains that produce therapeutically relevant effects in pre-clinical experiments. Progression of these strains as product candidates in diseases with high unmet need is based on prioritizing those with feasible drug development paths in terms of availability of informative animal models and existence of biomarkers to guide efficient clinical development.

(3) Tunable Switches: We also design and engineer proprietary switches to mediate the activity of the new pathways we introduce into our Synthetic Biotic medicines, with the goal of controlling the engineered circuit or its therapeutic output. To optimize the fitness of a Synthetic Biotic strain, it is critical that the effector is activated only at the appropriate time and place. The switches are based on engineering DNA elements called “inducible promoters” that are designed to respond to disease states, specific environmental signals, or exogenously added inducing molecules. Our goal is to design and develop Synthetic Biotic medicines programmed with switches to produce therapeutic effects at precisely the right time and location such as the anaerobic environment of the gut, or in the context of local inflammation or other pathogenic factors.

 

Advantages of Our Synthetic Biotic Drug Development Platform and Synthetic Biotic Living Medicines

We believe our platform has the potential to provide safe and effective therapies for patients given several attributes of our Synthetic Biotic approach:

Synthetic Biotic Medicines Have Potential to Address Unmet Need with Mechanisms Not Possible with Other Modalities

 

•

Consuming Toxins: Unlike other therapeutic approaches, Synthetic Biotic medicines can be programmed with a unique mechanistic activity. In our initial internal metabolic programs, we are engineering Synthetic Biotic medicines with entire pathways designed to degrade or “consume” toxic metabolites. We believe using a consumption pathway is advantageous compared to gene, RNA or enzyme replacement therapies that are limited to targeting a single gene or protein defect and may require several unique drug products to address genetically heterogeneous patient populations. By compensating with an entire pathway delivered in bacteria Synthetic Biotic medicines may provide a safe, therapeutic solution to broader disease populations as a single engineered therapeutic. Our SYNB1618 program is designed to consume Phe and has been shown to do so in both PKU patients and healthy volunteers. Our SYNB8802 program is designed to consume oxalate. The experience and lessons learned from this program are being applied to our additional preclinical programs.

 

•

Production of Therapeutic Molecules: Synthetic Biotic medicines can also be programmed to produce beneficial molecules. SYNB1891, our first oncology candidate is engineered to produce a STING agonist that has the potential to activate the immune system within the tumor microenvironment towards anti-tumor activity.

 

•

Combinations of Mechanisms: Many diseases with complex pathophysiology, require more than a single effector to achieve a clinical response. By incorporating multiple effectors or enzymes into a single strain, Synthetic Biotic medicines have the potential to more effectively address multifactorial disease biology. For example, Synthetic biotic medicines can be engineered with multiple enzymes which consume toxic metabolites more effectively than a single effector could otherwise provide.

Synthetic Biotic Medicines Provide Local Therapeutic Delivery to Reduce Safety Risk

We believe that when delivered locally, Synthetic Biotic medicines have the potential to avoid the risks of dose-limiting side effects often associated with systemic therapies, especially when combinations of systemic therapies are required. Our Synthetic Biotic programs for metabolic diseases are designed to be dosed orally, and act locally while transiting through the gut and, as a consequence, decrease toxic metabolite levels in the blood, thereby providing a systemic therapeutic benefit to the patient. This approach is well suited to regulate the amount of a metabolic byproduct in a patient’s body, particularly when there is unconstrained metabolite flux between the systemic circulation and the gut. Given the potential for chronic oral dosing, Synthetic Biotic medicines may have benefits in terms of dose prediction and reversibility of activity.

 

7

 

 

Synthetic Biotic Medicines are Rationally Designed to Achieve Predictable Drug-like Properties

We have demonstrated the ability to move a program from concept to clinical development in as little as three years for our lead programs. Features of our Synthetic Biotic platform enable a highly efficient drug discovery and development process and have the potential to advance product candidates more rapidly and efficiently than is typically possible with other novel or emerging modalities. These include:

 

•

Single Strain as Safe Chassis. There are several benefits of employing a single, safe and well-characterized probiotic bacterium such as E. coli Nissle as the background chassis. First, because our lead programs are based on E. coli Nissle, experience can be leveraged broadly across the portfolio, further optimizing the efficiency and reproducibility of discovery, development and manufacturing efforts. Next, the non-colonizing nature of E. coli Nissle can be combined with engineering approaches to optimize safety in terms of impact on the patient and the environment. E. coli Nissle can be engineered to require a specific exogenous nutrient supplement for growth, which limits the ability to replicate in the human body and environment. By controlling replication, we can control the number of cells being administered to a patient, which limits patient-to-patient variability. Also, dependence on an essential nutritional supplement not available in the environment reduces biocontainment risk. Moreover, the risk of a Synthetic Biotic medicine to the environment is further limited given that it is disadvantaged in terms of fitness due to its modifications.

 

•

Predictive Pharmacology and Biomarkers. Synthetic Biotic programs are designed to achieve a target activity, and the platform supports an iterative design-build-test cycle to improve performance for achieving this target. For example, Synthetic Biotic programs can be optimized by including multiple copies or regulated control of certain genes, by adding transporters for particular substrates or by optimizing enzymes for basic bacterial metabolism. These tools enable rational and iterative engineering cycles in the discovery phase.

Biomarkers as indicators of mechanistic and clinical activity may also be engineered into Synthetic Biotic medicines from the beginning to drive optimization and decision-making. By assessing the activities of our Synthetic Biotic programs in in vitro and in vivo preclinical models, we can model activity in humans. As we progress through clinical studies, we expect our predictive pharmacology models will be further refined to inform dosing and development decisions for our additional programs.

 

•

Stability and Manufacturing. Our lead Synthetic Biotic programs have advanced the platform by defining manufacturing processes that can be used for the entire portfolio. Our use of synthetic biology switches permits the precise control of engineered metabolic pathway activation. We use switches to suppress effector activity during manufacturing, enabling development of reproducible processes for generation of biomass and robust, cost-efficient scale up of product candidates.

Manufacturing efforts have demonstrated reproducibility, yield and stability during small, medium and Phase 1 clinical-scale campaigns where we have developed and executed processes to manufacture 3,000 to 5,000 doses of active drug. In December 2018, we entered into an agreement to lease GMP clean-room space from the Azzur Group, LLC. The agreement has expanded our manufacturing capabilities to enable in-house manufacturing of liquid and solid formulations for mid-stage clinical trials of our orally administered and intratumorally administered Synthetic Biotic medicines.

Our Product Pipeline

Approach to Selection of Therapeutic Area

We believe that our Synthetic Biotic platform has potential to address both metabolic and immune-mediated diseases and we are evaluating these medicines at different sites of action via different routes of administration, either orally or via injection. Our decision to focus initially on metabolic disease is based on the potential of the Synthetic Biotic platform to uniquely address conditions in which there is: (1) unmet medical need with (2) well understood biology that is (3) based on an imbalance of a metabolite that can be consumed by our strains and (4) where that metabolite is available within or originates from the gut lumen. Additional considerations include the availability of animal models, relevant biomarkers and feasible clinical development paths. Our initial clinical and pre-clinical programs have been focused on certain rare inherited or acquired metabolic diseases that share these characteristics. When delivered orally, our Synthetic Biotic medicines are designed to act from the gut to compensate for the dysfunctional metabolic pathway with the intended consequence of reducing systemic levels of the toxic metabolites. We believe that clinical success in these programs will enable us to demonstrate the potential of our oral Synthetic Biotic medicines to address metabolic dysfunction, while bringing meaningful change to lives of patients suffering from these debilitating conditions. Our lead therapeutic programs for metabolic disease are SYNB1618 being developed for the treatment of PKU and SYNB8802 being developed for the treatment of Enteric Hyperoxaluria.

 

8

 

 

We are leveraging our proprietary technology platform to develop Synthetic Biotic medicines to treat additional diseases, including metabolic diseases, inflammation and cancer. We have a clinical stage program in oncology that capitalizes on the natural immunostimulatory characteristic of our bacterial chassis, and we have used a rational approach to engineer the bacterium to produce specific effectors to stimulate the innate and adaptive arms of the immune system. We have generated other strains that have been engineered to produce effectors designed to alter the tumor microenvironment potentially enabling us to select combinations of relevant mechanisms and treatments to address specific tumor types.

 

Our Initial Programs: Overview of Metabolic Diseases

There are a number of metabolic diseases characterized by a dysfunctional metabolic pathway that causes a toxic accumulation of a metabolite which results in deleterious health consequences. In a subset of these diseases, the toxic metabolite originates in the gut or is available in the gut. Our Synthetic Biotic medicines can be engineered to consume such metabolites with the intended consequence of reducing systemic levels for therapeutic benefit. Although in some cases diet modification can be beneficial, high unmet medical need remains as there are few current therapeutic treatments for these diseases.

Rare Metabolic Diseases

Patients with rare metabolic diseases lack certain enzymes that are responsible for metabolizing commonly occurring byproducts of digestion. The absence of these enzymes is caused by either a genetic mutation characterized by a dysfunctional metabolic pathway including PKU or organ dysfunction, such as enteric hyperoxaluria. In patients with such diseases, byproducts can accumulate to toxic levels in the gut and systemically throughout the body to cause serious health consequences, including irreversible neurological dysfunction.

While there are hundreds of conditions that fall into this class, individual disorders are considered orphan diseases, with each disease affecting fewer than 200,000 patients in the United States and fewer than five per 10,000 people in the European Union. This includes amino acid metabolism disorders such as PKU.

SYNB1618 for PKU

PKU is an inherited metabolic disease caused by a genetic defect in the gene phenylalanine hydroxylase (PAH) leading to Phe accumulation in the blood and brain, where it is neurotoxic and can lead to neurological deficits and even death. Current disease management of PKU involves dietary protein restriction with the consumption of phenylalanine-free protein supplements. There are currently two approved medications for treatment of PKU:

 

•

Kuvan® (sapropterin dihydrochloride), an oral medication that is indicated for a subgroup of patients who have some residual PAH activity and does not eliminate the need for ongoing dietary management.

 

•

PalynziqTM (pegvaliase-pqpz), an injectable, pegylated, bacterial enzyme (phenylalanine ammonia-lyase or PAL) that metabolizes Phe and that is indicated for treatment of adult patients.

Despite recommendations supporting life-long control of Phe levels, compliance is challenging due to the highly restrictive nature of the diet, putting patients at risk for cognitive and psychiatric disease and supporting the need for novel treatment approaches.

Our Synthetic Biotic platform is well-suited to complement the missing enzyme function in PKU patients by providing alternative metabolic pathways to consume Phe. SYNB1618 is designed to remove excess Phe from the blood by transforming it into non-toxic metabolites. The FDA granted SYNB1618 orphan drug designation for PKU in October 2017 and Fast Track designation in April 2018.

Overview of PKU

Phe is an essential amino acid that enters the body primarily through dietary protein and can be toxic if not sufficiently broken down and eliminated. The metabolism of Phe by the liver is dependent on adequate function of the liver enzyme PAH and the cofactor tetrahydrobiopterin (BH4) necessary for its activity. When the PAH gene is mutated and/or the production of BH4 is blocked, Phe cannot be sufficiently broken down and accumulates to toxic levels (i.e., hyperphenylalaninemia), which can cause irreversible brain damage. PKU is an inherited metabolic disease that presents as a severe form of hyperphenylalaninemia.

9

 

The disease course of PKU typically involves worsening neurological function that begins in infancy or early childhood. The clinical manifestations vary depending on severity of the enzyme mutation, the time of diagnosis and treatment initiation, and compliance. Symptoms may be extensive, such as severe cognitive impairment, or they may reflect more moderate neurocognitive or physical issues, such as below average intelligence, behavioral or mood disorders, memory loss, difficulty concentrating, decreased motor function, eczema, body odor, and tremors or seizures. A woman with PKU who becomes pregnant could develop maternal PKU if her diet is not strictly controlled, and there is a risk that the baby will be born with one or more birth defects such as cognitive impairment, microcephaly or congenital heart disease.

Based on the success of newborn screening efforts that began in developed countries in the 1960s, it is believed that nearly all PKU patients under the age of 40 have been diagnosed at birth. The National PKU Alliance estimates that in the United States there are currently 16,500 people living with PKU and it is estimated that there are 50,000 patients worldwide.

Currently, management of PKU requires a heavily modified diet that restricts protein intake, combined with essential amino acid and vitamin supplementation. Special medical foods, including phenylalanine-free protein formula, provide patients with dietary protein and fulfill other nutrient needs. However, it is challenging for most PKU patients to adhere to the restricted diet to the level that provides the necessary control of Phe levels even with the efforts of supportive family and social networks. Patients often have trouble adhering to the diet, with particular challenges arising during times of increasing independence during adolescence. Furthermore, access to low protein foods can be challenging, as they are costlier and less nutritious than their higher protein, non-modified counterparts.

Kuvan® (sapropterin dihydrochloride) was the first drug approved for the treatment of PKU in 2007. It is indicated for the reduction of blood phenylalanine in patients with hyperphenylalaninemia with residual PAH activity as it is a synthetic form of the BH4 cofactor. Kuvan is to be used along with a Phe-restricted diet. Approximately 25-50% of PKU patients are responsive to oral (tablet or powder) administration of Kuvan.  However, Kuvan does not eliminate the need for ongoing dietary management in all patients. Large neutral amino acids have also demonstrated activity in blocking absorption of excess phenylalanine by the intestines and brain but are currently only administered in adolescents and adults.

PaylnziqTM (pegvaliase-pqpz) Injection, a pegylated form of recombinant phenylalanine ammonia lyase (PAL), an enzyme that metabolizes phenylalanine but does not require cofactor activity, was approved by the FDA in 2018 for adult patients with PKU and uncontrolled blood phenylalanine. While daily Palynziq injections have been proven to lower phenylalanine levels, many patients experience injection site reactions and/or develop antibodies to the product. A Black Box warning of a risk of anaphylaxis is included on the Palynziq label and Palynziq is currently only indicated for adult patients. Other therapeutics in early development include various gene therapy approaches, modified cell therapies and a modified orally delivered enzyme replacement therapy.

Despite recent improvements in PKU therapy, patients continue to suffer from poor outcomes. Even patients who are diagnosed and treated early have increased risk of neurocognitive abnormalities and psychiatric complications and are burdened by the life-long struggle to comply with strict dietary modifications. Available drug therapies demonstrate limited effectiveness, are accompanied by immunologic and other toxicities, and may still require patients to maintain a heavily restricted diet. We believe a truly transformative therapy would be orally dosed and provide sustained, safe concentrations of phenylalanine while enabling a normal or only moderately restricted diet. We believe that a Synthetic Biotic medicine could be an effective oral therapeutic that acts from the gut to consume excess Phe with the consequent effect of reducing levels in the blood without the need for severe Phe restriction or risk of systemic toxicities.

SYNB1618 Design

SYNB1618 is a strain of E. coli Nissle that we have engineered to express synthetic pathways for transporting and metabolizing Phe in patients with PKU following oral administration. SYNB1618 was designed to compensate for the missing enzyme function in patients with PKU with complementary pathways to reduce phenylalanine levels in the gut and, as a consequence, in the systemic circulation.

In designing SYNB1618, we integrated genes, including a form of the PAL enzyme that converts Phe to the non-toxic byproduct trans cinnamic acid (TCA), which is then converted in the liver to hippuric acid (HA) and excreted in the urine. TCA and HA function as useful biomarkers of SYNB1618 activity in vivo. SYNB1618 has also been engineered to express a second Phe-consuming pathway, L-amino acid deaminase (LAAD) that results in the production of another non-toxic product, phenylpyruvate (PP). A detailed description of the engineering of SYNB1618 and data from preclinical studies in an animal model of disease and healthy non-human primates was published in September 2018 (Nat. Biotechnol. 36, 857–864 (2018)).

10

 

SYNB1618 Preclinical Program

Preclinical Efficacy Studies

In vivo studies in a mouse model of PKU (enu2-/-) demonstrated that urinary HA concentrations increased in a dose-dependent fashion in SYNB1618-treated mice compared to mice treated with an unengineered E. coli Nissle control that did not have the phenylalanine degradation pathway. We also observed that subcutaneous injection of mice on a Phe-restricted diet with phenylalanine resulted in a rapid increase in blood phenylalanine concentrations. The increase associated with this phenylalanine challenge was significantly blunted upon oral administration of SYNB1618 compared to administration of the non-engineered control strain.  Similar data were generated with SYNB1618 in healthy non-human primates. With increasing oral doses of SYNB1618, we observed increasing levels of plasma TCA and urinary HA demonstrating that SYNB1618 is functional in the primate gut. Taken together, these data demonstrate that SYNB1618 has activity in the GI tract and can decrease blood Phe levels by degradation of recirculating phenylalanine, as well as dietary Phe. A detailed description of the engineering of SYNB1618 and data from preclinical studies in an animal model of disease and healthy non-human primates was published in September 2018 (Nat. Biotechnol. 36, 857–864 (2018)).  

SYNB1618 Clinical Development Plan

In April 2018, we initiated a Phase 1/2a, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, and gastrointestinal clearance of an early liquid formulation of SYNB1618. We treated healthy adult volunteers with single- or multiple-ascending doses of SYNB1618 and, having identified an MTD, a small cohort of PKU patients were treated with SYNB1618 as a single dose and as multiple doses.

Primary endpoints of the study were safety, tolerability and identification of a suitable dose to evaluate in patients with PKU. In addition, exploratory endpoints were designed to evaluate the pharmacodynamic effects of SYNB1618, including production of previously identified biomarkers related to SYNB1618 activity, TCA in plasma and HA in urine, and to provide mechanistic and clinical insights in both healthy volunteers and patients with PKU.

Fifty-six healthy volunteers were dosed orally with either SYNB1618 or placebo (ratio three to one), including 24 in six cohorts in the SAD portion of the study and 32 subjects in three cohorts of the MAD portion of the trial. In September 2017, we announced top-line data demonstrating that in healthy volunteers SYNB1618 was safe and well tolerated at doses up to 2x1011 CFU three times a day for seven days. Higher doses were associated with mild to moderate gastrointestinal symptoms, mainly nausea and vomiting. The data also demonstrated proof-of-mechanism for SYNB1618.

During the treatment part of the study, subjects were housed in a clinical unit and provided a defined diet. The activity of SYNB1618 was evaluated in fasted subjects in both the SAD and MAD cohorts after administration of a standardized breakfast drink containing a defined amount of protein. At one dose level in the SAD portion of the study, solid food containing an equivalent amount of protein was substituted for the liquid meal. In addition, a labeled Phe tracer (D5-Phe) was orally administered. Blood and urine were collected over a subsequent six-hour period and several metabolites were measured including Phe and SYNB1618-specific biomarkers of Phe metabolism, TCA in blood and HA in urine. This was conducted in the SAD cohorts on the day of dosing and in the MAD cohorts on Day -1 (baseline) and Day 7 (the last day of dosing).

A statistically significant dose-dependent increase in both plasma TCA and urinary HA was observed in SYNB1618-treated subjects but not in those treated with placebo.  Production of metabolites from Phe administered as a free amino acid was similar to Phe administered as whole protein. In addition, production of metabolites was similar whether the protein was administered as a liquid or as a solid meal. In healthy volunteers, who all have normal Phe metabolism, there was no impact on blood Phe levels.  All healthy volunteers enrolled in the study cleared SYNB1618 from their GI tracts within the expected timeframe.

In July 2019, we announced positive top-line clinical data from the patient cohorts of the Phase 1/2a study of the liquid formulation in which 14 subjects were treated with either SYNB1618 or placebo (3:1) with four treated with a single dose (7 x 1010) and 10 with multiple doses. The primary objectives were to evaluate safety and tolerability of the early liquid formulation in patients. Exploratory outcomes were related to the assessment of the pharmacodynamic effects of SYNB1618, including measurement of previously identified biomarkers, TCA and HA, related to SYNB1618’s engineered ability to consume Phe. A statistically significant increase in these biomarkers of SYNB1618 activity was observed in SYNB1618-treated subjects but not in those treated with placebo.

Based on the data from the Phase 1/2a study, which demonstrated that SYNB1618 was able to consume equivalent amounts of Phe in the GI-tract in both PKU patients and healthy volunteers, we studied a solid formulation of SYNB1618 in a bridging study in healthy volunteers. This study was designed to evaluate safety and tolerability and Phe-consuming activity, as determined by TCA and HA production, compared to the early liquid formulation. In December 2019, we announced that the solid formulation of SYNB1618 was better tolerated than the liquid and identified a maximum tolerated dose of 2 x 1012 live cells (5.3 x 1011 colony forming units, or CFUs).  The study further demonstrated that a dose ramp improved SYNB1618 tolerability, that the lyophilized strain maintained Phe-consuming activity, and that pH buffering was required for maximum activity of the strain.

11

 

SYNB1618 Upcoming Clinical Milestones

In the third quarter of 2020, we initiated a Phase 2 clinical trial with SYNB1618.  The Phase 2 trial, referred to as the SynPheny-1 Study, is designed to evaluate safety and tolerability of a solid formulation of SYNB1618 as well as its potential to lower blood Phe levels in adult PKU patients.

Synthetic Biotic Program for Enteric Hyperoxaluria

Overview of Enteric Hyperoxaluria

Hyperoxaluria is a disease which results from excessive levels of oxalate in the body.  Oxalate can be found naturally in the body or in foods with high oxalate levels such as leafy greens, potatoes, almonds, coffee and beans.  Humans do not have an inherent physiological need for oxalate and it is normally excreted through the kidney or reabsorbed through the intestine.   Excessive levels of oxalate, when present in the urine, bind with calcium in the kidney and lead to nephrolithiasis (kidney stone formation), nephrocalcinosis, and chronic kidney complications and renal disease.

There are two types of hyperoxaluria. Primary hyperoxaluria is a genetic condition wherein the body produces excessive levels of oxalate. Approved treatments for primary hyperoxaluria which address the genetic causes of primary hyperoxaluria are not beneficial to patients with enteric hyperoxaluria. Enteric hyperoxaluria results from a gastrointestinal problem, which causes malabsorption of oxalate from the diet.   Conditions that commonly result in enteric hyperoxaluria include inflammatory bowel disease, certain kinds of bariatric surgery, short bowel syndrome, cystic fibrosis and celiac disease.  

Patients with hyperoxaluria normally present to the healthcare system with kidney stones. There is a direct link between elevated urinary oxalate and increased probability of kidney stone events or other renal adverse outcomes in patients with enteric hyperoxaluria. Even modest reductions in urinary oxalate can reduced the odds of developing a kidney stone. A recent epidemiological study conducted in 297 patients with enteric hyperoxaluria demonstrated that a 20% reduction in urinary oxalate resulted in as much as a 25% reduction in risk of having a kidney stone in the subsequent year (D’Costa, Nephrol Dial Transplant 2020).

Kidney stones, of which 80% have been found to contain oxalate crystals, are extremely painful and have an estimated economic burden of over ~$5 billion on the U.S. healthcare system. Patients with kidney stones are treated with opioids to control the pain and the stones are either passed naturally or treated with shockwave lithotripsy to break apart the stone or removal by surgery. There is a 60-80% recurrence rate after a patient has had one kidney stone.  Recurrent kidney stones have been shown to lead to kidney damage, end stage renal disease, and the need for a kidney transplant.  

There are an estimated 200,000 to 250,000 patients with enteric hyperoxaluria in the United States, and more than 80,000 patients who experience recurrent kidney stones due to hyperoxaluria. Currently there are no approved pharmacological therapies for the reduction of oxalate levels in the urine in patients with Enteric Hyperoxaluria.  Existing treatment options are generally non-specific and include high fluid intake to increase urine output to more than two to three liters per day, a diet low in salt and oxalate, oral citrate and/or calcium and/or magnesium supplementation.

We believe there exists a clear need for therapies that lower dangerously high levels of urinary oxalate in enteric hyperoxaluria patients. We believe that a targeted chronic oral therapy that results in lower urinary oxalate levels would provide a substantial benefit for this underserved patient population.

 

12

 

 

SYNB8802 Preclinical Program

Preclinical Efficacy Studies

In vivo studies in both mouse and non-human primate studies demonstrated that SYNB8802 decreased urinary oxalate levels in an acute model of hyperoxaluria induced by dietary intervention in vivo. In mice, we observed reductions in C-13 labeled oxalate using both frozen liquid and lyophilized formulations of SYNB8802. In non-human primates whose oxalate was raised via dietary intervention, we observed statistically significant reductions of urinary oxalate levels, as well as statistically significant reductions in C-13 labeled oxalate, normalized by creatine levels.

A detailed description of the engineering of SYNB8802 and data from preclinical studies in an animal model of disease and healthy non-human primates was presented at the American Society of Nephrology Kidney Week 2020 conference (Renaud et al, poster number PO0650).  

SYNB8802 Upcoming Clinical Milestones

In May 2020, we announced the nomination of a clinical candidate for Enteric Hyperoxaluria, SYNB8802. We initiated a Phase 1 clinical trial of SYNB8802 in the fourth quarter of 2020.

SYNB8802 will be assessed for safety and tolerability, strain kinetics, changes in plasma and urine biomarkers of strain activity, and the potential to reduce urinary oxalate in the Phase 1 clinical study. The study has two parts: Part A is a multiple ascending dose study in healthy volunteers in whom we will induce temporary hyperoxaluria via diet; Part B is a placebo controlled, cross-over design study in patients with Enteric Hyperoxaluria following Roux-n-Y gastric bypass surgery.

Synthetic Biotic Medicines for Other Metabolic Disorders with High Unmet Need

The strain design and engineering, translational research, clinical and regulatory planning and scalable manufacturing of our PKU program has informed development of future clinical candidates, including the Enteric Hyperoxaluria program. Additional preclinical programs have been selected based on our expertise discovering and developing Synthetic Biotic medicines that consume a toxic metabolite known to be associated with the relevant clinical endpoint and to be accessible in the GI tract.

 

Our Synthetic Biotic Medicines for Immuno-Oncology

We believe boosting the body’s immune response against tumor cells is one of the most promising advances in the treatment of cancer. The so-called “hot tumors,” those with robust immune cell infiltration, specifically by T cells, have responded well to immunotherapies such as PD-1 and CTLA-4 checkpoint inhibitors. Checkpoint inhibitors work by blocking pathways that inhibit T cells thus enabling them to recognize and destroy the tumor. Checkpoint inhibitors have significantly extended the lives of patients with several cancer types and, in some cases, have resulted in complete clinical responses. However, a large proportion of tumors are “cold” (i.e., they lack T cells), and respond poorly to current immunotherapy.

Our goal is to leverage our Synthetic Biotic platform to design living medicines that can engage multiple immunomodulatory pathways to enhance tumor inflammation and promote robust T cell responses enabling broad tumor response and remission. We believe that such medicines have the potential to expand the patient population that could benefit from immunotherapy. Our initial approach is designed to deliver robust therapeutic combinations directly to the tumors, without significant systemic exposure. Synthetic Biotic medicines are also being developed to be administered by an intra-tumor injection or, in the case of GI cancers, by oral administration and can be engineered to perform three types of functions: metabolic consumption of an immune-suppressive metabolite, production of an immuno-activating metabolite, secretion or bacterial surface display of proteins (cytokines, chemokines, receptor ligands and single chain antibody domains, known as scFv).

13

 

We believe our Synthetic Biotic platform can be deployed in a rational, mechanistic way, and can deliver multiple validated mechanisms to elicit specific immune responses in the tumor microenvironment. Lack of effective presentation of tumor-specific antigens to T cells is recognized as a significant limitation to the initiation of immune responses in tumors. Our lead clinical program in immuno-oncology (SYNB1891) is an approach to activate the immune system and enhance T cell priming, capitalizing on the innate stimulatory effect of the E.coli Nissle chassis and supplementing this with the directed delivery of an additional immune-stimulatory factor.  SYNB1891 is an engineered E.coli Nissle strain designed to produce, but not secrete, a STING agonist. The STING pathway plays a critical role in the control of tumor growth by initiating an antitumor immune response and driving tumor regression. SYNB1891 can be delivered directly into the tumor, where it is engulfed by antigen presenting cells (APCs), enabling its localized site of action in the tumor microenvironment. The approach of using intratumoral injection elicits STING activation in the tumor, but not systemically, potentially decreasing the risk of adverse events that may arise from the production of systemic interferon. Moreover, as the STING agonist it produces is not secreted but is released directly into the APCs, immune cells such as T cells that might be negatively impacted by exposure are spared.

SYNB1891 is being evaluated in a Phase 1 open-label, multicenter, dose escalation trial in patients with refractory solid tumors and lymphoma. The study’s primary objectives are to evaluate safety and tolerability of escalating doses of intratumorally administered SYNB1891 as a monotherapy. Once a maximum tolerated dose is established, patients will receive escalating dose levels of SYNB1891 in combination with the PD-L1-blocking checkpoint inhibitor, atezolizumab, (Tecentriq®) to establish a recommended Phase 2 dose for the combination regimen.  

We released interim data from the ongoing monotherapy arm of this trial in December of 2020 which demonstrated target engagement and the production of biomarkers consistent with STING activation. In December of 2020 we also initiated the combination arm of the Phase 1 clinical trial.

Our Synthetic Biotic Medicines for Inflammatory Bowel Disease (IBD)

IBD is a group of diseases characterized by significant local inflammation in the GI tract typically driven by T cells, activated macrophages and compromised function of the epithelial barrier. IBD pathogenesis is linked to both genetic and environmental factors and may be caused by altered interactions between gut microbes and the intestinal immune system. Current approaches to treat IBD are focused on therapeutics that modulate the immune system and suppress inflammation. These therapies include steroids, such as prednisone, and tumor necrosis factor inhibitors, such as Humira® (adalimumab). However, these approaches are associated with systemic immunosuppression, which includes greater susceptibility to infectious diseases and cancer. According to the CDC, in 2015 an estimated 3.0 million adults in the United States are reported as being diagnosed with IBD.

Compromised gut barrier function also plays a central role in autoimmune diseases pathogenesis. A single layer of epithelial cells separates the luminal contents of the gut from the host circulatory system and the immune cells in the body. Disrupting the epithelial layer can lead to pathological exposure of foreign antigens from the lumen resulting in increased susceptibility to autoimmune disorders. The interplay between the gut microbiota and the host is thought to play a key role in the maintenance of the epithelial barrier as well as homeostatic immunity. Thus, enhancing barrier function and reducing inflammation in the gastrointestinal tract are potential therapeutic mechanisms for the treatment or prevention of autoimmune disorders. Our Synthetic Biotic platform allows for the effective programming of E. coli Nissle to execute these functions, including the metabolic production of factors such short chain fatty acids to enhance barrier function, and secreting proteins, such as immunomodulatory cytokines.

Among immune conditions, IBD is particularly attractive for our Synthetic Biotic platform, as it allows us to leverage knowledge and expertise gleaned from our oral metabolic programs to develop living medicines that can act locally at the site of disease in the gut. Because our approach is based on local delivery to the site of inflammation and not on systemic administration, we anticipate that our Synthetic Biotic medicines may offer an attractive safety profile in this setting. In 2015, we entered into a multi-year global collaboration with AbbVie focused on the discovery and development of Synthetic Biotic medicines for the treatment of IBD. This agreement was terminated in 2020 and all rights for the development of Synthetic Biotics in IBD were returned to Synlogic.

Collaboration Agreements

To accelerate the development and commercialization of Synthetic Biotic medicines to patients, we have formed, and intend to seek other opportunities to form, strategic alliances with collaborators that can expand our pipeline of therapeutic development and product candidates. We also work, and intend to seek additional opportunities to work, with multiple academic, research and translational medicine organizations and entities to deepen our understanding and development of living medicines with the potential to treat disease and disorders.

14

 

Ginkgo Bioworks

In June 2019 we entered into an agreement with Ginkgo. The agreement provided an $80.0 million equity investment at a premium in Synlogic by Ginkgo and entry into a long-term strategic platform collaboration to expand and accelerate the development of Synlogic’s pipeline of Synthetic Biotic medicines. We are using Ginkgo’s cell programming platform to build and test thousands of microbial strains to accelerate progression of early preclinical leads to drug candidates optimized for further clinical development.

As part of the agreement, Ginkgo purchased 6,340,771 shares of our common stock and accompanying Pre-Funded Warrants (the “Pre-Funded Warrants”) to purchase up to 2,548,117 shares of our common stock, at a combined price of $9.00 per share and Pre-Funded Warrant. Gross proceeds were approximately $80 million. Under the agreement, we made a prepayment to Ginkgo of $30.0 million for its foundry services that are being provided to us over an initial term of five years which can be extended. Upon the expiration of such initial term and, if applicable, such additional period, any portion of our prepayment that has not been used to purchase services from Ginkgo will be retained by Ginkgo. We have exclusive rights to any Synthetic Biotic medicines that we develop as part of the collaboration and to intellectual property covering such products.

AbbVie

In July 2015, we entered into a license agreement with our subsidiary Synlogic IBDCo, Inc. (IBDCo) and an Agreement and Plan of Merger with AbbVie (together, the AbbVie Agreements) to collaborate on the discovery and development of Synthetic Biotic medicines for the treatment of IBD. The AbbVie Agreements provided AbbVie with an exclusive option to acquire IBDCo, which would then have had an exclusive worldwide license to develop and commercialize up to three specified Synthetic Biotic medicines for the treatment of IBD. In May 2020, we announced the termination of this collaboration with AbbVie. Upon termination, we regained all rights to develop these and new IBD Synthetic Biotic medicines for all effectors targeting IBD. This allows us to fully leverage our expertise in strain engineering, quantitative biology, regulatory, and manufacturing to expand our wholly owned GI-based program portfolio to include IBD. We further regained the rights to partner these IBD programs.

Potential Future Collaborations

We believe strategic partnerships can be important drivers for accelerating our goal of developing Synthetic Biotic medicines, and we will continue to seek strategic alliances with collaborators who can help fund, develop and commercialize our novel therapeutic development and product candidates, particularly in large metabolic indications and immuno-oncology. As the potential application of our Synthetic Biotics platform is extremely broad, we also plan to continue to identify academic, research and translational medicine organizations and entities that can contribute expertise and resources to our programs, to allow us to more rapidly expand our impact to broader patient populations.

Intellectual Property and Technology Licenses

We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from our collaborators or other third parties. Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications in the United States and in certain jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, and product candidates that are important to the development and implementation of our business. We also rely on trade secrets and know-how relating to our proprietary technology and product candidates, continuing innovation, and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the field of synthetic biology. We additionally rely on data exclusivity, market exclusivity, and patent term extensions when available, and plan to seek and rely on regulatory protection afforded through orphan drug designations. Our commercial success may depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, and improvements; to preserve the confidentiality of our trade secrets; to maintain our licenses to use intellectual property owned by third parties; to defend and enforce our proprietary rights, including our patents; and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties.

We believe we are well positioned in terms of intellectual property because we:

 

•

have built and expanded, and intend to continue expansion in, a broad worldwide portfolio of intellectual property, including patents and patent applications, in areas relevant to the development, manufacturing and formulation of human therapeutic products using live biotherapeutics based on synthetic biology; and

15

 

 

•

intend to take additional steps, where appropriate, to further protect our intellectual property rights, including, for example, through the use of copyright and trademark protection, as well as regulatory protection available via orphan drug designations, data exclusivity, market exclusivity and patent term extensions.

We believe our intellectual property portfolio provides broad coverage of our Synthetic Biotic platform and applicable disease-related technologies, which are directed to diseases and conditions associated with hyperphenylalanemia, other rare metabolic diseases and metabolic disorders, autoimmune and other inflammatory disorders and oncology. As of March 18, 2021, we had 161 Synlogic-owned patents and patent applications in U.S. and foreign jurisdictions, of which 17 have been issued or allowed.

Synlogic Intellectual Property

Disease-related applications

The disease-related applications in our intellectual property portfolio relate to certain pathological conditions including, but not limited to hyperammonemia, hyperphenylalaninemia, certain inherited metabolic diseases and conditions, metabolic disorders, diseases and conditions associated with an inflammatory state, diseases associated with gut inflammation, compromised gut mucosal barrier (leaky gut), and various autoimmune disorders as well as use in immuno-oncology and provide coverage for engineered bacteria having genetic circuitry designed to specifically address those conditions and the associated disease states. The intellectual property portfolio provides coverage for compositions directed to engineered bacterial strains, methods of making the bacterial strains and methods for treating diseases. Currently, intellectual property relating to this technology includes pending applications in U.S. and foreign jurisdictions, as well as several issued U.S. patents directed to composition of matter and pharmaceutical composition claims covering our clinical candidates. The patent term for our current IP has expiration dates ranging from December 2035 to January 2038, depending on the indication and excluding any patent term adjustments or extensions.

 

Platform Technology Applications

In addition to the disease-related technology, our intellectual property portfolio also includes applications directed to platform technologies developed internally by us. Exemplary platform technologies include bacterial chassis-related and genetic circuitry-related technological developments, including, for example, improvements in inducible gene regulation, control of bacterial cell growth, including auto-regulation thereof, and systems for importing metabolites, as well as production of therapeutic effectors. These platform technologies, and our intellectual property coverage thereof, are broadly applicable to our therapeutic Synthetic Biotic medicines.

General Considerations

Individual patents extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. Generally, patents issued for applications filed in the United States are effective for 20 years from the earliest effective non-provisional filing date. In addition, in certain instances, a patent term can be extended to account for delays in prosecution at the U.S. Patent and Trademark Office (USPTO) and/or to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. For regulatory delays, the restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The duration of patents outside of the United States varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective non-provisional filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent.

The patent positions of companies like us are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of synthetic biology has emerged in the United States. The patent situation outside of the United States is even more uncertain. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us the future will be commercially useful in protecting our products and the methods used to manufacture those products. For additional risks, please see the section entitled “Risk Factors—Risks Related to Intellectual Property”.

16

 

 

Trademarks

Our registered trademark portfolio currently contains 21 registered trademarks, 1 allowance and 5 pending applications.

Other

Generally, we seek to protect our technology and product candidates, in part, by entering into confidentiality agreements with those who have access to our confidential information, including employees, contractors, consultants, collaborators, and advisors. In some circumstances, we may rely on trade secrets to protect our technology. We seek to preserve the integrity and confidentiality of our proprietary technology, trade secrets and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. Although we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or may be independently discovered by competitors. To the extent that company employees, contractors, consultants, collaborators, and advisors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For this and more comprehensive risks related to our proprietary technology, inventions, improvements and products, please see the section entitled “Risk Factors—Risks Related to Intellectual Property”.

Regulatory Matters

Government Regulation and Product Approval

Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new drug must be approved by the FDA through the New Drug Application (NDA) process and a new biologic must be approved by the FDA through the Biologics License Application (BLA), process before such products may be legally marketed in the United States.

U.S. Drug Development Process

In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and in the case of biologics, also under the Public Health Service Act (PHSA) and implementing regulations. Our product candidates will be regulated by the FDA as biologics. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA’s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biologic may be marketed in the United States generally involves the following:

 

•

completion of required preclinical laboratory tests, animal studies and formulation studies performed in accordance with Good Laboratory Practice (GLP) and other applicable regulations;

 

•

submission to the FDA of an investigational new drug application (IND) which must become effective before shipment of investigational product for human clinical trials may begin;

 

•

approval by an independent institutional review board, or IRB, or ethics committee at each clinical trial site before each clinical trial may be initiated;

 

•

performance of adequate and well-controlled human clinical trials performed in accordance with applicable IND regulations, Good Clinical Practice (GCP), and other clinical-trial related regulations to evaluate the safety and efficacy of the investigational product for each proposed indication;

 

•

development and approval of a companion diagnostic device, if the FDA or the sponsor believes that its use is essential for the safe and effective use of a corresponding product;

 

•

submission to the FDA of a BLA for marketing approval, including payment of application user fees;

17

 

 

 

•

satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the biologic is produced to assess compliance with GMP to assure that the facilities, methods and controls are adequate to preserve the product’s identity, strength, quality and purity;

 

•

potential FDA audit of the clinical trial sites to assure compliance with GCP and the integrity of the clinical data submitted in support of the BLA; and

 

•

FDA review and approval of the BLA, including satisfactory completion of an FDA advisory committee review of the product candidate, where appropriate or if applicable, prior to any commercial marketing or sale of the product in the United States.

Once a pharmaceutical candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry and formulation, animal toxicity and pharmacology studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies.

An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. In June 2016, the FDA issued an updated guidance for the industry entitled “Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing and Control Information,” which included recommendations from the FDA regarding the chemistry, manufacturing and control information that should be included in an IND for early clinical trials with live biotherapeutic products. This Guidance reflects the FDA’s thinking on a topic at the time that it was issued and although it is not binding on the FDA or a sponsor, it provided us with additional information about what should be included in our IND. The sponsor will also include in the IND a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if a first phase study lends itself to an efficacy evaluation. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after an IND for an investigational drug candidate is submitted to the FDA and human clinical trials have been initiated. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about ongoing or proposed clinical trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted.

All clinical trials must be conducted under the supervision of one or more qualified investigators, and in accordance with GCP requirements. They must be conducted under protocols detailing the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and timely safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. An institutional review board (IRB) at each institution participating in the clinical trial must review and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB rules and regulations. Study subjects must sign the IRB-approved informed consent form participating in a clinical trial.

In addition, an IRB representing each institution that is participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct a continuing review and reapprove the trial at least annually. The IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to clinical trial subjects. An IRB must operate in compliance with FDA regulations.

Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:

 

•

Phase 1: The product candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is usually conducted in patients.

 

•

Phase 2: This phase involves clinical trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.

 

•

Phase 3: Larger clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population, often at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall risk: benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.

18

 

Post-approval trials, sometimes referred to as Phase 4, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of a BLA.

The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the clinical protocol, GMP or IRB requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. Phase 1, Phase 2, and Phase 3 testing may not be completed successfully within any specified period, if at all.

During the development of a new biologic, sponsors have the opportunity to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before a BLA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end of Phase 2 meeting to discuss their Phase 2 clinical results with the FDA and to present their plans for the pivotal Phase 3 clinical trial that they believe will support approval of the new biologic. If this type of discussion occurs, a sponsor may be able to request a Special Protocol Assessment (SPA), the purpose of which is to reach agreement with the FDA on the design of the Phase 3 clinical trial protocol design and analysis that will form the primary basis of an efficacy claim.

Concurrent with clinical trials, companies usually complete the additional animal studies that may be required for approval and must also develop additional information about the chemistry and physical characteristics of the biologic and finalize a process for manufacturing the product in commercial quantities in accordance with GMP requirements. The manufacturing process must be capable of consistently producing acceptable quality batches of the product candidate and, among other things the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

While the IND is active and before approval, progress reports must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse reactions, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure. The annual report is customarily submitted in the form of a Drug Safety Update Report (DSUR) which is accepted as being equivalent to an IND Annual Report and also meets requirements of the EU (European Union) and ICH (International Conference on Harmonization).

There are also requirements governing the reporting of ongoing clinical trials and completed trial results to public registries. Sponsors of most clinical trials of FDA-regulated products are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to submit the results of their clinical trials after completion, within a specified time frame. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. However, there are evolving rules and increasing requirements for publication of all trial related information, and data and other information from trials involving drugs that never garner approval will require disclosure. Failure to post results of clinical trials in a timely fashion is subject to daily fines and other potential penalties.

U.S. Review and Approval Processes

Assuming successful completion of the required clinical testing, the results of the nonclinical studies and clinical trials, along with detailed information relating to the product’s chemistry, manufacturing, and controls, stability, quality control and product release procedures, proposed labeling, and other relevant information are submitted to the FDA as part of a BLA, requesting approval to market the product for one or more indications. The submission of a BLA is subject to the payment of a significant user fee (for example, for FY2020 this application fee exceeds $2.9 million); although a waiver of such fee may be obtained under certain limited circumstances, including where the biologic has been designated as an orphan drug. The sponsor of an approved BLA is also subject to an annual program fee, currently more than $300,000 per program. These fees are typically increased annually, but exemptions and waivers may be available under certain circumstances (such as a waiver for the first human drug application submitted by a qualifying small business and exemptions for orphan products).

19

 

Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, for original BLAs, the FDA has ten months from the filing date in which to complete its initial review of a standard application and respond to the applicant, and six months from the filing date for an application with priority review. The FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional information or clarification and a sponsor’s process to respond to such inquiries. This FDA review typically takes twelve months from the date the BLA is submitted to the FDA (for a standard review) and eight months from the date the BLA is submitted (for a “priority review”) because the FDA has approximately two months, or 60 days, after BLA submission to make a “filing” decision.

The FDA reviews all BLAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. The FDA may request additional information rather than accept a BLA for filing. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The review process may be extended by the FDA for three additional months to consider new information or in the case of a clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.

Before approving a BLA, the FDA will typically conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether the manufacturing processes and facilities comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with GCP requirements and the integrity of the clinical data submitted to the FDA.

The FDA may refer any BLA including applications for novel biologic candidates which present difficult questions of safety or efficacy, to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations when making final decisions on approval. The approval process is lengthy and often difficult, and the FDA may refuse to approve a BLA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information. Even if such data and information are submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. . After the FDA evaluates a BLA, it will issue an approval letter or a Complete Response Letter (CRL). An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL usually describes the specific deficiencies in the BLA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a CRL is issued, the sponsor must resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval. The FDA reviews a BLA to determine, among other things, whether the product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product’s continued safety, purity and potency.

BLAs receive either standard or priority review. A drug representing a significant improvement in treatment, prevention or diagnosis of disease may receive priority review. Priority review for an original BLA should occur within six months from the date that the BLA is filed. In addition, products studied for their safety and effectiveness in treating serious or life threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval and may be conditionally approved on the basis of adequate and well controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well controlled Phase 4 clinical trials. Priority review and accelerated approval do not change the standards for approval, but may expedite the approval process.

If a product receives regulatory approval, the approval is limited to the conditions of use (e.g., patient population, indication) described in the BLA, which could restrict the commercial value of the product. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require a sponsor to conduct Phase 4 testing which involves clinical trials designed to further assess a drug’s safety and effectiveness after BLA approval and may require testing and surveillance programs to monitor the safety of approved products which have been commercialized. The FDA may also place other conditions on approval including the requirement for a Risk Evaluation and Mitigation Strategy (REMS), to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial

20

 

promotion, distribution, prescription or dispensing of products. Marketing approval may be withdrawn for non-compliance with regulatory requirements or if problems occur following initial marketing.

The Pediatric Research Equity Act (PREA), requires a sponsor to conduct pediatric clinical trials for most newly approved drugs and biologics, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original BLAs and supplements thereto, must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug or biologic is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. Orphan indications are exempt from PREA. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.

Patent Term Restoration and Marketing Exclusivity

Depending upon the timing, duration and specifics of FDA approval of our drugs, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (referred to as the Hatch Waxman Amendments). The Hatch Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product’s approval date. The patent term restoration period is generally one half the time between the effective date of an IND, and the submission date of a BLA, plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension, and the extension must be applied for, prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of its currently-owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the filing of the relevant BLA.

Pediatric exclusivity is a type of non-patent marketing exclusivity available in the United States, and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. This six-month exclusivity may be granted if an NDA sponsor submits clinical pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA’s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application for the same biologic. The issuance of a written request does not require the sponsor to undertake the described clinical trials. To date, we have not received or requested any FDA written requests.

Biologics Price Competition and Innovation Act of 2009

The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010 (collectively, ACA), which included the BPCIA, amended the PHSA to create an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. A federal district court ruling in Texas struck down the Affordable Care Act in its entirety based on constitutionality last year, and in December 2019 the Fifth Circuit Court of Appeals upheld lower court’s finding that the individual mandate I the law is unconstitutional. However, the Fifth Circuit also reversed and remanded the case to the district court to determine if other reforms enacted as part of the Affordable Care Act but not specifically related to the individual mandate or health insurance, including the BPCIA, could be severed from the rest of the Affordable Care Act so as not to be declared invalid. It is unclear how this decision, subsequent appeals including potentially to the U.S. Supreme Court, and other efforts to repeal and replace the Affordable Care Act will affect the implementation of that law and our business. To date, the FDA has approved a number of biosimilars, and numerous biosimilars have been approved in Europe. The FDA has also issued several guidance documents outlining its approach to reviewing and approving biosimilars and interchangeable biosimilars. A biosimilar product is defined as one that is highly similar to a reference product notwithstanding minor differences in clinically-inactive components and for which there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency of the product. An interchangeable product is a biosimilar product that can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological

21

 

product without such alternation or switch. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product.

The biosimilar applicant must demonstrate that the product is biosimilar based on data from (1) analytical studies showing that the biosimilar product is highly similar to the reference product; (2) animal studies (including toxicity); and (3) one or more clinical trials to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is approved. In addition, the applicant must show that the biosimilar and reference products have the same mechanism of action for the conditions of use on the label, route of administration, dosage and strength, and the production facility must meet standards designed to assure product safety, purity and potency.

A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the first approved interchangeable biologic product will be granted an exclusivity period of up to one year after it is first commercially marketed. If pediatric studies are performed and accepted by the FDA as responsive to a Written Request, the 12-year exclusivity period will be extended for an additional six months. In addition, the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. “First licensure” typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a supplement for the reference product for a subsequent application filed by the same sponsor or manufacturer of the reference product (or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the “first licensure” of a biological product is determined on a case-by-case basis with data submitted by the sponsor.

The BPCIA is complex and only beginning to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation and meaning of the BPCIA is subject to significant uncertainty.

Orphan Drug Designation

Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally defined as a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use will be disclosed publicly by the FDA; the posting will also indicate whether a drug is no longer designated as an orphan drug. More than one product candidate may receive an orphan drug designation for the same indication. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.

If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to seven years of orphan product exclusivity, except in very limited circumstances. The FDA will not recognize orphan drug exclusive approval if a sponsor fails to demonstrate upon approval that the drug is clinically superior to a previously approved drug, regardless of whether or not the approved drug was designated an orphan drug or had orphan drug exclusivity. Thus orphan drug exclusivity could also block the approval of one of our products for seven years if a competitor obtains approval of the same drug, as defined by the FDA, and we are not able to show the clinical superiority of our drug or if our product candidate is determined to be contained within the competitor’s product for the same indication or disease.

In October 2017, the FDA granted SYNB1618 orphan drug designation for the treatment of PKU.

Fast Track, Breakthrough Therapy and Priority Review Designations

The FDA is authorized to designate certain products for expedited development or review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough therapy designation and priority review designation.

To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing

22

 

a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product. The FDA may also review sections of the NDA or BLA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor and the FDA agree on a schedule for the submission of the application sections, and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA. In addition, fast track designation may be withdrawn by the sponsor or rescinded by the FDA if the designation is no longer supported by data emerging in the clinical trial process.

In addition, with the enactment of FDASIA in 2012, Congress created a new regulatory program for product candidates designated by FDA as “breakthrough therapies” upon a request made by the IND sponsors. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs or biologics designated as breakthrough therapies are also eligible for accelerated approval of their respective marketing applications. The FDA must take certain actions with respect to breakthrough therapies, such as holding timely meetings with and providing advice to the product sponsor, intended to expedite the development and review of an application for approval of a breakthrough therapy.

Finally, the FDA may designate a product for priority review if it is a drug or biologic that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a case- by-case basis, whether the proposed drug represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA’s goal for taking action on a marketing application from ten months to six months for an original BLA or for an NDA for a new molecular entity from the date of filing.

Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, breakthrough therapy designation and priority review do not change the standards for approval and may not ultimately expedite the development or approval process.

In April 2018, the FDA granted Fast-Track designation for the use of SYNB1618 for the treatment of PKU.

Accelerated Approval Pathway

In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval from the FDA and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a drug or biologic when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform post-marketing clinical trials to verify and describe the predicted effect on IMM or other clinical endpoint, and the product may be subject to expedited withdrawal procedures. Drugs and biologics granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.

For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval when the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate long-term clinical benefit of a drug.

23

 

The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. For example, accelerated approval has been used extensively in the development and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large clinical trials to demonstrate a clinical or survival benefit.

The accelerated approval pathway is usually contingent on a sponsor’s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug’s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to confirm the predicted clinical benefit of the product during post-marketing studies, would allow the FDA to withdraw approval of the drug. All promotional materials for product candidates being considered and approved under the accelerated approval program are subject to prior review by the FDA.

Post-Approval Requirements

Following approval of a new product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting of adverse experiences with the product, product sampling and distribution restrictions, complying with promotion and advertising requirements, which include restrictions on promoting biologics for unapproved uses or patient populations (i.e., “off-label use”) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or a BLA supplement, which may require the applicant to develop additional data or conduct additional pre-clinical studies and clinical trials. The FDA may also place other conditions on approvals including the requirement for a REMS to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.

FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and finished product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. The manufacturing facilities for our product candidates must meet cGMP requirements and satisfy the FDA or comparable foreign regulatory authorities before any product is approved and our commercial products can be manufactured. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Future inspections by the FDA and other regulatory agencies may identify compliance issues at the facilities of our CMOs that may disrupt production or distribution or require substantial resources to correct. In addition, the discovery of conditions that violate these rules, including failure to conform to cGMPs, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved BLA, including voluntary recall and regulatory sanctions as described below.

Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur or are discovered after the product reaches the market. Later discovery of previously unknown problems with a product may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:

 

•

restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;

24

 

 

•

fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials;

 

•

refusal of the FDA to approve pending NDAs/BLAs or supplements to approved NDAs/BLAs, or suspension or revocation of product approvals;

 

•

product seizure or detention, or refusal to permit the import or export of products;

 

•

injunctions or the imposition of civil or criminal penalties; and

 

•

consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or mandated modification of promotional materials and labeling and the issuance of corrective information.

In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. Most recently, the Drug Supply Chain Security Act, or DSCSA, was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States, including most biological products. The DSCSA mandates phased-in and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers over a 10‑year period that is expected to culminate in November 2023.

From time to time, new legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. It is impossible to predict whether further legislative changes will be enacted, or FDA regulations, guidance or interpretations will be changed or what the impact of such changes, if any, may be.

Foreign Regulation

In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing the performance of clinical trials outside the U.S. and commercial sales and distribution of our products outside of the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the European Union, before we may commence clinical trials or market products in those countries or areas. It is not yet clear how the United Kingdom’s withdrawal from the European Union, now taking place on January 31, 2020, will affect the approval of medicinal products in the UK. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly between countries and jurisdictions and can involve additional testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.

European Union drug development, review and approval

In the European Union, our product candidates also may be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained. Similar to the United States, the various phases of pre-clinical and clinical research in the European Union are subject to significant regulatory controls.

The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP, and the related national implementing provisions of the individual EU Member States govern the system for the approval of clinical trials in the European Union. Under this system, an applicant must obtain prior approval from the competent national authority of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the competent ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by, among other documents, an IMPD (the Common Technical Document) with supporting information prescribed by Directive 2001/20/EC, Directive 2005/28/EC, where relevant the implementing national provisions of the individual EU Member States and further detailed in applicable guidance documents. All suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the competent national authority and the Ethics Committee of the Member State where they occurred.

In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (Clinical Trials Regulation) was adopted and it is anticipated to come into application in late 2020 or early 2021. The Clinical Trials Regulation will be directly applicable in all the EU Member States, repealing the current Clinical Trials Directive 2001/20/EC. Conduct of all clinical trials performed in the European Union will continue to be bound by currently applicable provisions until the new Clinical Trials Regulation becomes applicable. The

25

 

extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation will depend on when the Clinical Trials Regulation becomes applicable and on the duration of the individual clinical trial. If a clinical trial continues for more than three years from the day on which the Clinical Trials Regulation becomes applicable the Clinical Trials Regulation will at that time begin to apply to the clinical trial.

The new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, the “EU portal”; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned). Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials Regulation.

To obtain a marketing authorization of a drug in the European Union, we may submit marketing authorization applications, or MAA, either under the so-called centralized or national authorization procedures.

Centralized procedure

The centralized procedure provides for the grant of a single marketing authorization following a favorable opinion by the European Medicines Agency, or EMA, that is valid in all EU member states, as well as Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products, advanced-therapy medicines (such as gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products with a new active substance indicated for the treatment of specified diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions and viral diseases. The centralized procedure is optional for products that represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the Committee for Medicinal Products for Human Use, or the CHMP. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is of 150 days, excluding stop-clocks.

National authorization procedures

There are also two other possible routes to authorize medicinal products in several EU countries, which are available for investigational medicinal products that fall outside the scope of the centralized procedure:

Decentralized procedure. Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one EU country of medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of the centralized procedure.

Mutual recognition procedure. In the mutual recognition procedure, a medicine is first authorized in one EU Member State, in accordance with the national procedures of that country. Following this, further marketing authorizations can be sought from other EU countries in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization.

Under the above-described procedures, before granting the marketing authorization, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.

Conditional approval

In specific circumstances, E.U. legislation (Article 14(7) Regulation (EC) No 726/2004 and Regulation (EC) No 507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1) the risk-benefit balance of the product candidate is positive, (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3) the product fulfills unmet medical needs and (4) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still

26

 

required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.

Pediatric studies

Prior to obtaining a marketing authorization in the European Union, applicants have to demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as the Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine in children is not needed or is not appropriate, such as for diseases that only affect the elderly population.

Before a marketing authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP.

European Union regulatory exclusivity

In the European Union, new products authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the European Union during a period of eight years from the date on which the reference product was first authorized in the European Union. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference product in the EU. The ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.

European Union orphan designation and exclusivity

The criteria for designating an orphan medicinal product in the European Union, are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the European Union to justify investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the European Union, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the marketing authorization application if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.

The ten-year market exclusivity in the European Union may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if:

 

•

the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior;

 

•

the applicant consents to a second orphan medicinal product application; or

 

•

the applicant cannot supply enough orphan medicinal product.

27

 

 

PRIME designation

The EMA grants access to the Priority Medicines, or PRIME, program to investigational medicines for which it determines there to be preliminary data available showing the potential to address an unmet medical need and bring a major therapeutic advantage to patients. As part of the program, EMA provides early and enhanced dialogue and support to optimize the development of eligible medicines and speed up their evaluation, aiming to bring promising treatments to patients sooner. 

Periods of authorization and renewals

A marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the E.U. market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid (the so-called sunset clause).

Rest of the world regulation

For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from jurisdiction to jurisdiction. Additionally, the clinical trials must be conducted in accordance with cGCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.

If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.

Coverage, Pricing and Reimbursement

Sales of pharmaceutical products depend in significant part on the availability of third-party coverage and reimbursement. Third-party payors include government healthcare programs such as Medicare, managed care providers, private health insurers and other organizations. We anticipate third-party payors will provide reimbursement for our products. However, these third-party payors are increasingly challenging the price and examining the cost effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly-approved healthcare products. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost effectiveness of our products. Moreover, a payor’s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development. Our product candidates may not be considered cost effective. It is time consuming and expensive for us to seek reimbursement from third-party payors. Reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis.

Medicare is a federal healthcare program administered by the federal government that covers individuals age 65 and over as well as individuals with certain disabilities. Drugs may be covered under one or more sections of Medicare depending on the nature of the drug and the conditions associated with and site of administration. For example, under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities which provide coverage for outpatient prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Parts A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level.

28

 

Medicare Part B covers most injectable drugs given in an in-patient setting and some drugs administered by a licensed medical provider in hospital outpatient departments and doctors’ offices. Medicare Part B is administered by Medicare Administrative Contractors, which generally have the responsibility of making coverage decisions. Subject to certain payment adjustments and limits, Medicare generally pays for a Part B-covered drug based on a percentage of manufacturer-reported average sales price, which is regularly updated. We believe that our product candidates that are intended to be administered intratumorally will be subject to the Medicare Part B rules.

 

We expect that there will continue to be a number of federal and state proposals to implement governmental pricing controls and limit the growth of healthcare costs, including the cost of prescription drugs. For example, the ACA enacted in March 2010, was expected to have a significant impact on the health care industry. The ACA has been under scrutiny by the U.S. Congress almost since its passage, and certain sections of the ACA have not been fully implemented or effectively repealed. As a result, its longevity continues to be uncertain. In addition, ongoing initiatives in the U.S. have increased and will continue to increase pressure on drug pricing. The announcement or adoption of any such initiative could have an adverse effect on potential revenues from any product candidate that we may successfully develop.

In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. Moreover, a payor’s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on our profitability placing the medicinal product on the market. Other member states allow companies to fix their own prices for drug products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union and other countries do not follow price structures of the United States and generally prices tend to be significantly lower.

The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution (arbitrage between low-priced and high-priced member states) can further reduce prices. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements.

Other U.S. Health Care Laws and Regulations

If our product candidates are approved in the United States, we will have to comply with various U.S. federal and state laws, rules and regulations pertaining to health care fraud and abuse, including anti-kickback laws and physician self-referral laws, rules and regulations. Violations of the fraud and abuse laws are punishable by criminal and civil sanctions, including, in some instances, exclusion from participation in federal and state health care programs, including Medicare and Medicaid. These laws include:

 

•

the federal anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal health care program such as Medicare and Medicaid;

 

•

the federal False Claims Act imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;

 

•

the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any health care benefit program or making false statements relating to health care matters;

 

•

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH Act, and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;

 

•

the federal transparency requirements under the Physician Payments Sunshine Act require manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to

29

 

 

the Department of Health and Human Services information related to payments and other transfers of value to physicians, teaching hospitals, and certain advanced non-physician health care practitioners and physician ownership and investment interests; and

 

•

analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving health care items or services reimbursed by nongovernmental third-party payors, including private insurers.

Some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines, or the relevant compliance guidance promulgated by the federal government, in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures to the extent that those laws impose requirements that are more stringent than the Physician Payments Sunshine Act. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

Health Care Reform in the US and Potential Changes to Health Care Laws

The FDA’s and other regulatory authorities’ policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, in December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and devices and to spur innovation, but its ultimate implementation is uncertain. In addition, in August 2017, the FDA Reauthorization Act was signed into law, which reauthorized the FDA’s user fee programs and included additional drug and device provisions that build on the Cures Act. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.

As previously mentioned, primary trend in the US health care industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other health care funding and applying new payment methodologies. For example, in March 2010, the Affordable Care Act was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans; imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers’ outpatient drugs coverage under Medicare Part D; and established a Center for Medicare Innovation at the US Centers for Medicare and Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending.

Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. The current Presidential administration and members of the US Congress have indicated that they may continue to seek to modify, repeal or otherwise invalidate all, or certain provisions of, the Affordable Care Act. For example, the Tax Cuts and Jobs Acts was enacted in 2017, which, among other things, removed penalties for not complying with the individual mandate to carry health insurance. As noted above, a 2018 federal district court ruling struck down the Affordable Care Act in its entirety although the Fifth Circuit Court of Appeals recently limited it to the individual mandate and remanded the case to the district court to determine if other reforms not specifically related to the individual mandate or health insurance could be severed from the rest of the Affordable Care Act. It is unclear how this decision, subsequent appeals including potentially to the U.S. Supreme Court, and other efforts to repeal and replace the Affordable Care Act will affect the implementation of that law and our business.

In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act that affect health care expenditures. There has been heightened governmental scrutiny in recent years over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical and biologic products. Notably, on December 20, 2019, President Trump signed the Further Consolidated Appropriations Act for 2020 into law (P.L. 116-94) that includes a piece of bipartisan legislation called the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the “CREATES Act.” The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their

30

 

products, including by invoking the existence of a REMS for certain products, to deny generic and biosimilar product developers access to samples of brand products. Because generic and biosimilar product developers need samples to conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay in the entry of generic and biosimilar products. To remedy this concern, the CREATES Act establishes a private cause of action that permits a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on “commercially reasonable, market-based terms.” Whether and how generic and biosimilar product developments will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on our future commercial products are unknown.  

We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services.

Other Regulatory Matters

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. These operations may involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations may also produce hazardous waste products. We contract with third parties for the disposal of these materials and wastes. Our products are defined as Genetically Modified Organisms (GMO) or Genetically Modified Micro-organisms (GMM) and, dependent on their classification and containment, may be subject to regulation.

The United States does not have any federal legislation that is specific to genetically modified organisms.  GMOs are regulated pursuant to health, safety, and environmental legislation governing conventional products.  The U.S. approach to regulating GMOs is premised on the assumption that regulation should focus on the nature of the products, rather than the process in which they were produced.

The clinical development and marketing of GMM within the European Union, and elsewhere, falls under different regulations and practices in each country, which may involve approval by environmental or other regulatory bodies, as well as health authorities, and may establish the requirement for a risk assessment for the testing or authorization of the product.

Manufacturing

We have made and continue to make significant investments in our manufacturing organization, including process development and cGMP production infrastructure to establish manufacturing processes designed to support production of clinical trial material. The manufacturing processes are designed to enable us to reproducibly manufacture high quality living medicines at clinical scale and, later, at commercial scale to enable approval of our product candidates. We have built a fully integrated development and manufacturing organization with an internal process development group, quality group and manufacturing capabilities with the lease of cGMP cleanroom space in Waltham, Massachusetts. This facility enables us to produce clinical trial material for early to mid-stage studies of our rare metabolic disease and IO programs. We continue to build the organization to support scale-up and development towards commercialization. We currently expect to continue to work with contract manufacturing organizations (CMOs) for production of late-stage clinical trial material.

Clinical trial material for our Phase 1 studies of SYNB1020 for hyperammonemia and SYNB1618 for PKU were manufactured by a CMO. These first clinical trials used a liquid formulation as the drug presentation. Since then we have made additional investment in our formulation development that now enables production of both liquid and solid dose formulations for our clinical programs. The solid oral formulation capability allows us to produce a more user-friendly presentation for later stage clinical development and future commercial use. We are continuing to invest and investigate the utility of additional presentations for solid formulations of our Synthetic Biotic medicines including capsules.

To enable the production of high levels of cells, or biomass, we can engineer our Synthetic Biotic medicines with switches. These switches are comprised of transcription factor and promoter pairs that allow for controlled expression of the therapeutic effectors produced by our Synthetic Biotic medicines. To ensure the metabolic capacity of the cells is allotted to the production of a high level of biomass during manufacturing, the effector circuits in the Synthetic Biotic programs are not expressed during this growth phase. At the end of the manufacturing process, the circuits are then induced, or activated. This two-step approach was designed to enable a high level of biomass production as well as to deliver the required activity necessary at the time of administration. We continue to devote resources to process development and the generation of improved products.

31

 

As we progress in clinical development, we will need to increase our scale and eventually to commercial-scale manufacturing. We are in the process of assessing CMOs who meet our criteria to supply our late-stage clinical development and commercial supply. We will compare the merits of working with one or more CMOs who meet our criteria with the possibility of building GMP manufacturing capacity and capabilities internally.

Competition

The biotechnology industry is extremely competitive in the race to develop new products. While we believe we have significant competitive advantages with our industry-leading expertise in synthetic biology and metabolic engineering of non-pathogenic bacteria, our clinical development expertise, and strong intellectual property position, we currently face and will continue to face competition for our development programs from companies that use synthetic biology or cell therapy development platforms and from companies focused on more conventional therapeutic modalities such as small molecules and antibodies. The competition is likely to come from multiple sources, including larger pharmaceutical companies, biotechnology companies and academia. Many of these competitors may have access to greater capital and resources than us. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, in establishing clinical trial sites and patient registration for clinical trials, and in accessing technologies to enable our programs. For any products that we may ultimately commercialize, not only will we compete with any existing therapies and those therapies currently in development, but we will also have to compete with new therapies that may become available in the future.

Competitors include other synthetic biology companies developing other synthetic biology methods, cellular and microbiome-based companies, DNA and RNA-based companies, as well as companies developing small molecules or other biologics. In the case of indications that we are targeting with our own Synthetic Biotic medicines, competitors include, but are not limited to:

 

•

PKU

 

•

BioMarin, Inc. has two approved products and a development stage product;

 

•

PTC Therapeutics, Inc., Nestle Health Sciences S.A. (Codexis, Inc.), and Homology Medicines, Inc. have products in clinical trials;

 

•

Agios Pharmaceuticals, Inc., Generation Bio Co., American Gene Technologies International Inc., Sangamo Therapeutics, Inc., Sanofi, S.A., Trucode Gene Repair, Inc., SOM Biotech SL and others are developing product candidates

 

 

•

Enteric Hyperoxaluria

 

•

Allena Pharmaceuticals, Inc. has a recombinant enzyme in clinical trials;

 

•

Novome Biotechnologies, Inc., Federation Bio, Inc., Oxidien Pharmaceuticals, LLC and others are developing product candidates

 

 

 

•

Immuno-oncology

 

•

The field of immuno-oncology is highly competitive with many companies developing and commercializing a wide range of types of pharmaceutical products and combinations. Companies with STING agonists in clinical development include Merck & Co. Inc., Spring Bank Pharmaceuticals, Inc., GlaxoSmithKline plc., Bristol Myers Squibb Company, and Silicon Therapeutics. Examples of companies developing other modalities which target STING or similar mechanisms include companies such as Roche (Genentech) and Pfizer Inc. / Merck KgaA. Multiple companies develop and market antibodies called checkpoint inhibitors including Pfizer Inc., Roche (Genentech), Merck, Bristol-Myers Squibb Company, Eli Lilly & Co., and others. Other companies are developing and or marketing oncolytic viruses, cancer vaccines, cytotoxic agents, and other approaches to treat cancer.

Our Team: Executives, Founders and Scientific Advisors

Our team of executives has proven track records of successfully translating scientific visions into successful commercial therapeutic products, solving complex issues in developing novel therapeutics and progressing new and novel products through regulatory approval. Our scientific founders, Timothy Lu, M.D., Ph.D., and James Collins, Ph.D., are experts in the emerging field of synthetic biology. In addition to our management team and founders, we have established advisory relationships with researchers and clinicians dedicated to the development of Synthetic Biotic therapeutic products for patients with significant unmet medical needs and whose expertise spans synthetic biology, metabolic engineering, metabolism, immuno-modulation and immuno-oncology arenas. Our

32

 

scientific advisors include Dr. Lu and Dr. Collins; Paul Miller, Ph.D., Christopher Voigt, Ph.D., Cammie Lesser, M.D., Ph.D. and Kristala Prather, Ph.D., experts in synthetic biology and bacterial metabolism. We expect to expand our advisory boards as we grow. All of our founders and advisors are equity holders in us and receive compensation as scientific advisors. Although they are regularly available for scientific consultation, our arrangements with these individuals do not entitle us to any of their existing or future intellectual property derived from their independent research or research with other third parties.

Employees

As of March 18, 2021, we had 72 full-time employees. Of our full-time employees, 60 were primarily engaged in research and development activities. None of our employees are subject to a collective bargaining agreement. We believe that we have good relations with our employees.

Corporate Information and History

We were originally incorporated in the State of Delaware in December 2007 under the name “Mirna Therapeutics, Inc.” We carry on our business directly and through our subsidiaries.

Our subsidiary, Synlogic Operating Company, Inc. was incorporated in Delaware as TMC Therapeutics, Inc. on March 14, 2014. On July 15, 2014, TMC Therapeutics, Inc. changed its name to Synlogic, Inc. (Private Synlogic when referred to prior to the Merger (as defined below)). On July 2, 2015, the common and preferred shareholders of Private Synlogic executed the Synlogic, LLC Contribution Agreement, pursuant to which such common and preferred shareholders contributed such shareholders’ equity interests in Private Synlogic in exchange for common and preferred units in a newly formed parent company named Synlogic, LLC (the 2015 Reorganization). In addition, IBDCo was formed as a subsidiary of Synlogic, LLC, as part of the 2015 Reorganization, and we entered into a license, option and merger agreement with AbbVie for the development of treatments for IBD.

In May 2017, Private Synlogic completed a reorganization (“2017 Reorganization”) pursuant to which Synlogic, LLC merged with and into Private Synlogic, with Private Synlogic continuing as the surviving corporation. Pursuant to the 2017 Reorganization, the common units and preferred units of Synlogic, LLC, together consisting of Class A preferred units, contingently redeemable Class A preferred units and Class B preferred units, were exchanged for common stock and preferred stock of Private Synlogic, respectively. Additionally, Private Synlogic issued equity awards under the Synlogic 2017 Stock Incentive Plan (“2017 Plan”) to replace the canceled incentive units pursuant to the termination of the Synlogic, LLC 2015 Equity Incentive Plan (“2015 LLC Plan”).

On August 28, 2017, Synlogic, Inc., formerly known as Mirna Therapeutics, Inc. (NASDAQ: MIRN) (“Mirna”), completed its business combination with Private Synlogic pursuant to the Agreement and Plan of Merger and Reorganization, dated as of May 15, 2017, by and among Mirna, Meerkat Merger Sub, Inc. (“Merger Sub”), and Private Synlogic (the “Merger Agreement”), pursuant to which Merger Sub merged with and into Private Synlogic, with Private Synlogic surviving as a wholly owned subsidiary of Mirna (the “Merger”). On August 25, 2017, in connection with, and prior to the completion of the Merger, Mirna effected a reverse stock split of its common stock (the “Reverse Stock Split”), and on August 28, 2017, immediately after completion of the Merger, Mirna changed its name to “Synlogic, Inc.” (NASDAQ: SYBX).

Under the terms of the Merger Agreement, Mirna issued shares of its common stock to Private Synlogic’s stockholders, using an exchange ratio, after taking into account the Reverse Stock Split, for each share of Private Synlogic common stock and preferred stock outstanding immediately prior to the Merger (Exchange Ratio). In addition, Mirna assumed all of the stock options outstanding under the Synlogic 2017 Stock Incentive Plan (2017 Plan), with such stock options henceforth representing the right to purchase a number of shares of Mirna’s common stock equal to the Exchange Ratio multiplied by the number of shares of Private Synlogic common stock previously represented by such options. Mirna also assumed the 2017 Plan.

Our Internet address is www.synlogictx.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports, are available to you free of charge through our website as soon as reasonably practicable after such materials have been electronically filed with, or furnished to, the Securities and Exchange Commission (SEC).

 

33

 

 

Item 1A. Risk Factors.

Investing in our common stock involves a high degree of risk. Our business, prospects, financial condition or operating results could be materially adversely affected by the risks identified below, as well as other risks not currently known to us or that we currently consider immaterial. Furthermore, these factors represent risks and uncertainties that could cause actual results to differ materially from those implied by forward-looking statements. Accordingly, in evaluating our business, we encourage you to consider the following discussion of risk factors, in its entirety, in addition to other information contained in this Annual Report on Form 10-K and our other public filings with the SEC. The following risk factors may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future.

In the following discussion of risk factors, References to “we”, “us”, “our” and similar terms refer to the combined business of Synlogic, Inc. after the Merger on August 28, 2017.

Summary of Risk Factors

Our business is subject to numerous risks and uncertainties, including those highlighted in this section below, that represent challenges that we face in connection with the successful implementation of our strategy. The occurrence of one or more of the events or circumstances described in more detail in the risk factors below, alone or in combination with other events or circumstances, may have an adverse effect on our business, cash flows, financial condition and results of operations. Such risks include, but are not limited to:

 

•

We are a clinical-stage biopharmaceutical company with a history of losses, and we expect to continue to incur losses for the foreseeable future, and we may never achieve or maintain profitability.

 

•

We will require substantial additional funding, which may not be available on acceptable terms, or at all.

 

•

Our quarterly and annual operating results may fluctuate in the future. As a result, we may fail to meet the expectations of research analysts or investors, which could cause our stock price to decline.

 

•

Our stock price is volatile and our stockholders may not be able to resell shares of our common stock at or above the price they paid.

 

•

Our short operating history may make it difficult for stockholders to evaluate the success of our business to date and to assess our future viability.

 

•

Clinical trials are costly, time consuming and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.

 

•

The approach we are taking to discover and develop novel therapeutics using synthetic biology to create novel medicines is unproven and may never lead to marketable products.

 

•

Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial viability of an approved label, or result in significant negative consequences following marketing approval, if any.

 

•

Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.

 

•

If we experience delays or difficulties in the enrollment of patients in clinical trials, our costs might be higher than expected and our receipt of necessary regulatory approvals could be delayed or prevented.

 

•

We may face potential product liability claims, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use or misuse of our product candidates harms patients, or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals, if any, could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims. If we are unable to obtain adequate insurance or are required to pay for liabilities resulting from a claim excluded from, or beyond the limits of, our insurance coverage, such liability could adversely affect our financial condition.

 

•

A pandemic, epidemic, or outbreak of an infectious disease, such as COVID-19 may materially and adversely affect our business and our financial results.

 

•

Even if we obtain regulatory approval for a product candidate, we will remain subject to ongoing regulatory requirements.

 

•

We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.

 

•

We may be subject to, or may in the future become subject to, U.S. federal and state, and foreign laws and regulations imposing obligations on how we collect, use, disclose, store and process personal information. Our actual or perceived failure to comply with such obligations could result in liability or reputational harm and could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our customer base, and thereby decrease our revenue.

34

 

 

•

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business, financial condition or results of operations.

 

•

Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.

 

•

Ethical, legal and social concerns about synthetic biology and genetic engineering could limit or prevent the use of our technologies and limit our revenues.

 

•

We may not be successful in obtaining or maintaining necessary rights to Synthetic Biotic medicines, product candidates and processes for our development pipeline through acquisitions and in-licenses.

 

•

We may not have sufficient patent term protections for our product candidates to effectively protect our business.

 

•

If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our proposed markets.

 

•

Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.

 

•

We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful.

 

•

We may be subject to claims challenging the inventorship of our patents and other intellectual property.

 

•

We may not be able to protect our intellectual property rights throughout the world.

 

•

We rely, and expect to continue to rely, on third parties to conduct some aspects of our product formulation, research, preclinical, and clinical studies, and those third parties may not perform satisfactorily, including by failing to meet deadlines for the completion of such formulation, research or testing.

 

•

We rely on third-party supply and manufacturing partners for drug supplies for our late-stage clinical activities, and may do the same for any commercial supplies of our product candidates.

 

•

We may attempt to form collaborations in the future with respect to our product candidates, but we may not be able to do so, which may cause us to alter our development and commercialization plans.

 

•

If the market opportunities for our product candidates are smaller than we believe they are, we may not meet our revenue expectations and, assuming approval of a product candidate, our business may suffer. Because the patient populations in the market for our product candidates may be small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.

 

•

We face substantial competition and our competitors may discover, develop or commercialize products faster or more successfully than us.

 

•

Our employees, independent contractors, principal investigators, CROs, consultants and collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.

 

•

Our employment agreements with our executive officers may require us to pay severance benefits to any of those persons who are terminated in connection with a change of control, which could harm our business, financial condition or results of operations.

 

•

Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.

 

•

Future sales of our common stock or securities convertible or exchangeable for our common stock may depress our stock price.

 

•

Provisions of our charter documents or Delaware law could delay or prevent an acquisition of us, even if the acquisition would be beneficial to our stockholders, and could make it more difficult for you to change management.

 

•

We do not anticipate paying any cash dividends on our common stock in the foreseeable future; therefore, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

 

 

 

Risks Related to Our Financial Condition, Capital Requirements and Operating Results

We are a clinical-stage biopharmaceutical company with a history of losses, and we expect to continue to incur losses for the foreseeable future, and we may never achieve or maintain profitability.

We are a clinical-stage biopharmaceutical company focused on the development of Synthetic Biotic medicines and we have incurred significant operating losses since our inception. Our net loss was approximately $59.2 million and $51.4 million for the fiscal years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated deficit of approximately $230.3 million. To date, we have not generated any product revenue. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We have no products on the market and expect that it will be many years, if ever, before we have a product candidate ready for commercialization.

35

 

We have not generated, and do not expect to generate, any product revenue for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies and clinical trials, the regulatory review process for product candidates, and the development of manufacturing and marketing capabilities for any product candidates approved for commercial sale. The amount of our potential future losses is uncertain. To achieve profitability, we must successfully develop product candidates, obtain regulatory approvals to market and commercialize product candidates, manufacture any approved product candidates on commercially reasonable terms, establish a sales and marketing organization or suitable third-party alternatives for any approved product candidates and raise sufficient funds to finance our business activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease our value and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in our value could also cause our stockholders to lose all or part of their investment.

We will require substantial additional funding, which may not be available on acceptable terms, or at all.

We have used substantial funds to discover and develop our programs and proprietary drug development platform and will require substantial additional funds to conduct further research and development, including preclinical studies and clinical trials of our product candidates, seek regulatory approvals for our product candidates and manufacture and market any products that are approved for commercial sale. Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing research and development and corporate activities. Because we cannot be certain of the length of time or activities associated with successful development and commercialization of our product candidates, we are unable to estimate the actual funds we will require to develop and commercialize them.

We do not expect to realize any appreciable revenue from product sales or royalties in the foreseeable future, if at all. Our revenue sources will remain very limited unless and until our product candidates complete clinical development and are approved for commercialization and successfully marketed. To date, we have primarily financed our operations through sales of our securities, our third-party collaborations and the Merger. We intend to seek additional funding in the future through collaborations, equity or debt financings, credit or loan facilities or a combination of one or more of these financing sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity or convertible debt securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, may involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of equity securities received any distribution of corporate assets.

If we are unable to obtain funding on a timely basis or on acceptable terms, or at all, we may have to delay, limit or terminate our research and development programs and preclinical studies or clinical trials, if any, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our product candidates or technologies that we would otherwise pursue on our own.

Our quarterly and annual operating results may fluctuate in the future. As a result, we may fail to meet the expectations of research analysts or investors, which could cause our stock price to decline.

Our financial condition and operating results may fluctuate from quarter to quarter and year to year in the future due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following factors, as well as factors described elsewhere in this Annual Report on Form 10-K and others:

 

•

our ability to achieve or maintain profitability;

 

•

our ability to develop and maintain Synthetic Biotic technologies;

 

•

our ability to manage our growth;

 

•

the outcomes of research programs, clinical trials, or other product development and approval processes;

 

•

our ability to accurately report our financial results in a timely manner;

 

•

our dependence on, and the need to attract and retain, key management and other personnel;

 

•

our ability to obtain, protect and enforce our intellectual property rights;

 

•

our ability to prevent the theft or misappropriation of our intellectual property, know-how or technologies;

36

 

 

 

•

potential advantages that our competitors and potential competitors may have in securing funding or developing competing technologies or products; and

 

•

our ability to obtain additional capital that may be necessary to expand our business.

Due to the various factors mentioned above, and others, the results of any prior quarterly or annual periods should not be relied upon as indications of our future operating performance.

Our stock price is volatile and our stockholders may not be able to resell shares of our common stock at or above the price they paid.

The trading price of our common stock is highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, such as reports by industry analysts, investor perceptions or negative announcements by other companies involving similar technologies or diseases. These factors also include those discussed in this “Risk Factors” section of this Annual Report on Form 10-K and others such as:

 

•

announcements relating to collaborations that we may enter into with respect to the development or commercialization of our product candidates;

 

•

announcements relating to the receipt, modification or termination of government contracts or grants;

 

•

termination or delay of a development program;

 

•

product liability claims related to our clinical trials or product candidates;

 

•

prevailing economic conditions;

 

•

additions or departures of key personnel;

 

•

business disruptions caused by earthquakes or other natural disasters;

 

•

disputes concerning our intellectual property or other proprietary rights;

 

•

FDA or other U.S. or foreign regulatory actions affecting us or our industry;

 

•

sales of our common stock by the company, our executive officers and directors or our stockholders in the future;

 

•

future sales or issuances of equity or debt securities by us;

 

•

lack of an active, liquid and orderly market in our common stock;

 

•

fluctuations in our quarterly operating results; and

 

•

the issuance of new or changed securities analysts’ reports or recommendations regarding us.

In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that have been often unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our management would be diverted from the operation of our business.

Our short operating history may make it difficult for stockholders to evaluate the success of our business to date and to assess our future viability.

We are a clinical-stage biopharmaceutical company with a limited operating history. We commenced active operations in 2014. Our operations to date have been limited to organizing and staffing our company, research and development activities, business planning and raising capital. In April 2018, we announced that we dosed the first patient in our Phase 1b/2a clinical trial of SYNB1020 for treatment of hyperammonemia in patients with cirrhosis. Based on the data obtained in this clinical trial, the SYNB1020 program was discontinued in August 2019. In April 2018, we dosed our first subject in a Phase 1/2a clinical trial of SYNB1618 which is being developed for the treatment of patients with PKU. In January 2020, we announced that we had dosed the first subject in our Phase 1 clinical trial of SYNB1891 which is being developed for the treatment of patients with solid tumors and lymphoma. In May 2020, we announced the nomination of a clinical candidate for Enteric Hyperoxaluria, SYNB8802. We initiated a Phase 1 clinical trial of SYNB8802 in the fourth quarter of 2020. All of our other therapeutic programs are still in the preclinical development stage. We will need to transition from a company with a research focus to a company capable of supporting clinical

37

 

development and commercial activities. We have not yet demonstrated our ability to successfully complete large-scale, pivotal clinical trials, obtain marketing approvals, manufacture a commercial-scale product, or arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Typically, it takes many years to develop one new product candidate from the time it is discovered to the time that it becomes available for treating patients. We may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors that may hinder our success in commercializing one or more of our product candidates. Further, drug development is a capital-intensive and highly speculative undertaking that involves a substantial degree of risk. You should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in the early stages of development and clinical trials. Any forward-looking statements regarding our future prospects, plans or viability may not be as accurate as they may be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products.

Risks Related to the Development of Our Product Candidates

Clinical trials are costly, time consuming and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.

Clinical development of a product candidate is expensive, time consuming and involves significant risk. We cannot guarantee that any clinical trials we undertake to conduct will be conducted as planned or completed on schedule or at all. A failure of one or more clinical trials can occur at any stage of development. Events that may prevent successful or timely completion of clinical development of our product candidates include but are not limited to:

 

•

inability to generate satisfactory preclinical or other nonclinical data, including, toxicology, or other in vivo or in vitro data or diagnostics to support the initiation or continuation of clinical trials;

 

•

delays in reaching agreement on acceptable terms with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;

 

•

delays in obtaining required institutional review board approval at each clinical trial site;

 

•

failure to permit the conduct of a clinical trial by regulatory authorities, after review of an investigational new drug or equivalent foreign application or amendment;

 

•

delays in recruiting qualified patients in our clinical trials;

 

•

failure by clinical sites or CROs or other third parties to adhere to clinical trial requirements;

 

•

failure by us, clinical sites, CROs or other third parties to perform in accordance with the good clinical practices requirements of the FDA or applicable foreign regulatory guidelines;

 

•

patients dropping out of the clinical trials;

 

•

occurrence of adverse events, unacceptable side effects or toxicity issues associated with our product candidates;

 

•

imposition by the FDA of a clinical hold or the requirement by other similar regulatory agencies that one or more clinical trials be delayed or halted;

 

•

changes in regulatory requirements and guidance that require amending or submitting new clinical protocols or performing additional nonclinical studies;

 

•

the ultimate affordability of the cost of clinical trials of our product candidates;

 

•

negative or inconclusive results from our clinical trials that may result in us deciding, or regulators requiring us, to conduct additional clinical trials or abandon such clinical trials and/or clinical trials or development programs in other ongoing or planned indications for a product candidate; and

 

•

delays in identifying or reaching agreement on acceptable terms with third-party manufacturers, delays in developing and transferring a reproducible, scalable manufacturing process, or delays or failure in manufacturing sufficient quantities of our product candidates for use in clinical trials.

Any inability to successfully complete clinical development and obtain regulatory approval for our product candidates could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional preclinical studies and/or clinical trials, or the results obtained from such new formulation may not be consistent with previous results obtained. Clinical trial delays could also shorten any anticipated periods of patent exclusivity for our product candidates and may allow competitors to develop and bring products to market before we do which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.

38

 

The approach we are taking to discover and develop novel therapeutics using synthetic biology to create novel medicines is unproven and may never lead to marketable products.

The scientific discoveries that form the basis for our efforts to generate and develop our product candidates are relatively recent. The scientific evidence to support the feasibility of developing drugs based on our approach is both preliminary and limited. Synthetic Biotic medicines represent a novel therapeutic modality and their successful development by us may require additional studies and efforts to optimize their therapeutic potential. Any product candidates that we develop may not demonstrate in patients the therapeutic properties ascribed to them in laboratory and other preclinical studies, and they may interact with human biological systems in unforeseen, ineffective or even harmful ways. If we are not able to successfully develop and commercialize product candidates based upon this technological approach, we may never become profitable and the value of our capital stock may decline.

Our Synthetic Biotic product candidates are based on a relatively novel technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if at all.

We have concentrated our research and development efforts to date on a limited number of product candidates based on our Synthetic Biotic therapeutic platform and identifying our initial targeted disease indications. Our future success depends on our successful development of viable product candidates. There can be no assurance that we will not experience problems or delays in developing our product candidates and that such problems or delays will not cause unanticipated costs, or that any such development problems can be solved.

The clinical trial and manufacturing requirements of the FDA, the European Medicines Agency and other regulatory authorities, and the criteria these regulators use to determine the safety and efficacy of a product candidate, vary substantially according to the type, complexity, novelty and intended use and market of the product candidate. The regulatory approval process for novel product candidates such as Synthetic Biotic medicines may be more expensive and take longer than for other, better known or more extensively studied therapeutic modalities. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in either the United States or the European Union or how long it will take to commercialize our product candidates, even if approved for marketing. Approvals by the European Medicines Agency or national regulatory agencies may not be indicative of what the FDA, and vice versa, may require for approval and different or additional preclinical studies or clinical trials may be required to support regulatory approval in each respective jurisdiction. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product candidate to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects may be harmed.

We may not be successful in our efforts to use and expand our development platform to build a pipeline of product candidates.

A key element of our strategy is to use our targeted focus and experienced management and scientific team to create Synthetic Biotic medicines that can be deployed against a broad range of human diseases in order to build a pipeline of product candidates. Although our research and development efforts to date have resulted in potential product candidates, we may not be able to continue to identify and develop additional product candidates. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development. For example, these potential product candidates may be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize product candidates based upon our approach, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position. There is no assurance that we will be successful in our preclinical and clinical development, and the process of obtaining regulatory approvals will, in any event, require the expenditure of substantial time and financial resources.

Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial viability of an approved label, or result in significant negative consequences following marketing approval, if any.

Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or terminate our clinical trials or result in a restrictive label or delay regulatory approval by the FDA or comparable foreign authorities. Undesirable side effects and negative results for other indications may negatively impact the development and potential for approval of our product candidates for their proposed indications.

Additionally, even if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, potentially significant negative consequences could result, including but not limited to:

 

•

regulatory authorities may withdraw approvals of or revoke licenses for such products;

 

•

regulatory authorities may require additional warnings on the labels of such products;

39

 

 

 

•

we may be required to create a REMS plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;

 

•

we could be sued and held liable for harm caused to patients; and

 

•

our reputation may suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, even if approved, and could significantly harm our business, results of operations, and prospects.

Our product development program may not uncover all possible adverse events that patients who take our product candidates may experience. The number of subjects exposed to our product candidates during clinical trials and the average exposure time in the clinical development program may be inadequate to detect rare adverse events, or chance findings, that may only be detected once the product is administered to more patients and for greater periods of time.

Clinical trials by their nature use a sample of the potential patient population. However, with a limited number of patients and limited duration of exposure, we cannot be fully assured that uncommon or severe side effects of our product candidates will be uncovered. Such side effects may only be uncovered with a significantly larger number of patients exposed to the drug. If such safety problems occur or are identified after a product candidate reaches the market, the FDA may require that we amend the labeling of the product or recall the product, or may even withdraw approval for the product. Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, even if approved, and could significantly harm our business, results of operations, and prospects.

We are heavily dependent on the success of our product candidates. Some of our product candidates have produced results in preclinical settings to date, but none of our product candidates has completed all required clinical trials, and we cannot give any assurance that we will generate data for any of our product candidates sufficient to receive regulatory approval in our planned indications, which will be required before they can be commercialized.

We have invested substantially all of our efforts and financial resources to identify, acquire and develop our portfolio of product candidates. Our future success is dependent on our ability to successfully further develop, obtain regulatory approval for, and commercialize one or more product candidates. We currently generate no revenue from sales of any products, and we may never be able to develop or commercialize a product candidate.

On August 20, 2019, we announced that we were discontinuing our first therapeutic program to enter clinical trials, SYNB1020, an early stage clinical product candidate for the treatment of hyperammonemia. The decision to discontinue the program was based on top-line data from an interim analysis of a randomized, double-blind, placebo-controlled Phase 1b/2a study of the Synthetic Biotic medicine in 23 patients with cirrhosis and elevated blood ammonia. While SYNB1020 was well tolerated in Phase 1b/2a study, the study showed it did not lower blood ammonia in patients with cirrhosis. As a result, we have become more dependent on the success of our SYNB1618, SYNB1891 and SYNB8802 programs and new early development programs.

In addition, none of our product candidates has advanced into any pivotal clinical trial for our proposed indications and it may be years before any pivotal clinical trials are initiated and completed, if at all. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. We cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.

If we fail to obtain or maintain orphan drug exclusivity for some of our products, our competitors may obtain approval to sell competing drugs to treat the same conditions and our revenues will be reduced.

As part of our business strategy, we have developed and may in the future develop product candidates that may be eligible for FDA and European Commission orphan drug designation. In October 2017, the FDA granted orphan drug designation to SYNB1618 for the treatment of PKU. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat, diagnose or prevent rare diseases or conditions that affect fewer than 200,000 people in the United States. In the EU, orphan drug designation may be granted to drugs intended to treat, diagnose or prevent a life-threatening or chronically debilitating disease having a prevalence of no more than five in 10,000 people in the EU. The company that first obtains FDA approval for a designated orphan drug for the associated rare disease receives marketing exclusivity for use of that drug for the stated condition for a period of seven years. Orphan drug exclusive marketing rights may be lost under several circumstances, including a later determination by the FDA that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug. Similar regulations are in effect in the EU with a ten-year period of market exclusivity.

40

 

Because the extent and scope of patent protection for some of our product candidates may be limited, obtaining orphan drug designation is especially important for any product candidates that may be eligible for orphan drug designation. For eligible products, we plan to rely on the exclusivity period under the Orphan Drug Act to maintain a competitive position. If we do not obtain orphan drug designation for our product candidates that do not have broad patent protection, our competitors may then seek to sell a competing drug to treat the same condition and our revenues, if any, may be adversely affected thereby.

Even though we have obtained orphan drug designation for certain of our product candidates and intend to seek orphan drug designation for other product candidates, there is no assurance that we will be the first to obtain marketing approval for any particular rare indication. Further, even though we have obtained orphan drug designation for certain of our product candidates, or even if we obtain orphan drug designation for other potential product candidates, such designation may not effectively protect us from competition because different drugs can be approved for the same condition and the same drug can be approved for different conditions and potentially used off-label in the orphan indication. Even after an orphan drug is approved, the FDA can subsequently approve a competing drug for the same condition for several reasons, including, if the FDA concludes that the later drug is safer or more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process.

Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.

The results from preclinical studies or early clinical trials of a product candidate may not predict the results that will be obtained in subsequent subjects or in later stage clinical trials of that product candidate or any other product candidate. Flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and we may be unable to design and execute clinical trials to support regulatory approval of our product candidates. In addition, preclinical study and clinical trial data are often susceptible to varying interpretations and analyses. Product candidates that seemingly perform satisfactorily in preclinical studies and clinical trials may nonetheless fail to obtain regulatory approval. There is a high failure rate for drugs proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development could negatively affect our business and operating results.

If we experience delays or difficulties in the enrollment of patients in clinical trials, our costs might be higher than expected and our receipt of necessary regulatory approvals could be delayed or prevented.

Clinical trials of a new product candidate require the enrollment of a sufficient number of patients suffering from the disease or condition the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the potential patient population, the age and condition of the patients, the stage and severity of disease or condition, the nature and requirements of the protocol, the proximity of patients to clinical sites, the availability of effective treatments for the relevant disease or condition, the perceived risks, benefits and convenience of administration of the product candidate being studied, the patient referral practices of physicians, our efforts to facilitate timely enrollment in clinical trials, and the eligibility criteria for the clinical trial. Delays or difficulties in patient enrollment or difficulties retaining trial participants, including as a result of the availability of existing or other investigational treatments, can result in increased costs, longer development times or termination of a clinical trial.

In addition, our success may depend, in part, on our ability to identify patients who qualify for our clinical trials, or are likely to benefit from any product candidate that we may develop, which will require those potential patients to undergo a screening assay for the presence or absence of a particular genetic sequence or clinical trait. Genetically defined diseases generally, and especially those for which our current product candidates are targeted, may have relatively low prevalence. For example, we estimate there are approximately 16,500 patients that may be diagnosed with PKU in the United States. If we, or any third parties that we engage to assist us, are unable to successfully identify patients with these diseases, or experience delays in doing so, then we may not realize the full commercial potential of any product candidate we develop.

41

 

We may face potential product liability claims, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use or misuse of our product candidates harms patients, or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals, if any, could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims. If we are unable to obtain adequate insurance or are required to pay for liabilities resulting from a claim excluded from, or beyond the limits of, our insurance coverage, such liability could adversely affect our financial condition.

The use or misuse of our product candidates in clinical trials and the sale of any products for which we may obtain marketing approval exposes us to the risk of potential product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our product candidates and approved products, if any. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. Patients with the diseases targeted by our product candidates may already be in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which an adverse event is unrelated to our product candidates, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may delay our regulatory approval process or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.

Although we have product liability insurance, which covers any clinical trial we may conduct in the United States, our insurance may be insufficient to reimburse us for any expenses or losses we may suffer. We will also likely be required to increase our product liability insurance coverage for the advanced clinical trials that we plan to initiate. If we obtain marketing approval for any of our product candidates, we will need to expand our insurance coverage to include the sale of commercial products. There is no way to know if we will be able to continue to obtain product liability coverage and obtain expanded coverage we may require, in sufficient amounts to protect us against losses due to liability, on acceptable terms, or at all. We may not have sufficient resources to pay for any liabilities resulting from a claim excluded from, or beyond the limits of, our insurance coverage. Where we have provided indemnities in favor of third parties under our agreements with them, there is also a risk that these third parties could incur liability and bring a claim under such indemnities. An individual may bring a product liability claim against us alleging that one of our product candidates or products causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts. Any product liability claim brought against us, with or without merit, could result in:

 

•

withdrawal of clinical trial volunteers, investigators, patients or trial sites or limitations on approved indications;

 

•

the inability to commercialize, or if commercialized, decreased demand for, our product candidates;

 

•

if commercialized, product recalls, withdrawals of labeling, marketing or promotional restrictions or the need for product modification;

 

•

initiation of investigations by regulators;

 

•

loss of revenues;

 

•

substantial costs of litigation, including monetary awards to patients or other claimants;

 

•

liabilities that substantially exceed our product liability insurance, which we would then be required to pay ourselves;

 

•

an increase in our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, if at all;

 

•

the diversion of management’s attention from our business; and

 

•

damage to our reputation and the reputation of our products and our technology.

Product liability claims may subject us to the foregoing and other risks, which could have a material adverse effect on our business, financial condition or results of operations.

42

 

We or the third parties upon which we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Earthquakes or other natural disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business.

A pandemic, epidemic, or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect our business and our financial results.

The coronavirus outbreak has affected segments of the global economy and may materially affect our operations, including potentially significant interruption of our clinical trial activities. COVID-19 originated in Wuhan, China, in December 2019 the virus has since spread to multiple countries, including the United States, where we are currently conducting our clinical trials. The continued spread of the coronavirus may result in a period of business disruption, including material delays in our clinical trials. In addition, there could be a potential effect of COVID-19 to the business at FDA or other health authorities, which could result in delays of reviews and approvals, including with respect to our product candidates.

The continued spread globally could also have a material adverse effect our clinical trial operations in the United States and elsewhere, including our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography.

We are closely monitoring the potential impact of the coronavirus outbreak, and the associated restrictions on travel and work that have been implemented, on our business and pre-clinical and clinical trials. The extent to which the coronavirus impacts us will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. Over the coming weeks and months, we will continue to carefully monitor the situation with respect to each of our clinical trials and follow guidance from local and federal health authorities.

COVID-19 may also affect employees of third-party contract research organizations and contract manufacturing organizations located in affected geographies that we rely upon to carry out our clinical trials. In addition, we have taken precautionary measures, and may take additional measures, intended to help minimize the risk of the virus to our employees, including temporarily requiring all employees to work remotely, suspending all non-essential travel worldwide for our employees, and discouraging employee attendance at industry events and in-person work-related meetings, which could negatively affect our business.

We cannot presently predict the extent to which current or future business shutdowns and disruptions may impact or limit our ability or the ability of any of the third parties with which we engage to conduct business in the manner and on the timelines presently planned. Any such impacts or limitations could have a material adverse impact on our business and our results of operation and financial condition. While the potential economic impact brought by and the duration of the coronavirus outbreak may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.

Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters

We may seek breakthrough therapy designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.

We may seek a breakthrough therapy designation from the FDA for some of our product candidates. A breakthrough therapy is defined as a drug or biological product that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and for which preliminary clinical evidence indicates that the drug or biological product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs or biological products that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development. Drugs designated as breakthrough therapies by the FDA could also be eligible for accelerated approval.

43

 

Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify and are designated as breakthrough therapies, the FDA may later decide that the drugs or biological products no longer meet the conditions for designation and the designation may be rescinded.

We may seek Fast Track designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process.

If a product candidate is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for the condition, a product sponsor may apply for FDA Fast-Track designation. We were awarded Fast-Track designation for SYNB1618 in April 2018. Fast-Track designation does not ensure that we will receive marketing approval for the product candidate or that approval will be granted within any particular timeframe. We may not experience a faster development or regulatory review or approval process with Fast-Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast-Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast-Track designation alone does not guarantee qualification for the FDA’s priority review procedures.

Even if we obtain regulatory approval for a product candidate, we will remain subject to ongoing regulatory requirements.

If any of our product candidates are approved for marketing, we will be subject to ongoing regulatory requirements, including with respect to manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing clinical trials, and submission of safety, efficacy and other post-approval information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.

Manufacturers and manufacturers’ facilities are required to continuously comply with FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices (GMP) regulations and corresponding foreign regulatory manufacturing requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with GMP and adherence to commitments made in any BLA or marketing authorization application.

Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product candidate may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. We will be required to report adverse reactions and production problems, if any, to the FDA and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. If our original marketing approval for a product candidate was obtained through an accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial in order to confirm the clinical benefit for our products. An unsuccessful post-marketing clinical trial or failure to complete such a trial could result in the withdrawal of marketing approval.

If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, the regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:

 

•

issue warning letters;

 

•

impose civil or criminal penalties;

 

•

suspend or withdraw regulatory approval or revoke a license;

 

•

suspend any of our ongoing clinical trials;

 

•

refuse to approve pending applications or supplements to approved applications submitted by us;

 

•

impose restrictions on our operations, including closing our contract manufacturers’ facilities; or

 

•

require a product recall.

44

 

 

Any government investigation of alleged violations of law would be expected to require us to expend significant time and resources in response and could generate adverse publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to develop and commercialize our products and our value and operating results would be adversely affected.

Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, upon completion of this offering and in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

Healthcare legislative reform measures may have a material adverse effect on our financial condition or results of operations.

In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA, was passed, which was intended to substantially change the way health care is financed by both governmental health programs and private insurers, and significantly impact the U.S. pharmaceutical industry. The ACA, among other things, introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of specified branded prescription drugs, and promotes a new Medicare Part D coverage gap discount program.

The ACA has been under scrutiny by the U.S. Congress almost since its passage, and certain sections of the ACA have not been fully implemented or effectively repealed. As a result, its longevity continues to be uncertain. In addition, ongoing initiatives in the U.S. have increased and will continue to increase pressure on drug pricing. The announcement or adoption of any such initiative could have an adverse effect on potential revenues from any product candidate that we may successfully develop.

It is anticipated that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and an additional downward pressure on the reimbursement our customers may receive for our products. Further, there have been judicial and Congressional challenges to certain aspects of the ACA, and it is expected there will be additional challenges and amendments to the ACA in the future, especially with the recent change in administration. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.

45

 

We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.

If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and regulations. These laws may impact, among other things, our proposed sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:

 

•

the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;

 

•

federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;

 

•

the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;

 

•

HIPAA, as amended by the Health Information Technology and Clinical Health Act, and its implementing regulations, which imposes specified requirements relating to the privacy, security, and transmission of individually identifiable health information;

 

•

the federal physician sunshine requirements under the ACA require manufacturers of drugs, devices, biologics, and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations; and

 

•

state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including governmental and private payors, to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. For example, the ACA, among other things, amends the intent requirement of the federal anti-kickback and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the False Claims Act.

If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

We may be subject to, or may in the future become subject to, U.S. federal and state, and foreign laws and regulations imposing obligations on how we collect, use, disclose, store and process personal information. Our actual or perceived failure to comply with such obligations could result in liability or reputational harm and could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our customer base, and thereby decrease our revenue.

In many activities, including the conduct of clinical trials, we are subject to laws and regulations governing data privacy and the protection of health-related and other personal information. These laws and regulations govern our processing of personal data, including the collection, access, use, analysis, modification, storage, transfer, security breach notification, destruction and disposal of personal data. We must comply with laws and regulations associated with the international transfer of personal data based on the

46

 

location in which the personal data originates and the location in which it is processed. Although there are legal mechanisms to facilitate the transfer of personal data from the European Economic Area (EEA), and Switzerland to the United States, the decision of the European Court of Justice that invalidated the safe harbor framework has increased uncertainty around compliance with EU privacy law requirements. As a result of the decision, it was no longer possible to rely on safe harbor certification as a legal basis for the transfer of personal data from the European Union to entities in the United States. In February 2016, the European Commission announced an agreement with the Department of Commerce, or DOC, to replace the invalidated safe harbor framework with a new EU-U.S. “Privacy Shield.” On July 12, 2016, the European Commission adopted a decision on the adequacy of the protection provided by the Privacy Shield. The Privacy Shield is intended to address the requirements set out by the European Court of Justice in its recent ruling by imposing more stringent obligations on companies, providing stronger monitoring and enforcement by the DOC and Federal Trade Commission and making commitments on the part of public authorities regarding access to information.

The privacy and security of personally identifiable information stored, maintained, received or transmitted, including electronically, is subject to significant regulation in the United States and abroad. While we strive to comply with all applicable privacy and security laws and regulations, legal standards for privacy continue to evolve and any failure or perceived failure to comply may result in proceedings or actions against us by government entities or others, or could cause reputational harm, which could have a material adverse effect on our business.

Numerous foreign, federal and state laws and regulations govern collection, dissemination, use and confidentiality of personally identifiable health information, including state privacy and confidentiality laws (including state laws requiring disclosure of breaches); federal and state consumer protection and employment laws; HIPAA; and European and other foreign data protection laws. These laws and regulations are increasing in complexity and number, may change frequently and sometimes conflict.

HIPAA establishes a set of national privacy and security standards for the protection of individually identifiable health information, including protected health information, or PHI, by health plans, certain healthcare clearinghouses and healthcare providers that submit certain covered transactions electronically, or covered entities, and their ‘‘business associates,’’ which are persons or entities that perform certain services for, or on behalf of, a covered entity that involve creating, receiving, maintaining or transmitting PHI. While we are not currently a covered entity or business associate under HIPAA, we may receive identifiable information from these entities. Failure to receive this information properly could subject us to HIPAA’s criminal penalties, which may include fines up to $250,000 per violation and/or imprisonment. In addition, responding to government investigations regarding alleged violations of these and other laws and regulations, even if ultimately concluded with no findings of violations or no penalties imposed, can consume company resources and impact our business and, if public, harm our reputation.

In addition, various states, such as California and Massachusetts, have implemented similar privacy laws and regulations, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. California’s patient privacy laws, for example, provide for penalties of up to $250,000 and permit injured parties to sue for damages. The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and our clients and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on privacy issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify.

In addition, the interpretation and application of consumer, health-related, and data protection laws are often uncertain, contradictory, and in flux.

U.S.-based companies may certify compliance with the privacy principles of the Privacy Shield. Certification to the Privacy Shield, however, is not mandatory. If a U.S.-based company does not certify compliance with the Privacy Shield, it may rely on other authorized mechanisms to transfer personal data.

The privacy and data security landscape is still in flux. In October 2016, an action for annulment of the European Commission decision on the adequacy of Privacy Shield was brought before the European Court of Justice by three French digital rights advocacy groups, La Quadrature du Net, French Data Network and the Fédération FDN. This case, Case T738/16, is currently pending before the European Court of Justice. Should the European Court of Justice invalidate the Privacy Shield, it will no longer be possible to transfer data from the European Union to entities in the United States under a Privacy Shield certification, in which case other legal mechanisms would need to be put in place.

In addition, the European Parliament and the Council of the European Union adopted a comprehensive general data privacy regulation ("GDPR") in 2016 to replace the current European Union Data Protection Directive and related country-specific legislation. The GDPR took effect in May 2018 and governs the collection and use of personal data in the European Union. The GDPR, which is

47

 

wide-ranging in scope, will impose several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States, enhances enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to €20 million or 4% of the annual global revenues of the infringer, whichever is greater.

The legislative and regulatory landscape for privacy and data security continues to evolve, and there has been an increasing focus on privacy and data security issues which may affect our business. Failure to comply with current and future laws and regulations could result in government enforcement actions (including the imposition of significant penalties), criminal and civil liability for us and our officers and directors, private litigation and/or adverse publicity that negatively affects our business.

In the United States, California recently adopted the California Consumer Privacy Act of 2018, or CCPA, which came into effect beginning in January 2020. The CCPA has been characterized as the first “GDPR-like” privacy statute to be enacted in the United States because it mirrors a number of the key provisions of the EU General Data Protection Regulation. The CCPA establishes a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the State of California, imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business, financial condition or results of operations.

Our research and development activities and our third-party manufacturers’ and suppliers’ activities involve the controlled storage, use, and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers’ facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our research and development efforts, commercialization efforts and business operations and environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of specified materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently, and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. Given the nature of the research and development work conducted by us, we do not currently carry biological or hazardous waste insurance coverage.

 

Laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop, implement and maintain costly compliance programs.

To develop, manufacture and sell certain products outside the United States, we must dedicate resources to comply with numerous laws and regulations in each jurisdiction in which we operate. The Foreign Corrupt Practices Act (FCPA), prohibits any United States individual or business from paying, offering, authorizing payment or offering anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.

Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees may be considered government employees or foreign officials. In other circumstances, certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.

Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-United States nationals, of information classified for national security purposes, as well as certain products and

48

 

technical data relating to those products. These laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the U.S., which could limit our growth potential and increase our development costs.

The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA’s accounting provisions and export control laws.

Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.

Our internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of preclinical or clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of our product candidates could be delayed.

Ethical, legal and social concerns about synthetic biology and genetic engineering could limit or prevent the use of our technologies and limit our revenues.

Our technologies involve the use of synthetic biology and genetic engineering. Public perception about the safety and environmental hazards of, and ethical concerns over, synthetic biology and genetic engineering could influence public acceptance of our technologies, product candidates and processes. If we and our collaborators are not able to overcome the ethical, legal and social concerns relating to synthetic biology and genetic engineering, our technologies, product candidates and processes may not be accepted. These concerns could result in increased expenses, regulatory scrutiny and increased regulation, trade restrictions on imports of Synthetic Biotic medicines, delays or other impediments to our programs or the public acceptance and commercialization of Synthetic Biotic medicines. Further, there is a risk that Synthetic Biotic medicines made using our technologies could result in adverse health effects or other adverse events, which could also lead to negative publicity. We design and produce product candidates with characteristics comparable or disadvantaged to those found in naturally occurring organisms or enzymes in a controlled laboratory; however, the release of such organisms into uncontrolled environments could have unintended consequences. Any adverse effect resulting from such a release could have a material adverse effect on our business, financial condition or results of operations and we may have exposure to liability for any resulting harm.

Risks Related to Our Intellectual Property

We may not be successful in obtaining or maintaining necessary rights to Synthetic Biotic medicines, product candidates and processes for our development pipeline through acquisitions and in-licenses.

Presently, we have rights to certain intellectual property, through licenses from third parties and under patents and patent applications owned by us. The growth of our business will likely depend in part on our ability to obtain, maintain or enforce our and our licensors’ intellectual property rights and to acquire or in-license additional proprietary rights. For example, our programs may involve additional product candidates or delivery systems that may require the use of additional proprietary rights held by third parties. Our ultimate product candidates may also require specific formulations to work effectively and efficiently. These formulations may be covered by intellectual property rights held by others. We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business operations.

In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by other third parties. We may be unable to develop, acquire or in-license compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of other companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These companies could have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.

For example, we have previously and may continue to collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide an option to negotiate a license to any of the institution’s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for

49

 

intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to it. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.

In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to third-party intellectual property rights, our business, financial condition and prospects for growth could suffer.

We intend to rely on patent rights and the status of our product candidates, if approved, as biologics eligible for exclusivity under the Biologics Price Competition and Innovation Act (BPCIA). If Synlogic is unable to obtain or maintain exclusivity from the combination of these approaches, Synlogic may not be able to compete effectively in our markets.

We rely or will rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect the intellectual property related to our technologies and product candidates. Our success depends in large part on our and our licensors’ ability to obtain regulatory exclusivity and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technology and products.

We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates that are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unsolved. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.

We, independently or together with our licensors, have filed several patent applications covering various aspects of our product candidates. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.

Even if we cannot obtain and maintain effective protection of exclusivity from our regulatory efforts and intellectual property rights, including patent protection, data exclusivity or orphan drug exclusivity, for our product candidates, we believe that our product candidates will be protected by exclusivity that prevents approval of a biosimilar in the United States for a period of twelve years from the time the product to which it claims similarity was first approved. However, The Biologics Price Competition and Innovation Act of 2009, Title VII, Subtitle A of the Patent Protection and Affordable Care Act, Pub.L.No.111-148, 124 Stat.119, Sections 7001-02 signed into law March 23, 2010, and codified in 42 U.S.C. §262 (the BPCIA), created an elaborate and complex patent dispute resolution mechanism for biosimilars that could prevent us from launching our product candidates in the United States or could substantially delay such launches. Current biosimilars litigation are addressing certain requirements of the BPCIA which is creating uncertainty over how certain terms of the BPCIA should be construed and this, presents uncertainty for both the biologics innovator and biosimilar party. The BPCIA mechanism required for biosimilar applicants may pose greater risk that patent infringement litigation will disrupt our activities and add increased expenses as well as divert management’s attention. If a biosimilar version of one of our product candidates were approved in the United States, it could have a negative effect on our business.

We may not have sufficient patent term protections for our product candidates to effectively protect our business.

Patents have a limited term. In the United States, the statutory expiration of a patent is generally 20 years after it is filed. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition. In addition, upon issuance in the United States any patent term can be adjusted based on specified delays caused by the applicant(s) or the USPTO.

50

 

Patent term extensions under the Hatch-Waxman Act in the United States and under supplementary protection certificates in Europe may be available to extend the patent or data exclusivity terms of our product candidates. We will likely seek patent term extensions, and we cannot provide any assurances that any such patent term extensions will be obtained and, if so, for how long. As a result, we may not be able to maintain exclusivity for our product candidates for an extended period after regulatory approval, if any, which would negatively impact our business, financial condition, results of operations and prospects. If we do not have sufficient patent terms or regulatory exclusivity to protect our product candidates, our business and results of operations will be adversely affected.

Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products, and recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.

As is the case with other biotechnology companies, our success is heavily dependent on patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in specified circumstances and weakened the rights of patent owners in specified situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.

If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our proposed markets.

In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent. We also utilize processes for which patents are difficult to enforce. In addition, other elements of our products, and many elements of our product candidate discovery and development processes involve proprietary know-how, information or technology that is not covered by patents. Trade secrets may be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, collaborators, advisors, independent contractors or other third parties. We also seek to preserve the integrity and confidentiality of our data and trade secrets, including by maintaining physical and electronic security of our premises and our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, or misappropriation of our intellectual property by third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, and financial condition.

Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, collaborators, advisors, independent contractors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business, financial condition or results of operations. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.

Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.

Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technology without infringing the patent rights of third parties. Numerous third-party U.S. and non-U.S. issued patents and pending applications exist in the area of Synthetic Biotic medicines. We are aware of U.S. and foreign patents and pending patent applications owned by third parties that cover similar therapeutic uses as the product candidates we are developing. We are currently monitoring these patents and patent applications. We may in the future pursue available proceedings in the U.S. and foreign patent offices to challenge the validity of these patents and patent applications. In addition, or alternatively, we may consider whether to seek to negotiate a license of rights to technology covered by one or more of such patents and patent applications. If any patents or patent

51

 

applications cover our product candidates or technologies, we may not be free to manufacture or market our product candidates as planned, absent such a license, which may not be available to us on commercially reasonable terms, or at all.

It is also possible that we have failed to identify relevant third-party patents or applications. For example, applications filed before November 29, 2000 and applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our product candidates and technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patents may issue with claims of relevance to our technology. In addition, we may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of a current or future product candidate, or we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to specified limitations, be later amended in a manner that could cover our technologies, our product candidates or the use of our product candidates.

There have been many lawsuits and other proceedings filed by third parties involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, and reexamination, post-grant review and equivalent proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.

We depend, in part, on our licensors to file, prosecute, maintain, defend and enforce patents and patent applications that are material to our business.

While we normally seek and gain the right to fully prosecute the patent applications relating to our product candidates, there may be times when the patent applications enabling our product candidates are controlled by our licensors. If any of our existing or future licensors fail to appropriately and broadly prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using, importing, and selling competing products. In addition, even where we now have the right to control patent prosecution of patents and patent applications we have licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors in effect from actions prior to us assuming control over patent prosecution.

If we fail to comply with obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.

We are a party to certain intellectual property license agreements and expect to enter into additional license agreements in the future. Our existing agreements impose, and future license agreements may impose, certain obligations, including the payment of milestones and royalties based on revenues from sales of our products utilizing the technologies licensed from our licensors, and such obligations could adversely affect the overall profitability for us of any products that we may seek to commercialize. In addition, we will need to outsource and rely on third parties for many aspects of the clinical development, sales and marketing of our product candidates covered under our license agreements. Delay or failure by these third parties could adversely affect the continuation of our license agreements with our third-party licensors. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, these agreements may be subject to termination by the licensor which could have a material adverse effect on our business.

We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful.

Competitors may infringe our patents or the patents of our licensors. To cease such infringement or unauthorized use, we or one of our licensing partners may be required to file patent infringement claims against a third-party to enforce one of our patents which

52

 

can be expensive, time-consuming and unpredictable. In addition, in an infringement proceeding or a declaratory judgment action against us, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.

If we or one of our licensing partners were to initiate legal proceedings against a third-party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, clarity or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or other jurisdictions, even outside the context of litigation. Such mechanisms include re-examination, inter partes review, post-grant review and equivalent proceedings in foreign jurisdictions, such as opposition or derivation proceedings. Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity, unpatentability and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business.

Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions or correct inventorship with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to us from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation, derivation or interference proceedings may result in a decision adverse to our interests and, even if successful, may result in substantial costs and distract our management and other employees. In addition, we may be unable to raise the funds necessary to conduct our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. Any disclosure of confidential information could adversely affect our business. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.

We may be subject to claims challenging the inventorship of our patents and other intellectual property.

We may in the future be subject to claims that former employees, consultants, collaborators, advisors, independent contractors or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor or other claims challenging the inventorship of our patents or ownership of our intellectual property (including patents and intellectual property that we in-license). Therefore, our rights to these patents may not be exclusive and third parties, including competitors, may have access to intellectual property that is important to our business. In addition, co-owners from whom we do not yet have a license or assignment may raise claims surrounding inventorship or ownership of patents that ultimately issue from this patent family, potentially resulting in issued patents to which we would not have rights under our existing license agreements. Further, in jurisdictions outside the United States, a license may not be enforceable unless all the owners of the intellectual property agree or consent to the license. In addition, we may have inventorship disputes arising from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship of our patents. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

53

 

We may be subject to claims that our employees, consultants, collaborators, advisors, independent contractors or other third parties have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at universities, academic research institutions and at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we have written agreements with and make every effort to ensure that our employees, consultants, collaborators, advisors, independent contractors or other third parties do not use the proprietary information or intellectual property rights of others in their work for us, we may in the future be subject to claims that our employees, consultants, collaborators, advisors, independent contractors or other third parties have inadvertently or intentionally used or disclosed confidential information of these third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

We may not be able to protect our intellectual property rights throughout the world.

We have limited intellectual property rights outside the United States. Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and intellectual property rights in some countries outside the United States can have a different scope and strength and be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties (including competitors) from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but where enforcement rights are not as strong as those in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries, particularly some developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult in those jurisdictions for us to stop the infringement or misappropriation of our patents or other intellectual property rights, or the marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patents and other intellectual property rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, such proceedings could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing and could provoke third parties to assert claims of infringement or misappropriation against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

We have filed for trademark registration of certain marks relating to our current branding. If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Our unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our unregistered trademarks or trade names. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.

54

 

Risks Related to Our Reliance on Third Parties

We rely, and expect to continue to rely, on third parties to conduct some aspects of our product formulation, research, preclinical, and clinical studies, and those third parties may not perform satisfactorily, including by failing to meet deadlines for the completion of such formulation, research or testing.

We do not independently conduct all aspects of our drug discovery activities, compound development or preclinical studies of product candidates. We currently rely, and expect to continue to rely, on third parties to conduct some aspects of our research and development and preclinical studies. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities. Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, for product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our studies that support our clinical trial applications and our clinical trials are conducted in accordance with the study plan and protocols for the trial. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the necessary preclinical studies to enable us or our strategic alliance partners to select viable product candidates for clinical trial application submissions and will not be able to, or may be delayed in our efforts to, successfully develop and commercialize such product candidates.

We rely on third-party supply and manufacturing partners for drug supplies for our late-stage clinical activities, and may do the same for any commercial supplies of our product candidates.

We rely on third-party supply and manufacturing partners to supply the materials and components to manufacture late-stage clinical trial drug supplies. We have not yet manufactured or formulated any product candidate on a commercial scale and may not be able to do so for any of our product candidates. We will work to develop and optimize our manufacturing process, and we cannot be sure that the process will result in therapies that are safe, potent or effective.

There can be no assurance that our supply of research and development, preclinical and clinical development drugs and other materials will not be limited, interrupted, restricted in certain geographic regions or of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of any product formulation manufacturer we may engage could require significant effort and expertise because there may be a limited number of qualified replacements.

Synthetic Biotic medicines are complex and difficult to manufacture. We could experience production or technology transfer problems that result in delays in our development or commercialization schedules or otherwise adversely affect our business. Issues with the manufacturing process, even minor deviations from the normal process, could result in insufficient yield, product deficiencies or manufacturing failures that result in lot failures, insufficient inventory, and product recalls.

Many factors common to the manufacturing of most biologics and drugs could also cause production interruptions, including raw materials shortages, raw material failures, growth media failures, equipment malfunctions, facility contamination, labor problems, natural disasters, disruption in utility services, terrorist activities, or acts of god beyond our control. We also may encounter problems in hiring and retaining the experienced specialized personnel needed to operate our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.

Any problems in our manufacturing processes or facilities could make us a less attractive collaborator for academic research institutions and other parties, which could limit our access to additional attractive development programs, result in delays in our clinical development or marketing schedules and harm our business.

The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as GMP regulations. Any of our suppliers or manufacturers could fail to comply with such requirements or to perform our obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials could become limited or interrupted for other reasons. Under these circumstances, we may choose or be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, manufacture in collaboration with a third-party at their facilities, or enter into an agreement with another third-party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from transferring such skills or technology to another third-party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.

55

 

We may rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third-party’s failure to execute on our manufacturing requirements could adversely affect our business in a number of ways, including:

 

•

an inability to initiate or continue clinical trials of product candidates under development, which may impact our potential economic benefits;

 

•

delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;

 

•

loss of the cooperation of a collaborator;

 

•

subjecting our product candidates to additional inspections by regulatory authorities;

 

•

requirements to cease distribution or to recall batches of our product candidates; and

 

•

in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.

We enter into various contracts in the normal course of our business in which we indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations.

In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sublicensees’ exercise of rights under the agreement. With respect to our collaboration agreements, we indemnify our collaborators from any third-party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third-party. With respect to consulting agreements, we indemnify consultants from claims arising from the good faith performance of their services.

Should our obligation under an indemnification provision exceed applicable insurance coverage or should we be denied insurance coverage, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator to indemnify us and the collaborator is denied insurance coverage or the indemnification obligation exceeds the applicable insurance coverage, and if the collaborator does not have other assets available to indemnify us, our business, financial condition and results of operations could be adversely affected.

To the extent we are able to enter into collaborative arrangements or strategic alliances, we may be exposed to risks related to those collaborations and alliances.

We are currently party to agreements with AbbVie and Ginkgo. Biotechnology companies sometimes become dependent upon collaborative arrangements or strategic alliances to complete the development and commercialization of product candidates. If we elect to enter into collaborative arrangements or strategic alliances, these arrangements may place the development of our product candidates outside our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us.

Dependence on collaborative arrangements or strategic alliances would subject us to a number of risks, including the risk that:

 

•

we may not be able to control the amount and timing of resources that our collaborators may devote to the relevant product candidates;

 

•

our collaborators may experience financial difficulties;

 

•

we may be required to relinquish important rights, such as marketing and distribution rights;

 

•

business combinations or significant changes in a collaborator’s business strategy may also adversely affect a collaborator’s willingness or ability to complete our obligations under any arrangement;

 

•

a collaborator could independently move forward with a competing drug candidate developed either independently or in collaboration with others, including our competitors; and

 

•

collaborative arrangements are often terminated or allowed to expire, which would delay the development and may increase the cost of developing our drug candidates.

56

 

We may attempt to form collaborations in the future with respect to our product candidates, but we may not be able to do so, which may cause us to alter our development and commercialization plans.

We may attempt to form strategic collaborations, create joint ventures or enter into licensing arrangements with third parties with respect to our programs or platform that we believe will complement or augment our existing business. We may face significant competition in seeking appropriate strategic collaborators, and the negotiation process to secure appropriate terms is time consuming and complex. We may not be successful in our efforts to establish such a strategic collaboration for any product candidates and programs on terms that are acceptable to us, or at all. This may be because our product candidates and programs may be deemed to be at too early of a stage of development for collaborative effort, our research and development pipeline may be viewed as insufficient, the competitive or intellectual property landscape may be viewed as too intense or risky, and/or third parties may not view our product candidates and programs as having sufficient potential for commercialization, including the likelihood of an adequate safety and efficacy profile.

Any delays in identifying suitable collaborators and entering into agreements to develop and/or commercialize our product candidates could delay the development or commercialization of our product candidates, which may reduce their competitiveness even if they reach the market. Absent a strategic collaborator, we would need to undertake development and/or commercialization activities at our own expense. If we elect to fund and undertake development and/or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we are unable to do so, we may not be able to develop our product candidates or bring them to market and our business may be materially and adversely affected.

Risks Related to Commercialization of Our Product Candidates

If any of our product candidates is approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future products.

We currently have no sales, marketing or distribution capabilities or experience. If any of our product candidates is approved for marketing and commercialization, we will need to develop internal sales, marketing and distribution capabilities to commercialize such products, which would be expensive and time-consuming, or enter into collaborations with third parties to perform these services. If we decide to market our products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market our products or decide to co-promote products with collaborators, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of third parties and there can be no assurance that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved product. If we are not successful in commercializing any product approved for marketing and commercialization in the future, either on our own or through third parties, our business, financial condition, results of operations and prospects may be adversely affected.

If the market opportunities for our product candidates are smaller than we believe they are, we may not meet our revenue expectations and, assuming approval of a product candidate, our business may suffer. Because the patient populations in the market for our product candidates may be small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.

Given the small number of patients who have the diseases that we are targeting, our eligible patient population and pricing estimates may differ significantly from the actual market addressable by our product candidates. Our projections of both the number of people who have applicable diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. The potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our business, financial condition, results of operations and prospects.

We face substantial competition and our competitors may discover, develop or commercialize products faster or more successfully than us.

The development and commercialization of new products is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, universities and other research institutions worldwide with respect to our product candidates that we may seek to develop or commercialize in the future. For example, BioMarin, Inc., Nestlé Health Science S.A. (Codexis, Inc.), Homology Medicines, Inc., American Gene Technologies International Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Generation Bio Co., Agios Pharmaceuticals, Inc., Trucode Gene Repair, Inc., SOM Biotech

57

 

SL and other discovery stage companies have developed or are developing product candidates for the treatment of PKU. Allena Pharmaceuticals, Inc, Novome Biotechnologies, Inc., Federation Bio, Inc., Oxidien Pharmaceuticals L.L.C. and others are developing product candidates for enteric hyperoxaluria.  Merck & Co. Inc., Spring Bank Pharmaceuticals, Inc., GlaxoSmithKline plc., Bristol Myers Squibb Company, and Silicon Therapeutics have STING agonists in clinical development. companies developing other modalities which target STING or similar mechanisms include companies such as Roche (Genentech) and Pfizer Inc. / Merck KgaA. Multiple companies develop and market antibodies called checkpoint inhibitors including Pfizer Inc., Roche (Genentech), Merck, Bristol-Myers Squibb Company, Eli Lilly & Co, and others. Our competitors may succeed in developing, acquiring or licensing technologies and products that are more effective or less costly than the product candidates that we are currently developing or that we may develop, which could render our product candidates obsolete and noncompetitive. In addition to the competition we face from alternative therapies for the diseases we intend to target with our product candidates, we are also aware of several companies that are also working specifically to develop engineered bacteria as cellular drug therapies, such as Precigen, Inc. Further there are several companies working to develop other similar products. Third-party payors, including governmental and private insurers, may also encourage the use of generic products.

If our competitors obtain marketing approval from the FDA or comparable foreign regulatory authorities for their product candidates more rapidly than us, it could result in our competitors establishing a strong market position before we are able to enter the market.

Many of our competitors have materially greater name recognition and substantially greater financial, manufacturing, marketing, research and drug development resources than we do. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Large pharmaceutical companies in particular have extensive expertise in preclinical and clinical testing and in obtaining regulatory approvals for drugs. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. These organizations may also establish exclusive collaborative or licensing relationships with our competitors. Failure of our product candidates to effectively compete against established treatment options or in the future with new products currently in development would harm our business, financial condition, results of operations and prospects.

The commercial success of any of our current or future product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community.

Even with approvals from the FDA and comparable foreign regulatory authorities, the commercial success of our products will depend in part on the health care providers, patients, and third-party payors accepting our product candidates as medically useful, cost-effective, and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients and third-party payors. The degree of market acceptance of any of our products will depend on a number of factors, including but not limited to:

 

•

the efficacy of the product as demonstrated in clinical trials and potential advantages over competing treatments;

 

•

the safety and side effect profile of the product as demonstrated in clinical trials and potential advantages over competing treatments;

 

•

the prevalence and severity of the disease targeted;

 

•

the clinical indications for which approval is granted, including any limitations or warnings contained in a product’s approved labeling;

 

•

the convenience and ease of administration;

 

•

the cost of treatment;

 

•

the willingness of the patients and physicians to accept products engineered from bacteria and these therapies;

 

•

the perceived ratio of risk and benefit of these therapies by physicians, patients, and payers, and the willingness of physicians to recommend these therapies to patients based on such risks and benefits;

 

•

the marketing, sales and distribution support for the product;

 

•

the publicity concerning the products or competing products and treatments; and

 

•

the pricing and availability of third-party insurance coverage and reimbursement.

Even if a product displays a favorable efficacy and safety profile upon approval, market acceptance of the product remains uncertain. Efforts to educate the medical community and third-party payors on the benefits of the products may require significant

58

 

investment and resources and may never be successful. If our products fail to achieve an adequate level of acceptance by physicians, patients, third-party payors, and other health care providers, we will not be able to generate sufficient revenue to become or remain profitable.

We may not be successful in any efforts to identify, license, discover, develop, or commercialize additional product candidates.

Although a substantial amount of our effort will focus on the clinical testing, potential approval, and commercialization of our existing product candidates, the success of our business is also expected to depend in part upon our ability to identify, license, discover, develop, or commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our research programs or licensing efforts may fail to yield additional product candidates for clinical development and commercialization for a number of reasons, including but not limited to the following:

 

•

our research or business development methodology or search criteria and process may be unsuccessful in identifying potential product candidates;

 

•

we may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates;

 

•

our product candidates may not succeed in preclinical or clinical testing;

 

•

our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval;

 

•

competitors may develop alternatives that render our product candidates obsolete or less attractive;

 

•

product candidates we develop may be covered by third parties’ patents or other exclusive rights;

 

•

the market for a product candidate may change during development or commercialization so that such a product may become unreasonable to continue to develop or commercialize;

 

•

a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and

 

•

a product candidate may not be accepted as safe and effective by patients, the medical community, or third-party payors.

If any of these events occur, we may be forced to abandon our development efforts for one or more product candidates, or we may not be able to identify, license, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on our business, financial condition or results of operations and could potentially cause us to cease operations.

Failure to obtain or maintain adequate reimbursement or insurance coverage for products, if any, could limit our ability to market those products and decrease our ability to generate revenue.

The pricing, coverage, and reimbursement of our approved products, if any, must be sufficient to support our commercial efforts and other development programs and the availability and adequacy of coverage and reimbursement by third-party payors, including governmental and private insurers, are essential for most patients to be able to afford expensive treatments. Sales of our approved products, if any, will depend substantially, both domestically and abroad, on the extent to which the costs of our approved products, if any, will be paid for or reimbursed by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or government payors and private payors. If coverage and reimbursement are not available, or are available only in limited amounts, we may have to subsidize or provide products for free or we may not be able to successfully commercialize our products.

In addition, there is significant uncertainty related to the insurance coverage and reimbursement for newly approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare & Medicaid Services (CMS), an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel product candidates such as ours and what reimbursement codes our product candidates may receive if approved.

Outside the United States, international operations are generally subject to extensive governmental price controls and other price-restrictive regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of products. In many countries, the prices of products are subject to varying price control mechanisms as part of national health systems. Price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products, if any. Accordingly, in markets outside the United States, the potential revenue from the sale of our products may be insufficient to generate commercially reasonable revenue and profits.

59

 

Moreover, increasing efforts by governmental and private payors in the United States and abroad to limit or reduce healthcare costs may result in restrictions on coverage and the level of reimbursement for new products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with products due to the increasing trend toward managed healthcare, including the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs has and is expected to continue to increase in the future. As a result, profitability of our products, if any, may be more difficult to achieve even if they receive regulatory approval.

Risks Related to Our Business Operations and Employees

Our failure to attract and retain senior management and key scientific personnel may prevent us from successfully developing our product candidates or any future product candidate, conducting our clinical trials and commercializing any products.

Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We believe that our future success is highly dependent upon the contributions of our senior management, particularly our president and chief executive officer, chief medical officer, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of the products we develop.

Although we have not historically experienced significant difficulties attracting and retaining qualified employees, we could experience such problems in the future. For example, competition for qualified personnel in the biotechnology and pharmaceuticals field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all.

Our employees, independent contractors, principal investigators, CROs, consultants and collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.

We are exposed to the risk that our employees, independent contractors, consultants and collaborators may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (1) regulations of regulatory authorities in jurisdictions where we are performing activities in relation to our product candidates, including those laws requiring the reporting of true, complete and accurate information to such authorities; (2) manufacturing regulations and standards; (3) fraud and abuse and anti-corruption laws and regulations; or (4) laws that require the reporting of true and accurate financial information and data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, bias, misconduct, kickbacks, self-dealing and other abusive practices, and these laws may differ substantially from country to country. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These activities also include the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting ourselves from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending itself or asserting our rights, those actions could have a significant impact on our business including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in subsidized healthcare programs in a given country, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

Risks Related to Our Common Stock

Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.

Based on the beneficial ownership of our common stock as of March 18, 2021, our executive officers and directors, together with holders of 5% or more of our common stock outstanding and their respective affiliates, beneficially own approximately 39.2% of our common stock. Accordingly, these stockholders have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, consolidation or sale of all or substantially all of our assets or any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of the company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors’ perception that conflicts of interest may exist or arise.

60

 

Future sales of our common stock or securities convertible or exchangeable for our common stock may depress our stock price.

If our existing stockholders or holders of our options sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. The perception in the market that these sales may occur could also cause the trading price of our common stock to decline. As of March 18, 2021 there were a total of 39,657,841 shares of our common stock outstanding.

Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.

We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:

 

•

variations in the level of our operating expenses;

 

•

receipt, modification or termination of government contracts or grants, and the timing of payments we receive under these arrangements;

 

•

Our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make under these arrangements; and

 

•

any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved.

If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of the company’s stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.

Provisions of our charter documents or Delaware law could delay or prevent an acquisition of us, even if the acquisition would be beneficial to our stockholders, and could make it more difficult for you to change management.

Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control that our stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. In addition, these provisions may frustrate or prevent any attempt by our stockholders to replace or remove our current management by making it more difficult to replace or remove our Board of Directors. These provisions include:

 

•

a classified board of directors so that not all directors are elected at one time;

 

•

a prohibition on stockholder action through written consent;

 

•

no cumulative voting in the election of directors;

 

•

the exclusive right of our Board of Directors to elect a director to fill a vacancy created by the expansion of our Board of Directors or the resignation, death or removal of a director;

 

•

a requirement that special meetings of our Stockholders be called only by our Board of Directors, the chairman of our Board of Directors, the chief executive officer or, in the absence of a chief executive officer, the president;

 

•

an advance notice requirement for stockholder proposals and nominations;

 

•

the authority of our Board of Directors to issue preferred stock with such terms as our Board of Directors may determine; and

 

•

a requirement of approval of not less than 66 2/3% of all outstanding shares of our capital stock entitled to vote to amend any bylaws by stockholder action, or to amend specific provisions of our certificate of incorporation.

In addition, Delaware law prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person who, together with its affiliates, owns or within the last three years has owned 15% or more of the company’s voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Accordingly, Delaware law may discourage, delay or prevent a change in control of the company.

In addition, our amended and restated certificate of incorporation, to the fullest extent permitted by law, provides that the Court of Chancery of the State of Delaware will be the exclusive forum for: any derivative action or proceeding brought on our behalf; any

61

 

action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, or the DGCL, our amended and restated certificate of incorporation, or our amended and restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the Securities Act, inasmuch as Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rule and regulations thereunder. There is uncertainty as to whether a court would enforce such provision with respect to claims under the Securities Act, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.

This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.

Provisions in our charter and other provisions of Delaware law could limit the price that investors are willing to pay in the future for shares of our common stock.

We do not anticipate paying any cash dividends on our common stock in the foreseeable future; therefore, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

We have never declared or paid cash dividends on our common stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund our operations. In addition, the terms of any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline.

The trading market for our common stock will depend, in part, on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. In addition, if our operating results fail to meet the forecast of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our stock price and trading volume to decline.

Changes in, or interpretations of, accounting rules and regulations could result in unfavorable accounting charges or require us to change our compensation policies.

Accounting methods and policies for biopharmaceutical companies, including policies governing revenue recognition, research and development and related expenses and accounting for stock-based compensation, are subject to further review, interpretation and guidance from relevant accounting authorities, including the SEC. Changes to, or interpretations of, accounting methods or policies may require us to reclassify, restate or otherwise change or revise our financial statements, including those contained in this periodic report.

62

 

Item 1B. Unresolved Staff Comments.

None.

Item 2. Properties.

Our corporate headquarters and operations are located in Cambridge, Massachusetts. We currently lease laboratory and office space at 301 Binney Street in Cambridge. Our 301 Binney Street lease expires in 2028. We believe that our facilities are suitable and adequate for our needs for the foreseeable future.

From time to time, we are subject to various legal proceedings, claims and administrative proceedings that arise in the ordinary course of our business activities. Although the results of the litigation and claims cannot be predicated with certainty, as of the date of this report, we do not believe we are party to any claim, proceeding or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 4. Mine Safety Disclosures.

Not applicable.

63

 

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 

Market Information

Our common stock has been traded on The Nasdaq Capital Market under the symbol “SYBX” since August 28, 2017, prior to which it was traded under the symbol “MIRN”.  

 

Stockholders

As of March 18, 2021, there were approximately 111 stockholders of record of our common stock.

 

Dividends

We have never declared or paid any dividends to our stockholders since our inception and we do not plan to declare or pay cash dividends in the foreseeable future. We currently anticipate that we will retain any future earnings for the operation and expansion of our business.

Unregistered Sales of Securities

Not applicable.

 

Issuer Purchases of Equity Securities

None.

 

Item 6. Selected Financial Data.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

64

 

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Information

The Risk Factors in Part I, Item 1A of this Annual Report on Form 10-K, the audited financial statements and accompanying notes, included elsewhere in this Annual Report on Form 10-K, and this Management's Discussion and Analysis of Financial Condition and Results of Operations should be read together. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. Operating results are not necessarily indicative of results that may occur for the full fiscal year or any other future period. The term "Private Synlogic" refers to Synlogic, Inc. prior to the consummation of the Merger described herein. The term "Mirna" refers to Mirna Therapeutics, Inc. prior to the consummation of the Merger described herein. Unless otherwise indicated, references to the terms "Synlogic," “the Company," "we," "our" and "us" refer to Private Synlogic prior to the consummation of the Merger described herein and Synlogic, Inc. (formerly known as Mirna Therapeutics, Inc.) upon the consummation of the Merger described herein.

Overview

 

Business

Synlogic is a clinical-stage biopharmaceutical company focused on the discovery and development of Synthetic Biotic™ medicines. Synthetic Biotic medicines are generated from Synlogic’s proprietary drug discovery and development platform, leveraging a reproducible, modular approach to Synthetic Biology to develop beneficial microbes which perform or deliver critical therapeutic functions. Synthetic Biotic medicines are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synlogic’s goal is to discover, develop, and ultimately commercialize Synthetic Biotic medicines. Synlogic’s proprietary pipeline includes Synthetic Biotic medicines for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria. We are building a portfolio of partner-able assets in immunology and oncology.

In a clinical trial with our lead program SYNB1618, we have demonstrated consumption of phenylalanine (Phe), an amino acid that accumulates in a rare metabolic disorder known as PKU and are expanding our pipeline based on learnings from this program. We have also demonstrated that our pre-clinical candidate SYNB8802 can consume dietary oxalate and reduce hyperoxaluria in animal models. We are designing SYNB8802 to be tested in patients with Enteric Hyperoxaluria, a disease which leads to dangerously high levels of urinary oxalate and for which patients have few treatment options today.

We believe we have the core competencies in synthetic biology and manufacturing, as well as translational medicine, regulatory experience and clinical development to successfully discover and develop our Synthetic Biotic medicines. In June 2019, we announced an expanded collaboration with Ginkgo Bioworks, Inc. (Ginkgo) to complement our in-house expertise in strain design and development. Ginkgo uses software and automation to program and optimize microbial strains at a large scale. Ginkgo’s technology provides us with a synthetic biology-based cell programming platform for testing thousands of microbial strains to accelerate progression of early preclinical leads to drug candidates optimized for clinical development.  

While we believe that our Synthetic Biotic platform has potential to address a broad range of diseases, our initial pipeline focus is on metabolic diseases. We will consider leveraging partnerships to advance programs for other diseases including oncology and inflammatory disorders. Our most advanced programs target metabolic diseases that could potentially be treated by oral delivery of Synthetic Biotic medicines. These includes conditions caused by a genetic mutation characterized by a dysfunctional metabolic pathway including PKU, as well as acquired metabolic diseases caused by organ dysfunction, such as Enteric Hyperoxaluria. When delivered orally, Synthetic Biotic medicines are designed to function in the gut to consume a disease-causing toxic metabolite with the intended consequence of reducing its systemic or urinary levels. We believe that success in our metabolic disease programs will enable us to demonstrate the potential of our Synthetic Biotic medicines while bringing meaningful change to the lives of patients suffering from these debilitating conditions.

65

 

Impact of the COVID-19 pandemic on our business

In December 2019, an outbreak of a novel strain of coronavirus was identified in Wuhan, China. This virus continues to spread globally, has been declared a pandemic by the World Health Organization and has spread to over 100 countries, including the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to businesses and capital markets around the world. The extent to which the coronavirus impacts us will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. Our ability to enroll our clinical trials will be dependent on many factors, including the progression of the pandemic and its impact on patients and the investigators at our clinical trial sites. We are actively working with sites and investigators to mitigate these risks. Over the coming weeks and months, we will continue to carefully monitor the situation with respect to each of our clinical trials and follow guidance from local and federal health authorities.

Phenylketonuria

Our most advanced product candidate is SYNB1618, an oral therapy intended for the treatment of PKU, a rare metabolic disease in which Phe accumulates in the body as a result of genetic defects. Elevated levels of Phe are toxic to the brain and can lead to neurological dysfunction. SYNB1618 is designed to function in the gut of patients to reduce excess Phe, with the goal of lowering levels in the blood and other tissues. SYNB1618 has received both Fast Track designation and orphan drug designation for PKU from the U.S. Food and Drug Administration (FDA). We initiated a Phase 1/2a clinical trial of an early liquid formulation of SYNB1618 in April 2018 and announced top-line data from healthy volunteers evaluated in this study in September 2018. In July 2019, we announced data that demonstrated that SYNB1618 was safe and well-tolerated and achieved proof-of-mechanism of strain activity in both healthy volunteers and patients with PKU.

SYNB1618 is a member of a family of SYNB strains which consume Phe. We have additional Phe consuming strains for PKU in preclinical development. We have evaluated a lyophilized formulation of SYNB1618 in a bridging study in healthy volunteers. The study of this more patient- and commercialization-appropriate presentation of SYNB1618 demonstrated improved tolerability over the early liquid formulation. The next step for SYNB1618 is to conduct a Phase 2 clinical trial.  The Phase 2 trial, referred to as the SynPheny-1 Study, is designed to evaluate safety and tolerability of a solid formulation of SYNB1618 as well as its potential to lower blood Phe levels in adult PKU patients.

We continue to evaluate our clinical program progress as a result of the ongoing COVID-19 pandemic. The SynPheny-1 Study is designed to be flexible, with subjects physically coming to the clinic or participating from the patient's home utilizing home healthcare services. We initiated this study in the third quarter of 2020.

Enteric Hyperoxaluria

Enteric Hyperoxaluria is an acquired metabolic disorder with no approved treatment options. It is caused by increased absorption of dietary oxalate, which is present in many common foods including leafy greens, nuts, and chocolate. Enteric Hyperoxaluria often occurs as a result of a primary insult to the bowel, such as inflammatory bowel disease, short bowel syndrome, or surgical procedures such as Roux-en-Y bariatric weight-loss surgery. The disorder may cause dangerously high levels of urinary oxalate and progressive kidney damage.

The disorder can lead to high levels of urinary oxalate, which causes progressive kidney damage, kidney stone formation, and nephrocalcinosis. In May 2020, we announced the nomination of a clinical candidate for Enteric Hyperoxaluria, SYNB8802. We initiated a Phase 1 clinical trial of SYNB8802 in the fourth quarter of 2020.

SYNB8802 will be assessed for safety and tolerability, strain kinetics, changes in plasma and urine biomarkers of strain activity, and the potential to reduce urinary oxalate in the Phase 1 clinical study. The study has two parts: Part A is a multiple ascending dose study in healthy volunteers in whom we will induce temporary hyperoxaluria via diet; Part B is a placebo controlled, cross-over design study in patients with Enteric Hyperoxaluria following Roux-n-Y gastric bypass surgery.

Oncology

We have also developed a portfolio of Synthetic Biotic medicines to treat certain cancers which are designed to modify the tumor microenvironment, activate the immune system and result in tumor reduction. These Synthetic Biotic medicines could be used in combination with other cancer therapies such as checkpoint inhibitors. Our first Synthetic Biotic clinical immuno-oncology (“IO”) candidate is SYNB1891, an intratumorally administered Synthetic Biotic medicine engineered to act as a dual innate and adaptive

66

 

immune activator. SYNB1891 has been designed to activate the immune response in tumors via the E.coli Nissle chassis and production of cyclic di-AMP, an activator of the Stimulator of Interferon Genes, also referred to as the STING pathway.

In January 2020, we treated the first subject in a Phase 1 clinical trial of SYNB1891 in patients with advanced solid tumors and lymphoma.  The clinical trial is designed to identify a maximum tolerated dose (MTD) of SYNB1891 delivered as a monotherapy.  Once an MTD is identified, we will evaluate treatment of patients with a combination of SYNB1891 and the checkpoint inhibitor atezolizumab (Tecentriq), provided through a supply agreement with Roche. Despite the COVID-19 pandemic, the Phase 1 clinical trial has remained open and currently enrolled patients are continuing on trial. New patient enrollment in the study is also continuing. We released interim data from the ongoing monotherapy arm of this trial in December of 2020 which demonstrated target engagement and the production of biomarkers consistent with STING activation. In December of 2020 we also initiated the combination arm of the Phase 1 clinical trial.

Other Programs

Maple Syrup Urine Disease (MSUD) is an inherited, rare metabolic disease characterized by a deficiency of enzymes required to break down certain amino acids. We have been conducting studies to advance a pre-clinical candidate for MSUD.  Prototype strains did not meet pre-specified criteria for candidate declaration. Therefore, we discontinued efforts in MSUD in the third quarter of 2020 to prioritize other metabolic disorders.

In August 2019, we announced that we were discontinuing the development of SYNB1020, an early stage clinical product candidate for the treatment of hyperammonemia. The decision to discontinue the program was based on top-line data from an interim analysis of a randomized, double-blind, placebo-controlled Phase 1b/2a study of the Synthetic Biotic medicine in 23 patients with cirrhosis and elevated blood ammonia. While SYNB1020 was well tolerated in Phase 1b/2a study, the study showed it did not lower blood ammonia in patients with cirrhosis.

We are also leveraging our proprietary technology platform to develop Synthetic Biotic medicines to treat a broader range of human diseases. To achieve this goal, we collaborate with key disease experts who have developed robust models of relevant diseases and to inform our translational medicine strategy. These collaborators bring complementary expertise in preclinical development, clinical development and commercialization. Inflammatory bowel disease (IBD) is an attractive target for our technology as Synthetic Biotic medicines can be designed to locally deliver combinations of complementary therapeutics to potentially address the unmet medical need for maintenance of disease remissions. In May 2020, we announced the termination of our collaboration with AbbVie S.à.r.l. (“AbbVie”) to develop Synthetic Biotic medicines for the treatment of types of inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis.  Upon termination, we regained all rights to develop these and new IBD Synthetic Biotic medicines for all effectors targeting IBD. This allows us to fully leverage our expertise in strain engineering, quantitative biology, regulatory, and manufacturing to expand our wholly owned GI-based program portfolio to include IBD. We further regained the rights to partner these IBD programs. We may enter into additional strategic partnerships in the future to maximize the value of our programs and our Synthetic Biotic platform.

 

We currently operate in one reportable business segment—the discovery and development of Synthetic Biotic medicines. To date, we have dedicated substantially all of our activities to the research and development of our product candidates. As of March 2021, we have received approximately $340.1 million in proceeds as we financed our operations primarily through the sale of preferred stock, common stock, preferred units, warrants, payments received under the AbbVie collaboration agreement, interest earned on investments, and cash received in the Merger.

We have not generated any revenue to date from product sales and have incurred significant operating losses since our inception. We have incurred net losses of approximately $59.2 million and $51.4 million for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020 and 2019, we had an accumulated deficit of approximately $230.3 million and $171.1 million, respectively, and we expect to incur losses for the foreseeable future as we develop our product candidates. We expect our expenses and capital requirements will increase substantially in connection with our ongoing activities, as we:

 

•

complete preclinical studies, initiate and complete clinical trials for product candidates;

 

•

contract to manufacture product candidates;

 

•

advance research and development related activities to expand our product pipeline;

 

•

seek regulatory approval for our product candidates;

 

•

maintain, expand and protect our intellectual property portfolio;

67

 

 

 

•

hire additional staff, including clinical, scientific, and management personnel;

 

•

expand our existing infrastructure and secure space in a facility to support continued growth in our research and development efforts; and

 

•

add operational and finance personnel to support product development efforts and to support operating as a public company.

We do not expect to generate product revenue unless and until we successfully complete clinical development and obtain regulatory approvals for our product candidates, either alone or in collaboration with third parties. Additionally, we expect to utilize third-party contract research organizations (CROs) and contract manufacturing organizations (CMOs) to carry out our clinical development and manufacturing activities, and we do not yet have a commercial organization. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our internal commercialization capability to support product sales, marketing and distribution. Accordingly, we anticipate that we will seek to fund our operations through public or private equity or debt financings, collaborations or licenses, finance lease transactions or other available financing transactions. However, we may be unable to raise additional funds through these or other means when needed. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if it will be able to achieve or maintain profitability. Even if we are able to generate product revenue, we may not become profitable.

Financial Overview

Revenue

Revenue to date was generated from our collaboration agreement with AbbVie.  In May 2020, we announced the termination of our collaboration with AbbVie. Upon termination of the collaboration with AbbVie, we regained all rights to develop the IBD Synthetic Biotic medicines previously developed with AbbVie as well as new IBD Synthetic Biotic medicines for all effectors targeting IBD. Due to the termination of this Agreement, we do not expect further revenue from AbbVie. See Note 10, “Collaboration Agreements: AbbVie Collaboration” in the notes to the consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K for a full discussion of this arrangement. 

Research and Development Expense

Research and development expense consists of expenses incurred in connection with the discovery and development of our product candidates, including the conduct of preclinical and clinical studies and product development, which are expensed as they are incurred. These expenses consist primarily of:

 

•

compensation, benefits and other employee related expenses;

 

•

supplies to support our internal research and development efforts;

 

•

research and development related facility and depreciation costs;

 

•

leased manufacturing space; and

 

•

third-party contract costs relating to research, process and formulation development, preclinical and clinical studies and regulatory operations.

The lengthy process of securing regulatory approvals for new drugs requires the expenditure of substantial resources. Any delay or failure to obtain regulatory approvals would materially adversely affect our product candidate development efforts and our business overall. Given the inherent uncertainties of pharmaceutical product development, we cannot estimate with any degree of certainty the likelihood, timing or cost of obtaining regulatory approval and marketing our product candidates and thus, when, if ever, our product candidates will generate revenues and cash flows.

68

 

The successful development of our product candidates is highly uncertain and subject to a number of risks. Refer to the risk factors under the heading Risks Related to the Development of Our Product Candidates in Part II, Item 1A, found elsewhere in this Annual Report on Form 10-K.

We invest carefully in our pipeline, and the commitment of funding for each subsequent stage of our development programs is dependent upon the receipt of clear, supportive data. We anticipate that we will make determinations as to which additional programs to pursue and how much funding to direct to each program on an ongoing basis in response to the scientific and clinical data of each product candidate, as well as the competitive landscape and ongoing assessments of such product candidate’s commercial potential. We expect our research and development costs will be substantial for the foreseeable future. We expect costs associated with our SYNB1618, SYNB1891 and SYNB8802 programs to increase as the programs progress through clinical trials and new programs progress toward IND and into development.

We track direct research and development expenses, consisting principally of external costs, such as costs associated with contract research organizations and manufacturing of preclinical and clinical drug product and other outsourced research and development expenses to specific product programs. Costs related to specific product candidates are tracked upon the selection of a product candidate. We do not allocate employee and consulting-related costs, costs associated with our platform and facility expenses, including depreciation or other indirect costs, to specific product candidate programs because these costs are deployed across multiple product candidate programs under research and development and, as such, are separately classified. The table below summarizes our research and development expenses by categories of costs for the periods presented (in thousands):

 

 

 

Year ended December 31,

 

 

 

2020

 

 

2019

 

SYNB1020

 

$

40

 

 

$

2,606

 

SYNB1618

 

 

8,970

 

 

 

8,194

 

SYNB1891

 

 

2,018

 

 

 

2,527

 

SYNB8802

 

 

1,907

 

 

 

—

 

External pre-development candidate expenses and unallocated

   expenses

 

 

10,700

 

 

 

3,538

 

Internal research and development expenses

 

 

23,839

 

 

 

25,040

 

 

 

$

47,474

 

 

$

41,905

 

 

General and Administrative Expense

General and administrative expense consists primarily of compensation, benefits and other employee-related expenses for personnel in our administrative, finance, legal, information technology, investor relations, business development and human resource functions. Other costs include the legal costs of pursuing patent protection of our intellectual property, general and administrative related facility and information technology infrastructure costs and professional fees for accounting and legal services. We anticipate increases in expenses related to legal fees, accounting fees, costs for director and officer liability insurance, fees for investor relations services and costs associated with implementing and complying with corporate governance, internal controls and similar requirements applicable to public companies. We charge all general and administrative expenses to operations as incurred.

Other Income (Expense)

Interest and investment income consist of income earned on investments. Interest expense consists of expense related to our finance leases. Other expense consists primarily of gains and losses on foreign currency invoices.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses during the reported periods and related disclosures. These estimates and assumptions, including those related to revenue recognition and research and development expenses are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. These critical estimates and assumptions are based on our historical experience, our observance of trends in the industry, and various other factors that are believed to be reasonable under the circumstances and form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from our estimates under different assumptions or conditions.

69

 

We believe that the application of the following accounting policies, each of which require significant judgments and estimates on the part of management, are the most critical to aid in fully understanding and evaluating our reported financial results. Our significant accounting policies are more fully described in Note 2, “Summary of Significant Accounting Policies”, to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.

Revenue Recognition

We evaluate collaboration agreements with respect to FASB ASC Topic 808, Collaborative Arrangements, considering the nature and contractual terms of the arrangement and the nature of our business operations to determine the classification of the transactions. When we are an active participant in the activity and exposed to significant risks and rewards dependent on the commercial success of the collaboration, we will record our transactions on a gross basis in the consolidated financial statements and describe the rights and obligations under the collaborative arrangement in the notes to the consolidated financial statements.

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five-step analysis: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step analysis to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations and assesses whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

We may enter into collaboration agreements for research and development services, under which we may license certain rights to our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Variable consideration is constrained until it is deemed not be at significant risk of reversal.

In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements for which the collaboration partner is also a customer, we perform the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. As part of the accounting for these arrangements, we must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the contract term and pattern of satisfaction of the performance obligations under step (v) above. We use significant judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the goods and services we expect to provide. We use estimates to determine the timing of satisfaction of performance obligations, which may include the use of full time equivalent time as a measure of satisfaction of performance obligations.

Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in our consolidated balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.

Licenses of Intellectual Property

In assessing whether a promise or performance obligation is distinct from the other promises, we consider factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. In addition, we consider whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

70

 

Research and Development Services

If an arrangement is determined to contain a promise or obligation for us to perform research and development services, we must determine whether these services are distinct from the other promises in the arrangement. In assessing whether the services are distinct from the other promises, we consider the capabilities of the customer to perform these same services. In addition, we consider whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For research and development services that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Customer Options

If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. We evaluate the customer options for material rights, that is, the option to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on an alternative approach when the goods or services are both (i) similar to the original goods and services in the contract and (ii) provided in accordance with the terms of the original contract. Under this alternative, we allocate the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to a material right are not recognized as revenue until the option is exercised and the performance obligation is satisfied.

Milestone Payments

At the inception of each arrangement that includes milestone payments, we evaluate whether a significant reversal of cumulative revenue provided in conjunction with achieving the milestones is probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For other milestones, we evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, we reevaluate the probability of achievement of all milestones subject to constraint and, if necessary, adjusts our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.

Royalties

For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our licensing arrangements.

Contract Costs

We recognize as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, we recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, we have not incurred any incremental costs of obtaining a contract with a customer.

Research and Development Expense

All research and development expenses are expensed as incurred. Research and development expenses comprise costs incurred in performing research and development activities, including compensation, benefits and other employee costs; equity‑based compensation expense; laboratory and clinical supplies and other direct expenses; facilities expenses; overhead expenses; fees for contractual services, including preclinical studies, clinical trials, clinical manufacturing and raw materials; and other external expenses. Nonrefundable advance payments for research and development activities are capitalized and expensed over the related service period or as goods are received and services are performed. When third-party service providers’ billing terms do not coincide with our period-end, we are required to make estimates of our obligations to those third parties, including clinical trial costs, contractual service costs and costs for supply of our drug candidates, incurred in a given accounting period and record accruals at the end of the period. We base our estimates on the completion status of the research and development programs and the associated estimate of unbilled costs.

71

 

Results of Operations

The following discussion summarizes the key factors our management believes are necessary for an understanding of our consolidated financial results.

 

 

 

Year ended December 31,

 

 

 

2020

 

 

2019

 

 

 

(in thousands)

 

Revenue

 

$

545

 

 

$

2,224

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

47,474

 

 

 

41,905

 

General and administrative

 

 

13,537

 

 

 

14,728

 

Total operating expenses

 

 

61,011

 

 

 

56,633

 

Loss from operations

 

 

(60,466

)

 

 

(54,409

)

Other income (expense):

 

 

 

 

 

 

 

 

Interest and investment income

 

 

1,302

 

 

 

3,062

 

Interest expense

 

 

(6

)

 

 

(21

)

Other expense

 

 

(3

)

 

 

(5

)

Other income (expense), net

 

 

1,293

 

 

 

3,036

 

Net loss

 

$

(59,173

)

 

$

(51,373

)

 

Year Ended December 31, 2020 Compared to Year Ended December 31, 2019

Revenue

 

 

 

Years Ended

 

 

 

 

 

 

 

 

 

 

 

December 31,

 

 

Change

 

 

 

2020

 

 

2019

 

 

$

 

 

%

 

 

 

(dollars in thousands)

 

 

 

 

 

 

 

 

 

Revenue

 

$

545

 

 

$

2,224

 

 

$

(1,679

)

 

 

(75

)%

 

Revenue was $0.5 million for the year ended December 31, 2020 compared to $2.2 million for the year ended December 31, 2019. Revenue for the years ended December 31, 2020 and 2019 was related to the recognition of deferred revenue from services performed and payments received under the AbbVie collaboration. In May 2020, we announced the termination of our collaboration with AbbVie.

Operating Expenses

 

 

 

Years Ended

 

 

 

 

 

 

 

 

 

 

 

December 31,

 

 

Change

 

 

 

2020

 

 

2019

 

 

$

 

 

%

 

 

 

(dollars in thousands)

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

47,474

 

 

$

41,905

 

 

$

5,569

 

 

 

13

%

General and administrative

 

 

13,537

 

 

 

14,728

 

 

 

(1,191

)

 

 

(8

)%

Total operating expenses

 

$

61,011

 

 

$

56,633

 

 

$

4,378

 

 

 

8

%

 

 

Research and Development Expense

Research and development expense was $47.5 million for the year ended December 31, 2020 compared to $41.9 million for the year ended December 31, 2019. The increase of $5.6 million was primarily due to an increase of $8.9 million of non-clinical costs, $1.5 million in clinical development costs associated with our SYNB8802 program, and $0.8 million in clinical development costs associated with our SYNB1891 program. These increases were partially offset by decreases of $1.0 million in compensation, benefits and other employee-related expenses, $2.0 million in clinical development costs associated with our SYNB1020 program, $1.4 million in clinical development costs associated with our SYNB1618 program, $0.6 million in manufacturing costs associated with our SYNB1618 and SYNB1891 programs, $0.4 million of professional services, and $0.2 million of research and development support costs.

72

 

General and Administrative Expense

General and administrative expense was $13.5 million for the year ended December 31, 2020 compared to $14.7 million for the year ended December 31, 2019. The decrease of $1.2 million was due primarily to a decrease of $1.1 million in compensation, benefits and other employee-related expenses associated with decreased headcount, as well as a decrease of $0.6 million in professional services. The decreases were partially offset by an increase of $0.3 million in support costs and a $0.2 million increase in corporate fees.

 

Other Income (Expense)

 

 

 

Years Ended

 

 

 

 

 

 

December 31,

 

 

Change

 

 

 

2020

 

 

2019

 

 

$

 

 

%

 

 

 

(dollars in thousands)

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest and investment income

 

$

1,302

 

 

$

3,062

 

 

$

(1,760

)

 

 

(57

)%

Interest expense

 

 

(6

)

 

 

(21

)

 

 

15

 

 

 

(71

)%

Other expense

 

 

(3

)

 

 

(5

)

 

 

2

 

 

 

(40

)%

Other income (expense), net

 

$

1,293

 

 

$

3,036

 

 

$

(1,743

)

 

 

(57

)%

 

Other income (expense) for the year ended December 31, 2020 was $1.3 million compared to $3.1 million for the corresponding period in 2019. The decrease in other income (expense) of $1.8 million was related to a decrease in interest and investment income resulting from lower cash, cash equivalents and marketable securities balances and lower interest income generated by our investment account. 

 

Liquidity and Capital Resources

We have incurred losses since our inception on March 14, 2014 and, as of December 31, 2020, we had an accumulated deficit of approximately $230.3 million. We have financed our operations to date primarily through the sale of preferred stock, common stock, preferred units, warrants, payments received under our prior AbbVie collaboration agreement, interest earned on investments, and cash received in the Merger. During the year ended December 31, 2020, we received net proceeds of $13.5 million from the sale of 5,866,258 shares of our common stock in the ATM offering program. In June 2019, we issued to Ginkgo 6,340,771 shares of common stock and accompanying Pre-Funded Warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 2,548,117 shares of common stock, at a combined purchase price per share and Pre-Funded Warrant of $9.00. The Pre-Funded Warrants have an exercise price of $9.00 per share, with $8.99 of such exercise price paid at the closing of the offering. The net proceeds to us were approximately $79.9 million. At December 31, 2020, we had approximately $100.4 million in cash, cash equivalents, and short-term marketable securities. Our cash and cash equivalents include amounts held in money market funds, stated at cost plus unrealized gain and loss, which approximates fair market value.  Our available-for-sale securities include amounts held in corporate debt securities, commercial paper and U.S. government agency securities and treasuries. We invest cash in excess of immediate requirements in accordance with our investment policy, which limits the amounts we may invest in any one type of investment and requires all investments held by us to maintain minimum ratings from Nationally Recognized Statistical Rating Organizations so as to primarily achieve liquidity and capital preservation.

73

 

During the year ended December 31, 2020 our cash, cash equivalents and marketable securities balance decreased approximately $26.6 million. This decrease was primarily due to the cash used to operate our business, including payments related to, among other things, research and development and general and administrative expenses as we continue to invest in our primary drug candidates and support the development of our proprietary platform.  

The following table sets forth the major sources and uses of cash, cash equivalents and restricted cash for each of the periods below:

 

 

 

Years ended December 31,

 

 

 

2020

 

 

2019

 

 

 

(in thousands)

 

Net cash, cash equivalents and restricted cash (used in) provided by

 

 

 

 

 

 

 

 

Operating activities

 

$

(39,553

)

 

$

(75,468

)

Investing activities

 

 

32,482

 

 

 

10,796

 

Financing activities

 

 

13,394

 

 

 

79,604

 

Net increase in cash, cash equivalents and restricted cash

 

$

6,323

 

 

$

14,932

 

 

Cash Flows from Operating Activities

Net cash, cash equivalents and restricted cash used in operating activities was approximately $39.6 million for the year ended December 31, 2020. The primary use of cash was our net loss of approximately $59.2 million, which was partially offset by $8.3 million of non-cash items primarily including depreciation, equity-based compensation, and the right of use asset. There was an increase in working capital of $11.4 million, primarily related to decreases in prepaid research and development expenses, as result of our June 2019 services agreement with Ginkgo, decreases in prepaid expense and other current assets, offset by decreases in accounts payable, accrued expenses, operating lease liability and deferred revenue.

Net cash, cash equivalents and restricted cash used in operating activities was approximately $75.5 million for the year ended December 31, 2019. The primary use of cash was our net loss of approximately $51.4 million and a decrease in working capital of $31.0 million, of which $30.0 million related to prepaid research and development expenses, as a result of our June 2019 services agreement with Ginkgo, decreases in accounts payable and accrued expenses, and an increase in operating lease liability and right of use asset, as a result of the adoption of ASU 2016-02: Leases (Topic 842) effective January 1, 2019, offset by an increase in deferred revenue. Net loss was partially offset by $6.9 million of non-cash items primarily including depreciation, equity-based compensation and the right of use asset.

Cash Flows from Investing Activities

Net cash provided by investing activities for the year ended December 31, 2020 was $32.5 million and resulted primarily from the proceeds from maturity of marketable securities of $90.8 million and proceeds from redemption of marketable securities of $28.5 million. This was offset by the purchases of marketable securities of $86.5 million and property and equipment of $0.4 million.

Net cash provided by investing activities for the year ended December 31, 2019 was $10.8 million and resulted primarily from the purchases of marketable securities of $145.4 million and purchases of property and equipment of $1.3 million. These uses were partially offset by the proceeds of maturity of marketable securities of $157.5 million.

Cash Flows from Financing Activities

Net cash provided by financing activities for the year ended December 31, 2020 totaled $13.4 million, primarily related to net proceeds of $13.5 million from the sale of 5,866,258 shares of our common stock in the ATM offering program, offset by payments on our finance leases.

Net cash provided by financing activities for the year ended December 31, 2019 totaled $79.6 million related to net proceeds of $79.9 million from the sale of our common stock and Pre-Funded Warrants to Ginkgo in June 2019, offset by payments on our finance leases.

Funding Requirements

To date, we have not commercialized any products and have not achieved profitability. We anticipate that we will continue to incur substantial net losses for the next several years as we further develop our product candidates, invest in our proprietary platform technology and operate as a publicly traded company.

74

 

We have historically generated revenue from our AbbVie collaboration, but have not generated any product revenue since our inception and do not expect to generate any product revenue unless we receive regulatory approval for our product candidates. We believe that our cash, cash equivalents, and short-term marketable securities as of December 31, 2020, will be sufficient to meet our anticipated cash requirements for at least the next 12 months from the date of this filing. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially and negatively as a result of a number of factors, including the factors discussed in the section entitled “Risk Factors” in this Annual Report on Form 10-K. We have based our estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.

Due to the numerous risks and uncertainties associated with the development of our product candidates, we are unable to estimate precisely the amounts of capital outlays and operating expenditures necessary to complete the development of, and to obtain regulatory approval for, our product candidates. Our funding requirements will depend on many factors, including, but not limited to, the following:

 

•

the success of our research and development efforts;

 

•

the initiation, progress, timing, costs and results of clinical trials for our product candidates;

 

•

the time and costs involved in obtaining regulatory approvals for our product candidates;

 

•

the progress, timing and costs involved in developing manufacturing processes and agreements with third-party manufacturers;

 

•

the rate of progress and cost of our commercialization activities;

 

•

the expenses we incur in marketing and selling our product candidates;

 

•

the revenue generated by sales of our product candidates;

 

•

the emergence of competing or complementary technological developments;

 

•

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

 

•

the terms and timing of any additional collaborative, licensing or other arrangements that we may establish;

 

•

the acquisition of businesses, products and technologies;

 

•

our need to implement additional infrastructure and internal systems; and

 

•

our need to add personnel and financial and management information systems to support our product development and potential future commercialization efforts, and to enable us to operate as a public company.

As an early-stage company, we are subject to a number of risks common to other life science companies, including, but not limited to, the ability to raise additional capital, development by our competitors of new technological innovations, risk of failure in preclinical studies, the safety and efficacy of our product candidates in clinical trials, the regulatory approval process, the ability to efficiently manufacture our products, market acceptance of our products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology. Our therapeutic programs are currently pre-commercial, spanning discovery through early development and will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization of any product candidates. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. There can be no assurance that our research and development will be successfully completed, that adequate protection for our intellectual property will be obtained, that any products developed will obtain necessary regulatory approval or that any approved products will be commercially viable. Even if our product development efforts are successful, it is uncertain when, if ever, we will generate revenue from product sales. We may never achieve profitability, and unless and until we do, we will continue to need to raise additional capital or obtain financing from other sources, such as strategic collaborations or partnerships. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected.

Contractual Commitments and Obligations

Our commitments for operating leases relate to our lease of office and laboratory space at 301 Binney Street in Cambridge, Massachusetts and the GMP clean-room space leased from the Azzur Group, LLC, in Waltham, Massachusetts.

In July 2017, we entered into an agreement to lease approximately 41,346 square feet of laboratory and office space at 301 Binney Street in Cambridge, Massachusetts. Annual rent is approximately $3.3 million. The ten-year lease commenced in January

75

 

2018 and contains provisions for a free-rent period, annual rent increases and an allowance for tenant improvements. Additionally, we have paid for a tenant improvement investment of approximately $2.9 million. In conjunction with the lease, we established a letter of credit of approximately $1.0 million.

On December 7, 2018, Synlogic Operating Company, Inc., a wholly-owned subsidiary of Synlogic, Inc. (the “Company”), entered into a Statement of Work (the “SOW”) with Azzur Group, LLC (“Azzur”) pursuant to a Master Contract Services Agreement (the “Master Services Agreement”), dated September 8, 2018, between the Company and Azzur.

Pursuant to the SOW, Azzur has agreed to provide the Company with access to, and the use of, an approximately 700 square foot cleanroom space to be constructed in Waltham, Massachusetts (the “Azzur Suite”), for a period of 44 months, from May 1, 2019 to December 31, 2022 (the “Term”). Azzur has also agreed to provide the Company with storage space and personnel support at the Azzur Suite. The total estimated project cost during the Term for access to, and use of, the cleanroom and storage space, and the personnel support and other services, is $4.8 million.

The Company may terminate the SOW on four months’ prior written notice at any time during the Term. In addition, either party may terminate the Master Services Agreement (including the SOW) due to a breach by the other party and failure to cure. The Company is reasonably certain not to exercise the termination option through December 31, 2022.

As we are a clinical stage company, having entered the clinic for our first Phase 1 clinical trial in June 2017, we expect our most significant clinical trial expenditures will be with CROs and CMOs. These contracts generally are cancellable, with notice, at our option and do not have cancellation penalties.

 

Off-Balance Sheet Arrangements

We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, that would have been established for the purpose of facilitating off-balance sheet arrangements (as that term is defined in Item 303 (a)(4)(ii) of Regulation S-K) or other contractually narrow or limited purposes. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in those types of relationships. We enter into guarantees in the ordinary course of business related to the guarantee of our performance and the performance of our subsidiaries.

JOBS Act

Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other companies.

Recent Accounting Pronouncements

Please read Note 2, “Summary of Significant Accounting Policies” to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K.

76

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide this information required under this item.

Item 8. Consolidated Financial Statements and Supplementary Data.

Our consolidated financial statements, together with the independent registered public accounting firm report thereon, appear at pages F-1 through F-28 respectively, of this Annual Report on Form 10-K.

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

Definition and limitations of disclosure controls

Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act) are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management evaluates these controls and procedures on an ongoing basis.

There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. These limitations include the possibility of human error, the circumvention or overriding of the controls and procedures and reasonable resource constraints. In addition, because we have designed our system of controls based on certain assumptions, which we believe are reasonable, about the likelihood of future events, our system of controls may not achieve its desired purpose under all possible future conditions. Accordingly, our disclosure controls and procedures provide reasonable assurance, but not absolute assurance, of achieving their objectives.

Evaluation of Disclosure Controls and Procedures

Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Form 10-K, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control

There have not been any changes in our internal controls over financial reporting identified in connection with the evaluation of such internal control that occurred during our fiscal year ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, as amended. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

77

 

Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2020. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013). Based on our assessment, management believes that, as of December 31, 2020, our internal control over financial reporting is effective based on those criteria.

 

Inherent Limitations on the Effectiveness of Controls

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the controls are met.  Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues or misstatements, if any, within a company have been detected. Accordingly, our controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our control system are met. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Item 9B. Other Information.

None.

78

 

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

The response to this item is incorporated by reference from the discussion responsive thereto under the captions “Management and Corporate Governance Matters,” “Section 16(a) Beneficial Ownership Reporting Compliance,” and “Code of Conduct and Ethics” in the Company’s Proxy Statement for the 2021 Annual Meeting of Stockholders.

Item 11. Executive Compensation.

The response to this item is incorporated by reference from the discussion responsive thereto under the caption “Executive Officer and Director Compensation” in the Company’s Proxy Statement for the 2021 Annual Meeting of Stockholders.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The response to this item is incorporated by reference from the discussion responsive thereto under the caption “Security Ownership of Certain Beneficial Owners and Management” in the Company’s Proxy Statement for the 2021 Annual Meeting of Stockholders.

The response to this item is incorporated by reference from the discussion responsive thereto under the captions “Certain Relationships and Related Person Transactions” and “Management and Corporate Governance” in the Company’s Proxy Statement for the 2021 Annual Meeting of Stockholders.

Item 14. Principal Accounting Fees and Services.

The response to this item is incorporated by reference from the discussion responsive thereto under the caption “Independent Registered Public Accounting Firm” in the Company’s Proxy Statement for the 2021 Annual Meeting of Stockholders.

 

 

79

 

PART IV

Item 15. Exhibits, Financial Statement Schedules.

Item 15(a).The following documents are filed as part of this Annual Report on Form 10-K:

Item 15(a)(1) and (2)See “Consolidated Financial Statements and Supplementary Data” at Item 8 to this Annual Report on Form 10-K. Other financial statement schedules have not been included because they are not applicable, or the information is included in the financial statements or notes thereto.

 

Item 15(a)(3)The following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K.

Exhibit Index

 

Exhibit

Number

 

Exhibit Description

 

Filed

with this

Report

 

Incorporated by

Reference herein

from Form or

Schedule

 

Filing

Date

 

SEC

File/Reg.

Number

 

 

 

 

 

 

 

 

 

 

 

  2.1^

 

Agreement and Plan of Merger and Reorganization, dated as of May 15, 2017, by and among Mirna Therapeutics, Inc., Meerkat Merger Sub, Inc. and Synlogic, Inc.

 

 

 

8-K

(Exhibit 2.1)

 

05/16/2017

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

  3.1

 

Amended and Restated Certificate of Incorporation

 

 

 

8-K

(Exhibit 3.1)

 

10/6/2015

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

  3.2

 

Certificate of Amendment (Reverse Stock Split) to the Amended and Restated Certificate of Incorporation, dated August 25, 2017

 

 

 

8-K

(Exhibit 3.1)

 

08/28/2017

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

  3.3

 

Certificate of Amendment (Name Change) to the Amended and Restated Certificate of Incorporation

 

 

 

8-K

(Exhibit 3.2)

 

08/28/2017

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

  3.4

 

Amended and Restated Bylaws

 

 

 

8-K

(Exhibit 3.2)

 

10/6/2015

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

  4.1

 

Form of Common Stock Certificate

 

 

 

S-1/A

(Exhibit 4.2)

 

09/18/2015

 

333-206544

 

 

 

 

 

 

 

 

 

 

 

  4.2

 

Pre-Funded Warrant

 

 

 

8-K

(Exhibit 4.1)

 

06/12/2019

 

001-37566

  4.3

 

Description of Securities

 

 

 

10-K

(Exhibit 4.3)

 

         03/12/2020

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.1#

 

2015 Equity Incentive Award Plan

 

 

 

10-K

(Exhibit 10.1)

 

03/20/2018

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.2#

 

Form of Stock Option Grant Notice and Stock Option Agreement under the 2015 Equity Incentive Award Plan.

 

 

 

S-1/A

(Exhibit 10.9(B))

 

09/11/2015

 

333-206544

 

 

 

 

 

 

 

 

 

 

 

10.3#

 

Form of Restricted Stock Award Agreement and Restricted Stock Unit Award Grant Notice under the 2015 Equity Incentive Award Plan.

 

 

 

S-1/A

(Exhibit 10.9(C))

 

09/11/2015

 

333-206544

 

 

 

 

 

 

 

 

 

 

 

10.4#

 

2017 Stock Incentive Plan

 

 

 

10-K

(Exhibit 10.4)

 

03/20/2018

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.5#

 

Form of Stock Option Grant Notice and Stock Option Agreement under 2017 Stock Incentive Plan.

 

 

 

10-Q

(Exhibit 10.17)

 

11/13/2017

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.6#

 

Non‑Employee Director Compensation Program.

 

 

 

8-K

(Exhibit 10.1)

 

01/31/2020

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.7#

 

Form of Indemnification Agreement between the Company and each of its directors and officers

 

 

 

S-1/A

(Exhibit 10.13)

 

09/11/2015

 

333-206544

 

 

 

 

 

 

 

 

 

 

 

80

 

Exhibit

Number

 

Exhibit Description

 

Filed

with this

Report

 

Incorporated by

Reference herein

from Form or

Schedule

 

Filing

Date

 

SEC

File/Reg.

Number

 

 

 

 

 

 

 

 

 

 

 

10.8#

 

Offer Letter by and between Synlogic and Aoife M. Brennan, MB, BCh, BAO, MMSc, dated as of June 22, 2016

 

 

 

8-K

(Exhibit 10.6)

 

08/28/2017

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.9#

 

First Amendment to Offer Letter by and between Synlogic and Aoife M. Brennan, MB, BCh, BAO, MMSc, dated as of November 7, 2016

 

 

 

8-K

(Exhibit 10.7)

 

08/28/2017

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.10#

 

Second Amendment to Offer Letter by and between Synlogic and Aoife M. Brennan, MB, BCh, BAO, MMSc, dated as of May 8, 2017

 

 

 

8-K

(Exhibit 10.8)

 

08/28/2017

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.11#

 

Third Amendment to Offer Letter dated as of June 5, 2018, between Synlogic, Inc. and Aoife Brennan, MB, BCh, BAO, MMSc

 

 

 

10-Q

(Exhibit 10.1)

 

08/9/2018

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.12#

 

Amended and Restated Letter Agreement by and between Synlogic, Inc. and Aoife M. Brennan, MB, BCh, BAO, MMSc, dated as of October 1, 2018

 

 

 

10-Q

(Exhibit 10.1)

 

11/13/2018

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.13

 

Employment Letter Agreement dated July 17, 2019, by and between Synlogic and Richard Riese

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.14.1

 

Employment Letter Agreement dated November 28, 2018, by and between Synlogic and Antoine Awad

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.14.2

 

Promotion Letter, dated July 21, 2020, for Antoine Awad

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.15†^

 

Agreement and Plan of Merger by and among AbbVie S.à.r.l., Suffolk Merger Sub, Inc., Synlogic IBDCo, Inc., Synlogic, LLC, Synlogic, Inc. and the founders named therein, dated as of July 16, 2015; as amended by a First Amendment to Agreement and Plan of Merger, dated as of December 14, 2015

 

 

 

8-K

(Exhibit 10.12)

 

8/28/2017

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.16†^

 

Second Amendment to Agreement and Plan of Merger by and among AbbVie S.à.r.l., Synlogic IBDCo, Inc. and Synlogic Operating Company, Inc., dated as of September 27, 2018

 

 

 

10-Q

(Exhibit 10.2)

 

11/13/2018

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.17†^

 

Third Amendment to Agreement and Plan of Merger and First Amendment to License Agreement by and among AbbVie S.à.r.l., Synlogic IBDCo, Inc. and Synlogic Operating Company, Inc., dated as of December 18, 2018

 

 

 

10-K

(Exhibit 10.25)

 

03/12/2019

 

001-

37566

 

 

 

 

 

 

 

 

 

 

 

10.18†

 

License Agreement by and between Synlogic, Inc. and Synlogic IBDCo, Inc., dated as of July 16, 2015

 

 

 

8-K

(Exhibit 10.13)

 

8/28/2017

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.19

 

Sales Agreement, dated as of October 13, 2017 by and between the registrant and Cowen and Company, LLC

 

 

 

8-K

(Exhibit 1.1)

 

10/16/2017

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.20

 

Form of Subscription Agreement, dated as of April 6, 2018, by and among Synlogic, Inc. and certain investors.

 

 

 

8-K

(Exhibit 10.1)

 

04/6/2018

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.21†

 

Master Contract Services Agreement, dated as of September 8, 2018, between Synlogic, Inc. and Azzur Group (d/b/a Azzur of New England LLC).

 

 

 

10-K

(Exhibit 10.29)

 

03/12/2019

 

001-

37566

 

 

 

 

 

 

 

 

 

 

 

10.22†

 

Statement of Work dated September 10, 2018 pursuant to Master Contract Services Agreement between Synlogic, Inc. and Azzur Group (d/b/a Azzur of New England LLC).

 

 

 

10-K

(Exhibit 10.30)

 

03/12/2019

 

001-

37566

81

 

Exhibit

Number

 

Exhibit Description

 

Filed

with this

Report

 

Incorporated by

Reference herein

from Form or

Schedule

 

Filing

Date

 

SEC

File/Reg.

Number

 

 

 

 

 

 

 

 

 

 

 

10.23†

 

Statement of Work dated December 7, 2018 pursuant to Master Contract Services Agreement between Synlogic, Inc. and Azzur Group (d/b/a Azzur of New England LLC).

 

 

 

10-K

(Exhibit 10.31)

 

03/12/2019

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

10.24

 

Subscription Agreement dated June 11, 2019 by and between the Company and Ginkgo Bioworks, Inc.

 

 

 

8-K

(Exhibit 10.1)

 

06/12/2019

 

001-

37566

 

 

 

 

 

 

 

 

 

 

 

10.25†

 

Foundry Terms of Service Agreement dated June 11, 2019 by and between Synlogic Operating Company Inc. and Ginkgo Bioworks, Inc.

 

 

 

10-Q

(Exhibit 10.2)

 

08/08/2019

 

001-

37566

 

 

 

 

 

 

 

 

 

 

 

10.26

 

Consulting Agreement effective as of October 13, 2019 by and between the Company and Danforth Advisors, LLC, as amended

 

 

 

8-K

(Exhibit 10.1)

 

10/24/2019

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10.27

 

Synlogic, Inc. 2015 Employee Stock Purchase Plan, as amended

 

 

 

8-K

(Exhibit 10.1)

 

12/20/2019

 

001-37566

 

 

 

 

 

 

 

 

 

 

 

21.1

 

Subsidiaries of the registrant

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

23.1

 

Consent of Independent Registered Public Accounting Firm

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

24.1

 

Power of Attorney (included in the signature page hereto)

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

31.1

 

Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

31.2

 

Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

32.1

 

Certification required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

32.2

 

Certification required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.INS

 

Inline XBRL Instance Document.

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document.

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document.

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document.

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

X

 

 

 

 

 

 

 

^

The schedules and exhibits to this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.

#

Management contract or compensatory plans or arrangements.

†

Confidential treatment has been requested or granted as to certain portions, which portions have been omitted and filed separately with the SEC.

82

 

Item 16. Form 10-K Summary.

None.

83

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

Synlogic, Inc.

 

 

 

 

Date: March 25, 2021

 

By:

/s/ AOIFE BRENNAN

 

 

 

Aoife Brennan

 

 

 

President and Chief Executive Officer

(Principal Executive Officer)

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Aoife Brennan and Gregg Beloff his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

 

IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated opposite his name.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant in the capacities indicated below and on the dates indicated.

84

 

 

Name

 

Title

 

Date

 

 

 

 

 

/s/ AOIFE BRENNAN

 

President, Chief Executive Officer, and Director

 

March 25, 2021

Aoife Brennan

 

(Principal Executive Officer)

 

 

 

 

 

 

 

/s/ GREGG BELOFF

 

Interim Chief Financial Officer

 

March 25, 2021

Gregg Beloff

 

(Principal Financial Officer and Principal Accounting Officer)

 

 

 

 

 

 

 

/s/ PETER BARRETT

 

 

 

 

Peter Barrett

 

Chairman of the Board

 

March 25, 2021

 

 

 

 

 

/s/ MICHAEL BURGESS

 

 

 

 

Michael Burgess

 

Director

 

March 25, 2021

 

 

 

 

 

/s/ MICHAEL HEFFERNAN

 

 

 

 

Michael Heffernan

 

Director

 

March 25, 2021

 

 

 

 

 

/s/ PATRICIA HURTER

 

 

 

 

Patricia Hurter

 

Director

 

March 25, 2021

 

 

 

 

 

/s/ LISA KELLY-CROSWELL

 

 

 

 

Lisa Kelly-Croswell

 

Director

 

March 25, 2021

 

 

 

 

 

/s/ CHAU KHUONG

 

 

 

 

Chau Khuong

 

Director

 

March 25, 2021

 

 

 

 

 

/s/ NICK LESCHLY

 

 

 

 

Nick Leschly

 

Director

 

March 25, 2021

 

 

 

 

 

/s/ EDWARD MATHERS

 

 

 

 

Edward Mathers

 

Director

 

March 25, 2021

 

 

 

 

 

/s/ RICHARD P. SHEA

 

 

 

 

Richard P. Shea

 

Director

 

March 25, 2021

 

 

 

 

 

 

 

85

 

 

Index to Consolidated Financial Statements of Synlogic, Inc.

 

 

 

 

 

 

Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors

Synlogic, Inc.:

 

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Synlogic, Inc. and subsidiaries (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Evaluation of accrued expenses related to research and development activities performed by third parties

As discussed in Note 2 to the consolidated financial statements, costs incurred in research and development are expensed as incurred. When third-party service providers’ billing terms do not coincide with the Company’s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial costs, contractual services costs and costs for supply of its drug candidates, incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on its knowledge of the research and development programs, services performed for the period and the expected duration of the third-party service contract, where applicable.  As discussed in Note 7 to the consolidated financial statements, the accrued expenses balance related to research and development activities performed by third parties was $230 thousand at December 31, 2020.

We identified the evaluation of accrued expenses related to research and development activities performed by third parties as a critical audit matter.  The estimates made by the Company in determining the accrued expenses balance are based on a number of factors that can be challenging to assess, including the completion status of the research and development programs and the associated estimate of unbilled costs.

F-2

 

The following are the primary procedures we performed to address this critical audit matter.  We inspected contracts with third-party service providers, including any subsequent amendments, confirmed costs incurred to date with the respective third parties under the contracts, and inspected invoices to evaluate the amounts billed to date under the contracts.  Furthermore, to assess that all services rendered by the third parties prior to December 31, 2020 were appropriately included in the Company’s accrued expenses balance at December 31, 2020, we (1) inquired of the individuals at the Company who are responsible for overseeing the research and development activities of the third-party service providers to understand the progress of the respective programs; (2) inspected correspondence received from the third-party service providers, including status reports, and compared them to the estimates underlying the accrued expenses balance,  and (3) compared amounts ultimately invoiced by the third-party service providers subsequent to December 31, 2020 to the amounts accrued by the Company.

 

 

 

/s/ KPMG LLP

 

We have served as the Company’s auditor since 2015.

Boston, Massachusetts

March 25, 2021

 

 

 

F-3

 

SYNLOGIC, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(In thousands, except share and per share data)

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

32,507

 

 

$

26,184

 

Short-term marketable securities

 

 

67,937

 

 

 

93,387

 

Prepaid expenses and other current assets

 

 

6,402

 

 

 

13,675

 

Total current assets

 

 

106,846

 

 

 

133,246

 

Long-term marketable securities

 

 

—

 

 

 

7,502

 

Property and equipment, net

 

 

10,776

 

 

 

13,021

 

Right of use asset - operating lease

 

 

15,527

 

 

 

17,263

 

Restricted cash

 

 

1,097

 

 

 

1,097

 

Prepaid research and development, net of current portion

 

 

9,590

 

 

 

16,381

 

Other assets

 

 

4

 

 

 

64

 

Total assets

 

$

143,840

 

 

$

188,574

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

1,995

 

 

$

2,165

 

Accrued expenses

 

 

3,773

 

 

 

3,946

 

Deferred revenue

 

 

—

 

 

 

544

 

Lease liability - operating lease

 

 

2,531

 

 

 

2,000

 

Finance lease obligations

 

 

2

 

 

 

208

 

Total current liabilities

 

 

8,301

 

 

 

8,863

 

Long-term liabilities:

 

 

 

 

 

 

 

 

Lease liability - operating lease, net of current portion

 

 

20,273

 

 

 

22,804

 

Finance lease obligations, net of current portion

 

 

—

 

 

 

2

 

Other long-term liabilities

 

 

131

 

 

 

—

 

Total long-term liabilities

 

 

20,404

 

 

 

22,806

 

Commitments and contingencies (Note 14)

 

 

 

 

 

 

 

 

Stockholders' equity

 

 

 

 

 

 

 

 

Common stock, $0.001 par value

 

 

 

 

 

 

 

 

250,000,000 shares authorized as of December 31, 2020 and December 31, 2019.

   38,183,273 shares issued and outstanding as of December 31, 2020 and

   32,266,814 shares issued and outstanding as of December 31, 2019.

 

 

38

 

 

 

33

 

Additional paid-in capital

 

 

345,394

 

 

 

327,900

 

Accumulated other comprehensive loss

 

 

14

 

 

 

110

 

Accumulated deficit

 

 

(230,311

)

 

 

(171,138

)

Total stockholders' equity

 

 

115,135

 

 

 

156,905

 

Total liabilities and stockholders' equity

 

$

143,840

 

 

$

188,574

 

 

See accompanying notes to the consolidated financial statements.

F-4

 

Synlogic, INC. aND SUBSIDIARIES

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

 

 

 

Years ended December 31,

 

 

 

2020

 

 

2019

 

Revenue

 

$

545

 

 

$

2,224

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

47,474

 

 

 

41,905

 

General and administrative

 

 

13,537

 

 

 

14,728

 

Total operating expenses

 

 

61,011

 

 

 

56,633

 

Loss from operations

 

 

(60,466

)

 

 

(54,409

)

Other income (expense):

 

 

 

 

 

 

 

 

Interest and investment income

 

 

1,302

 

 

 

3,062

 

Interest expense

 

 

(6

)

 

 

(21

)

Other expense

 

 

(3

)

 

 

(5

)

Other income (expense), net

 

 

1,293

 

 

 

3,036

 

Net loss

 

$

(59,173

)

 

$

(51,373

)

 

 

 

 

 

 

 

 

 

Net loss per share - basic and diluted

 

$

(1.65

)

 

$

(1.70

)

Weighted-average common stock outstanding - basic and diluted

 

 

35,835,744

 

 

 

30,284,068

 

Comprehensive loss:

 

 

 

 

 

 

 

 

Net loss

 

$

(59,173

)

 

$

(51,373

)

Net unrealized (loss) gain on marketable securities

 

 

(96

)

 

 

175

 

Comprehensive loss

 

$

(59,269

)

 

$

(51,198

)

 

See accompanying notes to the consolidated financial statements.

 

F-5

 

Synlogic, INC. aND SUBSIDIARIES

Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

 

 

 

Common stock

 

 

Additional

 

 

Accumulated

other

 

 

 

 

 

 

 

 

 

 

 

$0.001 par value

 

 

paid-in

 

 

comprehensive

 

 

Accumulated

 

 

Total

 

 

 

Shares

 

 

Amount

 

 

capital

 

 

income (loss)

 

 

deficit

 

 

equity

 

Balance at December 31, 2018

 

 

25,401,479

 

 

$

25

 

 

$

243,903

 

 

$

(65

)

 

$

(119,765

)

 

$

124,098

 

Proceeds from issuance of common stock, net of issuance costs

 

 

6,340,771

 

 

 

7

 

 

 

56,990

 

 

 

—

 

 

 

—

 

 

 

56,997

 

Proceeds from issuance of pre-funded common stock warrants, net of

issuance costs

 

 

—

 

 

 

—

 

 

 

22,874

 

 

 

—

 

 

 

—

 

 

 

22,874

 

Issuance of restricted stock

 

 

585,600

 

 

 

1

 

 

 

(1

)

 

 

—

 

 

 

—

 

 

 

—

 

Cancellation of restricted stock

 

 

(61,036

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Equity-based compensation expense

 

 

—

 

 

 

—

 

 

 

4,134

 

 

 

—

 

 

 

—

 

 

 

4,134

 

Unrealized gain (loss) on securities

 

 

—

 

 

 

—

 

 

 

—

 

 

 

175

 

 

 

—

 

 

 

175

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(51,373

)

 

 

(51,373

)

Balance at December 31, 2019

 

 

32,266,814

 

 

$

33

 

 

$

327,900

 

 

$

110

 

 

$

(171,138

)

 

$

156,905

 

Proceeds from issuance of common stock in connection with at-the-market offering, net of issuance costs

 

 

5,866,258

 

 

 

5

 

 

 

13,529

 

 

 

—

 

 

 

—

 

 

 

13,534

 

Exercise of options

 

 

9,472

 

 

 

—

 

 

 

16

 

 

 

—

 

 

 

—

 

 

 

16

 

Issuance of restricted stock

 

 

226,335

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of common stock under employee stock purchase plan

 

 

29,857

 

 

 

—

 

 

 

42

 

 

 

—

 

 

 

—

 

 

 

42

 

Cancellation of restricted stock

 

 

(215,463

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Equity-based compensation expense

 

 

—

 

 

 

—

 

 

 

3,907

 

 

 

—

 

 

 

—

 

 

 

3,907

 

Unrealized gain (loss) on securities

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(96

)

 

 

—

 

 

 

(96

)

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(59,173

)

 

 

(59,173

)

Balance at December 31, 2020

 

 

38,183,273

 

 

$

38

 

 

$

345,394

 

 

$

14

 

 

$

(230,311

)

 

$

115,135

 

 

See accompanying notes to the consolidated financial statements.

 

 

 

F-6

 

 

Synlogic, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(In thousands) 

 

 

 

Year Ended

December 31,

 

 

Year Ended

December 31,

 

 

 

2020

 

 

2019

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(59,173

)

 

$

(51,373

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation

 

 

2,636

 

 

 

2,702

 

Equity-based compensation expense

 

 

3,907

 

 

 

4,134

 

Accretion/amortization of investment securities

 

 

(21

)

 

 

(1,282

)

Reduction in carrying amount of operating lease right of use asset

 

 

1,736

 

 

 

1,370

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

7,273

 

 

 

(12,263

)

Prepaid research and development, net of current portion

 

 

6,791

 

 

 

(16,381

)

Other assets

 

 

60

 

 

 

—

 

Accounts payable and accrued expenses

 

 

(349

)

 

 

(935

)

Deferred revenue

 

 

(544

)

 

 

276

 

Operating lease liabilities

 

 

(2,000

)

 

 

(1,716

)

   Other long-term liabilities

 

 

131

 

 

 

—

 

Net cash used in operating activities

 

 

(39,553

)

 

 

(75,468

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of marketable securities

 

 

(86,474

)

 

 

(145,418

)

Proceeds from maturity of marketable securities

 

 

90,836

 

 

 

157,465

 

Proceeds from redemption of marketable securities

 

 

28,515

 

 

 

—

 

Purchases of property and equipment

 

 

(395

)

 

 

(1,251

)

Net cash provided by investing activities

 

 

32,482

 

 

 

10,796

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Payments on finance lease obligations

 

 

(208

)

 

 

(266

)

Proceeds from issuance of common stock in connection with at-the-market offering, net of issuance costs

 

 

13,544

 

 

 

—

 

Proceeds from employee stock purchases and exercise of stock options

 

 

58

 

 

 

—

 

Proceeds from sale of common stock, net of issuance costs

 

 

—

 

 

 

56,996

 

Proceeds from sale of pre-funded warrants, net of issuance costs

 

 

—

 

 

 

22,874

 

Net cash provided by financing activities

 

 

13,394

 

 

 

79,604

 

Net increase in cash, cash equivalents and restricted cash

 

 

6,323

 

 

 

14,932

 

Cash, cash equivalents and restricted cash at beginning of period

 

 

27,281

 

 

 

12,349

 

Cash, cash equivalents and restricted cash at end of period

 

$

33,604

 

 

$

27,281

 

Supplemental disclosure of non-cash investing activities:

 

 

 

 

 

 

 

 

Property and equipment purchases included in accounts payable and accrued expenses

 

$

(4

)

 

$

(369

)

Assets acquired under operating lease obligation

 

$

—

 

 

$

2,714

 

Supplemental disclosure of non-cash financing activities:

 

 

 

 

 

 

 

 

Issuance costs included in accounts payable and accrued expenses

 

$

10

 

 

$

—

 

Cash paid for interest

 

$

6

 

 

$

21

 

 

See accompanying notes to the consolidated financial statements.

 

 

 

F-7

 

 

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements

(1)

Nature of Business

Organization

Synlogic, Inc., together with its wholly owned and consolidated subsidiaries (“Synlogic” or the “Company”), is a clinical-stage biopharmaceutical company focused on the drug discovery and development of Synthetic Biotic™ medicines. Synthetic Biotic medicines are generated from Synlogic’s proprietary drug discovery and development platform, leveraging a reproducible, modular approach to Synthetic Biology to develop beneficial microbes, which perform or deliver critical therapeutic functions. Synthetic Biotic medicines are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways or deliver combinations of therapeutic factors. Synlogic’s goal is to discover, develop and ultimately commercialize Synthetic Biotic medicines. Since incorporation, the Company has devoted substantially all of its efforts to the research and development of its product candidates.

Risks and Uncertainties

At December 31, 2020, the Company had approximately $100.4 million in cash, cash equivalents, and short-term marketable securities, $1.1 million of restricted cash and an accumulated deficit of approximately $230.3 million. Since its inception through December 31, 2020, the Company has primarily financed its operations through the issuance of preferred stock, units and warrants, the sale of its common stock, the AbbVie collaboration, and cash received in the Merger. In the absence of positive cash flows from operations, the Company is highly dependent on its ability to find additional sources of funding in the form of debt or equity financing. Management believes that the Company has sufficient cash to fund its operations through at least twelve months from the issuance of these financial statements.

As an early-stage company, the Company is subject to a number of risks common to other life science companies, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), the regulatory approval process, market acceptance of the Company’s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology. The Company’s therapeutic programs are currently pre-commercial, spanning discovery through early development and will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates.  These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance-reporting capabilities.  There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary regulatory approval or that any approved products will be commercially viable.  Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales.  The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital or obtain financing from other sources, such as strategic collaborations or partnerships.

(2)

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S.”) (“U.S. GAAP” or “GAAP”).

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.  On an on-going basis, the Company’s management evaluates its estimates, including those related to revenue recognition, income taxes including the valuation allowance for deferred tax assets, research and development accruals and prepaids, accrued expenses, investments, contingencies and equity-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.  Changes in estimates are reflected in reported results in the period in which they become known.

F-8

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

Cash Equivalents

The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents consist of money market funds, including money market funds held in a sweep account. Cash equivalents are stated at cost plus accrued interest, which approximates fair value. The amount of cash equivalents included in cash and cash equivalents was approximately $32.5 million and $13.5 million at December 31, 2020 and 2019, respectively.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash, cash equivalents, marketable securities and restricted cash. The Company uses high quality, accredited financial institutions to maintain its balances, and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.

Restricted Cash

The Company held cash of approximately $1.1 million at December 31, 2020 and 2019 in a letter of credit to secure its lease at the 301 Binney Street facility.  The Company has classified this deposit as long-term restricted cash on its balance sheet.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Cash and cash equivalents

 

$

32,507

 

 

$

26,184

 

Restricted cash included in other long-term assets

 

 

1,097

 

 

 

1,097

 

Total cash, cash equivalents, and restricted cash shown in

   the consolidated statement of cash flows

 

$

33,604

 

 

$

27,281

 

 

Fair Value

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values.  Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). The hierarchy consists of three levels: 

 

•

Level 1 – Utilize observable inputs such as quoted prices in active markets for identical assets or liabilities;

 

•

Level 2 – Utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves;

 

•

Level 3 – Utilize unobservable data points in which there is little or no market data, which require the Company to develop its own assumptions for the asset or liability.

The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of assets or liabilities between Level 1, Level 2 or Level 3 during the years ended December 31, 2020 and 2019.

Available-for-Sale Securities

The Company classifies all short-term investments with an original maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest and investment income. Realized gains and losses, and declines in value judged to be other than temporary on available-for-sale securities, are included in interest and investment income.

F-9

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest and investment income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary.

Property and Equipment

Property and equipment, including leasehold improvements, are recorded at cost and depreciated over their estimated useful lives using the straight‑line method. Repairs and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.

Depreciation begins at the time the asset is placed in service. Depreciation is provided over the following estimated useful lives:

 

Asset classification

 

Useful life

Computer and office equipment

 

3 years

Furniture and fixtures

 

5 years

Laboratory equipment

 

5 years

Leasehold improvements

 

Lesser of useful life or remaining lease term

 

Impairment of Long‑Lived Assets

Long‑lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value of the asset. To date, no such impairments have been recognized.

Leases

The Company uses judgement to assess if an arrangement is a lease at contract inception. An arrangement is a lease if the contract involves the use of a distinct identified asset, the lessor does not have substantive substitution rights and the Company obtains control of the asset throughout the period by obtaining substantially all of the economic benefit of the asset and the right to direct the use of the asset. Leases classified as operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities and noncurrent operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations, in our consolidated balance sheet.

ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company utilizes its incremental borrowing rate to determine the present value of lease payments. The incremental borrowing rate is the rate incurred to borrow similar funds, on a collateralized basis, over a comparable term in a similar economic environment.

The Company has elected to account for the lease and non-lease components for leases as a single component for classes of all underlying assets and allocate all of the contract consideration to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating expenses.

The lease term includes options to extend the lease when it is reasonably certain that option will be exercised. Leases with a term of 12 months or less are not recorded on the Company’s consolidated balance sheet.

F-10

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

Research and Development Costs

Costs incurred in research and development are expensed as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed.

Research and development expenses are comprised of costs incurred in performing research and development activities, including salary and benefits, equity-based compensation expense, laboratory supplies and other direct expenses, facilities expenses, overhead expenses, contractual services and other outside expenses.

When third-party service providers’ billing terms do not coincide with the Company’s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial costs, contractual services costs and costs for supply of its drug candidates, incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on the completion status of the research and development programs and the associated estimate of unbilled costs.

 

Revenue recognition

 

The Company generated revenue through a collaboration and license arrangement with AbbVie for the development and commercialization of product candidates prior to the termination of the arrangement in May 2020.

The Company evaluates collaboration agreements with respect to FASB ASC Topic 808, Collaborative Arrangements, considering the nature and contractual terms of the arrangement and the nature of its business operations to determine the classification of the transactions. When the Company is an active participant in the activity and exposed to significant risks and rewards dependent on the commercial success of the collaboration, it will record its transactions on a gross basis in the consolidated financial statements and describe the rights and obligations under the collaborative arrangement in the notes to the consolidated financial statements.

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five-step analysis: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step analysis to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company may enter into collaboration agreements for research and development services, under which the Company may license certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Variable consideration is constrained until it is deemed not be at significant risk of reversal.

In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements for which the collaboration partner is also a customer, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses significant judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the goods and services the Company expects to provide. The Company uses estimates to determine the timing of satisfaction of performance obligations, which may include the use of full time equivalent time as a measure of satisfaction of performance obligations.

F-11

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.

Licenses of Intellectual Property

In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Research and Development Services

If an arrangement is determined to contain a promise or obligation for the Company to perform research and development services, the Company must determine whether these services are distinct from the other promises in the arrangement. In assessing whether the services are distinct from the other promises, the Company considers the capabilities of the customer to perform these same services. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For research and development services that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Customer Options

If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, that is, the option to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on an alternative approach when the goods or services are both (i) similar to the original goods and services in the contract and (ii) provided in accordance with the terms of the original contract. Under this alternative, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to a material right are not recognized as revenue until the option is exercised and the performance obligation is satisfied.

Milestone Payments

At the inception of each arrangement that includes milestone payments, the Company evaluates whether a significant reversal of cumulative revenue provided in conjunction with achieving the milestones is probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For other milestones, the Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.

F-12

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

Royalties

For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.

Contract Costs

The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer.

Equity‑Based Compensation

The Company measures equity-based compensation to employees, non-employees and directors based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period. The fair value of each option and purchase rights under the employee stock purchase plan (“ESPP”) is estimated on the date of grant using the Black‑Scholes option‑pricing model. Expected volatility for the Company’s common stock is determined based on an average of the historical volatility of the Company and the historical volatility of a peer‑group of similar public companies. The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The expected term of purchase rights for the ESPP is based on the duration of an offering period. The assumed dividend yield is based upon the Company’s expectation of not paying dividends in the foreseeable future. The risk‑free interest rate is based upon the U.S. Treasury yield curve commensurate with the expected term at the time of grant or remeasurement. Forfeitures are recognized as they occur.

The Company classifies equity-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipients’ service payments are classified.

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company’s tax returns. Deferred taxes are determined based on the difference between the financial reporting and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.

Uncertain tax positions represent tax positions for which reserves have been established. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to be recognized in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.

F-13

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

Net Loss Per Share

Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and if dilutive, the weighted-average number of potential shares of common stock, including unvested restricted common stock, outstanding stock options and potential shares issuable under the ESPP.

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in one operating segment: discovery and development of synthetic biology therapeutics for the treatment of rare, infectious and other diseases. The Company’s chief executive officer, as chief operating decision maker, manages and allocates resources to the operations of the Company on a total company basis. All of the Company’s equipment, leasehold improvements and other fixed assets are physically located within the United States, and all agreements with its partners are denominated in U.S. dollars, except where noted.

 

New Accounting Pronouncements

 

New accounting pronouncements are issued by the FASB from time to time, and rules are issued by the SEC that the Company has or will adopt as of a specified date. Unless otherwise noted, management does not believe that any recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had, or is expected to have, a material impact on the Company’s present or future financial statements.

Recently Adopted Accounting Pronouncements

In December 2019, the FASB issued ASU 2019-12 – Income Taxes – (Topic 740): Simplifying the Accounting for Income Taxes, which provides amended guidance on income tax accounting. The amended guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year. Early adoption is permitted. The amended guidance, which simplifies the accounting for income taxes, includes the removal of exceptions to the general principles of ASC 740. The standard removed the exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items. The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13 - Fair Value Measurement - Disclosure Framework (Topic 820). The standard modifies the disclosure requirements for fair value measurements. The standard is effective for public companies for annual and interim periods beginning after December 15, 2019. The Company adopted the new guidance effective on January 1, 2020, which had an immaterial impact on the Company’s financial statement disclosures.

In August 2018, the FASB issued ASU 2018-15 - Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract. The standard requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.

In November 2018, the FASB issued ASU 2018-18 - Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606. The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.

 

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13 - Measurement of Credit Losses on Financial Statements. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-

F-14

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. In November 2019, the FASB issued ASU 2019-10 – Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which amended the effective date for certain companies. The standard is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December 15, 2022. Early adoption is available. The Company is currently evaluating the potential impact ASU 2016-13, and related updates, will have on its consolidated financial statements and disclosures.

In October 2020, the FASB issued an amendment, ASU 2020-08- Codification Improvements to Subtopic 310-20, Receivables – Nonrefundable Fees and Other Costs, to the guidance in ASU 2017-08, Receivables-Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. The amendment requires companies to reevaluate whether a callable debt security that has multiple call dates is within the scope of paragraph 310-20-65-2. The amendment shall be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is not permitted. The Company is currently evaluating the potential impact that ASU 2020-08 will have on its consolidated financial statements and disclosures.

 

 

 

(3)

Fair Value of Financial Instruments

The tables below present information about the Company’s assets that are measured at fair value on a recurring basis as of December 31, 2020 and 2019 and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, as described under Note 2, Summary of Significant Accounting Policies.  

The Company’s investment portfolio includes many fixed income securities that do not always trade on a daily basis.  As a result, the pricing services used by the Company applied other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare evaluations.  In addition, model processes were used to assess interest rate impact and develop prepayment scenarios.  These models take into consideration relevant credit information, perceived market movements, sector news and economic events.  The inputs into these models may include benchmark yields, reported trades, broker-dealer quotes, issuer spreads and other relevant data.

F-15

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

At December 31, 2020 and 2019, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands):

 

 

 

Fair Value Measurements at Reporting Date Using

 

 

 

December 31,

 

 

Quoted Prices in Active

Markets for Identical

Assets

 

 

Significant Other

Observable Inputs

 

 

Significant

Unobservable Inputs

 

Description

 

2020

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Money market funds

 

$

32,506

 

 

$

32,506

 

 

$

—

 

 

$

—

 

Commercial paper

 

 

40,477

 

 

 

—

 

 

 

40,477

 

 

 

—

 

Corporate debt securities

 

 

18,637

 

 

 

—

 

 

 

18,637

 

 

 

—

 

U.S. government agency securities and treasuries

 

 

8,823

 

 

 

8,823

 

 

 

—

 

 

 

—

 

Total

 

$

100,443

 

 

$

41,329

 

 

$

59,114

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements at Reporting Date Using

 

 

 

December 31,

 

 

Quoted Prices in Active

Markets for Identical

Assets

 

 

Significant Other

Observable Inputs

 

 

Significant

Unobservable Inputs

 

Description

 

2019

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Money market funds

 

$

3,240

 

 

$

3,240

 

 

$

—

 

 

$

—

 

Commercial paper (included in cash and

   cash equivalents)

 

 

4,249

 

 

 

—

 

 

 

4,249

 

 

 

—

 

Commercial paper (included in marketable

   securities)

 

 

20,501

 

 

 

—

 

 

 

20,501

 

 

 

—

 

Corporate debt securities (included in cash

   and cash equivalents)

 

 

6,005

 

 

 

—

 

 

 

6,005

 

 

 

—

 

Corporate debt securities (included in

   marketable securities)

 

 

71,383

 

 

 

—

 

 

 

71,383

 

 

 

—

 

U.S. government agency securities and

   treasuries

 

 

9,005

 

 

 

—

 

 

 

9,005

 

 

 

—

 

Total

 

$

114,383

 

 

$

3,240

 

 

$

111,143

 

 

$

—

 

 

Cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses at December 31, 2020 and December 31, 2019 are carried at amounts that approximate fair value due to their short-term maturities.  Finance lease obligations at December 31, 2020 and December 31, 2019 approximate fair value as they bear interest at a rate approximating a market interest rate.

(4)

Available-for-Sale Investments

The following tables summarize the available-for-sale securities held at December 31, 2020 and 2019 (in thousands):

 

December 31, 2020

 

Amortized cost

 

 

Gross unrealized

gains

 

 

Gross unrealized

losses

 

 

Fair Value

 

Commercial paper

 

$

40,467

 

 

$

11

 

 

$

(1

)

 

$

40,477

 

Corporate debt securities

 

 

18,634

 

 

 

4

 

 

 

(1

)

 

 

18,637

 

U.S. government agency securities

 

 

8,822

 

 

 

1

 

 

 

—

 

 

 

8,823

 

Total

 

$

67,923

 

 

$

16

 

 

$

(2

)

 

$

67,937

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2019

 

Amortized cost

 

 

Gross unrealized

gains

 

 

Gross unrealized

losses

 

 

Fair Value

 

Commercial paper

 

$

20,484

 

 

$

18

 

 

$

(1

)

 

$

20,501

 

Corporate debt securities

 

 

71,288

 

 

 

96

 

 

 

(1

)

 

 

71,383

 

U.S. government agency securities

 

 

9,005

 

 

 

2

 

 

 

(2

)

 

 

9,005

 

Total

 

$

100,777

 

 

$

116

 

 

$

(4

)

 

$

100,889

 

F-16

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

 

 

The contractual maturity of all securities held at December 31, 2020 was ten months or less.  There were eight investments in an unrealized loss position at December 31, 2020, none of which had been in an unrealized loss position for more than twelve months.  The aggregate fair value of the securities in an unrealized loss position at December 31, 2020 and 2019 was $20.1 million and $24.8 million, respectively. The Company reviews its investments for other-than-temporary impairment whenever the fair value of an investment is less than amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time.  To determine whether an impairment is other-than-temporary, the Company considers whether it has the ability and intent to hold the investment until a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary.  The Company did not hold any securities with an other-than-temporary impairment at December 31, 2020.

Gross realized gains and losses on the sales of investments have not been material to the Company’s consolidated statement of operations.

(5)

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Prepaid insurance

 

$

856

 

 

$

648

 

Prepaid research and development

 

 

4,771

 

 

 

11,989

 

Other prepaid expenses

 

 

528

 

 

 

390

 

Other current assets

 

 

247

 

 

 

648

 

 

 

$

6,402

 

 

$

13,675

 

 

(6)

Property and Equipment, net

Property and equipment, net consists of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Laboratory equipment

 

$

7,793

 

 

$

7,523

 

Computer and office equipment

 

 

769

 

 

 

782

 

Furniture and fixtures

 

 

421

 

 

 

421

 

Leasehold improvements

 

 

9,514

 

 

 

9,514

 

Construction in progress

 

 

528

 

 

 

412

 

 

 

 

19,025

 

 

 

18,652

 

Less accumulated depreciation

 

 

(8,249

)

 

 

(5,631

)

 

 

$

10,776

 

 

$

13,021

 

 

Depreciation expense on property and equipment was $2.6 million and $2.7 million in 2020 and 2019, respectively.

 

F-17

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

 

(7)

Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Payroll related

 

$

3,005

 

 

$

2,372

 

Professional fees

 

 

215

 

 

 

444

 

Research and development

 

 

230

 

 

 

1,005

 

Other

 

 

323

 

 

 

125

 

 

 

$

3,773

 

 

$

3,946

 

 

(8)

Common Stock

The Company’s common stock has the following characteristics:

 

•

The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders.

 

•

The holders of shares of common stock are entitled to receive dividends, if and when, declared by the Company’s board of directors. Since inception, no cash dividends have been declared.

In June 2019, the Company issued to Ginkgo Bioworks (“Ginkgo”) 6,340,771 shares of common stock and accompanying Pre-Funded Warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 2,548,117 shares of common stock, at a combined purchase price per share and Pre-Funded Warrant of $9.00. The Pre-Funded Warrants have an exercise price of $9.00 per share, with $8.99 of such exercise price paid at the closing of the offering. The proceeds, net of issuance costs, were approximately $79.9 million, $57.0 million related to the proceeds from sale of the common stock and $22.9 million related to the proceeds from sale of the Pre-Funded Warrants. The Pre-Funded Warrants may be exercised at any time until all of the Pre-Funded Warrants are exercised in full to the extent that, after giving effect to such issuance after exercise, Ginkgo would not beneficially own in excess of 19.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance. The Pre-Funded Warrants were classified as a component of permanent equity and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of common shares upon exercise. In addition, such warrants do not provide any guarantee of value or return. In addition, in connection with the issuance to Ginkgo of common stock and Pre-Funded Warrants, the Company expanded its existing collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. None of the Pre-Funded Warrants have been exercised as of December 31, 2020. (See Note 10).

The Company has a sales agreement with Cowen and Company, LLC (“Cowen”) with respect to an at-the-market (“ATM”) offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $17.3 million, through Cowen as its sales agent. In an ATM offering, exchange-listed companies incrementally sell newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices. During the year ended December 31, 2020, 5,866,258 shares of common stock were sold pursuant to the ATM, resulting in net proceeds of approximately $13.5 million. Subsequent to December 31, 2020, the Company is able to offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million.  

The Company has reserved for future issuance the following shares of common stock related to the potential warrant exercise, exercise of stock options, and the employee stock purchase plan:

 

 

December 31, 2020

 

Common stock issuable under pre-funded warrants

 

2,548,117

 

Options to purchase common stock

 

1,211,967

 

Employee Stock Purchase Plan

 

345,662

 

Total

 

4,105,746

 

F-18

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

 

 

(9)

Equity‑based Compensation and Equity Incentive Plans

 

Equity Plans

The Company currently has three active equity plans.

The 2015 Equity Incentive Award Plan (“2015 Plan”) functions as the primary equity plan for the Company. The 2015 Plan includes an “evergreen provision” that allows for an annual increase in the number of shares of common stock available for issuance under the 2015 Plan, which annual increase will be added on the first day of each fiscal year from 2016 through 2025, inclusive, and will be equal to the lesser of (i) five percent of the shares outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Board of Directors. The 2015 Plan provides for the granting of a variety of stock‑based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, deferred stock awards, dividend equivalent awards, stock payment awards, performance awards and other stock‑based awards.

The 2017 Stock Incentive Plan (the “2017 Plan”) provides for the grant of incentive stock options, non-qualified stock options, restricted and unrestricted stock awards and other stock-based awards.

The 2015 Employee Stock Purchase Plan (“ESPP”) allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations.  The ESPP generally provides for set offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last trading day of the offering period.  The Company suspended the ESPP in 2017. In December 2019, the Board reactivated the 2015 ESPP and approved an amendment to the ESPP to (i) reduce the permitted payroll deduction and number of shares of the Company’s common stock that a participant may purchase per calendar year and offering period under the ESPP and (ii) establish a period for enrollment for eligible participants. The reactivation of the 2015 ESPP was effective immediately. The Company’s executive officers are eligible to participate in the 2015 ESPP. There were 29,857 shares of common stock purchased under the ESPP during the year ended December 31, 2020.

 

 

Stock Options

The weighted average assumptions used in the Black-Scholes option-pricing model for stock options issued to employees and non-employees under the 2015 Plan and the 2017 Plan, during the years ended December 31, 2020 and 2019 were:

 

 

 

Year ended December 31,

 

 

Employees:

 

2020

 

 

2019

 

 

Expected term

 

6.2 years

 

 

6.2 years

 

 

Weighted-average, risk-free interest rate

 

0.6%

 

 

2.2%

 

 

Expected volatility

 

77.2%

 

 

71.1%

 

 

Dividend yield

 

 

—

 

 

 

—

 

 

 

F-19

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

 

The following table summarizes stock option activity under the 2015 and 2017 Plans.

 

 

 

Stock options outstanding

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

average

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

remaining

 

 

Aggregate

 

 

 

 

 

 

 

average

 

 

contractual

 

 

intrinsic

 

 

 

Number of

 

 

exercise

 

 

term

 

 

value (a)

 

 

 

options

 

 

price

 

 

(in years)

 

 

(in thousands)

 

Outstanding at December 31, 2019

 

 

2,286,419

 

 

$

9.24

 

 

 

8.7

 

 

$

43

 

Granted

 

 

1,627,654

 

 

 

1.90

 

 

 

 

 

 

 

—

 

Exercised

 

 

(9,472

)

 

 

1.70

 

 

 

 

 

 

 

6

 

Cancelled/Forfeited

 

 

(560,765

)

 

 

7.34

 

 

 

 

 

 

 

—

 

Outstanding at December 31, 2020

 

 

3,343,836

 

 

 

6.00

 

 

 

8.4

 

 

 

399

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vested or expected to vest at December 31, 2020

 

 

3,343,836

 

 

 

6.00

 

 

 

8.4

 

 

 

399

 

Exercisable at December 31, 2020

 

 

1,399,952

 

 

 

9.13

 

 

 

7.7

 

 

$

53

 

 

 

(a)

The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair market value of the underlying common stock for the options that were in the money at December 31, 2020 and 2019. 970,826 and 132,500 options were in the money at December 31, 2020 and 2019, respectively.

The weighted average grant date fair value per share of options granted during the years ended December 31, 2020 and 2019 was approximately $1.27 and $4.59, respectively. The total fair value of awards that vested during the years ended December 31, 2020 and 2019 was $3.4 million and $3.9 million, respectively.

As of December 31, 2020, there was approximately $4.3 million of unrecognized share-based compensation for unvested stock option grants which is expected to be recognized over a weighted average period of 2.1 years.  The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.  

Restricted Common Stock

During the years ended December 31, 2020 and 2019, 226,335 and 585,600 shares of restricted common stock were granted, respectively.

The following table shows restricted common stock activity:

 

 

 

Restricted stock awards

 

 

 

 

 

 

 

Weighted

average

grant date

 

 

 

Number of

 

 

fair value

 

 

 

shares

 

 

(per share)

 

Unvested at December 31, 2019

 

 

586,929

 

 

$

2.97

 

Granted

 

 

226,335

 

 

 

1.70

 

Vested

 

 

(119,594

)

 

 

2.30

 

Forfeited

 

 

(215,463

)

 

 

2.32

 

Unvested at December 31, 2020

 

 

478,207

 

 

$

2.19

 

 

The total fair value of shares that vested during the years ended December 31, 2020 and 2019 was $0.3 million and $0.1 million, respectively.

As of December 31, 2020, there was approximately $0.4 million of unrecognized share-based compensation related to restricted stock awards granted, which is expected to be recognized over a weighted average period of 2.1 years.  The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.  

 

F-20

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

 

Employee Stock Purchase Plan

The ESPP is considered a compensatory plan with the related compensation expense recognized over the six-month offering periods. The compensation expense for the year ended December 31, 2020 was $27,000.  There was no compensation expense related to the ESPP for the year ended December 31, 2019.

 

Equity Compensation

The Company has recorded total equity‑based compensation expense of approximately $3.9 million and $4.1 million, during the years ended December 31, 2020 and 2019, respectively. Equity compensation during the year ended December 31, 2020 is derived from stock options, restricted stock awards, and the ESPP. Equity compensation during the year ended December 31, 2019 is derived from stock options and restricted stock awards.

The following table summarizes equity‑based compensation expense within the Company’s consolidated statements of operations and comprehensive loss for the years ended December 31, 2020 and 2019 (in thousands):

 

 

 

Years ended December 31,

 

 

 

2020

 

 

2019

 

Research and development

 

$

1,724

 

 

$

1,377

 

General and administrative

 

 

2,183

 

 

 

2,757

 

 

 

$

3,907

 

 

$

4,134

 

 

The following table summarizes equity‑based compensation expense by type of award for the years ended December 31, 2020 and 2019 (in thousands):

 

 

 

Years ended December 31,

 

 

 

2020

 

 

2019

 

Stock options

 

$

3,200

 

 

$

3,789

 

Restricted stock awards

 

 

680

 

 

 

345

 

ESPP

 

 

27

 

 

 

—

 

 

 

$

3,907

 

 

$

4,134

 

 

(10)

Collaboration Agreements

 

Ginkgo Collaboration

 

In 2017, the Company established a technology collaboration with Ginkgo. In June 2019, in connection with the issuance to Ginkgo of an aggregate of 6,340,771 shares of common stock and Pre-Funded Warrants to purchase an aggregate of 2,548,117 common stock (See Note 8), the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. Under the 2019 expanded agreement, the Company made a prepayment to Ginkgo of $30.0 million for its foundry services that will be provided to the Company over an initial term of five years. The prepayment of foundry services is recorded in Prepaid expenses and other current assets and Prepaid research and development, net of current portion on the December 31, 2020 consolidated balance sheet. At December 31, 2020, the Company had remaining balances of $4.7 million and $8.9 million of current and non-current pre-paid research and development costs related to this transaction, respectively. Upon the expiration of such initial term and, if applicable, an additional period, any portion of the prepayment that has not been used to purchase services from Ginkgo will be retained by Ginkgo.

 

AbbVie Collaboration Agreement

In July 2015, the Company entered into the AbbVie Agreements under which the Company granted AbbVie an exclusive option to purchase IBDCo and, in exchange, agreed to collaborate in researching and developing an Investigational New Drug (“IND”) candidate for the treatment of IBD. The AbbVie Agreements set forth the Company’s and AbbVie’s respective obligations for development and delivery of an IND candidate package using reasonable commercial efforts.  

F-21

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

In May 2020, we announced the termination of our collaboration with AbbVie to develop Synthetic Biotic medicines for the treatment of types of IBD, including Crohn’s disease and ulcerative colitis.  Upon termination, we regained all rights to develop these and new IBD Synthetic Biotic medicines for all effectors targeting IBD. This allows us to fully leverage our expertise in strain engineering, quantitative biology, regulatory, and manufacturing to expand our wholly owned GI-based program portfolio to include IBD. We further regained the rights to partner these IBD programs.

Revenue associated with performance obligations under the AbbVie Agreements was recognized as the research and development services were provided using an input method, according to the full-time equivalents incurred. The research and development activities were expected to be performed over a period of approximately 54 months. The transfer of control occurred over time and, in management’s judgment, was the best measure of progress towards satisfying the performance obligation. The amounts received that had not yet been recognized as revenue were recorded in deferred revenue on the Company’s consolidated balance sheet.

For the years ended December 31, 2020 and 2019, the Company recognized $0.5 million and $2.2 million, respectively, as collaboration revenue in the Company’s consolidated statements of operations and comprehensive loss. There is no deferred revenue on the Company’s consolidated balance sheet as of December 31, 2020, as the remainder of the revenue was recognized when the agreement was terminated.

 

 

(11)

Net Loss per Share

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except for share and per share amounts):

 

 

 

2020

 

 

2019

 

Numerator:

 

 

 

 

 

 

 

 

Net loss

 

$

(59,173

)

 

$

(51,373

)

Denominator:

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding - basic and diluted

 

 

35,835,744

 

 

 

30,284,068

 

Net loss per share - basic and diluted

 

$

(1.65

)

 

$

(1.70

)

 

The Company’s potentially dilutive shares, which include outstanding stock options, unvested restricted common stock and potential shares issuable under the ESPP, are considered to be common share equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of the diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect.

 

 

 

As of December 31,

 

 

 

2020

 

 

2019

 

Unvested restricted common stock awards

 

 

478,207

 

 

 

586,929

 

Outstanding options to purchase common stock

 

 

3,343,836

 

 

 

2,286,419

 

Potential shares issuable under the ESPP

 

 

12,037

 

 

 

—

 

 

(12)

Income Taxes

 

During the years ended December 31, 2020 and 2019, the Company recorded no income tax benefits for the net operating losses incurred due to its uncertainty of reclaiming a benefit for those losses.

 

F-22

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

 

Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. Deferred tax assets consist of the following (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

61,181

 

 

$

46,362

 

Tax credit carryforwards

 

 

5,748

 

 

 

4,262

 

Accrued expenses

 

 

126

 

 

 

37

 

Property and equipment

 

 

279

 

 

 

—

 

Other long-term liabilities

 

 

36

 

 

 

—

 

Lease liabilities

 

 

6,230

 

 

 

6,776

 

Equity compensation

 

 

2,200

 

 

 

1,481

 

Amortizable intangibles

 

 

1,195

 

 

 

1,214

 

Other

 

 

38

 

 

 

138

 

Gross deferred tax assets

 

 

77,033

 

 

 

60,270

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Property and equipment

 

 

—

 

 

 

(1,720

)

Right of use assets

 

 

(4,242

)

 

 

(4,716

)

Gross deferred tax liabilities

 

 

(4,242

)

 

 

(6,436

)

Valuation allowance

 

 

(72,791

)

 

 

(53,834

)

Net deferred tax assets

 

$

—

 

 

$

—

 

 

Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of the Company’s deferred tax assets, which are comprised principally of net operating loss carryforwards, and determined that it is more likely than not that the Company will not recognize the benefits of the deferred tax assets. As a result, a full valuation allowance of approximately $72.8 million and $53.8 million was established at December 31, 2020 and 2019, respectively.

A reconciliation of the statutory federal income tax rate to the Company’s effective income tax rate is as follows (dollars in thousands):

 

 

 

Years ended December 31,

 

 

 

2020

 

 

2019

 

 

 

Tax Rate

 

 

Tax Rate

 

U.S. federal statutory rate

 

 

21

%

 

 

21

%

State income taxes, net of federal benefit

 

 

6

%

 

 

6

%

Other permanent differences

 

 

(1

)%

 

 

(1

)%

Tax credits

 

 

2

%

 

 

0

%

Other items

 

 

4

%

 

 

0

%

Net change in valuation allowance

 

 

(32

)%

 

 

(26

)%

Effective income tax rate

 

 

—

 

 

 

—

 

 

 

A roll-forward of the valuation allowance for the years ended December 31, 2020 and 2019 is as follows (in thousands):

 

 

 

Years ended December 31,

 

 

 

2020

 

 

2019

 

Balance at beginning of year

 

$

(53,834

)

 

$

(40,290

)

Increase in valuation allowance

 

 

(18,957

)

 

 

(13,544

)

Balance at end of year

 

$

(72,791

)

 

$

(53,834

)

 

F-23

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

 

As of December 31, 2020 and 2019, the Company had federal net operating loss carryforwards that may be available to reduce future taxable income of approximately $227.0 million and $172.9 million, respectively. Of the $227.0 million of federal net operating loss carryforwards, $79.4 million begin to expire in 2034. The remaining $147.6 of federal net operating loss carryforwards do not expire. The Company also had state net operating loss carryforwards that may be available to reduce future taxable income of approximately $213.6 million and $159.0 million, for the periods ended December 31, 2020 and 2019, respectively. The state net operating loss carryforwards begin to expire in 2029. In addition, at December 31, 2020, the Company had federal and state research and development tax credit carryforwards available to reduce future tax liabilities of approximately $3.5 million and $2.3 million, respectively.

Pursuant to Section 382 of the Internal Revenue Code of 1986 (“IRC”), certain substantial changes in the Company’s ownership may result in a limitation on the amount of net operating loss (“NOL”) carryforwards and research and development credit (“R&D credit”) carryforwards that may be used in future years. Utilization of the NOL and R&D credit carryforwards may be subject to a substantial annual limitation under Section 382 of the IRC due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and R&D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company has not completed a study to assess whether an ownership change has occurred, or whether there have been multiple ownership changes since its formation, due to the significant complexity and related costs associated with such a study. There could be additional ownership changes in the future that may result in additional limitations on the utilization of NOL carryforwards and credits.

The Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority. The Company has not recognized any liability for unrecognized tax benefits as of December 31, 2020.

The Company files tax returns, on an entity-level basis, as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. Tax years from 2016 to the present are open to examination under the statute. The Company’s policy is to record interest and penalties related to income taxes as part of the tax provision. There are no interest or penalties accrued at December 31, 2020 and 2019.

 

(13)

Leases

Operating Leases

In July 2017, the Company entered into an agreement to lease approximately 41,346 square feet of laboratory and office space at 301 Binney Street in Cambridge, Massachusetts.  Annual rent is approximately $3.3 million.  The ten-year lease commenced in January 2018 and contains provisions for a free-rent period, annual rent increases and an allowance for tenant improvements. The Company is responsible for real estate taxes, maintenance, and other operating expenses applicable to the leased premises. The Company has paid for tenant improvements of approximately $2.9 million. Additionally, the Company has capitalized approximately $6.6 million of landlord-funded tenant improvements. The Company was deemed to be the accounting owner of the tenant improvements primarily because it was responsible for project cost overruns, and as such, the amounts were recorded as a leasehold improvement. The landlord-funded tenant improvement allowance is being amortized as a reduction to lease expense ratably over the lease term.  In conjunction with the lease, the Company established a letter of credit of approximately $1.0 million secured by cash balances included in restricted cash. Variable payments based on our portion of the operating expenses, including real estate taxes and insurance, are recorded as a period expense when incurred. The Company has an option to extend the term by five years and an option to terminate the agreement if a similar agreement is executed with the landlord or an affiliate of the landlord. Neither option is reasonably certain of exercise and both are excluded from the lease liability calculation.

F-24

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

During the year ended December 31, 2018, the Company entered into an agreement with Azzur Group, LLC (“Azzur”) whereby Azzur agreed to provide the Company with access to, and the use of, an approximately 700 square foot cleanroom space to be constructed in Waltham, Massachusetts (the “Azzur Suite”), for a period of 44 months, from May 1, 2019 to December 31, 2022 (the “Term”). Azzur also agreed to provide the Company with storage space and personnel support at the Azzur Suite. The total estimated expenses to be incurred by the Company during the Term for access to, and use of, the cleanroom and storage space, and the personnel support and other services, is $4.8 million. The Company determined that the agreement contained an embedded lease because the Company controls the use of the Azzur Suite. Accordingly, the fixed and in-substance fixed consideration under the agreement was used to determine the ROU asset and lease liability at the lease commencement date.

 Leases classified as operating leases are included in operating lease ROU assets, current operating lease liabilities and noncurrent operating lease liabilities in our consolidated balance sheets. The operating lease right-of-use asset and operating lease liability represents the Binney Street lease and the Azzur Suite lease. Cash paid for amounts included in the present value of operating lease liabilities was $3.9 and $3.7 million during the years ended December 31, 2020 and 2019, respectively, which is included in operating cash flows.

The components of lease cost for operating leases for the years ended December 31, 2020 and 2019 were (in thousands):

 

 

For the year ended December 31,

 

Operating leases

2020

 

 

2019

 

Operating lease cost

$

3,628

 

 

$

3,344

 

Short-term lease cost

$

-

 

 

$

330

 

Variable lease cost

 

1,055

 

 

 

1,092

 

Total lease cost

 

4,683

 

 

 

4,766

 

 

The right-of-use asset for the operating lease is disclosed on the consolidated balance sheets.

The weighted average remaining lease term and the weighted average discount rate for operating leases were:

 

 

For the year ended December 31,

 

 

2020

 

 

2019

 

Weighted average discount rate

 

8.0

%

 

 

8.0

%

Weighted average remaining lease term (years)

 

7.2

 

 

 

8.2

 

 

The following table reconciles the undiscounted cash flows for the operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet: December 31, 2020

 

Maturity of lease liabilities

Operating Leases

 

 

(in thousands)

 

2021

$

4,236

 

2022

 

4,389

 

2023

 

3,574

 

2024

 

3,681

 

2025

 

3,792

 

Thereafter

 

10,595

 

Total lease payments

 

30,267

 

Less: imputed interest

 

7,463

 

Total lease liabilities

$

22,804

 

Current lease liabilities

 

2,531

 

Long-term lease liabilities

 

20,273

 

 

The lease cost for finance leases during the years ended December 31, 2020 and 2019, and the finance lease liability at December 31, 2020, were not material.

F-25

SYNLOGIC, INC. AND SUBSIDIARIES

 

Notes to Consolidated Financial Statements (continued)

 

(14)

Commitments and Contingencies

In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company is not currently a party to any material legal proceedings.

(15)

Employee Benefits

The Company has a defined contribution 401(k) plan for eligible employees. Employees are eligible to participate in the plan beginning on their date of hire. Under the terms of the plan, employees may make voluntary contributions as a percentage of compensation. The Company started to match employee contributions effective January 1, 2019. The Company matched 50% of the employee contributions to the 401(k) plan up to a maximum of 4% of the participating employee’s eligible earnings, resulting in a maximum company match of 2% of the participating employee’s eligible earnings, and subject to certain additional statutory dollar limitations.

(16)

Related-Party Transactions

In June 2019, the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. As of December 31, 2020, Ginkgo owns 6,340,771 shares of the Company’s outstanding common stock. See Note 10, Ginkgo Collaboration.

Under the agreement the Company made a prepayment to Ginkgo of $30.0 million for its foundry services that will be provided to the Company over an initial term of five years. At December 31, 2020, the Company had remaining balances of $4.7 million and $8.9 million of current and non-current pre-paid research and development costs related to this transaction, respectively. For the year ended December 31, 2020, the Company used $13.6 million of the pre-paid research and development expenses.

 

 

(17)

Selected Quarterly Data (Unaudited)

The following tables contain quarterly financial information for 2020 and 2019 (in thousands).  The Company believes that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented.  The operating results for any quarter are not necessarily indicative of results for any future period.

 

 

 

2020 Quarter Ended

 

 

 

March 31

 

 

 

 

June 30

 

 

 

 

September 30

 

 

December 31

 

Revenue

 

$

100

 

 

 

 

$

445

 

 

 

 

$

—

 

 

$

—

 

Operating expenses

 

 

16,498

 

 

 

 

 

16,382

 

 

 

 

 

13,437

 

 

 

14,694

 

Loss from operations

 

 

(16,398

)

 

 

 

 

(15,937

)

 

 

 

 

(13,437

)

 

 

(14,694

)

Net loss

 

 

(15,828

)

 

 

 

 

(15,535

)

 

 

 

 

(13,222

)

 

 

(14,588

)

Net loss per share - basic and diluted

 

$

(0.46

)

 

 

 

$

(0.44

)

 

 

 

$

(0.36

)

 

$

(0.39

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2019 Quarter Ended

 

 

 

March 31

 

 

 

 

June 30

 

 

 

 

September 30

 

 

December 31

 

Revenue

 

$

338

 

 

 

 

$

350

 

 

 

 

$

305

 

 

$

1,231

 

Operating expenses

 

 

14,035

 

 

 

 

 

13,445

 

 

 

 

 

14,443

 

 

 

14,710

 

Loss from operations

 

 

(13,697

)

 

 

 

 

(13,095

)

 

 

 

 

(14,138

)

 

 

(13,479

)

Net loss

 

 

(12,946

)

 

 

 

 

(12,344

)

 

 

 

 

(13,285

)

 

 

(12,798

)

Net loss per share - basic and diluted

 

$

(0.51

)

 

 

 

$

(0.45

)

 

 

 

$

(0.39

)

 

$

(0.37

)

 

Note: Four quarters may not sum to full year due to rounding.

 

F-26

 EX-10.13 2 sybx-ex1013_238.htm EX-10.13 sybx-ex1013_238.htm

 

Exhibit 10.13

 

 

 

Synlogic, Inc.

301 Binney Street, Suite 402

Cambridge, MA 02142

 

Revised

 

July 17, 2019

 

Richard Riese

 

 

Re:         Employment Letter Agreement

 

Dear Richard,

I am pleased to provide you with the terms and conditions of your employment by Synlogic, Inc. a Delaware corporation, Inc. (hereinafter referred to collectively with its subsidiaries as the “Company”).   This offer is contingent on the receipt of satisfactory professional references by Russell Reynolds.

 

1.

Position. Your position will be Chief Medical Officer (CMO), reporting to the Company’s Chief Executive Officer. In addition to performing duties and responsibilities associated with the position of Chief Medical Officer, from time to time the Company may assign you other related duties and responsibilities consistent with such position.

 

2.

Response and Start Date. This offer of employment will expire on July 19, 2019.  Please do not hesitate to contact me if you have any questions about these terms and conditions, or if I can provide any further information.  

It is expected that your employment will start on September 3, 2019, or such other later date as you and the Company may mutually agree (the “Start Date”).

 

3.

Nature of Relationship; Status.

(a) No provision of this Agreement shall be construed to create an express or implied employment contract for a specific period of time. Either you or the Company may terminate the employment relationship at any time and for any reason upon written notice to the other party as set forth herein.

(b) You will be expected to devote the necessary full-time business time and energies to the business and affairs of the Company in order to perform your duties and you shall perform the foregoing services at the principal office of the Company, or at any other location mutually agreed upon by you and the Company.

 

 

 

4.

Compensation

(a) Base Salary. Your initial salary during will be at the rate of $400,000 per annum, which shall be prorated for any partial year, month or week.

(b) Bonus Opportunity. You will have the opportunity to earn a bonus of up to forty percent (40%) of your annual base salary per year, based on the achievement of or progress toward individual departmental and/or corporate objectives and goals, as reasonably determined by the Board of Directors (the “Board”), provided that to be eligible for any such bonus, you must be employed by the Company in good standing at the time such bonus is awarded. To be eligible for any such bonus for a given Fiscal Year, your Start Date must be before November 1 in that Fiscal Year.  The bonus, if any, for the first Fiscal Year will be pro-rated from the Start Date.

(c) Equity. Subject to the terms of the Company’s then applicable equity incentive plan (“Incentive Plan”) and form of option agreement, and subject to approval by the Board of Directors of the Company at the first regularly scheduled meeting following the Start Date, you will be granted an option to purchase an aggregate of one hundred and fifty thousand (150,000) shares of common stock, at an exercise price per share equal to the Fair Market Value (as defined in the Incentive Plan) of the Common Stock on the date of the grant (such grant date to be the last trading day of the month in which the Board of Directors makes the grant), intended to qualify as an “incentive stock option” to the to the maximum extent allowed under Section 422 of the Internal Revenue Code. The option will vest as to one-fourth (1/4th) of the shares, on the first anniversary of the Start Date, and the remainder will vest at one-forty-eighth (1/48th) per month thereafter. All tax consequences resulting from the grant, vesting, or exercise of the option to or by you, or from the disposition by you of such shares of Common Stock, will be your responsibility. You also will be eligible for annual equity grants at the same time when other executives receive these grants.

(d) Expenses. You will be entitled to reimbursement for all ordinary and reasonable out-of-pocket business expenses that are reasonably incurred by you in furtherance of the Company’s business, following submission of reasonably detailed receipts.

(e) Sign-on Bonus.  You will be entitled to receive a separate sign-on bonus of fifty thousand dollars ($50,000), less any applicable withholding or other taxes.  The sign-on bonus will be payable at the same time as your annual bonus in Q1 2020.

 

5.

Benefits.

(a) Vacation. You will be eligible for four (4) weeks paid vacation on top of the standard Massachusetts vacation days. Vacation eligibility will accrue at a rate of five (5) days per fiscal quarter of service, and up to five (5) unused vacation days may be carried over from one year to the next year.

2

 

(b) Benefits. You will be eligible to participate in the benefits provided by the Company to its employees. Where any particular benefit is governed by a formal plan document, your eligibility and coverage will be determined by such document, and the Company may change its benefit offerings from time to time in its discretion to meet its business needs. The Company retains the right to change, add or cease any particular benefit.

 

6.

Confidentiality, Inventions and Non-Competition. The Company considers the protection of its confidential information and proprietary materials to be very important. Therefore, as a condition of your employment, you and the Company will become parties to an Non-Competition, Non-Solicitation, Invention and Non-Disclosure Agreement substantially in the form of Attachment A-1 to this letter (the “Related Agreement”).

 

7.

Termination and Severance. Your employment may be terminated by you or the Company as follows:

(a) the Company may terminate your employment for “Cause” (as defined below) upon written notice to you effectively immediately, in which case you will not be entitled to receive any form of payment other than your earned compensation through your date of separation and reimbursable expenses;

(b) you may terminate your employment voluntarily other than for “Good Reason” (as defined below) upon at least thirty (30) days’ prior written notice to the Company, in which case you will not be entitled to receive any form of payment other than your earned compensation through your date of separation and reimbursable expenses; and

(c) (i) the Company may terminate your employment other than for “Cause” upon  written notice to you and (ii) you may you terminate your employment voluntarily for “Good Reason” upon at least thirty (30) days’ prior written notice to the Company, whereupon, in each case subject to and conditioned upon your execution and delivery to the Company of a formal separation agreement (which will contain, among other obligations, your release of all claims against the Company and related persons and entities, and confidentiality/non-disparagement and non-compete provisions in a form and manner satisfactory to the Company), the Company will: (A) pay you salary continuation payments at your then Base Salary rate for a period of six (6) months (the “Severance Period”) following the termination of your employment, in accordance with the Company’s regularly established payroll procedure (the “Severance Payments”), and (B) provided you are eligible for and timely elect to continue receiving group medical insurance pursuant to the “COBRA” law, continue to pay the share of the premium for health coverage that is paid by the Company for active and similarly-situated employees who receive the same type of coverage until the earlier of (i) the last day of the Severance Period, or (ii) the date on which you become eligible for healthcare insurance with a subsequent employer, unless the Company’s provision of such COBRA payments will violate the nondiscrimination requirements of applicable law, in which case this benefit will not apply. In addition, within sixty (60) days following such resignation or termination, as applicable, the Company will pay you a lump-sum payment equal to the prorated portion of your current target bonus for the fiscal year in which you are terminated (with such

3

 

prorated portion determined by the number of days you were employed during such fiscal year). To the extent applicable, the Severance Payments, “COBRA” payments and lump-sum payment will commence (or, in the case of the lump-sum payment, be paid) within sixty (60) days after your termination, and once they commence, will include any unpaid amounts accrued from the date of your termination; provided, that, if such 60-day period spans two calendar years, then such payments in any event will commence, or if applicable, be paid in the second calendar year.

(d) For purposes of this letter, “Cause” means (i) your conviction of a felony, your plea of guilty or “no contest” to a felony, or your confession of guilt to a felony, in each case whether or not in connection with the performance of your duties to the Company, (ii) any act or omission by you which constitutes willful misconduct or negligence that results in loss, damage or injury to the Company or its prospects, including, but not limited to (A) disloyalty, dishonesty or a breach of fiduciary duty to the Company or its shareholders, (B) theft, fraud, embezzlement or other illegal conduct, or (C) deliberate disregard of a rule or policy of the Company, (iii) your failure, refusal or unwillingness to perform, to the reasonable satisfaction of the Board or Company. determined in good faith, any duty or responsibility assigned to you in connection with the performance of your duties hereunder, which failure of performance continues for a period of more than two weeks after written notice thereof has been provided to you by the Company or the Board, such notice to set forth in reasonable detail the nature of such failure of performance, or (iv) the material breach by you of any of the provisions of this letter or the Related Agreements.

(e) For purposes of this letter, “Good Reason” means, in the context of your resignation from your employment position with the Company, a resignation that occurs within thirty (30) days following: (i) a change in the principal location at which you provide services to the Company beyond fifty (50) miles from Cambridge, MA; (ii) a reduction in your compensation or a material reduction in your benefits, except such a reduction in connection with a general reduction in compensation or other benefits of all senior executives of the Company; (iii) a material breach of this letter by the Company that has not been cured within  two weeks days after written notice thereof by you to the Company; or (iv) a failure by the Company to obtain the assumption of this letter by any successor to the Company.

(f) In the event of your death or permanent disability (as defined below) while you are employed by the Company, your employment hereunder shall immediately and automatically terminate and the Company shall pay to you or your personal representative or designated beneficiary or, if no beneficiary has been designated by you, to your estate, any earned and unpaid base salary, pro-rated through the date of your death or permanent disability. For purposes of this letter, “Permanent Disability” shall mean your inability, due to physical or mental illness or disease, to perform the functions then performed by you for one hundred eighty (180) consecutive days, accompanied by the likelihood, in the opinion of a physician chosen by the Company and reasonably acceptable to you, that you will be unable to perform such functions within the reasonably foreseeable future; provided that the foregoing definition shall not include a disability for which the Company

4

 

is required to provide reasonable accommodation pursuant to the Americans with Disabilities Act or other similar statute or regulation.

(g) The time for payment, or schedule for payment, of any severance payments due hereunder may not be accelerated, except as provided for in the Treasury Regulations promulgated under Section 409A of the Internal Revenue Code of 1986 (the “Code”), or any law replacing or superseding such Section or regulations. Notwithstanding the preceding provisions of this Section 7(g), in the case that you are deemed a “specified employee” (as defined in Section 409A(2)(B)(i) of the Code), no severance payment may be made earlier than the date which is six (6) months after the termination of employment hereunder (or, if earlier, the date of the death of the Executive) if and to the extent required by applicable law or other rules of any stock exchange upon which any of shares of the Company’s capital stock are then traded.

 

8.

Change of Control.

(a) Notwithstanding anything to the contrary in any then outstanding option agreement or stock based award, and subject to any permitted action by the Board under the Company’s applicable equity plan to terminate options or other stock based awards upon a Change of Control, in the event that, within the twelve (12) month period that immediately follows or the thirty (30) day period immediately prior to a Change in Control (as defined below), your employment with the Company is terminated: (i) on account of your death or Permanent Disability, (ii) by the Company without Cause, or (iii) as a result of your resignation for Good Reason, then all of your then unvested restricted stock and/or options to purchase shares of the Company’s Common Stock shall accelerate and become fully vested. As used herein, “Change in Control” shall mean the (i) the sale of the Company by merger in which the shareholders of the Company in their capacity as such no longer own a majority of the outstanding equity securities of the Company (or its successor); (ii) any sale of all or substantially all of the assets or capital stock of the Company (other than in a spin-off or similar transaction); or (iii)) any other acquisition of the business of the Company, as determined by the Company’s Board of Directors in their sole discretion. For the avoidance of doubt, in no event shall a bona fide equity or debt financing of the Company, including a financing in which greater than 50% of the Company’s outstanding equity securities are acquired by a third-party be deemed a “Change of Control” for purposes of this letter.

 

9.

General.

(a) Entire Agreement. This letter, together with the Related Agreements, will constitute our entire agreement as to your employment by or consultancy for the Company and will supersede any prior agreements or understandings, whether in writing or oral.

(b) Notices. All notices, requests, consents and other communications hereunder will be in writing, will be addressed to the receiving party’s address set forth above or to such other address as a party may designate by notice hereunder, and will be either (i) delivered by hand, (ii) sent by overnight courier, (iii) sent by

5

 

registered mail, return receipt requested, postage prepaid (iv) sent by facsimile, electronic mail or electronic PDF transmission, in each case with confirmation retained. All notices, requests, consents and other communications hereunder will be deemed to have been given either (i) if by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, (iii) if sent by registered mail, on the fifth business day following the day such mailing is made or (iv) when confirmation is received, if sent by facsimile or electronic transmission.

(c) Modifications and Amendments. The terms and provisions of this letter may be modified or amended only by written agreement executed by the parties hereto.

(d) Waivers and Consents. The terms and provisions of this letter may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent will be deemed to be or will constitute a waiver or consent with respect to any other terms or provisions of this letter, whether or not similar. Each such waiver or consent will be effective only in the specific instance and for the purpose for which it was given, and will not constitute a continuing waiver or consent.

(e) Assignment. The Company may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of the Company’s business or that aspect of the Company’s business in which you are principally involved. You may not assign your rights and obligations under this letter without the prior written consent of the Company and any such attempted assignment by you without the prior written consent of the Company will be void.

(f) Benefit. All statements, representations, warranties, covenants and agreements in this letter will be binding on the parties hereto and will inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this letter will be construed to create any rights or obligations except between the Company and you, and no person or entity other than the Company will be regarded as a third party beneficiary of this letter.

(g) Governing Law. This letter and the rights and obligations of the parties hereunder will be construed in accordance with and governed by the law of The Commonwealth of Massachusetts, without giving effect to the conflict of law principles thereof.

(h) Jurisdiction, Venue and Service of Process. Any legal action or proceeding with respect to this letter will be brought in the courts of The Commonwealth of Massachusetts (or, if appropriate, a federal court located within The Commonwealth of Massachusetts). By execution and delivery of this letter, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the exclusive jurisdiction of the aforesaid courts.

6

 

(i) WAIVER OF JURY TRIAL. ANY ACTION, DEMAND, CLAIM OR COUNTERCLAIM ARISING UNDER OR RELATING TO THIS AGREEMENT WILL BE RESOLVED BY A JUDGE ALONE AND EACH OF THE COMPANY AND YOU WAIVE ANY RIGHT TO A JURY TRIAL THEREOF.

(j) Counterparts. This letter may be executed in two or more counterparts, and by different parties hereto on separate counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.

7

 

You may accept this offer of employment and the terms and conditions thereof by signing the enclosed additional copy of this letter and each of the Related Agreements, which execution will evidence your agreement with the terms and conditions set forth herein and therein, and returning them to the Company; provided that the provisions of this offer of employment are contingent upon completion of a background check and receipt of appropriate documentation of your work status.

 

Sincerely,

SYNLOGIC, INC.

 

By:

 

/s/ Adam Thomas

 

Name:

 

Adam J. Thomas

Title:

 

Chief Human Resources Officer

 

Accepted and Approved:

/s/ Richard Riese

Print Name: Richard Riese

 

 

 

Date: July 19, 2019

8

 EX-10.14.1 3 sybx-ex10141_239.htm EX-10.14.1 sybx-ex10141_239.htm

 

Exhibit 10.14.1

 

 

Synlogic, Inc.

301 Binney Street, Suite 402

Cambridge, MA 02142

 

 

November 28, 2018

 

Antoine Awad

 

 

Re:

Employment Letter Agreement

 

Dear Tony,

I am pleased to provide you with the terms and conditions of your employment by Synlogic, Inc. a Delaware corporation, Inc. (hereinafter referred to collectively with its subsidiaries as the “Company”).   This offer is contingent on the receipt of satisfactory professional references by Russell Reynolds.

 

1.

Position. Your position will be Head of Technical Operations, reporting to the Company’s Chief Executive Officer. In addition to performing duties and responsibilities associated with the position of Head of Technical Operations, from time to time the Company may assign you other related duties and responsibilities consistent with such position.

 

 

2.

Response and Start Date. Please do not hesitate to contact me if you have any questions about these terms and conditions, or if I can provide any further information.  

 

It is expected that your employment will start on December 10, 2018, but no later than December 17, 2018 (the “Start Date”).

 

3.

Nature of Relationship; Status.

 

(a) No provision of this Agreement shall be construed to create an express or implied employment contract for a specific period of time. Either you or the Company may terminate the employment relationship at any time and for any reason upon written notice to the other party as set forth herein.

(b) You will be expected to devote the necessary full-time business time and energies to the business and affairs of the Company in order to perform your duties and you shall perform the foregoing services at the principal office of the Company, or at any other location mutually agreed upon by you and the Company.

(c) The position at Synlogic is full-time and we anticipate you will devote your full energies to the role.  However, we understand that you have continued obligations to serve on a current advisory board at Verseau Therapeutics.  We support your continuation of this appointment provided (i) the obligation is

 

 

limited to a single advisory board/consultancy, (ii) the obligation does not exceed 5 hours per month, (iii) there is no conflict of interest with current or future Synlogic business, (iv) work for the advisory board is completed outside of Synlogic core hours, at a remote location, and on a 3rd parties computer and network, (v) any variance to the above terms is agreed in advance with the company.  

 

4.

Compensation

 

(a) Base Salary. Your initial salary during will be at the rate of $325,000 per annum, which shall be prorated for any partial year, month or week.

(b) Bonus Opportunity. You will have the opportunity to earn a bonus of up to thirty percent (30%) of your annual base salary per year, based on the achievement of or progress toward individual departmental and/or corporate objectives and goals, as reasonably determined by the Board of Directors (the “Board”), provided that to be eligible for any such bonus, you must be employed by the Company in good standing at the time such bonus is awarded.

(c) Equity. Subject to the terms of the Company’s then applicable equity incentive plan (“Incentive Plan”) and form of option agreement, and subject to approval by the Board of Directors of the Company at the first regularly scheduled meeting following the Start Date, you will be granted an option to purchase an aggregate of fifty thousand (50,000) shares of common stock, at an exercise price per share equal to the Fair Market Value (as defined in the Incentive Plan) of the Common Stock on the date of the grant, intended to qualify as an “incentive stock option” to the to the maximum extent allowed under Section 422 of the Internal Revenue Code. The option will vest as to one-fourth (1/4th) of the shares, on the first anniversary of the Start Date, and the remainder will vest at one-forty-eighth (1/48th) per month thereafter. All tax consequences resulting from the grant, vesting, or exercise of the option to or by you, or from the disposition by you of such shares of Common Stock, will be your responsibility. You also will be eligible for annual equity grants at the same time when other executives receive these grants.

(d) Expenses. You will be entitled to reimbursement for all ordinary and reasonable out-of-pocket business expenses that are reasonably incurred by you in furtherance of the Company’s business, following submission of reasonably detailed receipts.

(e)  Sign-on Bonus.  You will be entitled to receive a separate sign-on bonus of twenty thousand dollars ($20,000), less any applicable withholding or other taxes.  The sign-on bonus will be payable within two payroll cycles after your start date.  You understand and agree that in the event that you voluntarily terminate your employment or your employment is terminated on or before the second anniversary of your Start Date, you shall repay the sign-on bonus in full, and that the Company may deduct such payment from your wages or other amounts due to you at the time of termination as an established debt owed by you to the Company.

2

 

 

5.

Benefits.

 

(a) Vacation. You will be eligible for four (4) weeks paid vacation on top of the standard Massachusetts vacation days. Vacation eligibility will accrue at a rate of five (5) days per fiscal quarter of service, and up to five (5) unused vacation days may be carried over from one year to the next year.

(b) Benefits. You will be eligible to participate in the benefits provided by the Company to its employees. Where any particular benefit is governed by a formal plan document, your eligibility and coverage will be determined by such document, and the Company may change its benefit offerings from time to time in its discretion to meet its business needs. The Company retains the right to change, add or cease any particular benefit.

 

6.

Confidentiality, Inventions and Non-Competition. The Company considers the protection of its confidential information and proprietary materials to be very important. Therefore, as a condition of your employment, you and the Company will become parties to an Non-Competition, Non-Solicitation, Invention and Non-Disclosure Agreement substantially in the form of Attachment A-1 to this letter (the “Related Agreement”).

 

 

7.

Termination and Severance. Your employment may be terminated by you or the Company as follows:

 

(a) the Company may terminate your employment for “Cause” (as defined below) upon written notice to you effectively immediately, in which case you will not be entitled to receive any form of payment other than your earned compensation through your date of separation and reimbursable expenses;

(b) you may terminate your employment voluntarily other than for “Good Reason” (as defined below) upon at least thirty (30) days’ prior written notice to the Company, in which case you will not be entitled to receive any form of payment other than your earned compensation through your date of separation and reimbursable expenses; and

(c) (i) the Company may terminate your employment other than for “Cause” upon  written notice to you and (ii) you may you terminate your employment voluntarily for “Good Reason” upon at least thirty (30) days’ prior written notice to the Company, whereupon, in each case subject to and conditioned upon your execution and delivery to the Company of a formal separation agreement (which will contain, among other obligations, your release of all claims against the Company and related persons and entities, and confidentiality/non-disparagement and non-compete provisions in a form and manner satisfactory to the Company), the Company will: (A) pay you salary continuation payments at your then Base Salary rate for a period of six (6) months (the “Severance Period”) following the termination of your employment, in accordance with the Company’s regularly established payroll procedure (the “Severance Payments”), and (B) provided you are eligible for and timely elect to continue receiving group medical insurance pursuant to the “COBRA” law, continue to pay the share of the premium for health coverage that is paid by the Company for active and similarly-situated employees who receive the same type of coverage until the

3

 

earlier of (i) the last day of the Severance Period, or (ii) the date on which you become eligible for healthcare insurance with a subsequent employer, unless the Company’s provision of such COBRA payments will violate the nondiscrimination requirements of applicable law, in which case this benefit will not apply. In addition, within sixty (60) days following such resignation or termination, as applicable, the Company will pay you a lump-sum payment equal to the prorated portion of your current target bonus for the fiscal year in which you are terminated (with such prorated portion determined by the number of days you were employed during such fiscal year). To the extent applicable, the Severance Payments, “COBRA” payments and lump-sum payment will commence (or, in the case of the lump-sum payment, be paid) within sixty (60) days after your termination, and once they commence, will include any unpaid amounts accrued from the date of your termination; provided, that, if such 60-day period spans two calendar years, then such payments in any event will commence, or if applicable, be paid in the second calendar year.

(d) For purposes of this letter, “Cause” means (i) your conviction of a felony, your plea of guilty or “no contest” to a felony, or your confession of guilt to a felony, in each case whether or not in connection with the performance of your duties to the Company, (ii) any act or omission by you which constitutes willful misconduct or negligence that results in loss, damage or injury to the Company or its prospects, including, but not limited to (A) disloyalty, dishonesty or a breach of fiduciary duty to the Company or its shareholders, (B) theft, fraud, embezzlement or other illegal conduct, or (C) deliberate disregard of a rule or policy of the Company, (iii) your failure, refusal or unwillingness to perform, to the reasonable satisfaction of the Board or Company. determined in good faith, any duty or responsibility assigned to you in connection with the performance of your duties hereunder, which failure of performance continues for a period of more than two weeks after written notice thereof has been provided to you by the Company or the Board, such notice to set forth in reasonable detail the nature of such failure of performance, or (iv) the material breach by you of any of the provisions of this letter or the Related Agreements.

(e) For purposes of this letter, “Good Reason” means, in the context of your resignation from your employment position with the Company, a resignation that occurs within thirty (30) days following: (i) a change in the principal location at which you provide services to the Company beyond fifty (50) miles from Cambridge, MA; (ii) a reduction in your compensation or a material reduction in your benefits, except such a reduction in connection with a general reduction in compensation or other benefits of all senior executives of the Company; (iii) a material breach of this letter by the Company that has not been cured within  two weeks days after written notice thereof by you to the Company; or (iv) a failure by the Company to obtain the assumption of this letter by any successor to the Company.

(f) In the event of your death or permanent disability (as defined below) while you are employed by the Company, your employment hereunder shall immediately and automatically terminate and the Company shall pay to you or your personal representative or designated beneficiary or, if no beneficiary has been designated by you, to your estate, any earned and unpaid base salary, pro-rated through the date of your death or permanent disability. For purposes of this letter, “Permanent Disability” shall mean your inability,

4

 

due to physical or mental illness or disease, to perform the functions then performed by you for one hundred eighty (180) consecutive days, accompanied by the likelihood, in the opinion of a physician chosen by the Company and reasonably acceptable to you, that you will be unable to perform such functions within the reasonably foreseeable future; provided that the foregoing definition shall not include a disability for which the Company is required to provide reasonable accommodation pursuant to the Americans with Disabilities Act or other similar statute or regulation.

(g) The time for payment, or schedule for payment, of any severance payments due hereunder may not be accelerated, except as provided for in the Treasury Regulations promulgated under Section 409A of the Internal Revenue Code of 1986 (the “Code”), or any law replacing or superseding such Section or regulations. Notwithstanding the preceding provisions of this Section 7(g), in the case that you are deemed a “specified employee” (as defined in Section 409A(2)(B)(i) of the Code), no severance payment may be made earlier than the date which is six (6) months after the termination of employment hereunder (or, if earlier, the date of the death of the Executive) if and to the extent required by applicable law or other rules of any stock exchange upon which any of shares of the Company’s capital stock are then traded.

 

8.

Change of Control.

 

(a) Notwithstanding anything to the contrary in any then outstanding option agreement or stock based award, and subject to any permitted action by the Board under the Company’s applicable equity plan to terminate options or other stock based awards upon a Change of Control, in the event that, within the twelve (12) month period that immediately follows or the thirty (30) day period immediately prior to a Change in Control (as defined below), your employment with the Company is terminated: (i) on account of your death or Permanent Disability, (ii) by the Company without Cause, or (iii) as a result of your resignation for Good Reason, then all of your then unvested restricted stock and/or options to purchase shares of the Company’s Common Stock shall accelerate and become fully vested. As used herein, “Change in Control” shall mean the (i) the sale of the Company by merger in which the shareholders of the Company in their capacity as such no longer own a majority of the outstanding equity securities of the Company (or its successor); (ii) any sale of all or substantially all of the assets or capital stock of the Company (other than in a spin-off or similar transaction); or (iii)) any other acquisition of the business of the Company, as determined by the Company’s Board of Directors in their sole discretion. For the avoidance of doubt, in no event shall a bona fide equity or debt financing of the Company, including a financing in which greater than 50% of the Company’s outstanding equity securities are acquired by a third-party be deemed a “Change of Control” for purposes of this letter.

5

 

 

9.

General.

 

(a) Entire Agreement. This letter, together with the Related Agreements, will constitute our entire agreement as to your employment by or consultancy for the Company and will supersede any prior agreements or understandings, whether in writing or oral.

(b) Notices. All notices, requests, consents and other communications hereunder will be in writing, will be addressed to the receiving party’s address set forth above or to such other address as a party may designate by notice hereunder, and will be either (i) delivered by hand, (ii) sent by overnight courier, (iii) sent by registered mail, return receipt requested, postage prepaid (iv) sent by facsimile, electronic mail or electronic PDF transmission, in each case with confirmation retained. All notices, requests, consents and other communications hereunder will be deemed to have been given either (i) if by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, (iii) if sent by registered mail, on the fifth business day following the day such mailing is made or (iv) when confirmation is received, if sent by facsimile or electronic transmission.

(c) Modifications and Amendments. The terms and provisions of this letter may be modified or amended only by written agreement executed by the parties hereto.

(d) Waivers and Consents. The terms and provisions of this letter may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent will be deemed to be or will constitute a waiver or consent with respect to any other terms or provisions of this letter, whether or not similar. Each such waiver or consent will be effective only in the specific instance and for the purpose for which it was given, and will not constitute a continuing waiver or consent.

(e) Assignment. The Company may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of the Company’s business or that aspect of the Company’s business in which you are principally involved. You may not assign your rights and obligations under this letter without the prior written consent of the Company and any such attempted assignment by you without the prior written consent of the Company will be void.

(f) Benefit. All statements, representations, warranties, covenants and agreements in this letter will be binding on the parties hereto and will inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this letter will be construed to create any rights or obligations except between the Company and you, and no person or entity other than the Company will be regarded as a third party beneficiary of this letter.

6

 

(g) Governing Law. This letter and the rights and obligations of the parties hereunder will be construed in accordance with and governed by the law of The Commonwealth of Massachusetts, without giving effect to the conflict of law principles thereof.

(h) Jurisdiction, Venue and Service of Process. Any legal action or proceeding with respect to this letter will be brought in the courts of The Commonwealth of Massachusetts (or, if appropriate, a federal court located within The Commonwealth of Massachusetts). By execution and delivery of this letter, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the exclusive jurisdiction of the aforesaid courts.

(i) WAIVER OF JURY TRIAL. ANY ACTION, DEMAND, CLAIM OR COUNTERCLAIM ARISING UNDER OR RELATING TO THIS AGREEMENT WILL BE RESOLVED BY A JUDGE ALONE AND EACH OF THE COMPANY AND YOU WAIVE ANY RIGHT TO A JURY TRIAL THEREOF.

(j) Counterparts. This letter may be executed in two or more counterparts, and by different parties hereto on separate counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.

7

 

You may accept this offer of employment and the terms and conditions thereof by signing the enclosed additional copy of this letter and each of the Related Agreements, which execution will evidence your agreement with the terms and conditions set forth herein and therein, and returning them to the Company; provided that the provisions of this offer of employment are contingent upon completion of a background check and receipt of appropriate documentation of your work status.

 

 

Sincerely,

SYNLOGIC, INC.

 

 

By:

/s/ Adam Thomas

Name:

Adam J. Thomas

Title:

Chief Human Resources Officer

 

 

Accepted and Approved:

 

 

/s/ Antoine Awad

Print Name: Antoine Awad

 

Date: December 2, 2018

 

8

 EX-10.14.2 4 sybx-ex10142_240.htm EX-10.14.2 sybx-ex10142_240.htm

 

Exhibit 10.14.2

 

Synlogic, Inc.

301 Binney Street, Suite 402

Cambridge, MA 02142

 

 

To:         Antoine Awad

 

Date:      July 21, 2020

 

Re:         Promotion to COO

 

 

 

Dear Tony,  

 

We are delighted to confirm your promotion to COO, effective July 1, 2020.  

 

In recognition of your promotion your compensation will be adjusted as follows:

 

•

Base salary:   $376,000

•

Target Bonus:  40%

•

Promotion Equity Grant:  70,000 options

 

The balance of your terms and conditions remains unchanged and are therefore not re-stated here.  Please note:

 

•

Annual bonuses are discretionary and not guaranteed.  To be eligible for any such bonus, you must be employed by the Company in good standing at the time such bonus is paid.  

•

Equity awards are subject to the terms of the Company’s then applicable equity incentive plan (“Incentive Plan”) and form of option agreement, and subject to approval by the Board of Directors of the Company

 

Thank you for your contribution to Synlogic.  

 

Best wishes,

SYNLOGIC, INC.

By:

 

/s/ Aoife Brennan

Name:

 

Aoife Brennan

Title:

 

President & CEO

 

 

 EX-21.1 5 sybx-ex211_8.htm EX-21.1 sybx-ex211_8.htm

Exhibit 21.1

SUBSIDIARIES OF SYNLOGIC, INC.

 

Subsidiary

Jurisdiction

 

 

Synlogic IBDCo, Inc.

Delaware

Synlogic Operating Company, Inc.

Delaware

Synlogic Securities Corporation

Massachusetts

 

 EX-23.1 6 sybx-ex231_6.htm EX-23.1 sybx-ex231_6.htm

 

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Synlogic, Inc.

 

We consent to the incorporation by reference in the registration statements (Nos. 333-207299, 333-210466, 333-220841, 333-223798, 333-230224, 333-237104 and 333-237105) on Form S-8 and (Nos. 333-220948, 333-226730, and 333-233139) on Form S-3 of Synlogic, Inc. and subsidiaries of our report dated March 25, 2021, with respect to the consolidated balance sheets of Synlogic, Inc. and subsidiaries as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements), which report appears in the December 31, 2020 annual report on Form 10-K of Synlogic, Inc. and subsidiaries.

/s/ KPMG LLP

Boston, Massachusetts

March 25, 2021

 

 EX-31.1 7 sybx-ex311_9.htm EX-31.1 sybx-ex311_9.htm

 

Exhibit 31.1

CERTIFICATIONS UNDER SECTION 302

I, Aoife Brennan, certify that:

1.  I have reviewed this annual report on Form 10-K of Synlogic, Inc.;

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)  designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.  The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 25, 2021

By:

/s/ AOIFE BRENNAN

 

 

Aoife Brennan

 

 

President and Chief Executive Officer

(Principal Executive Officer)

 

 

 EX-31.2 8 sybx-ex312_7.htm EX-31.2 sybx-ex312_7.htm

 

Exhibit 31.2

CERTIFICATIONS UNDER SECTION 302

I, Gregg Beloff, certify that:

1.  I have reviewed this annual report on Form 10-K of Synlogic, Inc.;

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)  designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.  The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 25, 2021

By:

/s/ GREGG BELOFF

 

 

Gregg Beloff

 

 

Interim Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

 

 

 EX-32.1 9 sybx-ex321_12.htm EX-32.1 sybx-ex321_12.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Synlogic, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Aoife Brennan, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: March 25, 2021

 

By:

/s/ AOIFE BRENNAN

 

 

 

Aoife Brennan

 

 

 

President and Chief Executive Officer 

(Principal Executive Officer)

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 EX-32.2 10 sybx-ex322_10.htm EX-32.2 sybx-ex322_10.htm

 

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Synlogic, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gregg Beloff, Interim Chief Financial Officer, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: March 25, 2021

 

By:

/s/ GREGG BELOFF

 

 

 

Gregg Beloff

 

 

 

Interim Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 GRAPHIC 11 gfkh34aypiqb000001.jpg GRAPHIC begin 644 gfkh34aypiqb000001.jpg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end GRAPHIC 12 gfkh34aypiqb000002.jpg GRAPHIC begin 644 gfkh34aypiqb000002.jpg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sybx-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Statements of Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Nature of Business link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Fair Value of Financial Instruments link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Available-for-Sale Investments link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Prepaid Expenses and Other Current Assets link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Property and Equipment, Net link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Common Stock link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Equity-based Compensation and Equity Incentive Plans link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Collaboration Agreements link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Net Loss per Share link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Leases link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Employee Benefits link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Related-Party Transactions link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Selected Quarterly Data (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Fair Value of Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Available-for-Sale Investments (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Property and Equipment, Net (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Common Stock (Tables) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Equity-based Compensation and Equity Incentive Plans (Tables) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Net Loss per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Leases (Tables) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Selected Quarterly Data (Unaudited) (Tables) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Nature of Business - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Summary of Significant Accounting Policies - Schedule of Useful Life of Property and Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Available-for-Sale Investments - Summary of Available-for-Sale Securities Held (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Available-for-Sale Investments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Prepaid Expenses and Other Current Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Property and Equipment, Net - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Common Stock - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Common Stock - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees (Detail) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Detail) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Restricted Common Stock Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses by Award Type (Detail) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Collaboration Agreements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 100580 - Disclosure - Net Loss per Share - Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share (Detail) link:calculationLink link:presentationLink link:definitionLink 100590 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100600 - Disclosure - Income Taxes - Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100610 - Disclosure - Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate (Detail) link:calculationLink link:presentationLink link:definitionLink 100620 - Disclosure - Income Taxes - Schedule of Valuation Allowance - (Detail) link:calculationLink link:presentationLink link:definitionLink 100630 - Disclosure - Leases - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100640 - Disclosure - Leases - Components of Lease Cost for Operating Leases (Detail) link:calculationLink link:presentationLink link:definitionLink 100650 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases (Detail) link:calculationLink link:presentationLink link:definitionLink 100660 - Disclosure - Leases - Summary of Maturity of Lease Liabilities for Operating Leases (Detail) link:calculationLink link:presentationLink link:definitionLink 100670 - Disclosure - Leases - Summary of Maturity of Lease Liabilities for Operating Leases (Detail)2 link:calculationLink link:presentationLink link:definitionLink 100680 - Disclosure - Employee Benefits - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100690 - Disclosure - Related-Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100700 - Disclosure - Selected Quarterly Data (unaudited) (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 14 sybx-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 15 sybx-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 16 sybx-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Well Known Seasoned Issuer Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company ICFR Auditor Attestation Flag Icfr Auditor Attestation Flag Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Public Float Entity Public Float Title of 12(b) Security Security12b Title Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Interactive Data Current Entity Interactive Data Current Security Exchange Name Security Exchange Name Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Document Annual Report Document Annual Report Document Transition Report Document Transition Report Prepaid research and development noncurrent. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term marketable securities Available For Sale Securities Debt Securities Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Long-term marketable securities Available For Sale Securities Debt Securities Noncurrent Property and equipment, net Property Plant And Equipment Net Right of use asset - operating lease Operating Lease Right Of Use Asset Restricted cash Restricted Cash Noncurrent Prepaid research and development, net of current portion Prepaid Research And Development Noncurrent Other assets Other Assets Noncurrent Total assets Assets Liabilities and Stockholders' Equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current Deferred revenue Contract With Customer Liability Current Lease liability - operating lease Operating Lease Liability Current Finance lease obligations Finance Lease Liability Current Total current liabilities Liabilities Current Long-term liabilities: Liabilities Noncurrent [Abstract] Lease liability - operating lease, net of current portion Operating Lease Liability Noncurrent Finance lease obligations, net of current portion Finance Lease Liability Noncurrent Other long-term liabilities Other Liabilities Noncurrent Total long-term liabilities Liabilities Noncurrent Commitments and contingencies (Note 14) Commitments And Contingencies Stockholders' equity Stockholders Equity [Abstract] Common stock, $0.001 par value 250,000,000 shares authorized as of December 31, 2020 and December 31, 2019. 38,183,273 shares issued and outstanding as of December 31, 2020 and 32,266,814 shares issued and outstanding as of December 31, 2019. Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders' equity Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, authorized Common Stock Shares Authorized Common stock, Issued Common Stock Shares Issued Common stock, outstanding Common Stock Shares Outstanding Income Statement [Abstract] Revenue Revenues Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Other income (expense): Nonoperating Income Expense [Abstract] Interest and investment income Investment Income Nonoperating Interest expense Interest Expense Other expense Other Nonoperating Income Expense Other income (expense), net Nonoperating Income Expense Net loss Net Income Loss Net loss per share - basic and diluted Earnings Per Share Basic And Diluted Weighted-average common stock outstanding - basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Comprehensive loss: Comprehensive Income Net Of Tax [Abstract] Net loss Net unrealized (loss) gain on marketable securities Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Accumulated Other Comprehensive Income (Loss) Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock $0.001 Par Value Common Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income [Member] Accumulated Deficit Retained Earnings [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] At-the-market offering, At-the-market Offering At The Market Offering [Member] Statement [Line Items] Statement [Line Items] Balance Balance (in Shares) Shares Outstanding Proceeds from issuance of common stock, net of issuance costs Stock Issued During Period Value New Issues Proceeds from issuance of common stock, net of issuance costs, Shares Stock Issued During Period Shares New Issues Proceeds from issuance of pre-funded common stock warrants, net of issuance costs Adjustments To Additional Paid In Capital Warrant Issued Exercise of options Stock Issued During Period Value Stock Options Exercised Exercise of options, shares Stock Issued During Period Shares Stock Options Exercised Issuance of restricted stock Stock Issued During Period Value Restricted Stock Award Gross Issuance of restricted stock, shares Stock Issued During Period Shares Restricted Stock Award Gross Issuance of common stock under employee stock purchase plan Stock Issued During Period Value Employee Stock Purchase Plan Issuance of common stock under employee stock purchase plan, Shares Stock Issued During Period Shares Employee Stock Purchase Plans Cancellation of restricted stock Stock Issued During Period Shares Restricted Stock Award Forfeited Equity-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Unrealized gain (loss) on securities Balance Balance (in Shares) Reduction in carrying amount of operating lease right-of-use asset. Increase (decrease) in prepaid research and development net of current portion. Increase Decrease in Operating Lease Liability. Proceeds from employee stock purchases and exercise of stock options. Noncash purchase of property, plant and equipment in accounts payable and accrued liabilities adjustments. Assets acquired under operating lease obligation. Issuance costs included in accounts payable and accrued expenses. Noncash investing items. Noncash financing items. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation Depreciation Equity-based compensation expense Share Based Compensation Accretion/amortization of investment securities Accretion Amortization Of Discounts And Premiums Investments Reduction in carrying amount of operating lease right of use asset Reduction In Carrying Amount Of Operating Lease Right Of Use Asset Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid research and development, net of current portion Increase Decrease In Prepaid Research And Development Net Of Current Portion Other assets Increase Decrease In Other Operating Assets Accounts payable and accrued expenses Increase Decrease In Accounts Payable And Accrued Liabilities Deferred revenue Increase Decrease In Contract With Customer Liability Operating lease liabilities Increase Decrease In Operating Lease Liability Other long-term liabilities Increase Decrease In Other Noncurrent Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of marketable securities Payments To Acquire Available For Sale Securities Debt Proceeds from maturity of marketable securities Proceeds From Sale And Maturity Of Marketable Securities Proceeds from redemption of marketable securities Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities Purchases of property and equipment Payments To Acquire Property Plant And Equipment Net cash provided by investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Payments on finance lease obligations Finance Lease Principal Payments Proceeds from issuance/sale of common stock, net of issuance costs Proceeds From Issuance Of Common Stock Proceeds from employee stock purchases and exercise of stock options Proceeds From Employee Stock Purchases And Exercise Of Stock Options Proceeds from sale of pre-funded warrants, net of issuance costs Proceeds From Issuance Of Warrants Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash, cash equivalents and restricted cash at end of period Supplemental disclosure of non-cash investing activities: Noncash Investing Items [Abstract] Property and equipment purchases included in accounts payable and accrued expenses Noncash Purchase Of Property Plant And Equipment In Accounts Payable And Accrued Liabilities Adjustments Assets acquired under operating lease obligation Assets Acquired Under Operating Lease Obligation Supplemental disclosure of non-cash financing activities: Noncash Financing Items [Abstract] Issuance costs included in accounts payable and accrued expenses Issuance Costs Included In Accounts Payable And Accrued Expenses Cash paid for interest Interest Paid Net Documents Incorporated by Reference Documents Incorporated By Reference [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] Nature of Business Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Available for sale securities disclosure. Investments Debt And Equity Securities [Abstract] Available-for-Sale Investments Available For Sale Securities Disclosure [Text Block] Prepaid expenses and other current assets. Text Block [Abstract] Prepaid Expenses and Other Current Assets Prepaid Expenses And Other Current Assets [Text Block] Property Plant And Equipment [Abstract] Property and Equipment, Net Property Plant And Equipment Disclosure [Text Block] Payables And Accruals [Abstract] Accrued Expenses Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block] Equity [Abstract] Common Stock Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Equity-based Compensation and Equity Incentive Plans Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Earnings Per Share [Abstract] Net Loss per Share Earnings Per Share [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Leases [Abstract] Leases Leases Of Lessee Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Compensation And Retirement Disclosure [Abstract] Employee Benefits Compensation And Employee Benefit Plans [Text Block] Related Party Transactions [Abstract] Related-Party Transactions Related Party Transactions Disclosure [Text Block] Quarterly Financial Information Disclosure [Abstract] Selected Quarterly Data (Unaudited) Quarterly Financial Information [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Principles of Consolidation Consolidation Policy [Text Block] Use of Estimates Use Of Estimates Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Concentration of Credit Risk Concentration Risk Credit Risk Restricted Cash Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy Fair Value Fair Value Measurement Policy Policy [Text Block] Available-for-Sale Securities Marketable Securities Policy Property and Equipment Property Plant And Equipment Policy [Text Block] Impairment of Long-Lived Assets Property Plant And Equipment Impairment Leases Lessee Leases Policy [Text Block] Research and Development Costs Research And Development Expense Policy Revenue recognition Revenue From Contract With Customer Policy [Text Block] Equity-Based Compensation Share Based Compensation Option And Incentive Plans Policy Income Taxes Income Tax Policy [Text Block] Net Loss Per Share Earnings Per Share Policy [Text Block] Segment Information Segment Reporting Policy Policy [Text Block] New accounting pronouncements. New Accounting Pronouncements New Accounting Pronouncements Policy [Text Block] Recently adopted accounting pronouncements. Recently Adopted Accounting Pronouncements Recently Adopted Accounting Pronouncements Policy [Text Block] Recently Issued Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Schedule Of Restricted Cash And Cash Equivalents [Text Block] Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Schedule of Useful Life of Property and Equipment Schedule Of Property Plant And Equipment Useful Life Table [Text Block] Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Summary of Available-for-Sale Securities Held Schedule Of Available For Sale Securities Reconciliation Table [Text Block] Schedule of prepaid expenses and other current assets. Schedule of Prepaid Expenses and Other Current Assets Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block] Schedule of Property and Equipment, Net Property Plant And Equipment [Text Block] Schedule of Accrued Expenses Schedule Of Accrued Liabilities Table [Text Block] Schedule of shares of common stock reserved for future issuance. Schedule of Shares of Common Stock Reserved for Future Issuance Schedule Of Shares Of Common Stock Reserved For Future Issuance Table [Text Block] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Long term incentive plan 2015 and 2017. 2015 and 2017 Plan Long Term Incentive Plan2015 And2017 [Member] Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Schedule of Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Schedule of Restricted Common Stock Activity Nonvested Restricted Stock Shares Activity Table [Text Block] Schedule of Equity-based Compensation Expenses Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Schedule of Equity-based Compensation Expenses by Award Type Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Text Block] Schedule of Computation of Basic and Diluted Net Loss per Share Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities Schedule Of Deferred Tax Assets And Liabilities Table [Text Block] Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block] Schedule of Valuation Allowance Summary Of Valuation Allowance [Text Block] Components of Lease Cost for Operating Leases Lease Cost Table [Text Block] Lessee weighted average remaining lease term and weighted average discount rate. Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases Lessee Weighted Average Remaining Lease Term And Weighted Average Discount Rate Table [Text Block] Lessee, operating and finance lease, liability, maturity. Summary of Maturity of Lease Liabilities for Operating Leases Lessee Operating And Finance Lease Liability Maturity Table [Text Block] Selected Quarterly Data (unaudited) Schedule Of Quarterly Financial Information Table [Text Block] Cash, cash equivalents, and short-term marketable securities Cash Cash Equivalents And Short Term Investments Summary of significant accounting policies. Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Credit Facility Credit Facility [Axis] Credit Facility Credit Facility [Domain] Letter of Credit Letter Of Credit [Member] Accounting Standards Update Adjustments For New Accounting Pronouncements [Axis] Accounting Standards Update Type Of Adoption [Member] ASU 2019-12 Accounting Standards Update201912 [Member] ASU 2018-13 Accounting Standards Update201813 [Member] ASU 2018-15 Accounting Standards Update201815 [Member] ASU 2018-18 Accounting Standards Update201818 [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Cash equivalents maturity Additional Cash And Cash Equivalent Related Text Cash equivalents Cash Equivalents At Carrying Value Cash Cash Restricted cash included in other long-term assets Cash Collateral For Borrowed Securities Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows Represents net transfers in and out of assets and liabilities measured at fair value on a recurring basis using Level 1, Level 2 and Level 3 inputs. Transfers of assets and liabilities between Level 1, Level 2, or Level 3 Fair Value Asset Liability Transfers Between Level1 Level2 And Level3 Amount Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Computer and office equipment. Computer and Office Equipment Computer And Office Equipment [Member] Furniture and Fixtures Furniture And Fixtures [Member] Laboratory Equipment Equipment [Member] Leasehold Improvements Leasehold Improvements [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Useful life Property Plant And Equipment Useful Life Useful life Property Plant And Equipment Estimated Useful Lives Impairment charge Tangible Asset Impairment Charges Lessee, operating lease, existence of option to extend Lessee Operating Lease Existence Of Option To Extend Lessee, operating lease, option to extend Lessee Operating Lease Option To Extend Revenue, practical expedient, incremental cost of obtaining contract [true/false] Revenue Practical Expedient Incremental Cost Of Obtaining Contract Revenue, practical expedient, remaining performance obligation, description Revenue Practical Expedient Remaining Performance Obligation Description Description of tax benefit likely to be realized upon settlement Income Tax Examination Likelihood Of Unfavorable Settlement Number of operating segment Number Of Operating Segments Change in accounting principle, accounting standards update, adopted [true false] Change In Accounting Principle Accounting Standards Update Adopted Change in accounting principle, accounting standards update, adoption date Change In Accounting Principle Accounting Standards Update Adoption Date Change in accounting principle, accounting standards update, immaterial effect [true false] Change In Accounting Principle Accounting Standards Update Immaterial Effect Fair Value Asset Measured On Recurring Basis [Line Items] Fair Value Asset Measured On Recurring Basis [Table] Fair Value Asset Measured On Recurring Basis [Table] Fair Value Asset Measured On Recurring Basis [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Recurring Fair Value Measurements Recurring [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value Inputs Level1 [Member] Significant Other Observable Inputs (Level 2) Fair Value Inputs Level2 [Member] Significant Unobservable Inputs (Level 3) Fair Value Inputs Level3 [Member] Financial Instrument Financial Instrument [Axis] Financial Instruments Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] Corporate debt securities Corporate Debt Securities [Member] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Commercial paper Commercial Paper [Member] US treasury and government long-term debt securities. U.S. Government Agency Securities and Treasuries U S Treasury And Government Long Term Debt Securities [Member] Cash and Cash Equivalents Cash And Cash Equivalents [Axis] Cash and Cash Equivalents Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Money market funds Money Market Funds [Member] Fair Value Asset Measured On Recurring Basis [Line Items] Fair Value Asset Measured On Recurring Basis [Line Items] Cash and Cash Equivalents Cash And Cash Equivalents Fair Value Disclosure Short-term investments Investments Fair Value Disclosure Total assets Assets Fair Value Disclosure Marketable securities Marketable Securities Debt Securities Available For Sale [Table] Debt Securities Available For Sale [Table] U.S. government agency securities U S Government Agencies Debt Securities [Member] Schedule of Available-for-sale Securities [Line Items] Schedule Of Available For Sale Securities [Line Items] Amortized cost Available For Sale Debt Securities Amortized Cost Basis Gross unrealized gains Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Gross unrealized losses Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Fair Value Available For Sale Securities Debt Securities Other than temporary impairment losses investments number debt securities available for sale. Number of investments in unrealized loss position Debt Securities Available For Sale Unrealized Loss Position Number Of Positions Number of investments in unrealized loss position, more than twelve months Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions Aggregate fair value of securities in unrealized loss position Debt Securities Available For Sale Unrealized Loss Position Number of securities with other than temporary impairment Other Than Temporary Impairment Losses Investments Number Debt Securities Available For Sale Prepaid research and development, current. Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract] Prepaid insurance Prepaid Insurance Prepaid research and development Prepaid Research And Development Current Other prepaid expenses Other Prepaid Expense Current Other current assets Other Assets Current Total Depreciation expense Construction in Progress Construction In Progress [Member] Property and equipment, gross Property Plant And Equipment Gross Less accumulated depreciation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and equipment, net Accrued research and development, current. Payroll related Employee Related Liabilities Current Professional fees Accrued Professional Fees Current Research and development Accrued Research And Development Current Other Other Accrued Liabilities Current Total accrued expenses Stockholders Equity Note [Abstract] Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Common Stock Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Ginkgo Bioworks, Inc. Ginkgo Bioworks, Inc. Ginkgo Bioworks Inc [Member] Class of Warrant or Right Class Of Warrant Or Right [Axis] Class of Warrant or Right Class Of Warrant Or Right [Domain] Pre-Funded Warrants. Pre-Funded Warrants Pre Funded Warrants [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Maximum Maximum [Member] Minimum [Member] Minimum [Member] at the market. ATM At The Market [Member] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Cowen and company LLC. Cowen and Company, LLC Cowen And Company L L C [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Number of votes entitled to each share of common stock. Number of votes entitled to each share of common stock Number Of Votes Entitled To Each Share Of Common Stock Cash dividends Dividends Common Stock Cash Sale of common stock and prefunded warrant price per share. Class of warrant or right exercise price of warrants paid at closing of offering. Proceeds from issuance of common stock and pre funded warrants. Warrants exercised. Sale of common stock, shares Sale of stock, price per share Sale Of Common Stock And Prefunded Warrant Price Per Share Warrants to purchase shares of common stock Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Warrants exercise price per share Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Warrants exercise price per share paid at closing of offering Class Of Warrant Or Right Exercise Price Of Warrants Paid At Closing Of Offering Proceeds, net of issuance costs, from issuance of common stock and pre-funded warrants Proceeds From Issuance Of Common Stock And Pre Funded Warrants Proceeds from sale of common stock, net of issuance costs Warrants exercised Warrants Exercised Unbeneficial percentage of ownership after exercise of common stock outstanding effect to issuance. Unbeneficial percentage of ownership after exercise of common stock outstanding effect to issuance Unbeneficial Percentage Of Ownership After Exercise Of Common Stock Outstanding Effect To Issuance Common Stock Issuable Under Pre-Funded Warrants Option Indexed to Issuer's Equity Option Indexed To Issuers Equity Equity [Axis] Option Indexed to Issuer's Equity, Type Option Indexed To Issuers Equity Type [Domain] Options To Purchase Common Stock Employee Stock Option [Member] Employee Stock Purchase Plan Employee Stock [Member] Total Shares of Common Stock Reserved for Future Issuance Common Stock Capital Shares Reserved For Future Issuance Share based compensation arrangement by share based payment award percentage of shares outstanding. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Long Term Incentive Plan 2015. Plan 2015 Long Term Incentive Plan2015 [Member] ESPP Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Restricted Common Stock Restricted Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Percentage of shares outstanding Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Shares Outstanding Percentage of discount for employees under ESPP Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date Purchase price as a percentage of fair value under ESPP Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent Share-based compensation arrangement by share-based payment award, options outstanding, weighted average exercise price, and additional disclosures. Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price And Additional Disclosures [Abstract] Title of Individual Title Of Individual [Axis] Title of Individual Title Of Individual With Relationship To Entity [Domain] Employees and nonemployees. Employees and Nonemployees Employees And Nonemployees [Member] Expected term Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Weighted-average, risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Outstanding Beginning balance, Number of options Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Granted, Number of options Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Exercised, Number of options Cancelled/Forfeited, Number of options Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Outstanding Ending balance, Number of options Number of options, Vested or expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Number of options, Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Beginning balance, Weighted-average price Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Granted, Weighted-average price Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Exercised, Weighted-average price Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Cancelled/Forfeited, Weighted-average price Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Ending balance, Weighted-average price Weighted-average price Vested or expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price Weighted-average price, Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Outstanding, weighted average remaining contractual term (Year) Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Weighted average remaining contractual term, Vested or expected to vest Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 Weighted average remaining contractual term, Exercisable Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Share based compensation arrangement by share based payment award options grants in period intrinsic value. Share based compensation arrangement by share based payment award options forfeitures and expirations in period intrinsic value. Beginning balance, Aggregate Intrinsic Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Granted, Aggregate Intrinsic value Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Exercised, Aggregate Intrinsic value Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value Cancelled/Forfeited, Aggregate Intrinsic value Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value Ending balance, Aggregate Intrinsic value Aggregate Intrinsic value, Vested or expected to vest at December 31, 2020 Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value Aggregate Intrinsic value, Exercisable at December 31, 2020 Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 Share based compensation by share based arrangement award, options available for aggregate intrinsic value. Number of options in money Share Based Compensation By Share Based Arrangement Award Options Available For Aggregate Intrinsic Value Weighted average grant date fair value per share of options granted to employees Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Total fair value of awards vested Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value Employee unrecognized compensation expense Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Employee unrecognized compensation cost, period of recognition Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Beginning balance, Number of unvested shares/units Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number Granted, Number of shares/units Vested, Number of shares/units Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Forfeited, Number of shares/units Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Ending balance, Number of unvested shares/units Beginning balance, Unvested Grant date fair value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value Granted, Grant date fair value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value Vested, Grant date fair value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value Forfeited, Grant date fair value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value Ending balance, Unvested Grant date fair value Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development Expense Research And Development Expense [Member] General and Administrative Expense General And Administrative Expense [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Equity-based compensation expense Allocated Share Based Compensation Expense Stock Options Restricted Stock Awards Prepayment to related party for collaboration agreement. Related party transaction collaboration agreement, initial term. Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Ginkgo Collaboration Abb Vie agreement. Abb Vie Agreement Abb Vie Agreement [Member] Business Acquisition Business Acquisition [Axis] Business Acquisition, Acquiree Business Acquisition Acquiree [Domain] IBDCo [Member] Ibdco Ibdco [Member] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Number of shares sold Current pre-paid research and development Prepaid Expense Current Non-current pre-paid research and development Prepaid Expense Noncurrent Prepayment to related party for collaboration agreement Prepayment To Related Party For Collaboration Agreement Related party transaction collaboration agreement, initial term Related Party Transaction Collaboration Agreement Initial Term Anticipated completion period for research and development projects. Collaboration in research and development Anticipated Completion Of Research And Development Projects Period Recognition of revenue Current deferred revenue Earnings Per Share Reconciliation [Abstract] Numerator: Net Income Loss Available To Common Stockholders Diluted [Abstract] Net loss Denominator: Weighted Average Number Of Shares Outstanding [Abstract] Weighted-average common shares outstanding - basic and diluted Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Unvested Restricted Stock Awards [Member] Unvested Restricted Common Stock Awards Unvested Restricted Stock Awards [Member] Potential Shares Issuable Under ESPP Stock Compensation Plan [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Potentially Common Shares Excluded from Calculation of Net Loss Per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Income tax disclosure. Income tax disclosure. Income Tax Disclosure [Table] Income Tax Disclosure [Table] Income Tax Authority Income Tax Authority [Axis] Income Tax Authority Income Tax Authority [Domain] State State And Local Jurisdiction [Member] Income Tax Authority, Name Income Tax Authority Name [Axis] Income Tax Authority, Name Income Tax Authority Name [Domain] Federal Internal Revenue Service I R S [Member] Tax Credit Carryforward Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name Tax Credit Carryforward Name [Domain] Research and Development. Research [Member] Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] Income tax benefits for the net operating losses Income Tax Expense Benefit Deferred tax assets other long-term liabilities. Deferred tax assets lease liabilities. Deferred tax liabilities, right of use assets. Deferred tax assets: Deferred Tax Assets Net [Abstract] Net operating loss carryforwards Deferred Tax Assets Operating Loss Carryforwards Tax credit carryforwards Deferred Tax Assets Tax Credit Carryforwards Accrued expenses Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities Property and equipment Deferred Tax Assets Property Plant And Equipment Other long-term liabilities Deferred Tax Assets Other Long Term Liabilities Lease liabilities Deferred Tax Assets Lease Liabilities Equity compensation Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Amortizable intangibles Deferred Tax Assets Goodwill And Intangible Assets Other Deferred Tax Assets Other Gross deferred tax assets Deferred Tax Assets Gross Deferred tax liabilities: Deferred Tax Liabilities Net [Abstract] Property and equipment Deferred Tax Liabilities Property Plant And Equipment Right of use assets Deferred Tax Liabilities Right Of Use Assets Gross deferred tax liabilities Deferred Income Tax Liabilities Valuation allowance Deferred Tax Assets Valuation Allowance Net deferred tax assets Deferred Tax Assets Liabilities Net Valuation allowance U.S. federal statutory rate Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate State income taxes, net of federal benefit, Tax Rate Effective Income Tax Rate Reconciliation State And Local Income Taxes Other permanent differences, Tax Rate Effective Income Tax Rate Reconciliation Nondeductible Expense Other Tax credits, Tax Rate Effective Income Tax Rate Reconciliation Tax Credits Other items, Tax Rate Effective Income Tax Rate Reconciliation Other Adjustments Net change in valuation allowance, Tax Rate Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance Effective income tax rate Effective Income Tax Rate Continuing Operations Balance at beginning of year Increase in valuation allowance Valuation Allowance Deferred Tax Asset Change In Amount Balance at end of year Operating loss carryforwards expiration year. Operating loss carryforwards subject to expiration. Operating loss carryforwards not subject to expiration. Net operating loss carryforwards Operating Loss Carryforwards Net operating loss carryforwards subject to expiration Operating Loss Carryforwards Subject To Expiration Net operating loss carryforwards not subject to expiration Operating Loss Carryforwards Not Subject To Expiration Net operating loss carryforwards expiration year Operating Loss Carryforwards Expiration Year Tax credit carryforwards Tax Credit Carryforward Amount Unrecognized tax benefits Unrecognized Tax Benefits Income tax examination description Income Tax Examination Description Interest or penalties accrued Income Tax Examination Penalties And Interest Accrued Rentable Space Under Lease Agreement Operating leases rent expense annual rental payments. The amount the lessee agrees to invest into a tenant improvement of a leased property. Lessee Lease Description [Table] Lessee Lease Description [Table] Master contract services agreement. Master Services Agreement Master Contract Services Agreement [Member] Legal Entity Legal Entity [Axis] Entity Entity [Domain] Azzur Group Limited Liability Company. Azzur Group, LLC Azzur Group Limited Liability Company [Member] Lessee Lease Description [Line Items] Lessee Lease Description [Line Items] Laboratory and office space to be leased Rentable Space Under Lease Agreement Operating lease annual rent Operating Leases Rent Expense Annual Rental Payments Term of lease Lessee Operating Lease Term Of Contract Tenant improvement investment Tenant Improvement Investment Obligation Letter of credit Line Of Credit Facility Maximum Borrowing Capacity Renewal term of lease Lessee Operating Lease Renewal Term Lessee, operating lease, existence of option to terminate Lessee Operating Lease Existence Of Option To Terminate Access and Use of space under agreement. Term of agreement. Agreement expiration date. Estimated expenses to be incurred in access and use of space under agreement. Access and use of space under agreement Access And Use Of Space Under Agreement Term of agreement Term Of Agreement Agreement expiration date Agreement Expiration Date Estimated expenses to be incurred Estimated Expenses To Be Incurred In Access And Use Of Space Under Agreement Cash paid included in operating cash flows Operating Lease Payments Operating and variable lease cost. Operating lease cost. Operating leases Operating Lease Cost [Abstract] Operating lease cost Operating Lease Cost Short-term lease cost Short Term Lease Cost Variable lease cost Variable Lease Cost Operating and variable lease cost Operating And Variable Lease Cost Operating Lease, Weighted average discount rate Operating Lease Weighted Average Discount Rate Percent Operating Lease, Weighted average remaining lease term (years) Operating Lease Weighted Average Remaining Lease Term1 Operating Leases Operating Lease Liabilities Payments Due [Abstract] 2021 Lessee Operating Lease Liability Payments Due Next Twelve Months 2022 Lessee Operating Lease Liability Payments Due Year Two 2023 Lessee Operating Lease Liability Payments Due Year Three 2024 Lessee Operating Lease Liability Payments Due Year Four 2025 Lessee Operating Lease Liability Payments Due Year Five Thereafter Lessee Operating Lease Liability Payments Due After Year Five Total lease payments Lessee Operating Lease Liability Payments Due Less: imputed interest Lessee Operating Lease Liability Undiscounted Excess Amount Total lease liabilities Operating Lease Liability Current lease liabilities Long-term lease liabilities Eligible employees to contribute to 401(k) plan Defined Contribution Plan Employer Matching Contribution Percent Of Match Employee contribution Defined Contribution Plan Maximum Annual Contributions Per Employee Percent Maximum matching contributions as a percentage of eligible compensation Defined Contribution Plan Employer Matching Contribution Percent Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Current Pre-Paid Research and Development. Non Current Pre-Paid Research and Development Prepaid research and development expenses. Prepayment to related party for collaboration agreement Related party transaction collaboration agreement, initial term Current Pre-Paid Research and Development Current Pre Paid Research And Development Non Current Pre-Paid Research and Development Non Current Pre Paid Research And Development Prepaid research and development expenses Prepaid Research And Development Expenses Operating expenses Loss from operations EX-101.PRE 17 sybx-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 18 sybx-10k_20201231_htm.xml IDEA: XBRL DOCUMENT 0001527599 2020-01-01 2020-12-31 0001527599 2021-03-18 0001527599 2020-06-30 0001527599 2020-12-31 0001527599 2019-12-31 0001527599 2019-01-01 2019-12-31 0001527599 us-gaap:CommonStockMember 2018-12-31 0001527599 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001527599 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001527599 us-gaap:RetainedEarningsMember 2018-12-31 0001527599 2018-12-31 0001527599 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001527599 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001527599 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001527599 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001527599 us-gaap:CommonStockMember 2019-12-31 0001527599 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001527599 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001527599 us-gaap:RetainedEarningsMember 2019-12-31 0001527599 us-gaap:CommonStockMember sybx:AtTheMarketOfferingMember 2020-01-01 2020-12-31 0001527599 us-gaap:AdditionalPaidInCapitalMember sybx:AtTheMarketOfferingMember 2020-01-01 2020-12-31 0001527599 sybx:AtTheMarketOfferingMember 2020-01-01 2020-12-31 0001527599 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001527599 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001527599 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001527599 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001527599 us-gaap:CommonStockMember 2020-12-31 0001527599 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001527599 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001527599 us-gaap:RetainedEarningsMember 2020-12-31 0001527599 sybx:LongTermIncentivePlan2015And2017Member 2020-01-01 2020-12-31 0001527599 us-gaap:LetterOfCreditMember 2020-12-31 0001527599 us-gaap:LetterOfCreditMember 2019-12-31 0001527599 sybx:ComputerAndOfficeEquipmentMember 2020-01-01 2020-12-31 0001527599 us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-12-31 0001527599 us-gaap:EquipmentMember 2020-01-01 2020-12-31 0001527599 us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-12-31 0001527599 us-gaap:AccountingStandardsUpdate201912Member 2020-12-31 0001527599 us-gaap:AccountingStandardsUpdate201813Member 2020-12-31 0001527599 us-gaap:AccountingStandardsUpdate201815Member 2020-12-31 0001527599 us-gaap:AccountingStandardsUpdate201818Member 2020-12-31 0001527599 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0001527599 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001527599 us-gaap:FairValueMeasurementsRecurringMember sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember 2020-12-31 0001527599 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001527599 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001527599 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001527599 us-gaap:FairValueMeasurementsRecurringMember sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember sybx:USTreasuryAndGovernmentLongTermDebtSecuritiesMember 2019-12-31 0001527599 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001527599 us-gaap:CommercialPaperMember 2020-12-31 0001527599 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001527599 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001527599 us-gaap:CommercialPaperMember 2019-12-31 0001527599 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001527599 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001527599 us-gaap:EquipmentMember 2020-12-31 0001527599 us-gaap:EquipmentMember 2019-12-31 0001527599 sybx:ComputerAndOfficeEquipmentMember 2020-12-31 0001527599 sybx:ComputerAndOfficeEquipmentMember 2019-12-31 0001527599 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001527599 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001527599 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001527599 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001527599 us-gaap:ConstructionInProgressMember 2020-12-31 0001527599 us-gaap:ConstructionInProgressMember 2019-12-31 0001527599 2007-12-01 2020-12-31 0001527599 sybx:GinkgoBioworksIncMember us-gaap:CommonStockMember 2019-06-01 2019-06-30 0001527599 sybx:GinkgoBioworksIncMember 2019-06-30 0001527599 srt:MaximumMember sybx:PreFundedWarrantsMember sybx:GinkgoBioworksIncMember 2019-06-30 0001527599 sybx:PreFundedWarrantsMember sybx:GinkgoBioworksIncMember 2019-06-30 0001527599 sybx:GinkgoBioworksIncMember 2019-06-01 2019-06-30 0001527599 sybx:PreFundedWarrantsMember sybx:GinkgoBioworksIncMember 2019-06-01 2019-06-30 0001527599 sybx:PreFundedWarrantsMember sybx:GinkgoBioworksIncMember 2020-12-31 0001527599 srt:MaximumMember sybx:GinkgoBioworksIncMember sybx:PreFundedWarrantsMember 2019-06-01 2019-06-30 0001527599 sybx:CowenAndCompanyLLCMember sybx:AtTheMarketMember 2020-01-01 2020-12-31 0001527599 srt:MaximumMember sybx:CowenAndCompanyLLCMember sybx:AtTheMarketMember 2020-01-01 2020-12-31 0001527599 sybx:CowenAndCompanyLLCMember us-gaap:SubsequentEventMember sybx:AtTheMarketMember 2021-01-01 2021-03-25 0001527599 sybx:PreFundedWarrantsMember 2020-12-31 0001527599 us-gaap:EmployeeStockOptionMember 2020-12-31 0001527599 us-gaap:EmployeeStockMember 2020-12-31 0001527599 sybx:LongTermIncentivePlan2015Member 2019-01-01 2019-12-31 0001527599 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001527599 us-gaap:CommonStockMember us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001527599 sybx:EmployeesAndNonemployeesMember sybx:LongTermIncentivePlan2015And2017Member 2020-01-01 2020-12-31 0001527599 sybx:EmployeesAndNonemployeesMember sybx:LongTermIncentivePlan2015And2017Member 2019-01-01 2019-12-31 0001527599 sybx:LongTermIncentivePlan2015And2017Member 2019-12-31 0001527599 sybx:LongTermIncentivePlan2015And2017Member 2020-12-31 0001527599 sybx:LongTermIncentivePlan2015And2017Member 2019-01-01 2019-12-31 0001527599 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001527599 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001527599 us-gaap:RestrictedStockMember 2019-12-31 0001527599 us-gaap:RestrictedStockMember 2020-12-31 0001527599 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0001527599 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001527599 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001527599 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001527599 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001527599 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001527599 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001527599 us-gaap:CommonStockMember sybx:GinkgoBioworksIncMember 2019-06-01 2019-06-30 0001527599 sybx:PreFundedWarrantsMember sybx:GinkgoBioworksIncMember 2019-06-30 0001527599 sybx:GinkgoBioworksIncMember 2019-06-30 0001527599 sybx:GinkgoBioworksIncMember 2019-06-01 2019-06-30 0001527599 sybx:IbdcoMember sybx:AbbVieAgreementMember 2020-01-01 2020-12-31 0001527599 sybx:AbbVieAgreementMember 2020-01-01 2020-12-31 0001527599 sybx:AbbVieAgreementMember 2019-01-01 2019-12-31 0001527599 sybx:AbbVieAgreementMember 2020-12-31 0001527599 sybx:UnvestedRestrictedStockAwardsMember 2020-01-01 2020-12-31 0001527599 sybx:UnvestedRestrictedStockAwardsMember 2019-01-01 2019-12-31 0001527599 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001527599 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001527599 us-gaap:StockCompensationPlanMember 2020-01-01 2020-12-31 0001527599 us-gaap:InternalRevenueServiceIRSMember 2020-12-31 0001527599 us-gaap:InternalRevenueServiceIRSMember 2019-12-31 0001527599 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001527599 us-gaap:StateAndLocalJurisdictionMember 2018-12-31 0001527599 us-gaap:InternalRevenueServiceIRSMember 2020-01-01 2020-12-31 0001527599 us-gaap:StateAndLocalJurisdictionMember 2020-01-01 2020-12-31 0001527599 us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2020-12-31 0001527599 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2020-12-31 0001527599 2017-07-01 2017-07-31 0001527599 2017-07-31 0001527599 srt:MaximumMember 2017-07-31 0001527599 sybx:MasterContractServicesAgreementMember sybx:AzzurGroupLimitedLiabilityCompanyMember 2018-01-01 2018-12-31 0001527599 2018-01-01 2018-12-31 0001527599 sybx:GinkgoBioworksIncMember 2020-12-31 0001527599 sybx:GinkgoBioworksIncMember 2020-01-01 2020-12-31 0001527599 2020-01-01 2020-03-31 0001527599 2020-04-01 2020-06-30 0001527599 2020-07-01 2020-09-30 0001527599 2020-10-01 2020-12-31 0001527599 2019-01-01 2019-03-31 0001527599 2019-04-01 2019-06-30 0001527599 2019-07-01 2019-09-30 0001527599 2019-10-01 2019-12-31 shares iso4217:USD iso4217:USD shares sybx:Segment sybx:Investment sybx:Security sybx:Vote pure utr:sqft false FY 0001527599 --12-31 true true true true true true true true true true greater than 50% true true P10Y P8Y8M12D P8Y4M24D P8Y4M24D P7Y8M12D P7Y2M12D P8Y2M12D 10-K true 2020-12-31 2020 false 001-37566 SYNLOGIC, INC. DE 26-1824804 301 Binney St Suite 402 Cambridge MA 02142 617 401-9975 Common Stock, par value $0.001 per share SYBX NASDAQ No No Yes Yes Non-accelerated Filer true false false false 38000000.0 39657841 <p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the registrant’s definitive proxy statement for the 2021 annual meeting of stockholders to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2020.</p> 32507000 26184000 67937000 93387000 6402000 13675000 106846000 133246000 7502000 10776000 13021000 15527000 17263000 1097000 1097000 9590000 16381000 4000 64000 143840000 188574000 1995000 2165000 3773000 3946000 544000 2531000 2000000 2000 208000 8301000 8863000 20273000 22804000 2000 131000 20404000 22806000 0.001 0.001 250000000 250000000 38183273 38183273 32266814 32266814 38000 33000 345394000 327900000 14000 110000 -230311000 -171138000 115135000 156905000 143840000 188574000 545000 2224000 47474000 41905000 13537000 14728000 61011000 56633000 -60466000 -54409000 1302000 3062000 6000 21000 -3000 -5000 1293000 3036000 -59173000 -51373000 -1.65 -1.70 35835744 30284068 -59173000 -51373000 -96000 175000 -59269000 -51198000 25401479 25000 243903000 -65000 -119765000 124098000 6340771 7000 56990000 56997000 22874000 22874000 585600 1000 -1000 61036 4134000 4134000 175000 175000 -51373000 -51373000 32266814 33000 327900000 110000 -171138000 156905000 5866258 5000 13529000 13534000 9472 16000 16000 226335 29857 42000 42000 215463 3907000 3907000 -96000 -96000 -59173000 -59173000 38183273 38000 345394000 14000 -230311000 115135000 -59173000 -51373000 2636000 2702000 3907000 4134000 21000 1282000 1736000 1370000 -7273000 12263000 6791000 -16381000 -60000 -349000 -935000 -544000 276000 -2000000 -1716000 131000 -39553000 -75468000 86474000 145418000 90836000 157465000 28515000 395000 1251000 32482000 10796000 208000 266000 13544000 58000 56996000 22874000 13394000 79604000 6323000 14932000 27281000 12349000 33604000 27281000 -4000 -369000 2714000 10000 6000 21000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of Business </p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Organization</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Synlogic, Inc., together with its wholly owned and consolidated subsidiaries (“Synlogic” or the “Company”), is a clinical-stage biopharmaceutical company focused on the drug discovery and development of Synthetic Biotic™ medicines. Synthetic Biotic medicines are generated from Synlogic’s proprietary drug discovery and development platform, leveraging a reproducible, modular approach to Synthetic Biology to develop beneficial microbes, which perform or deliver critical therapeutic functions. Synthetic Biotic medicines are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways or deliver combinations of therapeutic factors. Synlogic’s goal is to discover, develop and ultimately commercialize Synthetic Biotic medicines. Since incorporation, the Company has devoted substantially all of its efforts to the research and development of its product candidates.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Risks and Uncertainties</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020, the Company had approximately $100.4 million in cash, cash equivalents, and short-term marketable securities, $1.1 million of restricted cash and an accumulated deficit of approximately $230.3 million. Since its inception through December 31, 2020, the Company has primarily financed its operations through the issuance of preferred stock, units and warrants, the sale of its common stock, the AbbVie collaboration, and cash received in the Merger. In the absence of positive cash flows from operations, the Company is highly dependent on its ability to find additional sources of funding in the form of debt or equity financing. Management believes that the Company has sufficient cash to fund its operations through at least twelve months from the issuance of these financial statements. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As an early-stage company, the Company is subject to a number of risks common to other life science companies, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), the regulatory approval process, market acceptance of the Company’s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology. The Company’s therapeutic programs are currently pre-commercial, spanning discovery through early development and will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates.  These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance-reporting capabilities.  There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary regulatory approval or that any approved products will be commercially viable.  Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales.  The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital or obtain financing from other sources, such as strategic collaborations or partnerships.</p> 100400000 1100000 -230300000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S.”) (“U.S. GAAP” or “GAAP”). </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.  On an on-going basis, the Company’s management evaluates its estimates, including those related to revenue recognition, income taxes including the valuation allowance for deferred tax assets, research and development accruals and prepaids, accrued expenses, investments, contingencies and equity-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.  Changes in estimates are reflected in reported results in the period in which they become known.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Equivalents </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents consist of money market funds, including money market funds held in a sweep account. Cash equivalents are stated at cost plus accrued interest, which approximates fair value. The amount of cash equivalents included in cash and cash equivalents was approximately $32.5 million and $13.5 million at December 31, 2020 and 2019, respectively.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash, cash equivalents, marketable securities and restricted cash. The Company uses high quality, accredited financial institutions to maintain its balances, and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company held cash of approximately $1.1 million at December 31, 2020 and 2019 in a letter of credit to secure its lease at the 301 Binney Street facility.  The Company has classified this deposit as long-term restricted cash on its balance sheet. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,507</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,184</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in other long-term assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,097</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,097</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash shown in</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   the consolidated statement of cash flows</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,604</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,281</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. <span style="color:#000000;"> Accounting Standards Codification (“ASC”) Topic 820, </span><span style="font-style:italic;color:#000000;">Fair Value Measurements and Disclosures</span><span style="color:#000000;">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). The hierarchy consists of three levels: </span></p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 1 – Utilize observable inputs such as quoted prices in active markets for identical assets or liabilities;</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 2 – Utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves;</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 3 – Utilize unobservable data points in which there is little or no market data, which require the Company to develop its own assumptions for the asset or liability. </span></p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of assets or liabilities between Level 1, Level 2 or Level 3 during the years ended December 31, 2020 and 2019. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Available-for-Sale Securities</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies all short-term investments with an original maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest and investment income. Realized gains and losses, and declines in value judged to be other than temporary on available-for-sale securities, are included in interest and investment income.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest and investment income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary. </span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, including leasehold improvements, are recorded at cost and depreciated over their estimated useful lives using the straight‑line method. Repairs and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation begins at the time the asset is placed in service. Depreciation is provided over the following estimated useful lives:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset classification</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Useful life</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer and office equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesser of useful life or remaining lease term</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long‑Lived Assets</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long‑lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value of the asset. To date, no such impairments have been recognized.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses judgement to assess if an arrangement is a lease at contract inception. An arrangement is a lease if the contract involves the use of a distinct identified asset, the lessor does not have substantive substitution rights and the Company obtains control of the asset throughout the period by obtaining substantially all of the economic benefit of the asset and the right to direct the use of the asset. Leases classified as operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities and noncurrent operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations, in our consolidated balance sheet.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company utilizes its incremental borrowing rate to determine the present value of lease payments. The incremental borrowing rate is the rate incurred to borrow similar funds, on a collateralized basis, over a comparable term in a similar economic environment.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected to account for the lease and non-lease components for leases as a single component for classes of all underlying assets and allocate all of the contract consideration to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating expenses.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease term includes options to extend the lease when it is reasonably certain that option will be exercised. Leases with a term of 12 months or less are not recorded on the Company’s consolidated balance sheet.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in research and development are expensed as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses are comprised of costs incurred in performing research and development activities, including salary and benefits, equity-based compensation expense, laboratory supplies and other direct expenses, facilities expenses, overhead expenses, contractual services and other outside expenses.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When third-party service providers’ billing terms do not coincide with the Company’s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial costs, contractual services costs and costs for supply of its drug candidates, incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on the completion status of the research and development programs and the associated estimate of unbilled costs.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue recognition</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">The Company generated revenue through a collaboration and license arrangement with AbbVie for the development and commercialization of product candidates prior to the termination of the arrangement in May 2020.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates collaboration agreements with respect to FASB ASC Topic 808, <span style="font-style:italic;">Collaborative Arrangements</span>, considering the nature and contractual terms of the arrangement and the nature of its business operations to determine the classification of the transactions. When the Company is an active participant in the activity and exposed to significant risks and rewards dependent on the commercial success of the collaboration, it will record its transactions on a gross basis in the consolidated financial statements and describe the rights and obligations under the collaborative arrangement in the notes to the consolidated financial statements.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five-step analysis: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step analysis to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may enter into collaboration agreements for research and development services, under which the Company may license certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Variable consideration is constrained until it is deemed not be at significant risk of reversal.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements for which the collaboration partner is also a customer, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses significant judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the goods and services the Company expects to provide. The Company uses estimates to determine the timing of satisfaction of performance obligations, which may include the use of full time equivalent time as a measure of satisfaction of performance obligations. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. </span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Licenses of Intellectual Property</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Research and Development Services</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement is determined to contain a promise or obligation for the Company to perform research and development services, the Company must determine whether these services are distinct from the other promises in the arrangement. In assessing whether the services are distinct from the other promises, the Company considers the capabilities of the customer to perform these same services. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For research and development services that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Customer Options</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, that is, the option to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on an alternative approach when the goods or services are both (i) similar to the original goods and services in the contract and (ii) provided in accordance with the terms of the original contract. Under this alternative, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to a material right are not recognized as revenue until the option is exercised and the performance obligation is satisfied.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Milestone Payments</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that includes milestone payments, the Company evaluates whether a significant reversal of cumulative revenue provided in conjunction with achieving the milestones is probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For other milestones, the Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Royalties</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Contract Costs</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Equity‑Based Compensation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures equity-based compensation to employees, non-employees and directors based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period. The fair value of each option and purchase rights under the employee stock purchase plan (“ESPP”) is estimated on the date of grant using the Black‑Scholes option‑pricing model. Expected volatility for the Company’s common stock is determined based on an average of the historical volatility of the Company and the historical volatility of a peer‑group of similar public companies. The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The expected term of purchase rights for the ESPP is based on the duration of an offering period. The assumed dividend yield is based upon the Company’s expectation of not paying dividends in the foreseeable future. The risk‑free interest rate is based upon the U.S. Treasury yield curve commensurate with the expected term at the time of grant or remeasurement. Forfeitures are recognized as they occur. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies equity-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipients’ service payments are classified.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company’s tax returns. Deferred taxes are determined based on the difference between the financial reporting and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uncertain tax positions represent tax positions for which reserves have been established. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to be recognized in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and if dilutive, the weighted-average number of potential shares of common stock, including unvested restricted common stock, outstanding stock options and potential shares issuable under the ESPP.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in one operating segment: discovery and development of synthetic biology therapeutics for the treatment of rare, infectious and other diseases. The Company’s chief executive officer, as chief operating decision maker, manages and allocates resources to the operations of the Company on a total company basis. All of the Company’s equipment, leasehold improvements and other fixed assets are physically located within the United States, and all agreements with its partners are denominated in U.S. dollars, except where noted.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">New Accounting Pronouncements</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New accounting pronouncements are issued by the FASB from time to time, and rules are issued by the SEC that the Company has or will adopt as of a specified date. Unless otherwise noted, management does not believe that any recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had, or is expected to have, a material impact on the Company’s present or future financial statements. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2019, the FASB issued ASU 2019-12 – </span><span style="font-style:italic;Background-color:#FFFFFF;">Income Taxes – (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="Background-color:#FFFFFF;">, which provides amended guidance on income tax accounting. The amended guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year. Early adoption is permitted. The amended guidance, which simplifies the accounting for income taxes, includes the removal of exceptions to the general principles of ASC 740. The standard removed the exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items. </span><span style="color:#000000;">The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13 - <span style="font-style:italic;">Fair Value Measurement - Disclosure Framework</span> <span style="font-style:italic;">(Topic 820).</span> The standard modifies the disclosure requirements for fair value measurements. The standard is effective for public companies for annual and interim periods beginning after December 15, 2019. <span style="color:#000000;">The Company adopted the new guidance effective on January 1, 2020, which had an immaterial </span>impact on the Company’s financial statement disclosures.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-15 - <span style="font-style:italic;">Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</span>. The standard requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. <span style="color:#000000;">The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU 2018-18 - <span style="font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606</span>, which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606. <span style="color:#000000;">The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Recently Issued</span><span style="Background-color:#FFFFFF;font-size:12pt;"> </span><span style="Background-color:#FFFFFF;">Accounting Pronouncements</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13 - <span style="font-style:italic;">Measurement of Credit Losses on Financial Statements</span>. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-</p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for-sale debt securities to</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, the FASB issued ASU 2019-10</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> – </span><span style="font-style:italic;">Financial Instruments</span><span style="font-style:italic;"> – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which amended the effective date for certain companies.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">standard is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December 15, 2022</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Early adoption is available. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is currently</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">evaluating the potential impact ASU 2016-13, and related updates, will have on its </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated financial statements and disclosures</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, the FASB issued an amendment, ASU 2020-08- <span style="font-style:italic;">Codification Improvements to Subtopic 310-20, Receivables – Nonrefundable Fees and Other Costs, </span>to the guidance in ASU 2017-08, <span style="font-style:italic;">Receivables-Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. </span>The amendment requires companies to reevaluate whether a callable debt security that has multiple call dates is within the scope of paragraph 310-20-65-2. <span style="color:#000000;">The amendment shall be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is not permitted. The Company is currently evaluating the potential impact that ASU 2020-08 will have on its consolidated financial statements and disclosures. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S.”) (“U.S. GAAP” or “GAAP”). </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.  On an on-going basis, the Company’s management evaluates its estimates, including those related to revenue recognition, income taxes including the valuation allowance for deferred tax assets, research and development accruals and prepaids, accrued expenses, investments, contingencies and equity-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.  Changes in estimates are reflected in reported results in the period in which they become known.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Equivalents </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents consist of money market funds, including money market funds held in a sweep account. Cash equivalents are stated at cost plus accrued interest, which approximates fair value. The amount of cash equivalents included in cash and cash equivalents was approximately $32.5 million and $13.5 million at December 31, 2020 and 2019, respectively.</p> three months or less 32500000 13500000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash, cash equivalents, marketable securities and restricted cash. The Company uses high quality, accredited financial institutions to maintain its balances, and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company held cash of approximately $1.1 million at December 31, 2020 and 2019 in a letter of credit to secure its lease at the 301 Binney Street facility.  The Company has classified this deposit as long-term restricted cash on its balance sheet. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,507</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,184</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in other long-term assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,097</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,097</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash shown in</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   the consolidated statement of cash flows</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,604</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,281</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> 1100000 1100000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,507</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,184</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in other long-term assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,097</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,097</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents, and restricted cash shown in</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   the consolidated statement of cash flows</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,604</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,281</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 32507000 26184000 1097000 1097000 33604000 27281000 <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. <span style="color:#000000;"> Accounting Standards Codification (“ASC”) Topic 820, </span><span style="font-style:italic;color:#000000;">Fair Value Measurements and Disclosures</span><span style="color:#000000;">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). The hierarchy consists of three levels: </span></p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 1 – Utilize observable inputs such as quoted prices in active markets for identical assets or liabilities;</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 2 – Utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves;</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level 3 – Utilize unobservable data points in which there is little or no market data, which require the Company to develop its own assumptions for the asset or liability. </span></p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of assets or liabilities between Level 1, Level 2 or Level 3 during the years ended December 31, 2020 and 2019. </p> 0 0 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Available-for-Sale Securities</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies all short-term investments with an original maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest and investment income. Realized gains and losses, and declines in value judged to be other than temporary on available-for-sale securities, are included in interest and investment income.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest and investment income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary. </span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, including leasehold improvements, are recorded at cost and depreciated over their estimated useful lives using the straight‑line method. Repairs and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation begins at the time the asset is placed in service. Depreciation is provided over the following estimated useful lives:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset classification</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Useful life</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer and office equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesser of useful life or remaining lease term</p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation begins at the time the asset is placed in service. Depreciation is provided over the following estimated useful lives:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Asset classification</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Useful life</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer and office equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.96%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lesser of useful life or remaining lease term</p></td> </tr> </table></div> P3Y P5Y P5Y Lesser of useful life or remaining lease term <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Long‑Lived Assets</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long‑lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value of the asset. To date, no such impairments have been recognized.</p> 0 <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses judgement to assess if an arrangement is a lease at contract inception. An arrangement is a lease if the contract involves the use of a distinct identified asset, the lessor does not have substantive substitution rights and the Company obtains control of the asset throughout the period by obtaining substantially all of the economic benefit of the asset and the right to direct the use of the asset. Leases classified as operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities and noncurrent operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations, in our consolidated balance sheet.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company utilizes its incremental borrowing rate to determine the present value of lease payments. The incremental borrowing rate is the rate incurred to borrow similar funds, on a collateralized basis, over a comparable term in a similar economic environment.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected to account for the lease and non-lease components for leases as a single component for classes of all underlying assets and allocate all of the contract consideration to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating expenses.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease term includes options to extend the lease when it is reasonably certain that option will be exercised. Leases with a term of 12 months or less are not recorded on the Company’s consolidated balance sheet.</p> options to extend the lease when it is reasonably certain that option will be exercised <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in research and development are expensed as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses are comprised of costs incurred in performing research and development activities, including salary and benefits, equity-based compensation expense, laboratory supplies and other direct expenses, facilities expenses, overhead expenses, contractual services and other outside expenses.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When third-party service providers’ billing terms do not coincide with the Company’s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial costs, contractual services costs and costs for supply of its drug candidates, incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on the completion status of the research and development programs and the associated estimate of unbilled costs.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue recognition</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">The Company generated revenue through a collaboration and license arrangement with AbbVie for the development and commercialization of product candidates prior to the termination of the arrangement in May 2020.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates collaboration agreements with respect to FASB ASC Topic 808, <span style="font-style:italic;">Collaborative Arrangements</span>, considering the nature and contractual terms of the arrangement and the nature of its business operations to determine the classification of the transactions. When the Company is an active participant in the activity and exposed to significant risks and rewards dependent on the commercial success of the collaboration, it will record its transactions on a gross basis in the consolidated financial statements and describe the rights and obligations under the collaborative arrangement in the notes to the consolidated financial statements.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five-step analysis: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step analysis to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may enter into collaboration agreements for research and development services, under which the Company may license certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Variable consideration is constrained until it is deemed not be at significant risk of reversal.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements for which the collaboration partner is also a customer, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses significant judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the goods and services the Company expects to provide. The Company uses estimates to determine the timing of satisfaction of performance obligations, which may include the use of full time equivalent time as a measure of satisfaction of performance obligations. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. </span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Licenses of Intellectual Property</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Research and Development Services</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement is determined to contain a promise or obligation for the Company to perform research and development services, the Company must determine whether these services are distinct from the other promises in the arrangement. In assessing whether the services are distinct from the other promises, the Company considers the capabilities of the customer to perform these same services. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For research and development services that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Customer Options</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, that is, the option to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on an alternative approach when the goods or services are both (i) similar to the original goods and services in the contract and (ii) provided in accordance with the terms of the original contract. Under this alternative, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to a material right are not recognized as revenue until the option is exercised and the performance obligation is satisfied.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Milestone Payments</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that includes milestone payments, the Company evaluates whether a significant reversal of cumulative revenue provided in conjunction with achieving the milestones is probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For other milestones, the Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Royalties</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Contract Costs</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer.</p> The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Equity‑Based Compensation</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures equity-based compensation to employees, non-employees and directors based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period. The fair value of each option and purchase rights under the employee stock purchase plan (“ESPP”) is estimated on the date of grant using the Black‑Scholes option‑pricing model. Expected volatility for the Company’s common stock is determined based on an average of the historical volatility of the Company and the historical volatility of a peer‑group of similar public companies. The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The expected term of purchase rights for the ESPP is based on the duration of an offering period. The assumed dividend yield is based upon the Company’s expectation of not paying dividends in the foreseeable future. The risk‑free interest rate is based upon the U.S. Treasury yield curve commensurate with the expected term at the time of grant or remeasurement. Forfeitures are recognized as they occur. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies equity-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipients’ service payments are classified.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company’s tax returns. Deferred taxes are determined based on the difference between the financial reporting and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uncertain tax positions represent tax positions for which reserves have been established. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to be recognized in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</p> greater than 50% <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and if dilutive, the weighted-average number of potential shares of common stock, including unvested restricted common stock, outstanding stock options and potential shares issuable under the ESPP.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in one operating segment: discovery and development of synthetic biology therapeutics for the treatment of rare, infectious and other diseases. The Company’s chief executive officer, as chief operating decision maker, manages and allocates resources to the operations of the Company on a total company basis. All of the Company’s equipment, leasehold improvements and other fixed assets are physically located within the United States, and all agreements with its partners are denominated in U.S. dollars, except where noted.</p> 1 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">New Accounting Pronouncements</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New accounting pronouncements are issued by the FASB from time to time, and rules are issued by the SEC that the Company has or will adopt as of a specified date. Unless otherwise noted, management does not believe that any recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had, or is expected to have, a material impact on the Company’s present or future financial statements. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2019, the FASB issued ASU 2019-12 – </span><span style="font-style:italic;Background-color:#FFFFFF;">Income Taxes – (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="Background-color:#FFFFFF;">, which provides amended guidance on income tax accounting. The amended guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year. Early adoption is permitted. The amended guidance, which simplifies the accounting for income taxes, includes the removal of exceptions to the general principles of ASC 740. The standard removed the exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items. </span><span style="color:#000000;">The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-13 - <span style="font-style:italic;">Fair Value Measurement - Disclosure Framework</span> <span style="font-style:italic;">(Topic 820).</span> The standard modifies the disclosure requirements for fair value measurements. The standard is effective for public companies for annual and interim periods beginning after December 15, 2019. <span style="color:#000000;">The Company adopted the new guidance effective on January 1, 2020, which had an immaterial </span>impact on the Company’s financial statement disclosures.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU 2018-15 - <span style="font-style:italic;">Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</span>. The standard requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. <span style="color:#000000;">The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU 2018-18 - <span style="font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606</span>, which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606. <span style="color:#000000;">The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.</span></p> 2020-01-01 2020-01-01 2020-01-01 2020-01-01 <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Recently Issued</span><span style="Background-color:#FFFFFF;font-size:12pt;"> </span><span style="Background-color:#FFFFFF;">Accounting Pronouncements</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13 - <span style="font-style:italic;">Measurement of Credit Losses on Financial Statements</span>. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-</p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for-sale debt securities to</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2019, the FASB issued ASU 2019-10</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> – </span><span style="font-style:italic;">Financial Instruments</span><span style="font-style:italic;"> – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which amended the effective date for certain companies.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">standard is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December 15, 2022</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Early adoption is available. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is currently</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">evaluating the potential impact ASU 2016-13, and related updates, will have on its </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated financial statements and disclosures</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, the FASB issued an amendment, ASU 2020-08- <span style="font-style:italic;">Codification Improvements to Subtopic 310-20, Receivables – Nonrefundable Fees and Other Costs, </span>to the guidance in ASU 2017-08, <span style="font-style:italic;">Receivables-Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. </span>The amendment requires companies to reevaluate whether a callable debt security that has multiple call dates is within the scope of paragraph 310-20-65-2. <span style="color:#000000;">The amendment shall be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is not permitted. The Company is currently evaluating the potential impact that ASU 2020-08 will have on its consolidated financial statements and disclosures. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:11pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value of Financial Instruments</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tables below present information about the Company’s assets that are measured at fair value on a recurring basis as of December 31, 2020 and 2019 and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, as described under Note 2<span style="font-style:italic;">, Summary of Significant Accounting Policies</span>.  </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s investment portfolio includes many fixed income securities that do not always trade on a daily basis.  As a result, the pricing services used by the Company applied other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare evaluations.  In addition, model processes were used to assess interest rate impact and develop prepayment scenarios.  These models take into consideration relevant credit information, perceived market movements, sector news and economic events.  The inputs into these models may include benchmark yields, reported trades, broker-dealer quotes, issuer spreads and other relevant data.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020 and 2019, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at Reporting Date Using</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in Active</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for Identical</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable Inputs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable Inputs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,506</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,506</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,477</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,477</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,637</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,637</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities and treasuries</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,823</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,823</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,443</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,329</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,114</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at Reporting Date Using</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in Active</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for Identical</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable Inputs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable Inputs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,240</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,240</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper (included in cash and</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   cash equivalents)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,249</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,249</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper (included in marketable</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   securities)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,501</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,501</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities (included in cash</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   and cash equivalents)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,005</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,005</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities (included in</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   marketable securities)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,383</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,383</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities and</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   treasuries</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,005</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,005</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,383</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,240</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,143</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses at December 31, 2020 and December 31, 2019 are carried at amounts that approximate fair value due to their short-term maturities.  Finance lease obligations at December 31, 2020 and December 31, 2019 approximate fair value as they bear interest at a rate approximating a market interest rate.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020 and 2019, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at Reporting Date Using</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in Active</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for Identical</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable Inputs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable Inputs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,506</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,506</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,477</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,477</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,637</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,637</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities and treasuries</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,823</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,823</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,443</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,329</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,114</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at Reporting Date Using</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in Active</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Markets for Identical</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable Inputs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable Inputs</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,240</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,240</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper (included in cash and</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   cash equivalents)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,249</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,249</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper (included in marketable</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   securities)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,501</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,501</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities (included in cash</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   and cash equivalents)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,005</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,005</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.02%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities (included in</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   marketable securities)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,383</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,383</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.02%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities and</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   treasuries</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,005</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,005</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.02%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,383</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,240</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,143</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> 32506000 32506000 0 40477000 40477000 0 18637000 18637000 0 8823000 8823000 0 0 100443000 41329000 59114000 0 3240000 3240000 0 4249000 4249000 0 20501000 20501000 0 6005000 6005000 0 71383000 71383000 0 9005000 9005000 0 114383000 3240000 111143000 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Available-for-Sale Investments</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the available-for-sale securities held at December 31, 2020 and 2019 (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,467</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,477</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,634</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,637</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,822</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,823</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,923</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,937</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,484</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,501</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,288</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,383</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,005</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,005</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,777</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,889</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The contractual maturity of all securities held at December 31, 2020 was ten months or less.  There were eight investments in an unrealized loss position at December 31, 2020, none of which had been in an unrealized loss position for more than twelve months.  The aggregate fair value of the securities in an unrealized loss position at December 31, 2020 and 2019 was $20.1 million and $24.8 million, respectively. The Company reviews its investments for other-than-temporary impairment whenever the fair value of an investment is less than amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time.  To determine whether an impairment is other-than-temporary, the Company considers whether it has the ability and intent to hold the investment until a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary.  The Company did not hold any securities with an other-than-temporary impairment at December 31, 2020. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross realized gains and losses on the sales of investments have not been material to the Company’s consolidated statement of operations.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the available-for-sale securities held at December 31, 2020 and 2019 (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,467</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,477</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,634</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,637</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,822</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,823</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,923</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,937</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,484</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,501</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,288</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,383</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,005</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,005</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,777</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,889</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 40467000 11000 1000 40477000 18634000 4000 1000 18637000 8822000 1000 8823000 67923000 16000 2000 67937000 20484000 18000 1000 20501000 71288000 96000 1000 71383000 9005000 2000 2000 9005000 100777000 116000 4000 100889000 8 0 20100000 24800000 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Prepaid Expenses and Other Current Assets</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consist of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">856</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">648</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,771</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,989</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other prepaid expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">528</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">390</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">247</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">648</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,675</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets consist of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">856</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">648</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,771</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,989</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other prepaid expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">528</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">390</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">247</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">648</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,675</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 856000 648000 4771000 11989000 528000 390000 247000 648000 6402000 13675000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Property and Equipment, net</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,793</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,523</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer and office equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">769</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">782</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,514</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,514</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">528</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,652</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,249</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,631</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,776</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense on property and equipment was $2.6 million and $2.7 million in 2020 and 2019, respectively. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,793</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,523</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer and office equipment</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">769</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">782</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,514</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,514</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">528</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,652</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,249</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,631</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,776</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 7793000 7523000 769000 782000 421000 421000 9514000 9514000 528000 412000 19025000 18652000 8249000 5631000 10776000 13021000 2600000 2700000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Accrued Expenses</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll related</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,005</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,372</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">444</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,005</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">323</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,773</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,946</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll related</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,005</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,372</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">444</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,005</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">323</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,773</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,946</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 3005000 2372000 215000 444000 230000 1005000 323000 125000 3773000 3946000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Common Stock</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s common stock has the following characteristics:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders.</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">•</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">The holders of shares of common stock are entitled to receive dividends, if and when, declared by the Company’s board of directors. Since inception, no cash dividends have been declared.</span></p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company issued to Ginkgo Bioworks (“Ginkgo”) 6,340,771 shares of common stock and accompanying Pre-Funded Warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 2,548,117 shares of common stock, at a combined purchase price per share and Pre-Funded Warrant of $9.00. The Pre-Funded Warrants have an exercise price of $9.00 per share, with $8.99 of such exercise price paid at the closing of the offering. The proceeds, net of issuance costs, were approximately $79.9 million, $57.0 million related to the proceeds from sale of the common stock and $22.9 million related to the proceeds from sale of the Pre-Funded Warrants. <span style="color:#000000;">The Pre-Funded Warrants may be exercised at any time until all of the Pre-Funded Warrants are exercised in full to the extent that, after giving effect to such issuance after exercise, Ginkgo would not beneficially own </span>in excess of 19.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance.<span style="color:#000000;"> </span>The Pre-Funded Warrants were classified as a component of permanent equity and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately <span style="color:#000000;">exercisable</span>, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of common shares upon exercise. In addition, such warrants do not provide any guarantee of value or return. In addition, in connection with the issuance to Ginkgo of common stock and Pre-Funded Warrants, the Company expanded its existing collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. None of the Pre-Funded Warrants have been exercised as of December 31, 2020. (See Note 10).</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a sales agreement with Cowen and Company, LLC (“Cowen”) with respect to an at-the-market (“ATM”) offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $17.3 million, through Cowen as its sales agent. In an ATM offering, exchange-listed companies incrementally sell newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices. During the year ended December 31, 2020, 5,866,258 shares of common stock were sold pursuant to the ATM, resulting in net proceeds of approximately $13.5 million. Subsequent to December 31, 2020, the Company is able to offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million.  </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reserved for future issuance the following shares of common stock related to the potential warrant exercise, exercise of stock options, and the employee stock purchase plan:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issuable under pre-funded warrants</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,548,117</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,211,967</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345,662</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,105,746</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:11pt;"> </p> 1 0 6340771 2548117 9.00 9.00 8.99 79900000 57000000.0 22900000 0.1999 0 17300000 5866258 13500000 50000000.0 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reserved for future issuance the following shares of common stock related to the potential warrant exercise, exercise of stock options, and the employee stock purchase plan:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock issuable under pre-funded warrants</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,548,117</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,211,967</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345,662</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,105,746</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 2548117 1211967 345662 4105746 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Equity‑based Compensation and Equity Incentive Plans</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Equity Plans</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has three active equity plans. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2015 Equity Incentive Award Plan (“2015 Plan”) functions as the primary equity plan for the Company. The 2015 Plan includes an “evergreen provision” that allows for an annual increase in the number of shares of common stock available for issuance under the 2015 Plan, which annual increase will be added on the first day of each fiscal year from 2016 through 2025, inclusive, and will be equal to the lesser of (i) five percent of the shares outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Board of Directors. The 2015 Plan provides for the granting of a variety of stock‑based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, deferred stock awards, dividend equivalent awards, stock payment awards, performance awards and other stock‑based awards.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2017 Stock Incentive Plan (the “2017 Plan”) provides for the grant of incentive stock options, non-qualified stock options, restricted and unrestricted stock awards and other stock-based awards. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2015 Employee Stock Purchase Plan (“ESPP”) allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations.  The ESPP generally provides for set offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last trading day of the offering period.  The Company suspended the ESPP in 2017. In December 2019, the Board reactivated the 2015 ESPP and approved an amendment to the ESPP to (i) reduce the permitted payroll deduction and number of shares of the Company’s common stock that a participant may purchase per calendar year and offering period under the ESPP and (ii) establish a period for enrollment for eligible participants. The reactivation of the 2015 ESPP was effective immediately. The Company’s executive officers are eligible to participate in the 2015 ESPP. There were 29,857 shares of common stock purchased under the ESPP during the year ended December 31, 2020.</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Options</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average assumptions used in the Black-Scholes option-pricing model for stock options issued to employees and non-employees under the 2015 Plan and the 2017 Plan, during the years ended December 31, 2020 and 2019 were:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.12%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.12%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average, risk-free interest rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.12%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77.2%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71.1%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.12%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under the 2015 and 2017 Plans.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock options outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value<sup style="font-size:85%;line-height:120%;vertical-align:top"> (a)</sup></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,286,419</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.24</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000487">8.7</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,627,654</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.90</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,472</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.70</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(560,765</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.34</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,343,836</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000488">8.4</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested or expected to vest at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,343,836</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000489">8.4</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,399,952</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.13</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000490">7.7</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(a)</sup></span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:9pt;font-family:Times New Roman;color:#000000;">The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair market value of the underlying common stock for the options that were in the money at December 31, 2020 and 2019. 970,826 and 132,500 options were in the money at December 31, 2020 and 2019, respectively</span>.</p></td></tr></table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value per share of options granted during the years ended December 31, 2020 and 2019 was approximately $1.27 and $4.59, respectively. The total fair value of awards that vested during the years ended December 31, 2020 and 2019 was $3.4 million and $3.9 million, respectively.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, there was approximately $4.3 million of unrecognized share-based compensation for unvested stock option grants which is expected to be recognized over a weighted average period of 2.1 years.  The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.   </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Common Stock</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020 and 2019, 226,335 and 585,600 shares of restricted common stock were granted, respectively. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows restricted common stock activity:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock awards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">grant date</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">fair value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(per share)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586,929</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.97</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226,335</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.70</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(119,594</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.30</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(215,463</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.32</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">478,207</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.19</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total fair value of shares that vested during the years ended December 31, 2020 and 2019 was $0.3 million and $0.1 million, respectively.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, there was approximately $0.4 million of unrecognized share-based compensation related to restricted stock awards granted, which is expected to be recognized over a weighted average period of 2.1 years.  The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.  </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ESPP is considered a compensatory plan with the related compensation expense recognized over the six-month offering periods. The compensation expense for the year ended December 31, 2020 was $27,000.  There was no compensation expense related to the ESPP for the year ended December 31, 2019.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"> </p> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Compensation</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has recorded total equity‑based compensation expense of approximately $3.9 million and $4.1 million, during the years ended December 31, 2020 and 2019, respectively. Equity compensation during the year ended December 31, 2020 is derived from stock options, restricted stock awards, and the ESPP. Equity compensation during the year ended December 31, 2019 is derived from stock options and restricted stock awards.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes equity‑based compensation expense within the Company’s consolidated statements of operations and comprehensive loss for the years ended December 31, 2020 and 2019 (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,724</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,377</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,183</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,757</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,907</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,134</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes equity‑based compensation expense by type of award for the years ended December 31, 2020 and 2019 (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,789</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock awards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">680</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,907</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,134</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> 0.05 0.15 0.85 29857 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average assumptions used in the Black-Scholes option-pricing model for stock options issued to employees and non-employees under the 2015 Plan and the 2017 Plan, during the years ended December 31, 2020 and 2019 were:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.54%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.12%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.12%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average, risk-free interest rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.12%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77.2%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71.1%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.12%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.54%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> P6Y2M12D P6Y2M12D 0.006 0.022 0.772 0.711 0 0 <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under the 2015 and 2017 Plans.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock options outstanding</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value<sup style="font-size:85%;line-height:120%;vertical-align:top"> (a)</sup></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,286,419</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.24</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000487">8.7</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,627,654</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.90</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,472</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.70</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(560,765</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.34</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,343,836</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000488">8.4</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested or expected to vest at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,343,836</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.00</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000489">8.4</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,399,952</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.13</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000490">7.7</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:5pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(a)</sup></span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Arial;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:9pt;font-family:Times New Roman;color:#000000;">The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair market value of the underlying common stock for the options that were in the money at December 31, 2020 and 2019. 970,826 and 132,500 options were in the money at December 31, 2020 and 2019, respectively</span>.</p></td></tr></table></div> 2286419 9.24 43000 1627654 1.90 9472 1.70 6000 560765 7.34 3343836 6.00 399000 3343836 6.00 399000 1399952 9.13 53000 970826 132500 1.27 4.59 3400000 3900000 4300000 P2Y1M6D 226335 585600 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows restricted common stock activity:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock awards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">grant date</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">fair value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(per share)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586,929</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.97</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226,335</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.70</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(119,594</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.30</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(215,463</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.32</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at December 31, 2020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">478,207</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.19</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 586929 2.97 226335 1.70 119594 2.30 215463 2.32 478207 2.19 300000 100000 400000 P2Y1M6D 27000 0 3900000 4100000 <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes equity‑based compensation expense within the Company’s consolidated statements of operations and comprehensive loss for the years ended December 31, 2020 and 2019 (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,724</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,377</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,183</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,757</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,907</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,134</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 1724000 1377000 2183000 2757000 3907000 4134000 <p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes equity‑based compensation expense by type of award for the years ended December 31, 2020 and 2019 (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,200</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,789</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock awards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">680</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ESPP</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,907</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,134</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 3200000 3789000 680000 345000 27000 3907000 4134000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">0</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaboration Agreements</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Ginkgo Collaboration</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, the Company established a technology collaboration with Ginkgo. In June 2019, in connection with the issuance to Ginkgo of an aggregate of 6,340,771 shares of common stock and Pre-Funded Warrants to purchase an aggregate of 2,548,117 common stock (See Note 8), the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. Under the 2019 expanded agreement, the Company made a prepayment to Ginkgo of $30.0 million for its foundry services that will be provided to the Company over an initial term of five years. The prepayment of foundry services is recorded in Prepaid expenses and other current assets and Prepaid research and development, net of current portion on the December 31, 2020 consolidated balance sheet. <span style="color:#000000;">At December 31, 2020, the Company had remaining balances of $4.7 million and $8.9 million of current and non-current pre-paid research and development costs related to this transaction, respectively. </span>Upon the expiration of such initial term and, if applicable, an additional period, any portion of the prepayment that has not been used to purchase services from Ginkgo will be retained by Ginkgo.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">AbbVie Collaboration Agreement</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, the Company entered into the AbbVie Agreements under which the Company granted AbbVie an exclusive option to purchase IBDCo and, in exchange, agreed to collaborate in researching and developing an Investigational New Drug (“IND”) candidate for the treatment of IBD. The AbbVie Agreements set forth the Company’s and AbbVie’s respective obligations for development and delivery of an IND candidate package using reasonable commercial efforts.  </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, we announced the termination of our collaboration with AbbVie to develop Synthetic Biotic medicines for the treatment of types of IBD, including Crohn’s disease and ulcerative colitis.  Upon termination, we regained all rights to develop these and new IBD Synthetic Biotic medicines for all effectors targeting IBD. This allows us to fully leverage our expertise in strain engineering, quantitative biology, regulatory, and manufacturing to expand our wholly owned GI-based program portfolio to include IBD. We further regained the rights to partner these IBD programs. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue associated with performance obligations under the AbbVie Agreements was recognized as the research and development services were provided using an input method, according to the full-time equivalents incurred. The research and development activities were expected to be performed over a period of approximately 54 months. The transfer of control occurred over time and, in management’s judgment, was the best measure of progress towards satisfying the performance obligation. The amounts received that had not yet been recognized as revenue were recorded in deferred revenue on the Company’s consolidated balance sheet.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2020 and 2019, the Company recognized $0.5 million and $2.2 million, respectively, as collaboration revenue in the Company’s consolidated statements of operations and comprehensive loss. There is no deferred revenue on the Company’s consolidated balance sheet as of December 31, 2020, as the remainder of the revenue was recognized when the agreement was terminated.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;"> </p> 6340771 2548117 30000000.0 P5Y 4700000 8900000 P54M 500000 2200000 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss per Share</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except for share and per share amounts):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,173</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,373</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding - basic and diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,835,744</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,284,068</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.65</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.70</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s potentially dilutive shares, which include outstanding stock options, unvested restricted common stock and potential shares issuable under the ESPP, are considered to be common share equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of the diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock awards</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">478,207</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586,929</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding options to purchase common stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,343,836</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,286,419</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential shares issuable under the ESPP</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,037</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except for share and per share amounts):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,173</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,373</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.1%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding - basic and diluted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,835,744</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,284,068</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.1%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.65</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.70</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> -59173000 -51373000 35835744 30284068 -1.65 -1.70 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of the diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested restricted common stock awards</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">478,207</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586,929</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding options to purchase common stock</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,343,836</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,286,419</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential shares issuable under the ESPP</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,037</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 478207 586929 3343836 2286419 12037 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the years ended December 31, 2020 and 2019, the Company recorded no income tax benefits for the net operating losses incurred due to its uncertainty of reclaiming a benefit for those losses. </span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. </span>Deferred tax assets consist of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,181</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,362</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carryforwards</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,748</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,262</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,230</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,776</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,200</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,481</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortizable intangibles</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,195</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,214</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,033</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,270</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,720</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,242</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,716</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,242</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,436</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,791</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,834</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of the Company’s deferred tax assets, which are comprised principally of net operating loss carryforwards, and determined that it is more likely than not that the Company will not recognize the benefits of the deferred tax assets. As a result, a full valuation allowance of approximately $72.8 million and $53.8 million was established at December 31, 2020 and 2019, respectively.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">A reconciliation of the statutory federal income tax rate to the Company’s effective income tax rate is as follows (dollars in thousands):</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tax Rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tax Rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal statutory rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other permanent differences</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other items</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.33%;text-indent:0%;font-size:5pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A roll-forward <span style="Background-color:#FFFFFF;color:#000000;">of the valuation allowance for the years ended December 31, </span>2020<span style="Background-color:#FFFFFF;color:#000000;"> and </span>2019<span style="Background-color:#FFFFFF;color:#000000;"> is as follows (in thousands):</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,834</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,290</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,957</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,544</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,791</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,834</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the Company had federal net operating loss carryforwards that may be available to reduce future taxable income of approximately $227.0 million and $172.9 million, respectively. Of the $227.0 million of federal net operating loss carryforwards, $79.4 million begin to expire in 2034. The remaining $147.6 of federal net operating loss carryforwards do not expire. The Company also had state net operating loss carryforwards that may be available to reduce future taxable income of approximately $213.6 million and $159.0 million, for the periods ended December 31, 2020 and 2019, respectively. The state net operating loss carryforwards begin to expire in 2029. In addition, at December 31, 2020, the Company had federal and state research and development tax credit carryforwards available to reduce future tax liabilities of approximately $3.5 million and $2.3 million, respectively. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 382 of the Internal Revenue Code of 1986 (“IRC”), certain substantial changes in the Company’s ownership may result in a limitation on the amount of net operating loss (“NOL”) carryforwards and research and development credit (“R&amp;D credit”) carryforwards that may be used in future years. Utilization of the NOL and R&amp;D credit carryforwards may be subject to a substantial annual limitation under Section 382 of the IRC due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company has not completed a study to assess whether an ownership change has occurred, or whether there have been multiple ownership changes since its formation, due to the significant complexity and related costs associated with such a study. There could be additional ownership changes in the future that may result in additional limitations on the utilization of NOL carryforwards and credits.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based<span style="font-family:Arial;"> </span>on the technical merits of the position. For tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority. The Company has not recognized any liability for unrecognized tax benefits as of December 31, 2020.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files tax returns, on an entity-level basis, as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. Tax years from 2016 to the present are open to examination under the statute. The Company’s policy is to record interest and penalties related to income taxes as part of the tax provision. There are no interest or penalties accrued at December 31, 2020 and 2019.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.06%;font-family:Times New Roman;font-size:11pt;"> </p> 0 0 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. </span>Deferred tax assets consist of the following (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,181</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,362</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carryforwards</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,748</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,262</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,230</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,776</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,200</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,481</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortizable intangibles</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,195</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,214</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,033</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,270</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,720</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,242</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,716</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,242</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,436</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,791</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,834</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> 61181000 46362000 5748000 4262000 126000 37000 279000 36000 6230000 6776000 2200000 1481000 1195000 1214000 38000 138000 77033000 60270000 1720000 4242000 4716000 4242000 6436000 72791000 53834000 72800000 53800000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">A reconciliation of the statutory federal income tax rate to the Company’s effective income tax rate is as follows (dollars in thousands):</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tax Rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tax Rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal statutory rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other permanent differences</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other items</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"> </p> 0.21 0.21 0.06 0.06 -0.01 -0.01 0.02 0 0.04 0 -0.32 -0.26 <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A roll-forward <span style="Background-color:#FFFFFF;color:#000000;">of the valuation allowance for the years ended December 31, </span>2020<span style="Background-color:#FFFFFF;color:#000000;"> and </span>2019<span style="Background-color:#FFFFFF;color:#000000;"> is as follows (in thousands):</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,834</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,290</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,957</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,544</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,791</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,834</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> 53834000 40290000 18957000 13544000 72791000 53834000 227000000.0 172900000 79400000 2034 147600000 213600000 159000000.0 2029 3500000 2300000 0 In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. Tax years from 2016 to the present are open to examination under the statute. 0 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2017, the Company entered into an agreement to lease approximately 41,346 square feet of laboratory and office space at 301 Binney Street in Cambridge, Massachusetts.  Annual rent is approximately $3.3 million.  The <span style="-sec-ix-hidden:F_000622">ten-year</span> lease commenced in January 2018 and contains provisions for a free-rent period, annual rent increases and an allowance for tenant improvements. <span style="Background-color:#FFFFFF;color:#000000;">Th</span>e Company is <span style="color:#000000;">responsible for real estate taxes, maintenance, and other operating expenses applicable to the leased premises.</span> The Company has paid for tenant improvements of approximately $2.9 million<span style="Background-color:#FFFFFF;color:#000000;">. Additionally, the Company has capitalized approximately $6.6 million of landlord-funded tenant improvements. </span> <span style="Background-color:#FFFFFF;color:#000000;">The Company was deemed to be the accounting owner of the tenant improvements primarily because it was responsible for project cost overruns, and as such, the amounts were recorded as a leasehold improvement. The landlord-funded tenant improvement allowance is being amortized as a reduction to lease expense ratably over the lease term.  </span>In conjunction with the lease, the Company established a letter of credit of approximately $1.0 million secured by cash balances included in restricted cash. Variable payments based on our portion of the operating expenses, including real estate taxes and insurance, are recorded as a period expense when incurred. The Company has an option to extend the term by five years and an option to terminate the agreement if a similar agreement is executed with the landlord or an affiliate of the landlord. Neither option is reasonably certain of exercise and both are excluded from the lease liability calculation.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2018,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> entered into </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an agreement</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with Azzur Group, LLC (“Azzur”)</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> whereby</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Azzur agreed to provide the Company with access to, and the use of, an approximately </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> square foot cleanroom space to be constructed in Waltham, Massachusetts (the “Azzur Suite”), for a period of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44 months</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, from May 1, 2019 to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2022</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (the “Term”). Azzur also agreed to provide the Company with storage space and personnel support at the Azzur Suite. The total estimated </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses to be incurred by the Company</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> during the Term for access to, and use of, the cleanroom and storage space, and the personnel support and other services, is $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Company determined that the </span><span style="Background-color:#FFFFFF;color:#000000;">agreement </span><span style="Background-color:#FFFFFF;color:#000000;">contained an embedded lease </span><span style="Background-color:#FFFFFF;color:#000000;">because the Company controls the use of the Azzur Suite. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, the fixed and in-substance fixed consideration under the agreement was used to determine the ROU asset and lease liability at the lease commencement date.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Leases classified as operating leases are included in operating lease ROU assets, current operating lease liabilities and noncurrent operating lease liabilities in our consolidated balance sheets. The operating lease right-of-use asset and operating lease liability represents the Binney Street lease and the Azzur Suite lease. Cash paid for amounts included in the present value of operating lease liabilities was $3.9 and $3.7 million during the years ended December 31, 2020 and 2019, respectively, which is included in operating cash flows.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost for operating leases for the years ended December 31, 2020 and 2019 were (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.08%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.9%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.9%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,628</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,344</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.9%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term lease cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">330</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.9%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,055</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,092</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.9%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,683</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,766</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The right-of-use asset for the operating lease is disclosed on the consolidated balance sheets.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average remaining lease term and the weighted average discount rate for operating leases were:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average discount rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease term (years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000644">7.2</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.8%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000645">8.2</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reconciles the undiscounted cash flows for the operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet: <span style="Background-color:#FFFFFF;color:#000000;">December 31, 2020</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity of lease liabilities</p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,236</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,389</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,574</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,681</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,792</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.16%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,595</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,267</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.16%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,463</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,804</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current lease liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,531</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,273</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease cost for finance leases during the years ended December 31, 2020 and 2019, and the finance lease liability at December 31, 2020, were not material.</p> 41346 3300000 2900000 6600000 1000000.0 P5Y 700 P44M 2022-12-31 4800000 3900000 3700000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease cost for operating leases for the years ended December 31, 2020 and 2019 were (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.08%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.9%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.9%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,628</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,344</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.9%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term lease cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">330</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.9%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,055</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,092</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.9%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,683</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,766</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 3628000 3344000 330000 1055000 1092000 4683000 4766000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average remaining lease term and the weighted average discount rate for operating leases were:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average discount rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease term (years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.64%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000644">7.2</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.8%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000645">8.2</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 0.080 0.080 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table reconciles the undiscounted cash flows for the operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet: <span style="Background-color:#FFFFFF;color:#000000;">December 31, 2020</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity of lease liabilities</p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,236</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,389</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,574</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,681</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,792</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.16%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,595</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,267</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.16%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,463</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,804</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current lease liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,531</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.82%;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,273</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 4236000 4389000 3574000 3681000 3792000 10595000 30267000 7463000 22804000 2531000 20273000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company is not currently a party to any material legal proceedings. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Employee Benefits</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company has a defined contribution 401(k) plan for eligible employees. Employees are eligible to participate in the plan beginning on their date of hire. Under the terms of the plan, employees may make voluntary contributions as a percentage of compensation. The Company started to match employee contributions effective January 1, 2019. The Company matched 50% of the employee contributions to the 401(k) plan up to a maximum of 4% of the participating employee’s eligible earnings, resulting in a maximum company match of 2% of the participating employee’s eligible earnings, and subject to certain additional statutory dollar limitations. </span></p> 0.50 0.04 0.02 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Related-Party Transactions</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. As of December 31, 2020, Ginkgo owns 6,340,771 shares of the Company’s outstanding common stock.<span style="font-family:Calibri;"> </span>See Note 10, <span style="font-style:italic;">Ginkgo Collaboration</span>.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the agreement the Company made a prepayment to Ginkgo of $30.0 million for its foundry services that will be provided to the Company over an initial term of five years. At December 31, 2020, the Company had remaining balances of $4.7 million and $8.9 million of current and non-current pre-paid research and development costs related to this transaction, respectively. For the year ended December 31, 2020, the Company used $13.6 million of the pre-paid research and development expenses.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"> </p> 6340771 30000000.0 P5Y 4700000 8900000 13600000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Selected Quarterly Data (Unaudited)</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables contain quarterly financial information for 2020 and 2019 (in thousands).  The Company believes that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented.  The operating results for any quarter are not necessarily indicative of results for any future period.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 Quarter Ended</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">445</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,498</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,382</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,437</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,694</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,398</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,937</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,437</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,694</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,828</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,535</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,222</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,588</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.46</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.44</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.36</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.39</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 Quarter Ended</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">338</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">305</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,231</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,035</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,445</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,443</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,710</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,697</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,138</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,479</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,946</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,344</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,285</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,798</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.51</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.45</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.39</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.37</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables contain quarterly financial information for 2020 and 2019 (in thousands).  The Company believes that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented.  The operating results for any quarter are not necessarily indicative of results for any future period.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 Quarter Ended</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">445</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,498</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,382</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,437</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,694</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,398</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,937</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,437</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,694</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,828</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,535</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,222</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,588</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.46</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.44</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.36</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.39</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 Quarter Ended</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.82%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">338</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">305</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,231</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,035</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,445</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,443</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,710</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,697</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,138</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,479</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,946</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,344</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,285</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,798</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share - basic and diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.51</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.45</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.39</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.82%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.37</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"> </p> 100000 445000 16498000 16382000 13437000 14694000 -16398000 -15937000 -13437000 -14694000 -15828000 -15535000 -13222000 -14588000 -0.46 -0.44 -0.36 -0.39 338000 350000 305000 1231000 14035000 13445000 14443000 14710000 -13697000 -13095000 -14138000 -13479000 -12946000 -12344000 -13285000 -12798000 -0.51 -0.45 -0.39 -0.37 XML 19 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Mar. 18, 2021
Jun. 30, 2020
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2020    
Document Fiscal Year Focus 2020    
Document Fiscal Period Focus FY    
Trading Symbol SYBX    
Entity Registrant Name SYNLOGIC, INC.    
Entity Central Index Key 0001527599    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   39,657,841  
Entity Public Float     $ 38.0
Title of 12(b) Security Common Stock, par value $0.001 per share    
Entity File Number 001-37566    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 26-1824804    
Entity Interactive Data Current Yes    
Security Exchange Name NASDAQ    
Entity Address, Address Line One 301 Binney St    
Entity Address, Address Line Two Suite 402    
Entity Address, City or Town Cambridge    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02142    
City Area Code 617    
Local Phone Number 401-9975    
Document Annual Report true    
Document Transition Report false    
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the registrant’s definitive proxy statement for the 2021 annual meeting of stockholders to be filed pursuant to Regulation 14A with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2020.

    

XML 20 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 32,507 $ 26,184
Short-term marketable securities 67,937 93,387
Prepaid expenses and other current assets 6,402 13,675
Total current assets 106,846 133,246
Long-term marketable securities   7,502
Property and equipment, net 10,776 13,021
Right of use asset - operating lease 15,527 17,263
Restricted cash 1,097 1,097
Prepaid research and development, net of current portion 9,590 16,381
Other assets 4 64
Total assets 143,840 188,574
Current liabilities:    
Accounts payable 1,995 2,165
Accrued expenses 3,773 3,946
Deferred revenue   544
Lease liability - operating lease 2,531 2,000
Finance lease obligations 2 208
Total current liabilities 8,301 8,863
Long-term liabilities:    
Lease liability - operating lease, net of current portion 20,273 22,804
Finance lease obligations, net of current portion   2
Other long-term liabilities 131  
Total long-term liabilities 20,404 22,806
Commitments and contingencies (Note 14)
Stockholders' equity    
Common stock, $0.001 par value 250,000,000 shares authorized as of December 31, 2020 and December 31, 2019. 38,183,273 shares issued and outstanding as of December 31, 2020 and 32,266,814 shares issued and outstanding as of December 31, 2019. 38 33
Additional paid-in capital 345,394 327,900
Accumulated other comprehensive loss 14 110
Accumulated deficit (230,311) (171,138)
Total stockholders' equity 115,135 156,905
Total liabilities and stockholders' equity $ 143,840 $ 188,574
XML 21 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2020
Dec. 31, 2019
Statement Of Financial Position [Abstract]    
Common stock, par value $ 0.001 $ 0.001
Common stock, authorized 250,000,000 250,000,000
Common stock, Issued 38,183,273 32,266,814
Common stock, outstanding 38,183,273 32,266,814
XML 22 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]    
Revenue $ 545 $ 2,224
Operating expenses:    
Research and development 47,474 41,905
General and administrative 13,537 14,728
Total operating expenses 61,011 56,633
Loss from operations (60,466) (54,409)
Other income (expense):    
Interest and investment income 1,302 3,062
Interest expense (6) (21)
Other expense (3) (5)
Other income (expense), net 1,293 3,036
Net loss $ (59,173) $ (51,373)
Net loss per share - basic and diluted $ (1.65) $ (1.70)
Weighted-average common stock outstanding - basic and diluted 35,835,744 30,284,068
Comprehensive loss:    
Net loss $ (59,173) $ (51,373)
Net unrealized (loss) gain on marketable securities (96) 175
Comprehensive loss $ (59,269) $ (51,198)
XML 23 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
At-the-market Offering
Common Stock $0.001 Par Value
Common Stock $0.001 Par Value
At-the-market Offering
Additional Paid-in Capital
Additional Paid-in Capital
At-the-market Offering
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance at Dec. 31, 2018 $ 124,098   $ 25   $ 243,903   $ (65) $ (119,765)
Balance (in Shares) at Dec. 31, 2018     25,401,479          
Proceeds from issuance of common stock, net of issuance costs 56,997   $ 7   56,990      
Proceeds from issuance of common stock, net of issuance costs, Shares     6,340,771          
Proceeds from issuance of pre-funded common stock warrants, net of issuance costs 22,874       22,874      
Issuance of restricted stock     $ 1   (1)      
Issuance of restricted stock, shares     585,600          
Cancellation of restricted stock     (61,036)          
Equity-based compensation expense 4,134       4,134      
Unrealized gain (loss) on securities 175           175  
Net loss (51,373)             (51,373)
Balance at Dec. 31, 2019 156,905   $ 33   327,900   110 (171,138)
Balance (in Shares) at Dec. 31, 2019     32,266,814          
Proceeds from issuance of common stock, net of issuance costs   $ 13,534   $ 5   $ 13,529    
Proceeds from issuance of common stock, net of issuance costs, Shares       5,866,258        
Exercise of options 16       16      
Exercise of options, shares     9,472          
Issuance of restricted stock, shares     226,335          
Issuance of common stock under employee stock purchase plan 42       42      
Issuance of common stock under employee stock purchase plan, Shares     29,857          
Cancellation of restricted stock     (215,463)          
Equity-based compensation expense 3,907       3,907      
Unrealized gain (loss) on securities (96)           (96)  
Net loss (59,173)             (59,173)
Balance at Dec. 31, 2020 $ 115,135   $ 38   $ 345,394   $ 14 $ (230,311)
Balance (in Shares) at Dec. 31, 2020     38,183,273          
XML 24 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:    
Net loss $ (59,173) $ (51,373)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 2,636 2,702
Equity-based compensation expense 3,907 4,134
Accretion/amortization of investment securities (21) (1,282)
Reduction in carrying amount of operating lease right of use asset 1,736 1,370
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 7,273 (12,263)
Prepaid research and development, net of current portion 6,791 (16,381)
Other assets 60  
Accounts payable and accrued expenses (349) (935)
Deferred revenue (544) 276
Operating lease liabilities (2,000) (1,716)
Other long-term liabilities 131  
Net cash used in operating activities (39,553) (75,468)
Cash flows from investing activities:    
Purchases of marketable securities (86,474) (145,418)
Proceeds from maturity of marketable securities 90,836 157,465
Proceeds from redemption of marketable securities 28,515  
Purchases of property and equipment (395) (1,251)
Net cash provided by investing activities 32,482 10,796
Cash flows from financing activities:    
Payments on finance lease obligations (208) (266)
Proceeds from issuance/sale of common stock, net of issuance costs   56,996
Proceeds from employee stock purchases and exercise of stock options 58  
Proceeds from sale of pre-funded warrants, net of issuance costs   22,874
Net cash provided by financing activities 13,394 79,604
Net increase in cash, cash equivalents and restricted cash 6,323 14,932
Cash, cash equivalents and restricted cash at beginning of period 27,281 12,349
Cash, cash equivalents and restricted cash at end of period 33,604 27,281
Supplemental disclosure of non-cash investing activities:    
Property and equipment purchases included in accounts payable and accrued expenses (4) (369)
Assets acquired under operating lease obligation   2,714
Supplemental disclosure of non-cash financing activities:    
Issuance costs included in accounts payable and accrued expenses 10  
Cash paid for interest 6 $ 21
At-the-market Offering    
Cash flows from financing activities:    
Proceeds from issuance/sale of common stock, net of issuance costs $ 13,544  
XML 25 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Nature of Business
 12 Months Ended
Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Nature of Business

(1)

Nature of Business

Organization

Synlogic, Inc., together with its wholly owned and consolidated subsidiaries (“Synlogic” or the “Company”), is a clinical-stage biopharmaceutical company focused on the drug discovery and development of Synthetic Biotic™ medicines. Synthetic Biotic medicines are generated from Synlogic’s proprietary drug discovery and development platform, leveraging a reproducible, modular approach to Synthetic Biology to develop beneficial microbes, which perform or deliver critical therapeutic functions. Synthetic Biotic medicines are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways or deliver combinations of therapeutic factors. Synlogic’s goal is to discover, develop and ultimately commercialize Synthetic Biotic medicines. Since incorporation, the Company has devoted substantially all of its efforts to the research and development of its product candidates.

Risks and Uncertainties

At December 31, 2020, the Company had approximately $100.4 million in cash, cash equivalents, and short-term marketable securities, $1.1 million of restricted cash and an accumulated deficit of approximately $230.3 million. Since its inception through December 31, 2020, the Company has primarily financed its operations through the issuance of preferred stock, units and warrants, the sale of its common stock, the AbbVie collaboration, and cash received in the Merger. In the absence of positive cash flows from operations, the Company is highly dependent on its ability to find additional sources of funding in the form of debt or equity financing. Management believes that the Company has sufficient cash to fund its operations through at least twelve months from the issuance of these financial statements.

As an early-stage company, the Company is subject to a number of risks common to other life science companies, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), the regulatory approval process, market acceptance of the Company’s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology. The Company’s therapeutic programs are currently pre-commercial, spanning discovery through early development and will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates.  These efforts require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance-reporting capabilities.  There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary regulatory approval or that any approved products will be commercially viable.  Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales.  The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital or obtain financing from other sources, such as strategic collaborations or partnerships.
XML 26 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

(2)

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S.”) (“U.S. GAAP” or “GAAP”).

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.  On an on-going basis, the Company’s management evaluates its estimates, including those related to revenue recognition, income taxes including the valuation allowance for deferred tax assets, research and development accruals and prepaids, accrued expenses, investments, contingencies and equity-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.  Changes in estimates are reflected in reported results in the period in which they become known.

Cash Equivalents

The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents consist of money market funds, including money market funds held in a sweep account. Cash equivalents are stated at cost plus accrued interest, which approximates fair value. The amount of cash equivalents included in cash and cash equivalents was approximately $32.5 million and $13.5 million at December 31, 2020 and 2019, respectively.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash, cash equivalents, marketable securities and restricted cash. The Company uses high quality, accredited financial institutions to maintain its balances, and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.

Restricted Cash

The Company held cash of approximately $1.1 million at December 31, 2020 and 2019 in a letter of credit to secure its lease at the 301 Binney Street facility.  The Company has classified this deposit as long-term restricted cash on its balance sheet.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Cash and cash equivalents

 

$

32,507

 

 

$

26,184

 

Restricted cash included in other long-term assets

 

 

1,097

 

 

 

1,097

 

Total cash, cash equivalents, and restricted cash shown in

   the consolidated statement of cash flows

 

$

33,604

 

 

$

27,281

 

 

Fair Value

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values.  Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). The hierarchy consists of three levels: 

 

•

Level 1 – Utilize observable inputs such as quoted prices in active markets for identical assets or liabilities;

 

•

Level 2 – Utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves;

 

•

Level 3 – Utilize unobservable data points in which there is little or no market data, which require the Company to develop its own assumptions for the asset or liability.

The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of assets or liabilities between Level 1, Level 2 or Level 3 during the years ended December 31, 2020 and 2019.

Available-for-Sale Securities

The Company classifies all short-term investments with an original maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest and investment income. Realized gains and losses, and declines in value judged to be other than temporary on available-for-sale securities, are included in interest and investment income.

The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest and investment income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary.

Property and Equipment

Property and equipment, including leasehold improvements, are recorded at cost and depreciated over their estimated useful lives using the straight‑line method. Repairs and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.

Depreciation begins at the time the asset is placed in service. Depreciation is provided over the following estimated useful lives:

 

Asset classification

 

Useful life

Computer and office equipment

 

3 years

Furniture and fixtures

 

5 years

Laboratory equipment

 

5 years

Leasehold improvements

 

Lesser of useful life or remaining lease term

 

Impairment of Long‑Lived Assets

Long‑lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value of the asset. To date, no such impairments have been recognized.

Leases

The Company uses judgement to assess if an arrangement is a lease at contract inception. An arrangement is a lease if the contract involves the use of a distinct identified asset, the lessor does not have substantive substitution rights and the Company obtains control of the asset throughout the period by obtaining substantially all of the economic benefit of the asset and the right to direct the use of the asset. Leases classified as operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities and noncurrent operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations, in our consolidated balance sheet.

ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company utilizes its incremental borrowing rate to determine the present value of lease payments. The incremental borrowing rate is the rate incurred to borrow similar funds, on a collateralized basis, over a comparable term in a similar economic environment.

The Company has elected to account for the lease and non-lease components for leases as a single component for classes of all underlying assets and allocate all of the contract consideration to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating expenses.

The lease term includes options to extend the lease when it is reasonably certain that option will be exercised. Leases with a term of 12 months or less are not recorded on the Company’s consolidated balance sheet.

Research and Development Costs

Costs incurred in research and development are expensed as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed.

Research and development expenses are comprised of costs incurred in performing research and development activities, including salary and benefits, equity-based compensation expense, laboratory supplies and other direct expenses, facilities expenses, overhead expenses, contractual services and other outside expenses.

When third-party service providers’ billing terms do not coincide with the Company’s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial costs, contractual services costs and costs for supply of its drug candidates, incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on the completion status of the research and development programs and the associated estimate of unbilled costs.

 

Revenue recognition

 

The Company generated revenue through a collaboration and license arrangement with AbbVie for the development and commercialization of product candidates prior to the termination of the arrangement in May 2020.

The Company evaluates collaboration agreements with respect to FASB ASC Topic 808, Collaborative Arrangements, considering the nature and contractual terms of the arrangement and the nature of its business operations to determine the classification of the transactions. When the Company is an active participant in the activity and exposed to significant risks and rewards dependent on the commercial success of the collaboration, it will record its transactions on a gross basis in the consolidated financial statements and describe the rights and obligations under the collaborative arrangement in the notes to the consolidated financial statements.

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five-step analysis: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step analysis to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company may enter into collaboration agreements for research and development services, under which the Company may license certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Variable consideration is constrained until it is deemed not be at significant risk of reversal.

In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements for which the collaboration partner is also a customer, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses significant judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the goods and services the Company expects to provide. The Company uses estimates to determine the timing of satisfaction of performance obligations, which may include the use of full time equivalent time as a measure of satisfaction of performance obligations.

Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.

Licenses of Intellectual Property

In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Research and Development Services

If an arrangement is determined to contain a promise or obligation for the Company to perform research and development services, the Company must determine whether these services are distinct from the other promises in the arrangement. In assessing whether the services are distinct from the other promises, the Company considers the capabilities of the customer to perform these same services. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For research and development services that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Customer Options

If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, that is, the option to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on an alternative approach when the goods or services are both (i) similar to the original goods and services in the contract and (ii) provided in accordance with the terms of the original contract. Under this alternative, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to a material right are not recognized as revenue until the option is exercised and the performance obligation is satisfied.

Milestone Payments

At the inception of each arrangement that includes milestone payments, the Company evaluates whether a significant reversal of cumulative revenue provided in conjunction with achieving the milestones is probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For other milestones, the Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.

Royalties

For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.

Contract Costs

The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer.

Equity‑Based Compensation

The Company measures equity-based compensation to employees, non-employees and directors based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period. The fair value of each option and purchase rights under the employee stock purchase plan (“ESPP”) is estimated on the date of grant using the Black‑Scholes option‑pricing model. Expected volatility for the Company’s common stock is determined based on an average of the historical volatility of the Company and the historical volatility of a peer‑group of similar public companies. The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The expected term of purchase rights for the ESPP is based on the duration of an offering period. The assumed dividend yield is based upon the Company’s expectation of not paying dividends in the foreseeable future. The risk‑free interest rate is based upon the U.S. Treasury yield curve commensurate with the expected term at the time of grant or remeasurement. Forfeitures are recognized as they occur.

The Company classifies equity-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipients’ service payments are classified.

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company’s tax returns. Deferred taxes are determined based on the difference between the financial reporting and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.

Uncertain tax positions represent tax positions for which reserves have been established. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to be recognized in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.

Net Loss Per Share

Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and if dilutive, the weighted-average number of potential shares of common stock, including unvested restricted common stock, outstanding stock options and potential shares issuable under the ESPP.

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in one operating segment: discovery and development of synthetic biology therapeutics for the treatment of rare, infectious and other diseases. The Company’s chief executive officer, as chief operating decision maker, manages and allocates resources to the operations of the Company on a total company basis. All of the Company’s equipment, leasehold improvements and other fixed assets are physically located within the United States, and all agreements with its partners are denominated in U.S. dollars, except where noted.

 

New Accounting Pronouncements

 

New accounting pronouncements are issued by the FASB from time to time, and rules are issued by the SEC that the Company has or will adopt as of a specified date. Unless otherwise noted, management does not believe that any recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had, or is expected to have, a material impact on the Company’s present or future financial statements.

Recently Adopted Accounting Pronouncements

In December 2019, the FASB issued ASU 2019-12 – Income Taxes – (Topic 740): Simplifying the Accounting for Income Taxes, which provides amended guidance on income tax accounting. The amended guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year. Early adoption is permitted. The amended guidance, which simplifies the accounting for income taxes, includes the removal of exceptions to the general principles of ASC 740. The standard removed the exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items. The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13 - Fair Value Measurement - Disclosure Framework (Topic 820). The standard modifies the disclosure requirements for fair value measurements. The standard is effective for public companies for annual and interim periods beginning after December 15, 2019. The Company adopted the new guidance effective on January 1, 2020, which had an immaterial impact on the Company’s financial statement disclosures.

In August 2018, the FASB issued ASU 2018-15 - Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract. The standard requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.

In November 2018, the FASB issued ASU 2018-18 - Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606. The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.

 

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13 - Measurement of Credit Losses on Financial Statements. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-

for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. In November 2019, the FASB issued ASU 2019-10 – Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which amended the effective date for certain companies. The standard is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December 15, 2022. Early adoption is available. The Company is currently evaluating the potential impact ASU 2016-13, and related updates, will have on its consolidated financial statements and disclosures.

In October 2020, the FASB issued an amendment, ASU 2020-08- Codification Improvements to Subtopic 310-20, Receivables – Nonrefundable Fees and Other Costs, to the guidance in ASU 2017-08, Receivables-Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. The amendment requires companies to reevaluate whether a callable debt security that has multiple call dates is within the scope of paragraph 310-20-65-2. The amendment shall be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is not permitted. The Company is currently evaluating the potential impact that ASU 2020-08 will have on its consolidated financial statements and disclosures.

 
XML 27 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value of Financial Instruments
 12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments

(3)

Fair Value of Financial Instruments

The tables below present information about the Company’s assets that are measured at fair value on a recurring basis as of December 31, 2020 and 2019 and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, as described under Note 2, Summary of Significant Accounting Policies.  

The Company’s investment portfolio includes many fixed income securities that do not always trade on a daily basis.  As a result, the pricing services used by the Company applied other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare evaluations.  In addition, model processes were used to assess interest rate impact and develop prepayment scenarios.  These models take into consideration relevant credit information, perceived market movements, sector news and economic events.  The inputs into these models may include benchmark yields, reported trades, broker-dealer quotes, issuer spreads and other relevant data.

At December 31, 2020 and 2019, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands):

 

 

 

Fair Value Measurements at Reporting Date Using

 

 

 

December 31,

 

 

Quoted Prices in Active

Markets for Identical

Assets

 

 

Significant Other

Observable Inputs

 

 

Significant

Unobservable Inputs

 

Description

 

2020

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Money market funds

 

$

32,506

 

 

$

32,506

 

 

$

—

 

 

$

—

 

Commercial paper

 

 

40,477

 

 

 

—

 

 

 

40,477

 

 

 

—

 

Corporate debt securities

 

 

18,637

 

 

 

—

 

 

 

18,637

 

 

 

—

 

U.S. government agency securities and treasuries

 

 

8,823

 

 

 

8,823

 

 

 

—

 

 

 

—

 

Total

 

$

100,443

 

 

$

41,329

 

 

$

59,114

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements at Reporting Date Using

 

 

 

December 31,

 

 

Quoted Prices in Active

Markets for Identical

Assets

 

 

Significant Other

Observable Inputs

 

 

Significant

Unobservable Inputs

 

Description

 

2019

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Money market funds

 

$

3,240

 

 

$

3,240

 

 

$

—

 

 

$

—

 

Commercial paper (included in cash and

   cash equivalents)

 

 

4,249

 

 

 

—

 

 

 

4,249

 

 

 

—

 

Commercial paper (included in marketable

   securities)

 

 

20,501

 

 

 

—

 

 

 

20,501

 

 

 

—

 

Corporate debt securities (included in cash

   and cash equivalents)

 

 

6,005

 

 

 

—

 

 

 

6,005

 

 

 

—

 

Corporate debt securities (included in

   marketable securities)

 

 

71,383

 

 

 

—

 

 

 

71,383

 

 

 

—

 

U.S. government agency securities and

   treasuries

 

 

9,005

 

 

 

—

 

 

 

9,005

 

 

 

—

 

Total

 

$

114,383

 

 

$

3,240

 

 

$

111,143

 

 

$

—

 

 

Cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses at December 31, 2020 and December 31, 2019 are carried at amounts that approximate fair value due to their short-term maturities.  Finance lease obligations at December 31, 2020 and December 31, 2019 approximate fair value as they bear interest at a rate approximating a market interest rate.
XML 28 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Available-for-Sale Investments
 12 Months Ended
Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]  
Available-for-Sale Investments

(4)

Available-for-Sale Investments

The following tables summarize the available-for-sale securities held at December 31, 2020 and 2019 (in thousands):

 

December 31, 2020

 

Amortized cost

 

 

Gross unrealized

gains

 

 

Gross unrealized

losses

 

 

Fair Value

 

Commercial paper

 

$

40,467

 

 

$

11

 

 

$

(1

)

 

$

40,477

 

Corporate debt securities

 

 

18,634

 

 

 

4

 

 

 

(1

)

 

 

18,637

 

U.S. government agency securities

 

 

8,822

 

 

 

1

 

 

 

—

 

 

 

8,823

 

Total

 

$

67,923

 

 

$

16

 

 

$

(2

)

 

$

67,937

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2019

 

Amortized cost

 

 

Gross unrealized

gains

 

 

Gross unrealized

losses

 

 

Fair Value

 

Commercial paper

 

$

20,484

 

 

$

18

 

 

$

(1

)

 

$

20,501

 

Corporate debt securities

 

 

71,288

 

 

 

96

 

 

 

(1

)

 

 

71,383

 

U.S. government agency securities

 

 

9,005

 

 

 

2

 

 

 

(2

)

 

 

9,005

 

Total

 

$

100,777

 

 

$

116

 

 

$

(4

)

 

$

100,889

 

 

 

The contractual maturity of all securities held at December 31, 2020 was ten months or less.  There were eight investments in an unrealized loss position at December 31, 2020, none of which had been in an unrealized loss position for more than twelve months.  The aggregate fair value of the securities in an unrealized loss position at December 31, 2020 and 2019 was $20.1 million and $24.8 million, respectively. The Company reviews its investments for other-than-temporary impairment whenever the fair value of an investment is less than amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time.  To determine whether an impairment is other-than-temporary, the Company considers whether it has the ability and intent to hold the investment until a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary.  The Company did not hold any securities with an other-than-temporary impairment at December 31, 2020.

Gross realized gains and losses on the sales of investments have not been material to the Company’s consolidated statement of operations.
XML 29 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Prepaid Expenses and Other Current Assets
 12 Months Ended
Dec. 31, 2020
Text Block [Abstract]  
Prepaid Expenses and Other Current Assets

(5)

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Prepaid insurance

 

$

856

 

 

$

648

 

Prepaid research and development

 

 

4,771

 

 

 

11,989

 

Other prepaid expenses

 

 

528

 

 

 

390

 

Other current assets

 

 

247

 

 

 

648

 

 

 

$

6,402

 

 

$

13,675

 
XML 30 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment, Net
 12 Months Ended
Dec. 31, 2020
Property Plant And Equipment [Abstract]  
Property and Equipment, Net

(6)

Property and Equipment, net

Property and equipment, net consists of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Laboratory equipment

 

$

7,793

 

 

$

7,523

 

Computer and office equipment

 

 

769

 

 

 

782

 

Furniture and fixtures

 

 

421

 

 

 

421

 

Leasehold improvements

 

 

9,514

 

 

 

9,514

 

Construction in progress

 

 

528

 

 

 

412

 

 

 

 

19,025

 

 

 

18,652

 

Less accumulated depreciation

 

 

(8,249

)

 

 

(5,631

)

 

 

$

10,776

 

 

$

13,021

 

 

Depreciation expense on property and equipment was $2.6 million and $2.7 million in 2020 and 2019, respectively.

 

 
XML 31 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Expenses
 12 Months Ended
Dec. 31, 2020
Payables And Accruals [Abstract]  
Accrued Expenses

(7)

Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Payroll related

 

$

3,005

 

 

$

2,372

 

Professional fees

 

 

215

 

 

 

444

 

Research and development

 

 

230

 

 

 

1,005

 

Other

 

 

323

 

 

 

125

 

 

 

$

3,773

 

 

$

3,946

 
XML 32 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Common Stock
 12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Common Stock

(8)

Common Stock

The Company’s common stock has the following characteristics:

 

•

The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders.

 

•

The holders of shares of common stock are entitled to receive dividends, if and when, declared by the Company’s board of directors. Since inception, no cash dividends have been declared.

In June 2019, the Company issued to Ginkgo Bioworks (“Ginkgo”) 6,340,771 shares of common stock and accompanying Pre-Funded Warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 2,548,117 shares of common stock, at a combined purchase price per share and Pre-Funded Warrant of $9.00. The Pre-Funded Warrants have an exercise price of $9.00 per share, with $8.99 of such exercise price paid at the closing of the offering. The proceeds, net of issuance costs, were approximately $79.9 million, $57.0 million related to the proceeds from sale of the common stock and $22.9 million related to the proceeds from sale of the Pre-Funded Warrants. The Pre-Funded Warrants may be exercised at any time until all of the Pre-Funded Warrants are exercised in full to the extent that, after giving effect to such issuance after exercise, Ginkgo would not beneficially own in excess of 19.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance. The Pre-Funded Warrants were classified as a component of permanent equity and were recorded at the issuance date using a relative fair value allocation method. The Pre-Funded Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the holders to receive a fixed number of common shares upon exercise. In addition, such warrants do not provide any guarantee of value or return. In addition, in connection with the issuance to Ginkgo of common stock and Pre-Funded Warrants, the Company expanded its existing collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. None of the Pre-Funded Warrants have been exercised as of December 31, 2020. (See Note 10).

The Company has a sales agreement with Cowen and Company, LLC (“Cowen”) with respect to an at-the-market (“ATM”) offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $17.3 million, through Cowen as its sales agent. In an ATM offering, exchange-listed companies incrementally sell newly issued shares into the secondary trading market through a designated broker-dealer at prevailing market prices. During the year ended December 31, 2020, 5,866,258 shares of common stock were sold pursuant to the ATM, resulting in net proceeds of approximately $13.5 million. Subsequent to December 31, 2020, the Company is able to offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million.  

The Company has reserved for future issuance the following shares of common stock related to the potential warrant exercise, exercise of stock options, and the employee stock purchase plan:

 

 

December 31, 2020

 

Common stock issuable under pre-funded warrants

 

2,548,117

 

Options to purchase common stock

 

1,211,967

 

Employee Stock Purchase Plan

 

345,662

 

Total

 

4,105,746

 

 

 
XML 33 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Equity-based Compensation and Equity Incentive Plans
 12 Months Ended
Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Equity-based Compensation and Equity Incentive Plans

(9)

Equity‑based Compensation and Equity Incentive Plans

 

Equity Plans

The Company currently has three active equity plans.

The 2015 Equity Incentive Award Plan (“2015 Plan”) functions as the primary equity plan for the Company. The 2015 Plan includes an “evergreen provision” that allows for an annual increase in the number of shares of common stock available for issuance under the 2015 Plan, which annual increase will be added on the first day of each fiscal year from 2016 through 2025, inclusive, and will be equal to the lesser of (i) five percent of the shares outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Board of Directors. The 2015 Plan provides for the granting of a variety of stock‑based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, deferred stock awards, dividend equivalent awards, stock payment awards, performance awards and other stock‑based awards.

The 2017 Stock Incentive Plan (the “2017 Plan”) provides for the grant of incentive stock options, non-qualified stock options, restricted and unrestricted stock awards and other stock-based awards.

The 2015 Employee Stock Purchase Plan (“ESPP”) allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations.  The ESPP generally provides for set offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last trading day of the offering period.  The Company suspended the ESPP in 2017. In December 2019, the Board reactivated the 2015 ESPP and approved an amendment to the ESPP to (i) reduce the permitted payroll deduction and number of shares of the Company’s common stock that a participant may purchase per calendar year and offering period under the ESPP and (ii) establish a period for enrollment for eligible participants. The reactivation of the 2015 ESPP was effective immediately. The Company’s executive officers are eligible to participate in the 2015 ESPP. There were 29,857 shares of common stock purchased under the ESPP during the year ended December 31, 2020.

 

 

Stock Options

The weighted average assumptions used in the Black-Scholes option-pricing model for stock options issued to employees and non-employees under the 2015 Plan and the 2017 Plan, during the years ended December 31, 2020 and 2019 were:

 

 

 

Year ended December 31,

 

 

Employees:

 

2020

 

 

2019

 

 

Expected term

 

6.2 years

 

 

6.2 years

 

 

Weighted-average, risk-free interest rate

 

0.6%

 

 

2.2%

 

 

Expected volatility

 

77.2%

 

 

71.1%

 

 

Dividend yield

 

 

—

 

 

 

—

 

 

 

 

The following table summarizes stock option activity under the 2015 and 2017 Plans.

 

 

 

Stock options outstanding

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

average

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

remaining

 

 

Aggregate

 

 

 

 

 

 

 

average

 

 

contractual

 

 

intrinsic

 

 

 

Number of

 

 

exercise

 

 

term

 

 

value (a)

 

 

 

options

 

 

price

 

 

(in years)

 

 

(in thousands)

 

Outstanding at December 31, 2019

 

 

2,286,419

 

 

$

9.24

 

 

 

8.7

 

 

$

43

 

Granted

 

 

1,627,654

 

 

 

1.90

 

 

 

 

 

 

 

—

 

Exercised

 

 

(9,472

)

 

 

1.70

 

 

 

 

 

 

 

6

 

Cancelled/Forfeited

 

 

(560,765

)

 

 

7.34

 

 

 

 

 

 

 

—

 

Outstanding at December 31, 2020

 

 

3,343,836

 

 

 

6.00

 

 

 

8.4

 

 

 

399

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vested or expected to vest at December 31, 2020

 

 

3,343,836

 

 

 

6.00

 

 

 

8.4

 

 

 

399

 

Exercisable at December 31, 2020

 

 

1,399,952

 

 

 

9.13

 

 

 

7.7

 

 

$

53

 

 

 

(a)

The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair market value of the underlying common stock for the options that were in the money at December 31, 2020 and 2019. 970,826 and 132,500 options were in the money at December 31, 2020 and 2019, respectively.

The weighted average grant date fair value per share of options granted during the years ended December 31, 2020 and 2019 was approximately $1.27 and $4.59, respectively. The total fair value of awards that vested during the years ended December 31, 2020 and 2019 was $3.4 million and $3.9 million, respectively.

As of December 31, 2020, there was approximately $4.3 million of unrecognized share-based compensation for unvested stock option grants which is expected to be recognized over a weighted average period of 2.1 years.  The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.  

Restricted Common Stock

During the years ended December 31, 2020 and 2019, 226,335 and 585,600 shares of restricted common stock were granted, respectively.

The following table shows restricted common stock activity:

 

 

 

Restricted stock awards

 

 

 

 

 

 

 

Weighted

average

grant date

 

 

 

Number of

 

 

fair value

 

 

 

shares

 

 

(per share)

 

Unvested at December 31, 2019

 

 

586,929

 

 

$

2.97

 

Granted

 

 

226,335

 

 

 

1.70

 

Vested

 

 

(119,594

)

 

 

2.30

 

Forfeited

 

 

(215,463

)

 

 

2.32

 

Unvested at December 31, 2020

 

 

478,207

 

 

$

2.19

 

 

The total fair value of shares that vested during the years ended December 31, 2020 and 2019 was $0.3 million and $0.1 million, respectively.

As of December 31, 2020, there was approximately $0.4 million of unrecognized share-based compensation related to restricted stock awards granted, which is expected to be recognized over a weighted average period of 2.1 years.  The total unrecognized share-based compensation cost will be adjusted for actual forfeitures as they occur.  

 

 

Employee Stock Purchase Plan

The ESPP is considered a compensatory plan with the related compensation expense recognized over the six-month offering periods. The compensation expense for the year ended December 31, 2020 was $27,000.  There was no compensation expense related to the ESPP for the year ended December 31, 2019.

 

Equity Compensation

The Company has recorded total equity‑based compensation expense of approximately $3.9 million and $4.1 million, during the years ended December 31, 2020 and 2019, respectively. Equity compensation during the year ended December 31, 2020 is derived from stock options, restricted stock awards, and the ESPP. Equity compensation during the year ended December 31, 2019 is derived from stock options and restricted stock awards.

The following table summarizes equity‑based compensation expense within the Company’s consolidated statements of operations and comprehensive loss for the years ended December 31, 2020 and 2019 (in thousands):

 

 

 

Years ended December 31,

 

 

 

2020

 

 

2019

 

Research and development

 

$

1,724

 

 

$

1,377

 

General and administrative

 

 

2,183

 

 

 

2,757

 

 

 

$

3,907

 

 

$

4,134

 

 

The following table summarizes equity‑based compensation expense by type of award for the years ended December 31, 2020 and 2019 (in thousands):

 

 

 

Years ended December 31,

 

 

 

2020

 

 

2019

 

Stock options

 

$

3,200

 

 

$

3,789

 

Restricted stock awards

 

 

680

 

 

 

345

 

ESPP

 

 

27

 

 

 

—

 

 

 

$

3,907

 

 

$

4,134

 

 
XML 34 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration Agreements
 12 Months Ended
Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Collaboration Agreements

(10)

Collaboration Agreements

 

Ginkgo Collaboration

 

In 2017, the Company established a technology collaboration with Ginkgo. In June 2019, in connection with the issuance to Ginkgo of an aggregate of 6,340,771 shares of common stock and Pre-Funded Warrants to purchase an aggregate of 2,548,117 common stock (See Note 8), the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. Under the 2019 expanded agreement, the Company made a prepayment to Ginkgo of $30.0 million for its foundry services that will be provided to the Company over an initial term of five years. The prepayment of foundry services is recorded in Prepaid expenses and other current assets and Prepaid research and development, net of current portion on the December 31, 2020 consolidated balance sheet. At December 31, 2020, the Company had remaining balances of $4.7 million and $8.9 million of current and non-current pre-paid research and development costs related to this transaction, respectively. Upon the expiration of such initial term and, if applicable, an additional period, any portion of the prepayment that has not been used to purchase services from Ginkgo will be retained by Ginkgo.

 

AbbVie Collaboration Agreement

In July 2015, the Company entered into the AbbVie Agreements under which the Company granted AbbVie an exclusive option to purchase IBDCo and, in exchange, agreed to collaborate in researching and developing an Investigational New Drug (“IND”) candidate for the treatment of IBD. The AbbVie Agreements set forth the Company’s and AbbVie’s respective obligations for development and delivery of an IND candidate package using reasonable commercial efforts.  

In May 2020, we announced the termination of our collaboration with AbbVie to develop Synthetic Biotic medicines for the treatment of types of IBD, including Crohn’s disease and ulcerative colitis.  Upon termination, we regained all rights to develop these and new IBD Synthetic Biotic medicines for all effectors targeting IBD. This allows us to fully leverage our expertise in strain engineering, quantitative biology, regulatory, and manufacturing to expand our wholly owned GI-based program portfolio to include IBD. We further regained the rights to partner these IBD programs.

Revenue associated with performance obligations under the AbbVie Agreements was recognized as the research and development services were provided using an input method, according to the full-time equivalents incurred. The research and development activities were expected to be performed over a period of approximately 54 months. The transfer of control occurred over time and, in management’s judgment, was the best measure of progress towards satisfying the performance obligation. The amounts received that had not yet been recognized as revenue were recorded in deferred revenue on the Company’s consolidated balance sheet.

For the years ended December 31, 2020 and 2019, the Company recognized $0.5 million and $2.2 million, respectively, as collaboration revenue in the Company’s consolidated statements of operations and comprehensive loss. There is no deferred revenue on the Company’s consolidated balance sheet as of December 31, 2020, as the remainder of the revenue was recognized when the agreement was terminated.

 
XML 35 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss per Share
 12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
Net Loss per Share

(11)

Net Loss per Share

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except for share and per share amounts):

 

 

 

2020

 

 

2019

 

Numerator:

 

 

 

 

 

 

 

 

Net loss

 

$

(59,173

)

 

$

(51,373

)

Denominator:

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding - basic and diluted

 

 

35,835,744

 

 

 

30,284,068

 

Net loss per share - basic and diluted

 

$

(1.65

)

 

$

(1.70

)

 

The Company’s potentially dilutive shares, which include outstanding stock options, unvested restricted common stock and potential shares issuable under the ESPP, are considered to be common share equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of the diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect.

 

 

 

As of December 31,

 

 

 

2020

 

 

2019

 

Unvested restricted common stock awards

 

 

478,207

 

 

 

586,929

 

Outstanding options to purchase common stock

 

 

3,343,836

 

 

 

2,286,419

 

Potential shares issuable under the ESPP

 

 

12,037

 

 

 

—

 

 
XML 36 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes
 12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Income Taxes

(12)

Income Taxes

 

During the years ended December 31, 2020 and 2019, the Company recorded no income tax benefits for the net operating losses incurred due to its uncertainty of reclaiming a benefit for those losses.

 

 

Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. Deferred tax assets consist of the following (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

61,181

 

 

$

46,362

 

Tax credit carryforwards

 

 

5,748

 

 

 

4,262

 

Accrued expenses

 

 

126

 

 

 

37

 

Property and equipment

 

 

279

 

 

 

—

 

Other long-term liabilities

 

 

36

 

 

 

—

 

Lease liabilities

 

 

6,230

 

 

 

6,776

 

Equity compensation

 

 

2,200

 

 

 

1,481

 

Amortizable intangibles

 

 

1,195

 

 

 

1,214

 

Other

 

 

38

 

 

 

138

 

Gross deferred tax assets

 

 

77,033

 

 

 

60,270

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Property and equipment

 

 

—

 

 

 

(1,720

)

Right of use assets

 

 

(4,242

)

 

 

(4,716

)

Gross deferred tax liabilities

 

 

(4,242

)

 

 

(6,436

)

Valuation allowance

 

 

(72,791

)

 

 

(53,834

)

Net deferred tax assets

 

$

—

 

 

$

—

 

 

Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of the Company’s deferred tax assets, which are comprised principally of net operating loss carryforwards, and determined that it is more likely than not that the Company will not recognize the benefits of the deferred tax assets. As a result, a full valuation allowance of approximately $72.8 million and $53.8 million was established at December 31, 2020 and 2019, respectively.

A reconciliation of the statutory federal income tax rate to the Company’s effective income tax rate is as follows (dollars in thousands):

 

 

 

Years ended December 31,

 

 

 

2020

 

 

2019

 

 

 

Tax Rate

 

 

Tax Rate

 

U.S. federal statutory rate

 

 

21

%

 

 

21

%

State income taxes, net of federal benefit

 

 

6

%

 

 

6

%

Other permanent differences

 

 

(1

)%

 

 

(1

)%

Tax credits

 

 

2

%

 

 

0

%

Other items

 

 

4

%

 

 

0

%

Net change in valuation allowance

 

 

(32

)%

 

 

(26

)%

Effective income tax rate

 

 

—

 

 

 

—

 

 

 

A roll-forward of the valuation allowance for the years ended December 31, 2020 and 2019 is as follows (in thousands):

 

 

 

Years ended December 31,

 

 

 

2020

 

 

2019

 

Balance at beginning of year

 

$

(53,834

)

 

$

(40,290

)

Increase in valuation allowance

 

 

(18,957

)

 

 

(13,544

)

Balance at end of year

 

$

(72,791

)

 

$

(53,834

)

 

 

As of December 31, 2020 and 2019, the Company had federal net operating loss carryforwards that may be available to reduce future taxable income of approximately $227.0 million and $172.9 million, respectively. Of the $227.0 million of federal net operating loss carryforwards, $79.4 million begin to expire in 2034. The remaining $147.6 of federal net operating loss carryforwards do not expire. The Company also had state net operating loss carryforwards that may be available to reduce future taxable income of approximately $213.6 million and $159.0 million, for the periods ended December 31, 2020 and 2019, respectively. The state net operating loss carryforwards begin to expire in 2029. In addition, at December 31, 2020, the Company had federal and state research and development tax credit carryforwards available to reduce future tax liabilities of approximately $3.5 million and $2.3 million, respectively.

Pursuant to Section 382 of the Internal Revenue Code of 1986 (“IRC”), certain substantial changes in the Company’s ownership may result in a limitation on the amount of net operating loss (“NOL”) carryforwards and research and development credit (“R&D credit”) carryforwards that may be used in future years. Utilization of the NOL and R&D credit carryforwards may be subject to a substantial annual limitation under Section 382 of the IRC due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and R&D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company has not completed a study to assess whether an ownership change has occurred, or whether there have been multiple ownership changes since its formation, due to the significant complexity and related costs associated with such a study. There could be additional ownership changes in the future that may result in additional limitations on the utilization of NOL carryforwards and credits.

The Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority. The Company has not recognized any liability for unrecognized tax benefits as of December 31, 2020.

The Company files tax returns, on an entity-level basis, as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. Tax years from 2016 to the present are open to examination under the statute. The Company’s policy is to record interest and penalties related to income taxes as part of the tax provision. There are no interest or penalties accrued at December 31, 2020 and 2019.

 
XML 37 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Leases
 12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
Leases

(13)

Leases

Operating Leases

In July 2017, the Company entered into an agreement to lease approximately 41,346 square feet of laboratory and office space at 301 Binney Street in Cambridge, Massachusetts.  Annual rent is approximately $3.3 million.  The ten-year lease commenced in January 2018 and contains provisions for a free-rent period, annual rent increases and an allowance for tenant improvements. The Company is responsible for real estate taxes, maintenance, and other operating expenses applicable to the leased premises. The Company has paid for tenant improvements of approximately $2.9 million. Additionally, the Company has capitalized approximately $6.6 million of landlord-funded tenant improvements. The Company was deemed to be the accounting owner of the tenant improvements primarily because it was responsible for project cost overruns, and as such, the amounts were recorded as a leasehold improvement. The landlord-funded tenant improvement allowance is being amortized as a reduction to lease expense ratably over the lease term.  In conjunction with the lease, the Company established a letter of credit of approximately $1.0 million secured by cash balances included in restricted cash. Variable payments based on our portion of the operating expenses, including real estate taxes and insurance, are recorded as a period expense when incurred. The Company has an option to extend the term by five years and an option to terminate the agreement if a similar agreement is executed with the landlord or an affiliate of the landlord. Neither option is reasonably certain of exercise and both are excluded from the lease liability calculation.

During the year ended December 31, 2018, the Company entered into an agreement with Azzur Group, LLC (“Azzur”) whereby Azzur agreed to provide the Company with access to, and the use of, an approximately 700 square foot cleanroom space to be constructed in Waltham, Massachusetts (the “Azzur Suite”), for a period of 44 months, from May 1, 2019 to December 31, 2022 (the “Term”). Azzur also agreed to provide the Company with storage space and personnel support at the Azzur Suite. The total estimated expenses to be incurred by the Company during the Term for access to, and use of, the cleanroom and storage space, and the personnel support and other services, is $4.8 million. The Company determined that the agreement contained an embedded lease because the Company controls the use of the Azzur Suite. Accordingly, the fixed and in-substance fixed consideration under the agreement was used to determine the ROU asset and lease liability at the lease commencement date.

 Leases classified as operating leases are included in operating lease ROU assets, current operating lease liabilities and noncurrent operating lease liabilities in our consolidated balance sheets. The operating lease right-of-use asset and operating lease liability represents the Binney Street lease and the Azzur Suite lease. Cash paid for amounts included in the present value of operating lease liabilities was $3.9 and $3.7 million during the years ended December 31, 2020 and 2019, respectively, which is included in operating cash flows.

The components of lease cost for operating leases for the years ended December 31, 2020 and 2019 were (in thousands):

 

 

For the year ended December 31,

 

Operating leases

2020

 

 

2019

 

Operating lease cost

$

3,628

 

 

$

3,344

 

Short-term lease cost

$

-

 

 

$

330

 

Variable lease cost

 

1,055

 

 

 

1,092

 

Total lease cost

 

4,683

 

 

 

4,766

 

 

The right-of-use asset for the operating lease is disclosed on the consolidated balance sheets.

The weighted average remaining lease term and the weighted average discount rate for operating leases were:

 

 

For the year ended December 31,

 

 

2020

 

 

2019

 

Weighted average discount rate

 

8.0

%

 

 

8.0

%

Weighted average remaining lease term (years)

 

7.2

 

 

 

8.2

 

 

The following table reconciles the undiscounted cash flows for the operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet: December 31, 2020

 

Maturity of lease liabilities

Operating Leases

 

 

(in thousands)

 

2021

$

4,236

 

2022

 

4,389

 

2023

 

3,574

 

2024

 

3,681

 

2025

 

3,792

 

Thereafter

 

10,595

 

Total lease payments

 

30,267

 

Less: imputed interest

 

7,463

 

Total lease liabilities

$

22,804

 

Current lease liabilities

 

2,531

 

Long-term lease liabilities

 

20,273

 

 

The lease cost for finance leases during the years ended December 31, 2020 and 2019, and the finance lease liability at December 31, 2020, were not material.
XML 38 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

(14)

Commitments and Contingencies

In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company is not currently a party to any material legal proceedings.

XML 39 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Employee Benefits
 12 Months Ended
Dec. 31, 2020
Compensation And Retirement Disclosure [Abstract]  
Employee Benefits

(15)

Employee Benefits

The Company has a defined contribution 401(k) plan for eligible employees. Employees are eligible to participate in the plan beginning on their date of hire. Under the terms of the plan, employees may make voluntary contributions as a percentage of compensation. The Company started to match employee contributions effective January 1, 2019. The Company matched 50% of the employee contributions to the 401(k) plan up to a maximum of 4% of the participating employee’s eligible earnings, resulting in a maximum company match of 2% of the participating employee’s eligible earnings, and subject to certain additional statutory dollar limitations.

XML 40 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Related-Party Transactions
 12 Months Ended
Dec. 31, 2020
Related Party Transactions [Abstract]  
Related-Party Transactions

(16)

Related-Party Transactions

In June 2019, the Company expanded its collaboration and entered into an agreement with Ginkgo for the research and development of engineered microbial therapeutic products. As of December 31, 2020, Ginkgo owns 6,340,771 shares of the Company’s outstanding common stock. See Note 10, Ginkgo Collaboration.

Under the agreement the Company made a prepayment to Ginkgo of $30.0 million for its foundry services that will be provided to the Company over an initial term of five years. At December 31, 2020, the Company had remaining balances of $4.7 million and $8.9 million of current and non-current pre-paid research and development costs related to this transaction, respectively. For the year ended December 31, 2020, the Company used $13.6 million of the pre-paid research and development expenses.

 
XML 41 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Selected Quarterly Data (Unaudited)
 12 Months Ended
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]  
Selected Quarterly Data (Unaudited)

(17)

Selected Quarterly Data (Unaudited)

The following tables contain quarterly financial information for 2020 and 2019 (in thousands).  The Company believes that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented.  The operating results for any quarter are not necessarily indicative of results for any future period.

 

 

 

2020 Quarter Ended

 

 

 

March 31

 

 

 

 

June 30

 

 

 

 

September 30

 

 

December 31

 

Revenue

 

$

100

 

 

 

 

$

445

 

 

 

 

$

—

 

 

$

—

 

Operating expenses

 

 

16,498

 

 

 

 

 

16,382

 

 

 

 

 

13,437

 

 

 

14,694

 

Loss from operations

 

 

(16,398

)

 

 

 

 

(15,937

)

 

 

 

 

(13,437

)

 

 

(14,694

)

Net loss

 

 

(15,828

)

 

 

 

 

(15,535

)

 

 

 

 

(13,222

)

 

 

(14,588

)

Net loss per share - basic and diluted

 

$

(0.46

)

 

 

 

$

(0.44

)

 

 

 

$

(0.36

)

 

$

(0.39

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2019 Quarter Ended

 

 

 

March 31

 

 

 

 

June 30

 

 

 

 

September 30

 

 

December 31

 

Revenue

 

$

338

 

 

 

 

$

350

 

 

 

 

$

305

 

 

$

1,231

 

Operating expenses

 

 

14,035

 

 

 

 

 

13,445

 

 

 

 

 

14,443

 

 

 

14,710

 

Loss from operations

 

 

(13,697

)

 

 

 

 

(13,095

)

 

 

 

 

(14,138

)

 

 

(13,479

)

Net loss

 

 

(12,946

)

 

 

 

 

(12,344

)

 

 

 

 

(13,285

)

 

 

(12,798

)

Net loss per share - basic and diluted

 

$

(0.51

)

 

 

 

$

(0.45

)

 

 

 

$

(0.39

)

 

$

(0.37

)

 
XML 42 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S.”) (“U.S. GAAP” or “GAAP”).

Principles of Consolidation

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Synlogic and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.  On an on-going basis, the Company’s management evaluates its estimates, including those related to revenue recognition, income taxes including the valuation allowance for deferred tax assets, research and development accruals and prepaids, accrued expenses, investments, contingencies and equity-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.  Changes in estimates are reflected in reported results in the period in which they become known.
Cash Equivalents

Cash Equivalents

The Company considers all highly liquid investment instruments with a remaining maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents consist of money market funds, including money market funds held in a sweep account. Cash equivalents are stated at cost plus accrued interest, which approximates fair value. The amount of cash equivalents included in cash and cash equivalents was approximately $32.5 million and $13.5 million at December 31, 2020 and 2019, respectively.
Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk include amounts held as cash, cash equivalents, marketable securities and restricted cash. The Company uses high quality, accredited financial institutions to maintain its balances, and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.
Restricted Cash

Restricted Cash

The Company held cash of approximately $1.1 million at December 31, 2020 and 2019 in a letter of credit to secure its lease at the 301 Binney Street facility.  The Company has classified this deposit as long-term restricted cash on its balance sheet.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Cash and cash equivalents

 

$

32,507

 

 

$

26,184

 

Restricted cash included in other long-term assets

 

 

1,097

 

 

 

1,097

 

Total cash, cash equivalents, and restricted cash shown in

   the consolidated statement of cash flows

 

$

33,604

 

 

$

27,281

 

 
Fair Value

Fair Value

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values.  Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). The hierarchy consists of three levels: 

 

•

Level 1 – Utilize observable inputs such as quoted prices in active markets for identical assets or liabilities;

 

•

Level 2 – Utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves;

 

•

Level 3 – Utilize unobservable data points in which there is little or no market data, which require the Company to develop its own assumptions for the asset or liability.

The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of assets or liabilities between Level 1, Level 2 or Level 3 during the years ended December 31, 2020 and 2019.

Available-for-Sale Securities

Available-for-Sale Securities

The Company classifies all short-term investments with an original maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income (loss). The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest and investment income. Realized gains and losses, and declines in value judged to be other than temporary on available-for-sale securities, are included in interest and investment income.

The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest and investment income. To determine whether an other-than-temporary impairment exists, the Company considers whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability of the cost of the investment outweighs evidence to the contrary.

Property and Equipment

Property and Equipment

Property and equipment, including leasehold improvements, are recorded at cost and depreciated over their estimated useful lives using the straight‑line method. Repairs and maintenance costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.

Depreciation begins at the time the asset is placed in service. Depreciation is provided over the following estimated useful lives:

 

Asset classification

 

Useful life

Computer and office equipment

 

3 years

Furniture and fixtures

 

5 years

Laboratory equipment

 

5 years

Leasehold improvements

 

Lesser of useful life or remaining lease term
Impairment of Long-Lived Assets

Impairment of Long‑Lived Assets

Long‑lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If this comparison indicates that there is impairment, the amount of impairment is calculated as the difference between the carrying value and fair value of the asset. To date, no such impairments have been recognized.
Leases

Leases

The Company uses judgement to assess if an arrangement is a lease at contract inception. An arrangement is a lease if the contract involves the use of a distinct identified asset, the lessor does not have substantive substitution rights and the Company obtains control of the asset throughout the period by obtaining substantially all of the economic benefit of the asset and the right to direct the use of the asset. Leases classified as operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities and noncurrent operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations, in our consolidated balance sheet.

ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company utilizes its incremental borrowing rate to determine the present value of lease payments. The incremental borrowing rate is the rate incurred to borrow similar funds, on a collateralized basis, over a comparable term in a similar economic environment.

The Company has elected to account for the lease and non-lease components for leases as a single component for classes of all underlying assets and allocate all of the contract consideration to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating expenses.

The lease term includes options to extend the lease when it is reasonably certain that option will be exercised. Leases with a term of 12 months or less are not recorded on the Company’s consolidated balance sheet.
Research and Development Costs

Research and Development Costs

Costs incurred in research and development are expensed as incurred. The Company defers and capitalizes nonrefundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed.

Research and development expenses are comprised of costs incurred in performing research and development activities, including salary and benefits, equity-based compensation expense, laboratory supplies and other direct expenses, facilities expenses, overhead expenses, contractual services and other outside expenses.

When third-party service providers’ billing terms do not coincide with the Company’s period-end, the Company is required to make estimates of its obligations to those third parties, including clinical trial costs, contractual services costs and costs for supply of its drug candidates, incurred in a given accounting period and record accruals at the end of the period. The Company bases its estimates on the completion status of the research and development programs and the associated estimate of unbilled costs.
Revenue recognition

 

Revenue recognition

 

The Company generated revenue through a collaboration and license arrangement with AbbVie for the development and commercialization of product candidates prior to the termination of the arrangement in May 2020.

The Company evaluates collaboration agreements with respect to FASB ASC Topic 808, Collaborative Arrangements, considering the nature and contractual terms of the arrangement and the nature of its business operations to determine the classification of the transactions. When the Company is an active participant in the activity and exposed to significant risks and rewards dependent on the commercial success of the collaboration, it will record its transactions on a gross basis in the consolidated financial statements and describe the rights and obligations under the collaborative arrangement in the notes to the consolidated financial statements.

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five-step analysis: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step analysis to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company may enter into collaboration agreements for research and development services, under which the Company may license certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Variable consideration is constrained until it is deemed not be at significant risk of reversal.

In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements for which the collaboration partner is also a customer, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses significant judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the goods and services the Company expects to provide. The Company uses estimates to determine the timing of satisfaction of performance obligations, which may include the use of full time equivalent time as a measure of satisfaction of performance obligations.

Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.

Licenses of Intellectual Property

In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Research and Development Services

If an arrangement is determined to contain a promise or obligation for the Company to perform research and development services, the Company must determine whether these services are distinct from the other promises in the arrangement. In assessing whether the services are distinct from the other promises, the Company considers the capabilities of the customer to perform these same services. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For research and development services that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Customer Options

If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, that is, the option to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on an alternative approach when the goods or services are both (i) similar to the original goods and services in the contract and (ii) provided in accordance with the terms of the original contract. Under this alternative, the Company allocates the total amount of consideration expected to be received from the customer to the total goods or services expected to be provided to the customer. Amounts allocated to a material right are not recognized as revenue until the option is exercised and the performance obligation is satisfied.

Milestone Payments

At the inception of each arrangement that includes milestone payments, the Company evaluates whether a significant reversal of cumulative revenue provided in conjunction with achieving the milestones is probable and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. For other milestones, the Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.

Royalties

For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.

Contract Costs

The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer.
Equity-Based Compensation

Equity‑Based Compensation

The Company measures equity-based compensation to employees, non-employees and directors based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period. The fair value of each option and purchase rights under the employee stock purchase plan (“ESPP”) is estimated on the date of grant using the Black‑Scholes option‑pricing model. Expected volatility for the Company’s common stock is determined based on an average of the historical volatility of the Company and the historical volatility of a peer‑group of similar public companies. The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The expected term of purchase rights for the ESPP is based on the duration of an offering period. The assumed dividend yield is based upon the Company’s expectation of not paying dividends in the foreseeable future. The risk‑free interest rate is based upon the U.S. Treasury yield curve commensurate with the expected term at the time of grant or remeasurement. Forfeitures are recognized as they occur.

The Company classifies equity-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipients’ service payments are classified.
Income Taxes

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company’s tax returns. Deferred taxes are determined based on the difference between the financial reporting and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.

Uncertain tax positions represent tax positions for which reserves have been established. The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to be recognized in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.
Net Loss Per Share

Net Loss Per Share

Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the sum of the weighted-average number of shares of common stock outstanding during the period and if dilutive, the weighted-average number of potential shares of common stock, including unvested restricted common stock, outstanding stock options and potential shares issuable under the ESPP.
Segment Information

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates in one operating segment: discovery and development of synthetic biology therapeutics for the treatment of rare, infectious and other diseases. The Company’s chief executive officer, as chief operating decision maker, manages and allocates resources to the operations of the Company on a total company basis. All of the Company’s equipment, leasehold improvements and other fixed assets are physically located within the United States, and all agreements with its partners are denominated in U.S. dollars, except where noted.
New Accounting Pronouncements

New Accounting Pronouncements

 

New accounting pronouncements are issued by the FASB from time to time, and rules are issued by the SEC that the Company has or will adopt as of a specified date. Unless otherwise noted, management does not believe that any recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had, or is expected to have, a material impact on the Company’s present or future financial statements.

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In December 2019, the FASB issued ASU 2019-12 – Income Taxes – (Topic 740): Simplifying the Accounting for Income Taxes, which provides amended guidance on income tax accounting. The amended guidance is effective for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year. Early adoption is permitted. The amended guidance, which simplifies the accounting for income taxes, includes the removal of exceptions to the general principles of ASC 740. The standard removed the exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items. The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13 - Fair Value Measurement - Disclosure Framework (Topic 820). The standard modifies the disclosure requirements for fair value measurements. The standard is effective for public companies for annual and interim periods beginning after December 15, 2019. The Company adopted the new guidance effective on January 1, 2020, which had an immaterial impact on the Company’s financial statement disclosures.

In August 2018, the FASB issued ASU 2018-15 - Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract. The standard requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.

In November 2018, the FASB issued ASU 2018-18 - Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606, which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted for under Topic 606. The Company adopted the new guidance effective on January 1, 2020 which had an immaterial impact on its consolidated financial statements.
Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13 - Measurement of Credit Losses on Financial Statements. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-

for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. In November 2019, the FASB issued ASU 2019-10 – Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which amended the effective date for certain companies. The standard is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December 15, 2022. Early adoption is available. The Company is currently evaluating the potential impact ASU 2016-13, and related updates, will have on its consolidated financial statements and disclosures.

In October 2020, the FASB issued an amendment, ASU 2020-08- Codification Improvements to Subtopic 310-20, Receivables – Nonrefundable Fees and Other Costs, to the guidance in ASU 2017-08, Receivables-Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. The amendment requires companies to reevaluate whether a callable debt security that has multiple call dates is within the scope of paragraph 310-20-65-2. The amendment shall be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early application is not permitted. The Company is currently evaluating the potential impact that ASU 2020-08 will have on its consolidated financial statements and disclosures.

 
XML 43 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Cash and cash equivalents

 

$

32,507

 

 

$

26,184

 

Restricted cash included in other long-term assets

 

 

1,097

 

 

 

1,097

 

Total cash, cash equivalents, and restricted cash shown in

   the consolidated statement of cash flows

 

$

33,604

 

 

$

27,281

 
Schedule of Useful Life of Property and Equipment

Depreciation begins at the time the asset is placed in service. Depreciation is provided over the following estimated useful lives:

 

Asset classification

 

Useful life

Computer and office equipment

 

3 years

Furniture and fixtures

 

5 years

Laboratory equipment

 

5 years

Leasehold improvements

 

Lesser of useful life or remaining lease term
XML 44 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value of Financial Instruments (Tables)
 12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis

At December 31, 2020 and 2019, the Company has classified assets measured at fair value on a recurring basis as follows (in thousands):

 

 

 

Fair Value Measurements at Reporting Date Using

 

 

 

December 31,

 

 

Quoted Prices in Active

Markets for Identical

Assets

 

 

Significant Other

Observable Inputs

 

 

Significant

Unobservable Inputs

 

Description

 

2020

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Money market funds

 

$

32,506

 

 

$

32,506

 

 

$

—

 

 

$

—

 

Commercial paper

 

 

40,477

 

 

 

—

 

 

 

40,477

 

 

 

—

 

Corporate debt securities

 

 

18,637

 

 

 

—

 

 

 

18,637

 

 

 

—

 

U.S. government agency securities and treasuries

 

 

8,823

 

 

 

8,823

 

 

 

—

 

 

 

—

 

Total

 

$

100,443

 

 

$

41,329

 

 

$

59,114

 

 

$

—

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements at Reporting Date Using

 

 

 

December 31,

 

 

Quoted Prices in Active

Markets for Identical

Assets

 

 

Significant Other

Observable Inputs

 

 

Significant

Unobservable Inputs

 

Description

 

2019

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Money market funds

 

$

3,240

 

 

$

3,240

 

 

$

—

 

 

$

—

 

Commercial paper (included in cash and

   cash equivalents)

 

 

4,249

 

 

 

—

 

 

 

4,249

 

 

 

—

 

Commercial paper (included in marketable

   securities)

 

 

20,501

 

 

 

—

 

 

 

20,501

 

 

 

—

 

Corporate debt securities (included in cash

   and cash equivalents)

 

 

6,005

 

 

 

—

 

 

 

6,005

 

 

 

—

 

Corporate debt securities (included in

   marketable securities)

 

 

71,383

 

 

 

—

 

 

 

71,383

 

 

 

—

 

U.S. government agency securities and

   treasuries

 

 

9,005

 

 

 

—

 

 

 

9,005

 

 

 

—

 

Total

 

$

114,383

 

 

$

3,240

 

 

$

111,143

 

 

$

—

 

 
XML 45 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Available-for-Sale Investments (Tables)
 12 Months Ended
Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]  
Summary of Available-for-Sale Securities Held

The following tables summarize the available-for-sale securities held at December 31, 2020 and 2019 (in thousands):

 

December 31, 2020

 

Amortized cost

 

 

Gross unrealized

gains

 

 

Gross unrealized

losses

 

 

Fair Value

 

Commercial paper

 

$

40,467

 

 

$

11

 

 

$

(1

)

 

$

40,477

 

Corporate debt securities

 

 

18,634

 

 

 

4

 

 

 

(1

)

 

 

18,637

 

U.S. government agency securities

 

 

8,822

 

 

 

1

 

 

 

—

 

 

 

8,823

 

Total

 

$

67,923

 

 

$

16

 

 

$

(2

)

 

$

67,937

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2019

 

Amortized cost

 

 

Gross unrealized

gains

 

 

Gross unrealized

losses

 

 

Fair Value

 

Commercial paper

 

$

20,484

 

 

$

18

 

 

$

(1

)

 

$

20,501

 

Corporate debt securities

 

 

71,288

 

 

 

96

 

 

 

(1

)

 

 

71,383

 

U.S. government agency securities

 

 

9,005

 

 

 

2

 

 

 

(2

)

 

 

9,005

 

Total

 

$

100,777

 

 

$

116

 

 

$

(4

)

 

$

100,889

 
XML 46 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Prepaid Expenses and Other Current Assets (Tables)
 12 Months Ended
Dec. 31, 2020
Text Block [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Prepaid insurance

 

$

856

 

 

$

648

 

Prepaid research and development

 

 

4,771

 

 

 

11,989

 

Other prepaid expenses

 

 

528

 

 

 

390

 

Other current assets

 

 

247

 

 

 

648

 

 

 

$

6,402

 

 

$

13,675

 
XML 47 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment, Net (Tables)
 12 Months Ended
Dec. 31, 2020
Property Plant And Equipment [Abstract]  
Schedule of Property and Equipment, Net

Property and equipment, net consists of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Laboratory equipment

 

$

7,793

 

 

$

7,523

 

Computer and office equipment

 

 

769

 

 

 

782

 

Furniture and fixtures

 

 

421

 

 

 

421

 

Leasehold improvements

 

 

9,514

 

 

 

9,514

 

Construction in progress

 

 

528

 

 

 

412

 

 

 

 

19,025

 

 

 

18,652

 

Less accumulated depreciation

 

 

(8,249

)

 

 

(5,631

)

 

 

$

10,776

 

 

$

13,021

 
XML 48 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2020
Payables And Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

 

 

December 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Payroll related

 

$

3,005

 

 

$

2,372

 

Professional fees

 

 

215

 

 

 

444

 

Research and development

 

 

230

 

 

 

1,005

 

Other

 

 

323

 

 

 

125

 

 

 

$

3,773

 

 

$

3,946

 
XML 49 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Common Stock (Tables)
 12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Schedule of Shares of Common Stock Reserved for Future Issuance

The Company has reserved for future issuance the following shares of common stock related to the potential warrant exercise, exercise of stock options, and the employee stock purchase plan:

 

 

December 31, 2020

 

Common stock issuable under pre-funded warrants

 

2,548,117

 

Options to purchase common stock

 

1,211,967

 

Employee Stock Purchase Plan

 

345,662

 

Total

 

4,105,746

 
XML 50 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Equity-based Compensation and Equity Incentive Plans (Tables)
 12 Months Ended
Dec. 31, 2020
Schedule of Restricted Common Stock Activity

The following table shows restricted common stock activity:

 

 

 

Restricted stock awards

 

 

 

 

 

 

 

Weighted

average

grant date

 

 

 

Number of

 

 

fair value

 

 

 

shares

 

 

(per share)

 

Unvested at December 31, 2019

 

 

586,929

 

 

$

2.97

 

Granted

 

 

226,335

 

 

 

1.70

 

Vested

 

 

(119,594

)

 

 

2.30

 

Forfeited

 

 

(215,463

)

 

 

2.32

 

Unvested at December 31, 2020

 

 

478,207

 

 

$

2.19

 
Schedule of Equity-based Compensation Expenses

The following table summarizes equity‑based compensation expense within the Company’s consolidated statements of operations and comprehensive loss for the years ended December 31, 2020 and 2019 (in thousands):

 

 

 

Years ended December 31,

 

 

 

2020

 

 

2019

 

Research and development

 

$

1,724

 

 

$

1,377

 

General and administrative

 

 

2,183

 

 

 

2,757

 

 

 

$

3,907

 

 

$

4,134

 
Schedule of Equity-based Compensation Expenses by Award Type

The following table summarizes equity‑based compensation expense by type of award for the years ended December 31, 2020 and 2019 (in thousands):

 

 

 

Years ended December 31,

 

 

 

2020

 

 

2019

 

Stock options

 

$

3,200

 

 

$

3,789

 

Restricted stock awards

 

 

680

 

 

 

345

 

ESPP

 

 

27

 

 

 

—

 

 

 

$

3,907

 

 

$

4,134

 
2015 and 2017 Plan  
Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees

The weighted average assumptions used in the Black-Scholes option-pricing model for stock options issued to employees and non-employees under the 2015 Plan and the 2017 Plan, during the years ended December 31, 2020 and 2019 were:

 

 

 

Year ended December 31,

 

 

Employees:

 

2020

 

 

2019

 

 

Expected term

 

6.2 years

 

 

6.2 years

 

 

Weighted-average, risk-free interest rate

 

0.6%

 

 

2.2%

 

 

Expected volatility

 

77.2%

 

 

71.1%

 

 

Dividend yield

 

 

—

 

 

 

—

 

 
Schedule of Stock Option Activity

The following table summarizes stock option activity under the 2015 and 2017 Plans.

 

 

 

Stock options outstanding

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

average

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

remaining

 

 

Aggregate

 

 

 

 

 

 

 

average

 

 

contractual

 

 

intrinsic

 

 

 

Number of

 

 

exercise

 

 

term

 

 

value (a)

 

 

 

options

 

 

price

 

 

(in years)

 

 

(in thousands)

 

Outstanding at December 31, 2019

 

 

2,286,419

 

 

$

9.24

 

 

 

8.7

 

 

$

43

 

Granted

 

 

1,627,654

 

 

 

1.90

 

 

 

 

 

 

 

—

 

Exercised

 

 

(9,472

)

 

 

1.70

 

 

 

 

 

 

 

6

 

Cancelled/Forfeited

 

 

(560,765

)

 

 

7.34

 

 

 

 

 

 

 

—

 

Outstanding at December 31, 2020

 

 

3,343,836

 

 

 

6.00

 

 

 

8.4

 

 

 

399

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vested or expected to vest at December 31, 2020

 

 

3,343,836

 

 

 

6.00

 

 

 

8.4

 

 

 

399

 

Exercisable at December 31, 2020

 

 

1,399,952

 

 

 

9.13

 

 

 

7.7

 

 

$

53

 

 

(a)

The aggregate intrinsic value is calculated as the difference between the exercise price of the options and the fair market value of the underlying common stock for the options that were in the money at December 31, 2020 and 2019. 970,826 and 132,500 options were in the money at December 31, 2020 and 2019, respectively.
XML 51 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss per Share (Tables)
 12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
Schedule of Computation of Basic and Diluted Net Loss per Share

The following table sets forth the computation of basic and diluted net loss per share (in thousands, except for share and per share amounts):

 

 

 

2020

 

 

2019

 

Numerator:

 

 

 

 

 

 

 

 

Net loss

 

$

(59,173

)

 

$

(51,373

)

Denominator:

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding - basic and diluted

 

 

35,835,744

 

 

 

30,284,068

 

Net loss per share - basic and diluted

 

$

(1.65

)

 

$

(1.70

)
Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share

The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of the diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect.

 

 

 

As of December 31,

 

 

 

2020

 

 

2019

 

Unvested restricted common stock awards

 

 

478,207

 

 

 

586,929

 

Outstanding options to purchase common stock

 

 

3,343,836

 

 

 

2,286,419

 

Potential shares issuable under the ESPP

 

 

12,037

 

 

 

—

 
XML 52 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities

 

 

Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. Deferred tax assets consist of the following (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

61,181

 

 

$

46,362

 

Tax credit carryforwards

 

 

5,748

 

 

 

4,262

 

Accrued expenses

 

 

126

 

 

 

37

 

Property and equipment

 

 

279

 

 

 

—

 

Other long-term liabilities

 

 

36

 

 

 

—

 

Lease liabilities

 

 

6,230

 

 

 

6,776

 

Equity compensation

 

 

2,200

 

 

 

1,481

 

Amortizable intangibles

 

 

1,195

 

 

 

1,214

 

Other

 

 

38

 

 

 

138

 

Gross deferred tax assets

 

 

77,033

 

 

 

60,270

 

Deferred tax liabilities:

 

 

 

 

 

 

 

 

Property and equipment

 

 

—

 

 

 

(1,720

)

Right of use assets

 

 

(4,242

)

 

 

(4,716

)

Gross deferred tax liabilities

 

 

(4,242

)

 

 

(6,436

)

Valuation allowance

 

 

(72,791

)

 

 

(53,834

)

Net deferred tax assets

 

$

—

 

 

$

—

 

 
Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate

A reconciliation of the statutory federal income tax rate to the Company’s effective income tax rate is as follows (dollars in thousands):

 

 

 

Years ended December 31,

 

 

 

2020

 

 

2019

 

 

 

Tax Rate

 

 

Tax Rate

 

U.S. federal statutory rate

 

 

21

%

 

 

21

%

State income taxes, net of federal benefit

 

 

6

%

 

 

6

%

Other permanent differences

 

 

(1

)%

 

 

(1

)%

Tax credits

 

 

2

%

 

 

0

%

Other items

 

 

4

%

 

 

0

%

Net change in valuation allowance

 

 

(32

)%

 

 

(26

)%

Effective income tax rate

 

 

—

 

 

 

—

 

 
Schedule of Valuation Allowance

A roll-forward of the valuation allowance for the years ended December 31, 2020 and 2019 is as follows (in thousands):

 

 

 

Years ended December 31,

 

 

 

2020

 

 

2019

 

Balance at beginning of year

 

$

(53,834

)

 

$

(40,290

)

Increase in valuation allowance

 

 

(18,957

)

 

 

(13,544

)

Balance at end of year

 

$

(72,791

)

 

$

(53,834

)
XML 53 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
Components of Lease Cost for Operating Leases

The components of lease cost for operating leases for the years ended December 31, 2020 and 2019 were (in thousands):

 

 

For the year ended December 31,

 

Operating leases

2020

 

 

2019

 

Operating lease cost

$

3,628

 

 

$

3,344

 

Short-term lease cost

$

-

 

 

$

330

 

Variable lease cost

 

1,055

 

 

 

1,092

 

Total lease cost

 

4,683

 

 

 

4,766

 
Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases

The weighted average remaining lease term and the weighted average discount rate for operating leases were:

 

 

For the year ended December 31,

 

 

2020

 

 

2019

 

Weighted average discount rate

 

8.0

%

 

 

8.0

%

Weighted average remaining lease term (years)

 

7.2

 

 

 

8.2

 
Summary of Maturity of Lease Liabilities for Operating Leases

 

The following table reconciles the undiscounted cash flows for the operating leases at December 31, 2020 to the operating lease liabilities recorded on the balance sheet: December 31, 2020

 

Maturity of lease liabilities

Operating Leases

 

 

(in thousands)

 

2021

$

4,236

 

2022

 

4,389

 

2023

 

3,574

 

2024

 

3,681

 

2025

 

3,792

 

Thereafter

 

10,595

 

Total lease payments

 

30,267

 

Less: imputed interest

 

7,463

 

Total lease liabilities

$

22,804

 

Current lease liabilities

 

2,531

 

Long-term lease liabilities

 

20,273

 
XML 54 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Selected Quarterly Data (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]  
Selected Quarterly Data (unaudited)

The following tables contain quarterly financial information for 2020 and 2019 (in thousands).  The Company believes that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented.  The operating results for any quarter are not necessarily indicative of results for any future period.

 

 

 

2020 Quarter Ended

 

 

 

March 31

 

 

 

 

June 30

 

 

 

 

September 30

 

 

December 31

 

Revenue

 

$

100

 

 

 

 

$

445

 

 

 

 

$

—

 

 

$

—

 

Operating expenses

 

 

16,498

 

 

 

 

 

16,382

 

 

 

 

 

13,437

 

 

 

14,694

 

Loss from operations

 

 

(16,398

)

 

 

 

 

(15,937

)

 

 

 

 

(13,437

)

 

 

(14,694

)

Net loss

 

 

(15,828

)

 

 

 

 

(15,535

)

 

 

 

 

(13,222

)

 

 

(14,588

)

Net loss per share - basic and diluted

 

$

(0.46

)

 

 

 

$

(0.44

)

 

 

 

$

(0.36

)

 

$

(0.39

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2019 Quarter Ended

 

 

 

March 31

 

 

 

 

June 30

 

 

 

 

September 30

 

 

December 31

 

Revenue

 

$

338

 

 

 

 

$

350

 

 

 

 

$

305

 

 

$

1,231

 

Operating expenses

 

 

14,035

 

 

 

 

 

13,445

 

 

 

 

 

14,443

 

 

 

14,710

 

Loss from operations

 

 

(13,697

)

 

 

 

 

(13,095

)

 

 

 

 

(14,138

)

 

 

(13,479

)

Net loss

 

 

(12,946

)

 

 

 

 

(12,344

)

 

 

 

 

(13,285

)

 

 

(12,798

)

Net loss per share - basic and diluted

 

$

(0.51

)

 

 

 

$

(0.45

)

 

 

 

$

(0.39

)

 

$

(0.37

)

 
XML 55 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Nature of Business - Additional Information (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]    
Cash, cash equivalents, and short-term marketable securities $ 100,400  
Restricted cash 1,097 $ 1,097
Accumulated deficit $ (230,311) $ (171,138)
XML 56 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Additional Information (Detail)
 1 Months Ended 12 Months Ended
Jul. 31, 2017
Dec. 31, 2020
USD ($)
Segment
Dec. 31, 2019
USD ($)
Summary Of Significant Accounting Policies [Line Items]      
Cash equivalents maturity   three months or less  
Cash equivalents   $ 32,500,000 $ 13,500,000
Transfers of assets and liabilities between Level 1, Level 2, or Level 3   0 0
Impairment charge   $ 0  
Lessee, operating lease, existence of option to extend true true  
Lessee, operating lease, option to extend   options to extend the lease when it is reasonably certain that option will be exercised  
Revenue, practical expedient, incremental cost of obtaining contract [true/false]   true  
Revenue, practical expedient, remaining performance obligation, description   The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that we otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer  
Description of tax benefit likely to be realized upon settlement   greater than 50%  
Number of operating segment | Segment   1  
ASU 2019-12      
Summary Of Significant Accounting Policies [Line Items]      
Change in accounting principle, accounting standards update, adopted [true false]   true  
Change in accounting principle, accounting standards update, adoption date   Jan. 01, 2020  
Change in accounting principle, accounting standards update, immaterial effect [true false]   true  
ASU 2018-13      
Summary Of Significant Accounting Policies [Line Items]      
Change in accounting principle, accounting standards update, adopted [true false]   true  
Change in accounting principle, accounting standards update, adoption date   Jan. 01, 2020  
Change in accounting principle, accounting standards update, immaterial effect [true false]   true  
ASU 2018-15      
Summary Of Significant Accounting Policies [Line Items]      
Change in accounting principle, accounting standards update, adopted [true false]   true  
Change in accounting principle, accounting standards update, adoption date   Jan. 01, 2020  
Change in accounting principle, accounting standards update, immaterial effect [true false]   true  
ASU 2018-18      
Summary Of Significant Accounting Policies [Line Items]      
Change in accounting principle, accounting standards update, adopted [true false]   true  
Change in accounting principle, accounting standards update, adoption date   Jan. 01, 2020  
Change in accounting principle, accounting standards update, immaterial effect [true false]   true  
Letter of Credit      
Summary Of Significant Accounting Policies [Line Items]      
Cash   $ 1,100,000 $ 1,100,000
XML 57 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Accounting Policies [Abstract]      
Cash and cash equivalents $ 32,507 $ 26,184  
Restricted cash included in other long-term assets 1,097 1,097  
Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows $ 33,604 $ 27,281 $ 12,349
XML 58 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Schedule of Useful Life of Property and Equipment (Detail)
 12 Months Ended
Dec. 31, 2020
Computer and Office Equipment  
Property Plant And Equipment [Line Items]  
Useful life 3 years
Furniture and Fixtures  
Property Plant And Equipment [Line Items]  
Useful life 5 years
Laboratory Equipment  
Property Plant And Equipment [Line Items]  
Useful life 5 years
Leasehold Improvements  
Property Plant And Equipment [Line Items]  
Useful life Lesser of useful life or remaining lease term
XML 59 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail) - Recurring - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Fair Value Asset Measured On Recurring Basis [Line Items]    
Total assets $ 100,443 $ 114,383
Money market funds    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Cash and Cash Equivalents 32,506 3,240
Commercial paper    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Cash and Cash Equivalents 40,477 4,249
Marketable securities   20,501
U.S. Government Agency Securities and Treasuries    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Short-term investments 8,823 9,005
Corporate debt securities    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Cash and Cash Equivalents 18,637 6,005
Marketable securities   71,383
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Total assets 41,329 3,240
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Cash and Cash Equivalents 32,506 3,240
Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Government Agency Securities and Treasuries    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Short-term investments 8,823  
Significant Other Observable Inputs (Level 2)    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Total assets 59,114 111,143
Significant Other Observable Inputs (Level 2) | Commercial paper    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Cash and Cash Equivalents 40,477 4,249
Marketable securities   20,501
Significant Other Observable Inputs (Level 2) | U.S. Government Agency Securities and Treasuries    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Short-term investments 0 9,005
Significant Other Observable Inputs (Level 2) | Corporate debt securities    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Cash and Cash Equivalents 18,637 6,005
Marketable securities   71,383
Significant Unobservable Inputs (Level 3)    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Total assets 0 0
Significant Unobservable Inputs (Level 3) | Money market funds    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Cash and Cash Equivalents 0 0
Significant Unobservable Inputs (Level 3) | Commercial paper    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Cash and Cash Equivalents 0 0
Marketable securities   0
Significant Unobservable Inputs (Level 3) | U.S. Government Agency Securities and Treasuries    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Short-term investments 0 0
Significant Unobservable Inputs (Level 3) | Corporate debt securities    
Fair Value Asset Measured On Recurring Basis [Line Items]    
Cash and Cash Equivalents $ 0 0
Marketable securities   $ 0
XML 60 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Available-for-Sale Investments - Summary of Available-for-Sale Securities Held (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Schedule of Available-for-sale Securities [Line Items]    
Amortized cost $ 67,923 $ 100,777
Gross unrealized gains 16 116
Gross unrealized losses (2) (4)
Fair Value 67,937 100,889
Commercial paper    
Schedule of Available-for-sale Securities [Line Items]    
Amortized cost 40,467 20,484
Gross unrealized gains 11 18
Gross unrealized losses (1) (1)
Fair Value 40,477 20,501
Corporate debt securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized cost 18,634 71,288
Gross unrealized gains 4 96
Gross unrealized losses (1) (1)
Fair Value 18,637 71,383
U.S. government agency securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized cost 8,822 9,005
Gross unrealized gains 1 2
Gross unrealized losses   (2)
Fair Value $ 8,823 $ 9,005
XML 61 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Available-for-Sale Investments - Additional Information (Detail)
$ in Millions
Dec. 31, 2020
USD ($)
Investment
Security
Dec. 31, 2019
USD ($)
Investments Debt And Equity Securities [Abstract]    
Number of investments in unrealized loss position 8  
Number of investments in unrealized loss position, more than twelve months 0  
Aggregate fair value of securities in unrealized loss position | $ $ 20.1 $ 24.8
Number of securities with other than temporary impairment | Security 0  
XML 62 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Prepaid Expenses and Other Current Assets (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]    
Prepaid insurance $ 856 $ 648
Prepaid research and development 4,771 11,989
Other prepaid expenses 528 390
Other current assets 247 648
Total $ 6,402 $ 13,675
XML 63 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment, Net - Additional Information (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Property Plant And Equipment [Abstract]    
Depreciation expense $ 2,636 $ 2,702
XML 64 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 19,025 $ 18,652
Less accumulated depreciation (8,249) (5,631)
Property and equipment, net 10,776 13,021
Laboratory Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 7,793 7,523
Computer and Office Equipment    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 769 782
Furniture and Fixtures    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 421 421
Leasehold Improvements    
Property Plant And Equipment [Line Items]    
Property and equipment, gross 9,514 9,514
Construction in Progress    
Property Plant And Equipment [Line Items]    
Property and equipment, gross $ 528 $ 412
XML 65 R47.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Payables And Accruals [Abstract]    
Payroll related $ 3,005 $ 2,372
Professional fees 215 444
Research and development 230 1,005
Other 323 125
Total accrued expenses $ 3,773 $ 3,946
XML 66 R48.htm IDEA: XBRL DOCUMENT v3.21.1
Common Stock - Additional Information (Detail)
 1 Months Ended 3 Months Ended 12 Months Ended 157 Months Ended
Jun. 30, 2019
USD ($)
$ / shares
shares
Mar. 25, 2021
USD ($)
Dec. 31, 2020
USD ($)
Vote
shares
Dec. 31, 2019
USD ($)
shares
Dec. 31, 2020
USD ($)
shares
Class Of Stock [Line Items]          
Number of votes entitled to each share of common stock | Vote     1    
Cash dividends         $ 0
Proceeds from sale of common stock, net of issuance costs       $ 56,996,000  
Proceeds from sale of pre-funded warrants, net of issuance costs       $ 22,874,000  
Ginkgo Bioworks, Inc.          
Class Of Stock [Line Items]          
Sale of stock, price per share | $ / shares $ 9.00        
Proceeds, net of issuance costs, from issuance of common stock and pre-funded warrants $ 79,900,000        
Proceeds from sale of common stock, net of issuance costs $ 57,000,000.0        
Ginkgo Bioworks, Inc. | Pre-Funded Warrants          
Class Of Stock [Line Items]          
Warrants exercise price per share | $ / shares $ 9.00        
Warrants exercise price per share paid at closing of offering | $ / shares $ 8.99        
Proceeds from sale of pre-funded warrants, net of issuance costs $ 22,900,000        
Warrants exercised | shares     0   0
Ginkgo Bioworks, Inc. | Pre-Funded Warrants | Maximum          
Class Of Stock [Line Items]          
Warrants to purchase shares of common stock | shares 2,548,117        
Cowen and Company, LLC | ATM          
Class Of Stock [Line Items]          
Sale of common stock, shares | shares     5,866,258    
Proceeds from sale of common stock, net of issuance costs     $ 13,500,000    
Cowen and Company, LLC | ATM | Subsequent Event          
Class Of Stock [Line Items]          
Proceeds from sale of common stock, net of issuance costs   $ 50,000,000.0      
Cowen and Company, LLC | Maximum | ATM          
Class Of Stock [Line Items]          
Proceeds from sale of common stock, net of issuance costs     $ 17,300,000    
Common Stock          
Class Of Stock [Line Items]          
Sale of common stock, shares | shares       6,340,771  
Common Stock | Ginkgo Bioworks, Inc.          
Class Of Stock [Line Items]          
Sale of common stock, shares | shares 6,340,771        
Pre-Funded Warrants | Ginkgo Bioworks, Inc. | Maximum          
Class Of Stock [Line Items]          
Unbeneficial percentage of ownership after exercise of common stock outstanding effect to issuance 19.99%        
XML 67 R49.htm IDEA: XBRL DOCUMENT v3.21.1
Common Stock - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail)
Dec. 31, 2020
shares
Class Of Stock [Line Items]  
Total Shares of Common Stock Reserved for Future Issuance 4,105,746
Employee Stock Purchase Plan  
Class Of Stock [Line Items]  
Total Shares of Common Stock Reserved for Future Issuance 345,662
Options To Purchase Common Stock  
Class Of Stock [Line Items]  
Total Shares of Common Stock Reserved for Future Issuance 1,211,967
Common Stock Issuable Under Pre-Funded Warrants  
Class Of Stock [Line Items]  
Total Shares of Common Stock Reserved for Future Issuance 2,548,117
XML 68 R50.htm IDEA: XBRL DOCUMENT v3.21.1
Equity-based Compensation and Equity Incentive Plans - Additional Information (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average grant date fair value per share of options granted to employees $ 1.27 $ 4.59
Total fair value of awards vested $ 3,400,000 $ 3,900,000
Employee unrecognized compensation expense $ 4,300,000  
Employee unrecognized compensation cost, period of recognition 2 years 1 month 6 days  
Equity-based compensation expense $ 3,907,000 4,134,000
Restricted Common Stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total fair value of awards vested 300,000 $ 100,000
Employee unrecognized compensation expense $ 400,000  
Employee unrecognized compensation cost, period of recognition 2 years 1 month 6 days  
Granted 226,335 585,600
Equity-based compensation expense $ 680,000 $ 345,000
Common Stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Issuance of common stock under employee stock purchase plan, Shares 29,857  
ESPP    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Percentage of discount for employees under ESPP 15.00%  
Purchase price as a percentage of fair value under ESPP 85.00%  
Equity-based compensation expense $ 27,000 $ 0
ESPP | Common Stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Issuance of common stock under employee stock purchase plan, Shares 29,857  
Plan 2015    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Percentage of shares outstanding   5.00%
XML 69 R51.htm IDEA: XBRL DOCUMENT v3.21.1
Equity-based Compensation and Equity Incentive Plans - Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees (Detail) - Employees and Nonemployees - 2015 and 2017 Plan
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term 6 years 2 months 12 days 6 years 2 months 12 days
Weighted-average, risk-free interest rate 0.60% 2.20%
Expected volatility 77.20% 71.10%
Dividend yield 0.00% 0.00%
XML 70 R52.htm IDEA: XBRL DOCUMENT v3.21.1
Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Detail) - 2015 and 2017 Plan - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding Beginning balance, Number of options 2,286,419  
Granted, Number of options 1,627,654  
Exercised, Number of options (9,472)  
Cancelled/Forfeited, Number of options (560,765)  
Outstanding Ending balance, Number of options 3,343,836 2,286,419
Number of options, Vested or expected to vest 3,343,836  
Number of options, Exercisable 1,399,952  
Beginning balance, Weighted-average price $ 9.24  
Granted, Weighted-average price 1.90  
Exercised, Weighted-average price 1.70  
Cancelled/Forfeited, Weighted-average price 7.34  
Ending balance, Weighted-average price 6.00 $ 9.24
Weighted-average price Vested or expected to vest 6.00  
Weighted-average price, Exercisable $ 9.13  
Outstanding, weighted average remaining contractual term (Year) 8 years 4 months 24 days 8 years 8 months 12 days
Weighted average remaining contractual term, Vested or expected to vest 8 years 4 months 24 days  
Weighted average remaining contractual term, Exercisable 7 years 8 months 12 days  
Beginning balance, Aggregate Intrinsic $ 43  
Exercised, Aggregate Intrinsic value 6  
Ending balance, Aggregate Intrinsic value 399 $ 43
Aggregate Intrinsic value, Vested or expected to vest at December 31, 2020 399  
Aggregate Intrinsic value, Exercisable at December 31, 2020 $ 53  
XML 71 R53.htm IDEA: XBRL DOCUMENT v3.21.1
Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Parenthetical) (Detail) - shares
Dec. 31, 2020
Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price And Additional Disclosures [Abstract]    
Number of options in money 970,826 132,500
XML 72 R54.htm IDEA: XBRL DOCUMENT v3.21.1
Equity-based Compensation and Equity Incentive Plans - Schedule of Restricted Common Stock Activity (Detail) - Restricted Common Stock - $ / shares
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Beginning balance, Number of unvested shares/units 586,929  
Granted, Number of shares/units 226,335 585,600
Vested, Number of shares/units (119,594)  
Forfeited, Number of shares/units (215,463)  
Ending balance, Number of unvested shares/units 478,207 586,929
Beginning balance, Unvested Grant date fair value $ 2.97  
Granted, Grant date fair value 1.70  
Vested, Grant date fair value 2.30  
Forfeited, Grant date fair value 2.32  
Ending balance, Unvested Grant date fair value $ 2.19 $ 2.97
XML 73 R55.htm IDEA: XBRL DOCUMENT v3.21.1
Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Equity-based compensation expense $ 3,907 $ 4,134
Research and Development Expense    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Equity-based compensation expense 1,724 1,377
General and Administrative Expense    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Equity-based compensation expense $ 2,183 $ 2,757
XML 74 R56.htm IDEA: XBRL DOCUMENT v3.21.1
Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses by Award Type (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Equity-based compensation expense $ 3,907,000 $ 4,134,000
ESPP    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Equity-based compensation expense 27,000 0
Stock Options    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Equity-based compensation expense 3,200,000 3,789,000
Restricted Stock Awards    
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]    
Equity-based compensation expense $ 680,000 $ 345,000
XML 75 R57.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2019
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Recognition of revenue   $ 445,000 $ 100,000 $ 1,231,000 $ 305,000 $ 350,000 $ 338,000 $ 545,000 $ 2,224,000
Current deferred revenue       $ 544,000         $ 544,000
Common Stock                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Number of shares sold                 6,340,771
Ginkgo Collaboration                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Current pre-paid research and development $ 4,700,000         4,700,000      
Non-current pre-paid research and development 8,900,000         $ 8,900,000      
Prepayment to related party for collaboration agreement $ 30,000,000.0                
Related party transaction collaboration agreement, initial term 5 years                
Ginkgo Collaboration | Pre-Funded Warrants                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Warrants to purchase shares of common stock 2,548,117         2,548,117      
Ginkgo Collaboration | Common Stock                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Number of shares sold 6,340,771                
Abb Vie Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Recognition of revenue               500,000 $ 2,200,000
Current deferred revenue               $ 0  
Abb Vie Agreement | Ibdco                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Collaboration in research and development               54 months  
XML 76 R58.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Numerator:                    
Net loss $ (14,588) $ (13,222) $ (15,535) $ (15,828) $ (12,798) $ (13,285) $ (12,344) $ (12,946) $ (59,173) $ (51,373)
Denominator:                    
Weighted-average common shares outstanding - basic and diluted                 35,835,744 30,284,068
Net loss per share - basic and diluted $ (0.39) $ (0.36) $ (0.44) $ (0.46) $ (0.37) $ (0.39) $ (0.45) $ (0.51) $ (1.65) $ (1.70)
XML 77 R59.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss per Share - Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share (Detail) - shares
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Unvested Restricted Common Stock Awards    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Potentially Common Shares Excluded from Calculation of Net Loss Per share 478,207 586,929
Stock Options    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Potentially Common Shares Excluded from Calculation of Net Loss Per share 3,343,836 2,286,419
Potential Shares Issuable Under ESPP    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Potentially Common Shares Excluded from Calculation of Net Loss Per share 12,037  
XML 78 R60.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Additional Information (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Tax Disclosure [Line Items]      
Income tax benefits for the net operating losses $ 0 $ 0  
Valuation allowance $ 72,791,000 53,834,000 $ 40,290,000
Description of tax benefit likely to be realized upon settlement greater than 50%    
Unrecognized tax benefits $ 0    
Income tax examination description In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. Tax years from 2016 to the present are open to examination under the statute.    
Interest or penalties accrued $ 0 0  
Federal      
Income Tax Disclosure [Line Items]      
Net operating loss carryforwards 227,000,000.0 172,900,000  
Net operating loss carryforwards subject to expiration 79,400,000    
Net operating loss carryforwards not subject to expiration $ 147,600,000    
Net operating loss carryforwards expiration year 2034    
Federal | Research and Development.      
Income Tax Disclosure [Line Items]      
Tax credit carryforwards $ 3,500,000    
State      
Income Tax Disclosure [Line Items]      
Net operating loss carryforwards   $ 213,600,000 $ 159,000,000.0
Net operating loss carryforwards expiration year 2029    
State | Research and Development.      
Income Tax Disclosure [Line Items]      
Tax credit carryforwards $ 2,300,000    
XML 79 R61.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Deferred tax assets:      
Net operating loss carryforwards $ 61,181 $ 46,362  
Tax credit carryforwards 5,748 4,262  
Accrued expenses 126 37  
Property and equipment 279    
Other long-term liabilities 36    
Lease liabilities 6,230 6,776  
Equity compensation 2,200 1,481  
Amortizable intangibles 1,195 1,214  
Other 38 138  
Gross deferred tax assets 77,033 60,270  
Deferred tax liabilities:      
Property and equipment   (1,720)  
Right of use assets (4,242) (4,716)  
Gross deferred tax liabilities (4,242) (6,436)  
Valuation allowance $ (72,791) $ (53,834) $ (40,290)
XML 80 R62.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate (Detail)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]    
U.S. federal statutory rate 21.00% 21.00%
State income taxes, net of federal benefit, Tax Rate 6.00% 6.00%
Other permanent differences, Tax Rate (1.00%) (1.00%)
Tax credits, Tax Rate 2.00% 0.00%
Other items, Tax Rate 4.00% 0.00%
Net change in valuation allowance, Tax Rate (32.00%) (26.00%)
XML 81 R63.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Schedule of Valuation Allowance - (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]    
Balance at beginning of year $ (53,834) $ (40,290)
Increase in valuation allowance (18,957) (13,544)
Balance at end of year $ (72,791) $ (53,834)
XML 82 R64.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Additional Information (Detail)
 1 Months Ended 12 Months Ended
Jul. 31, 2017
USD ($)
ft²
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
ft²
Lessee Lease Description [Line Items]        
Laboratory and office space to be leased | ft² 41,346      
Operating lease annual rent $ 3,300,000      
Term of lease 10 years      
Tenant improvement investment $ 2,900,000      
Letter of credit $ 1,000,000.0      
Lessee, operating lease, existence of option to extend true true    
Renewal term of lease 5 years      
Lessee, operating lease, existence of option to terminate true      
Agreement expiration date       Dec. 31, 2022
Estimated expenses to be incurred       $ 4,800,000
Cash paid included in operating cash flows   $ 3,900,000 $ 3,700,000  
Master Services Agreement | Azzur Group, LLC        
Lessee Lease Description [Line Items]        
Access and use of space under agreement | ft²       700
Term of agreement       44 months
Maximum        
Lessee Lease Description [Line Items]        
Tenant improvement investment $ 6,600,000      
XML 83 R65.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Components of Lease Cost for Operating Leases (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Operating leases    
Operating lease cost $ 3,628 $ 3,344
Short-term lease cost   330
Variable lease cost 1,055 1,092
Operating and variable lease cost $ 4,683 $ 4,766
XML 84 R66.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases (Detail)
Dec. 31, 2020
Dec. 31, 2019
Leases [Abstract]    
Operating Lease, Weighted average discount rate 8.00% 8.00%
Operating Lease, Weighted average remaining lease term (years) 7 years 2 months 12 days 8 years 2 months 12 days
XML 85 R67.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Summary of Maturity of Lease Liabilities for Operating Leases (Detail) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Operating Leases    
2021 $ 4,236  
2022 4,389  
2023 3,574  
2024 3,681  
2025 3,792  
Thereafter 10,595  
Total lease payments 30,267  
Less: imputed interest 7,463  
Total lease liabilities 22,804  
Current lease liabilities 2,531 $ 2,000
Long-term lease liabilities $ 20,273 $ 22,804
XML 86 R68.htm IDEA: XBRL DOCUMENT v3.21.1
Employee Benefits - Additional Information (Detail)
 12 Months Ended
Dec. 31, 2020
Compensation And Retirement Disclosure [Abstract]  
Eligible employees to contribute to 401(k) plan 50.00%
Employee contribution 4.00%
Maximum matching contributions as a percentage of eligible compensation 2.00%
XML 87 R69.htm IDEA: XBRL DOCUMENT v3.21.1
Related-Party Transactions - Additional Information (Detail) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Jun. 30, 2019
Dec. 31, 2020
Dec. 31, 2019
Related Party Transaction [Line Items]      
Common stock, outstanding   38,183,273 32,266,814
Ginkgo Bioworks, Inc.      
Related Party Transaction [Line Items]      
Common stock, outstanding   6,340,771  
Prepayment to related party for collaboration agreement $ 30.0    
Related party transaction collaboration agreement, initial term 5 years    
Current Pre-Paid Research and Development   $ 4.7  
Non Current Pre-Paid Research and Development   8.9  
Prepaid research and development expenses   $ 13.6  
XML 88 R70.htm IDEA: XBRL DOCUMENT v3.21.1
Selected Quarterly Data (unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]                    
Revenue     $ 445 $ 100 $ 1,231 $ 305 $ 350 $ 338 $ 545 $ 2,224
Operating expenses $ 14,694 $ 13,437 16,382 16,498 14,710 14,443 13,445 14,035 61,011 56,633
Loss from operations (14,694) (13,437) (15,937) (16,398) (13,479) (14,138) (13,095) (13,697) (60,466) (54,409)
Net loss $ (14,588) $ (13,222) $ (15,535) $ (15,828) $ (12,798) $ (13,285) $ (12,344) $ (12,946) $ (59,173) $ (51,373)
Net loss per share - basic and diluted $ (0.39) $ (0.36) $ (0.44) $ (0.46) $ (0.37) $ (0.39) $ (0.45) $ (0.51) $ (1.65) $ (1.70)
EXCEL 89 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>] M9!:GST9>$)+#ORY[6E;[7V_I-U#W?6/HCGVC1^.EJ$L-P;CWVY M4+7TO]FE:F#/W+I:!MAT]V._=$I6?J%4J,TXV=HJQK74S>A@_[6O2S?&&S:H M,FC;0&-LN-'JR?_<'S?%H_;Z3AL=7J:C[G^C1J+6C:[U=U5-1ULCX1?VZ0_K M]'?;!&EFI;/&3$>3?L>-CU$"&;2GQM @1)G#9]5W!LO%(X]6G5 M7W4 7!1#MZ=AASNM.G ^R&/8MD97 28$8/)I@&+C4B+( ME(!,/Q!R%B'B#[RP MR] Z%9F.6J\;Y?%8V2:XMGFY9FU=2_?2W5%]WVCXF83YY[ L;0OS#X+<(2!W M>"%/I';B1IJV"^");F!$:VE@:O3!M36"W"4@=WDA#Q^E-A).N0D_WYQ)HX#O M4?G0/8UXZMZBYNXM7LI+IY92@UR>H1.O?&>:B[!03ARW#D\[$U(QS(Z!3 (F M0;!?)\)_6KV,/_A5G*N $2G)3)@M T/$M>IG)#$7Y94)NUCJVC;=_/R F2B- M3)@]$N]@>-F\DQX"!H Q8MU1_?W%F)1()NPF,3""K>O1#N^=4FN#EW+(A%LB MT.^9]5[ V("$1CJ%R2B+3)@U>LA: BPS%)AL )E0=DB8[?"U7AK[HI0X4HV:ZV%"3_D@8?;!56Q4 MU>:EC%*X=A+FCVZA.2 DUQS,.I@I TM?F-[^;(%1.?,B8#DIQ<9?C6PKG$@E ME!T29CN0^=YM@C$I823,PJ Q4XQ)"2-A%@:9F ZC27DC8?8&G9H*C$E))&&6 M")F;#J-)>25A]@J1FXJ-:UQ>2"CA)-SKD97\-+(!@?\%US\HV:3,LL&)ZIMP ME'!29N&0&>O@64PIZZ3,UEG/"-^,)%GG8C8.3@W?A*,\DS)[IL\1W\2BO)(R M>X5,)H9/'^65],.+6F)3'%:5CD=*@S$IKZ2?6>.ZS3 FY964V2LT9HXQ*:^D MS%ZA,0M0 DWRKPFP=*H.$"11C4A;*F"U$8\XP)F6AC'MULYKH AMT6[6F&_H8D[)0 MQFRA0;J+-=F_X<68E(4R9@NM8.)(QOP28U(6RI@M1.?G>*3GE(5R[H(:B8E3 MCYRR4/ZIJQV<>N24A7)F"]&8./7(*0OES!:B,;)+'F)2%VV>?URJVN&-HQ)6:A@ MMM!_F*C\\;?2]XM8I3M\Q)CD5V;,%GH+\UNLTL4O2>T<8U(6*I@MM/:>>?B8 M8DS*0@6SA=Y_Z]SQ8DS*0@5W1>Z]:G$;J\5X+;1-66B[L]"X.]@?[%=P8QI5 MG<,I/+27TI273L0__:=761Z_IYBWQAQ#VT5S9F7U^M'TZP??!_\"4$L#!!0 M ( !4U>5+;=K!Q,0( (DI : >&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'/-VDMNHT 4A>&M6"P@N.Z+I!5GU)-,HVP .>6'8AM$T4JR^[:<@7U0 M#WH2<4:H0%S^T0<"'E_RH1WWW:GL]GU9?!X/I[*J=N/8_ZKKLM[E8UONNCZ? MSDRR[GL5J\ML,VCZNJ_CQ<=Y?ZLDEWY\G5XOEM50W/;ZFJYPX2 M")+Y@Q2"=/X@@R";/\@AR.@GH+@=Z">@N!WH)Z"X'>@GH+@=Z">@N!WH)Z M"X'>@GH+@=Z*>BN!WHIZ*X'>BGHK@=XZ>5E"H+>BWDJ@MZ+>2J"WHMY*H+>B MWDJ@MZ+>2J"WHMY*H+>AWD:@MZ'>1J"WH=Y&H+>AWD:@MTU>=A/H;:BW$>AM MJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^CM MDX^5!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>@?J'01Z!^H=!'H'ZAT$>@?J'01Z M!^H=!'H'ZAT$>L?D9Q,"O0/U#@*] _4. KT#]0X"O1O4N_E)O?ZMJ(\_0502P,$% @ %35Y4J3(PW?Z M 0 M"@ !, !;0V]N=&5N=%]4>7!E&ULS=K+3L,P$ 707ZFR18WK M)P_1;H ML. '3#*E49/8LETH?X^3 A((*E"1N)M&K>VY$X]T5CV_>_84)]NN M[>.\6*7DSQB+U8HZ&TOGJ<\K2QTM)LV3:ZV^>?8N'Y>!&IC,;G8;1RRYH7UOFTJF_(Z>^SK3RG3UX0RGQSW MQ%7CXU'>4+ O$X:5[P->S]T\4@A-39-;&]*U[?(NMFU93,\MQ7)_B2]Z=,ME M4U'MJDV7CY31![)U7!&EKBUW18_V)Z=\P[3[Y ?GCV7V!>:=M\'YF"<6Z/=Q M;R,93D]]+D0A-?M?\3TQES[X_6B8=DWU#[/S]3ZYL![G$=GX./R./\[XO?XO M^Q @?4B0/A1('QJD#P/2QS%('R<@?9R"],%G*(V@B,I12.4HIG(45#F*JAR% M58[B*D>!E:/(*E!D%2BR"A19!8JL D56@2*K0)%5H,@J4&05*+)*%%DEBJP2 M15:)(JM$D56BR"I19)4HLDH4626*K I%5H4BJT*15:'(JE!D52BR*A19%8JL M"D56A2*K1I%5H\BJ4635*+)J%%DUBJP:15:-(JM&D56CR&I09#4HLAH460V* MK 9%5H,BJT&1U:#(:E!D-2BR'O^GK/?.K?\X?GR6G6WZMWPV_EEQ\0)02P$" M% ,4 " 5-7E2!T%-8H$ "Q $ @ $ 9&]C M4')O<',O87!P+GAM;%!+ 0(4 Q0 ( !4U>5) P0FH[P "L" 1 M " :\ !D;V-05*97)PC$ 8 )PG 3 " &UL4$L! A0#% @ %35Y4D&/\]T!!P 7QL !@ M ("!#@@ 'AL+W=O5(B29D-!08 $<8 8 " @44/ !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% M @ %35Y4A\"/CUK! @P\ !@ ("!'Q@ 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ %35Y4H< ]5'X!P M]1( !@ ("!$2H 'AL+W=O5*FG1@^QR, *1X 8 " @3\R M !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ %35Y4FNVRNWJ! \ L !D M ("!AEP 'AL+W=OH " "H!0 &0 @(&G80 >&PO=V]R:W-H965T M5)/U[5T!0, &\& 9 M " @5YD !X;"]W;W)K&UL4$L! A0# M% @ %35Y4C(LV(IP @ ,04 !D ("!FF< 'AL+W=O M0% P M#@ &0 @(%!:@ >&PO=V]R:W-H965T5)$6%1DEPH (,? 9 " @5QP M !X;"]W;W)K&UL4$L! A0#% @ %35Y4I)% M(EHE!P ,Q$ !D ("!*GL 'AL+W=O&PO=V]R:W-H965T5*<\&K,/@D #08 9 " @;>& !X;"]W;W)K&UL4$L! A0#% @ %35Y4FFRS;U+!P >1( !D M ("!+) 'AL+W=O&PO M=V]R:W-H965T5(NIC]$'P, M !4' 9 " @<&: !X;"]W;W)K&UL4$L! A0#% @ %35Y4KY4,6YH P JP< !D ("! M%YX 'AL+W=O&PO=V]R:W-H965T5+E#1"R*B4 #V# 9 M " @;RE !X;"]W;W)K&UL4$L! A0#% M @ %35Y4CY-_8"W P A@@ !D ("!'&UL4$L! A0#% @ %35Y4DNHT6V+ M @ C04 !D ("!==8 'AL+W=O&PO=V]R:W-H965T5*D^U0*>0( "\% 9 " @3K< !X;"]W;W)K&UL4$L! A0#% @ %35Y4B&PO=V]R M:W-H965T5+TJ>&UL M4$L! A0#% @ %35Y4H+(03C7! W0L !D ("!*NP M 'AL+W=O&PO=V]R:W-H965T5+U:\PST , *L( 9 M " @37U !X;"]W;W)K&UL4$L! A0#% @ M%35Y4JIJ:3&1 @ \P4 !D ("!//D 'AL+W=O&PO=V]R:W-H965T5*E]G*\P0( !4' 9 " @5<" 0!X;"]W M;W)K&UL4$L! A0#% @ %35Y4IL:PSS- @ M&0D !D ("!3P4! 'AL+W=O)X% !(@ &0 @(%3 M" $ >&PO=V]R:W-H965T5)- M$4,ZV0, '40 9 " @2@. 0!X;"]W;W)K&UL4$L! A0#% @ %35Y4NIPKGBO @ S 8 !D M ("!.!(! 'AL+W=O%0$ >&PO=V]R:W-H M965T5*M @7&3 ( #,% 9 M " @?H7 0!X;"]W;W)K&UL4$L! M A0#% @ %35Y4@/2I=1< P 30T !D ("!?1H! 'AL M+W=O&PO=V]R:W-H965T5*0@TPCC@4 <: 9 " M@=D@ 0!X;"]W;W)K&UL4$L! A0#% @ %35Y M4J6J#-Z8 @ 70@ !D ("!GB8! 'AL+W=O&PO=V]R:W-H965T5)<2,=;%0, )\( 9 " @6 N 0!X;"]W;W)K M&UL4$L! A0#% @ %35Y4CS(HXG*! 1Q, M !D ("!K#$! 'AL+W=O&PO=V]R:W-H965T5)BP--, M+@, 'D* 9 " @6,Y 0!X;"]W;W)K&UL4$L! A0#% @ %35Y4NW6W,GI @ ' D !D M ("!R#P! 'AL+W=O[:!_\" "L"@ &0 @('H/P$ >&PO=V]R:W-H965T M5(M3NY3W@0 .,6 9 M " @1Y# 0!X;"]W;W)K&UL4$L! A0# M% @ %35Y4@Z[.8*B P 70T !D ("!,T@! 'AL+W=O M&PO=V]R:W-H965T5(IJ7VIP@0 L2 9 " @4%/ M 0!X;"]W;W)K&UL4$L! A0#% @ %35Y4O2V ME2GG P E T !D ("!.E0! 'AL+W=O&PO=V]R:W-H965T5)ULU]XF0( (L& 9 " @85; 0!X;"]W;W)K&UL4$L! A0#% @ %35Y4IE7FTA.! Q@\ !D M ("!55X! 'AL+W=O$QX<" #H!@ &0 @(':8@$ >&PO M=V]R:W-H965T5)S,P%C/@( M / % 9 " @9AE 0!X;"]W;W)K&UL4$L! A0#% @ %35Y4AAP<%CH @ 40D !D ("! M#6@! 'AL+W=O&PO=V]R:W-H965T5)#,5W^5 , #(* 9 M " @<]M 0!X;"]W;W)K&UL4$L! A0#% M @ %35Y4C4D5O)6! 4!$ !D ("!6G$! 'AL+W=O&PO5*7BKL

5)^9(H;904 '0N / " 2-Z 0!X M;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " 5-7E2VW:P<3$" ")*0 &@ M @ &U?P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$" M% ,4 " 5-7E2I,C#=_H! "T* $P @ $>@@$ 6T-O F;G1E;G1?5'EP97-=+GAM;%!+!08 3@!. %D5 !)A $ ! end XML 90 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 91 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 92 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 160 400 1 false 51 0 false 9 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 100050 - Statement - Consolidated Statements of Cash Flows Sheet http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - Nature of Business Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNatureOfBusiness Nature of Business Notes 7 false false R8.htm 100070 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 100080 - Disclosure - Fair Value of Financial Instruments Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 9 false false R10.htm 100090 - Disclosure - Available-for-Sale Investments Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestments Available-for-Sale Investments Notes 10 false false R11.htm 100100 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 11 false false R12.htm 100110 - Disclosure - Property and Equipment, Net Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet Property and Equipment, Net Notes 12 false false R13.htm 100120 - Disclosure - Accrued Expenses Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpenses Accrued Expenses Notes 13 false false R14.htm 100130 - Disclosure - Common Stock Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStock Common Stock Notes 14 false false R15.htm 100140 - Disclosure - Equity-based Compensation and Equity Incentive Plans Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlans Equity-based Compensation and Equity Incentive Plans Notes 15 false false R16.htm 100150 - Disclosure - Collaboration Agreements Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreements Collaboration Agreements Notes 16 false false R17.htm 100160 - Disclosure - Net Loss per Share Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShare Net Loss per Share Notes 17 false false R18.htm 100170 - Disclosure - Income Taxes Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 18 false false R19.htm 100180 - Disclosure - Leases Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeases Leases Notes 19 false false R20.htm 100190 - Disclosure - Commitments and Contingencies Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 100200 - Disclosure - Employee Benefits Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEmployeeBenefits Employee Benefits Notes 21 false false R22.htm 100210 - Disclosure - Related-Party Transactions Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions Related-Party Transactions Notes 22 false false R23.htm 100220 - Disclosure - Selected Quarterly Data (Unaudited) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited Selected Quarterly Data (Unaudited) Notes 23 false false R24.htm 100230 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 24 false false R25.htm 100240 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 25 false false R26.htm 100250 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstruments 26 false false R27.htm 100260 - Disclosure - Available-for-Sale Investments (Tables) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsTables Available-for-Sale Investments (Tables) Tables http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestments 27 false false R28.htm 100270 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 28 false false R29.htm 100280 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet 29 false false R30.htm 100290 - Disclosure - Accrued Expenses (Tables) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpenses 30 false false R31.htm 100300 - Disclosure - Common Stock (Tables) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockTables Common Stock (Tables) Tables http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStock 31 false false R32.htm 100310 - Disclosure - Equity-based Compensation and Equity Incentive Plans (Tables) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansTables Equity-based Compensation and Equity Incentive Plans (Tables) Tables http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlans 32 false false R33.htm 100320 - Disclosure - Net Loss per Share (Tables) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables Net Loss per Share (Tables) Tables http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShare 33 false false R34.htm 100330 - Disclosure - Income Taxes (Tables) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxes 34 false false R35.htm 100340 - Disclosure - Leases (Tables) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeases 35 false false R36.htm 100350 - Disclosure - Selected Quarterly Data (Unaudited) (Tables) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables Selected Quarterly Data (Unaudited) (Tables) Tables http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited 36 false false R37.htm 100360 - Disclosure - Nature of Business - Additional Information (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail Nature of Business - Additional Information (Detail) Details 37 false false R38.htm 100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 38 false false R39.htm 100380 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) Details 39 false false R40.htm 100390 - Disclosure - Summary of Significant Accounting Policies - Schedule of Useful Life of Property and Equipment (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail Summary of Significant Accounting Policies - Schedule of Useful Life of Property and Equipment (Detail) Details 40 false false R41.htm 100400 - Disclosure - Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail) Details 41 false false R42.htm 100410 - Disclosure - Available-for-Sale Investments - Summary of Available-for-Sale Securities Held (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail Available-for-Sale Investments - Summary of Available-for-Sale Securities Held (Detail) Details 42 false false R43.htm 100420 - Disclosure - Available-for-Sale Investments - Additional Information (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsAdditionalInformationDetail Available-for-Sale Investments - Additional Information (Detail) Details 43 false false R44.htm 100430 - Disclosure - Prepaid Expenses and Other Current Assets (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail Prepaid Expenses and Other Current Assets (Detail) Details http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables 44 false false R45.htm 100440 - Disclosure - Property and Equipment, Net - Additional Information (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail Property and Equipment, Net - Additional Information (Detail) Details 45 false false R46.htm 100450 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail) Details 46 false false R47.htm 100460 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail Accrued Expenses - Schedule of Accrued Expenses (Detail) Details 47 false false R48.htm 100470 - Disclosure - Common Stock - Additional Information (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail Common Stock - Additional Information (Detail) Details 48 false false R49.htm 100480 - Disclosure - Common Stock - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail Common Stock - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail) Details 49 false false R50.htm 100490 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Additional Information (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail Equity-based Compensation and Equity Incentive Plans - Additional Information (Detail) Details 50 false false R51.htm 100500 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail Equity-based Compensation and Equity Incentive Plans - Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees (Detail) Details 51 false false R52.htm 100510 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Detail) Details 52 false false R53.htm 100520 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Parenthetical) (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanParentheticalDetail Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Parenthetical) (Detail) Details 53 false false R54.htm 100530 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Restricted Common Stock Activity (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail Equity-based Compensation and Equity Incentive Plans - Schedule of Restricted Common Stock Activity (Detail) Details 54 false false R55.htm 100540 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses (Detail) Details 55 false false R56.htm 100550 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses by Award Type (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses by Award Type (Detail) Details 56 false false R57.htm 100560 - Disclosure - Collaboration Agreements - Additional Information (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail Collaboration Agreements - Additional Information (Detail) Details 57 false false R58.htm 100570 - Disclosure - Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Detail) Details 58 false false R59.htm 100580 - Disclosure - Net Loss per Share - Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail Net Loss per Share - Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share (Detail) Details 59 false false R60.htm 100590 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 60 false false R61.htm 100600 - Disclosure - Income Taxes - Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail Income Taxes - Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities (Detail) Details 61 false false R62.htm 100610 - Disclosure - Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate (Detail) Details 62 false false R63.htm 100620 - Disclosure - Income Taxes - Schedule of Valuation Allowance - (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfValuationAllowanceDetail Income Taxes - Schedule of Valuation Allowance - (Detail) Details 63 false false R64.htm 100630 - Disclosure - Leases - Additional Information (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail Leases - Additional Information (Detail) Details 64 false false R65.htm 100640 - Disclosure - Leases - Components of Lease Cost for Operating Leases (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail Leases - Components of Lease Cost for Operating Leases (Detail) Details 65 false false R66.htm 100650 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateForOperatingLeasesDetail Leases - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases (Detail) Details 66 false false R67.htm 100660 - Disclosure - Leases - Summary of Maturity of Lease Liabilities for Operating Leases (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail Leases - Summary of Maturity of Lease Liabilities for Operating Leases (Detail) Details 67 false false R68.htm 100680 - Disclosure - Employee Benefits - Additional Information (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetail Employee Benefits - Additional Information (Detail) Details 68 false false R69.htm 100690 - Disclosure - Related-Party Transactions - Additional Information (Detail) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail Related-Party Transactions - Additional Information (Detail) Details 69 false false R70.htm 100700 - Disclosure - Selected Quarterly Data (unaudited) (Details) Sheet http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedDetails Selected Quarterly Data (unaudited) (Details) Details http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables 70 false false All Reports Book All Reports sybx-10k_20201231.htm sybx-20201231.xsd sybx-20201231_cal.xml sybx-20201231_def.xml sybx-20201231_lab.xml sybx-20201231_pre.xml sybx-ex1013_238.htm sybx-ex10141_239.htm sybx-ex10142_240.htm sybx-ex211_8.htm sybx-ex231_6.htm sybx-ex311_9.htm sybx-ex312_7.htm sybx-ex321_12.htm sybx-ex322_10.htm gfkh34aypiqb000001.jpg gfkh34aypiqb000002.jpg http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 95 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sybx-10k_20201231.htm": { "axisCustom": 0, "axisStandard": 26, "contextCount": 160, "dts": { "calculationLink": { "local": [ "sybx-20201231_cal.xml" ] }, "definitionLink": { "local": [ "sybx-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "sybx-10k_20201231.htm" ] }, "labelLink": { "local": [ "sybx-20201231_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "sybx-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "sybx-20201231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 516, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 22, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 26 }, "keyCustom": 49, "keyStandard": 351, "memberCustom": 15, "memberStandard": 32, "nsprefix": "sybx", "nsuri": "http://www.synlogictx.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "sybx:AvailableForSaleSecuritiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Available-for-Sale Investments", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestments", "shortName": "Available-for-Sale Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "sybx:AvailableForSaleSecuritiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "sybx:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Prepaid Expenses and Other Current Assets", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "sybx:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Property and Equipment, Net", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Accrued Expenses", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Common Stock", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Equity-based Compensation and Equity Incentive Plans", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlans", "shortName": "Equity-based Compensation and Equity Incentive Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Collaboration Agreements", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreements", "shortName": "Collaboration Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Net Loss per Share", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Income Taxes", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Leases", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Balance Sheets", "role": "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Commitments and Contingencies", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Employee Benefits", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEmployeeBenefits", "shortName": "Employee Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Related-Party Transactions", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions", "shortName": "Related-Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Selected Quarterly Data (Unaudited)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited", "shortName": "Selected Quarterly Data (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "sybx:AvailableForSaleSecuritiesDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Available-for-Sale Investments (Tables)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsTables", "shortName": "Available-for-Sale Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "sybx:AvailableForSaleSecuritiesDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "sybx:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "sybx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "sybx:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "sybx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Accrued Expenses (Tables)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "sybx:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Common Stock (Tables)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockTables", "shortName": "Common Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "sybx:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Equity-based Compensation and Equity Incentive Plans (Tables)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansTables", "shortName": "Equity-based Compensation and Equity Incentive Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Net Loss per Share (Tables)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Income Taxes (Tables)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Leases (Tables)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Selected Quarterly Data (Unaudited) (Tables)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables", "shortName": "Selected Quarterly Data (Unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Nature of Business - Additional Information (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail", "shortName": "Nature of Business - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalCashAndCashEquivalentRelatedText", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalCashAndCashEquivalentRelatedText", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail", "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:CashCollateralForBorrowedSecurities", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "sybx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_us-gaapPropertyPlantAndEquipmentByTypeAxis_sybxComputerAndOfficeEquipmentMember_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Summary of Significant Accounting Policies - Schedule of Useful Life of Property and Equipment (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail", "shortName": "Summary of Significant Accounting Policies - Schedule of Useful Life of Property and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "sybx:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_us-gaapPropertyPlantAndEquipmentByTypeAxis_sybxComputerAndOfficeEquipmentMember_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail", "shortName": "Fair Value of Financial Instruments - Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "sybx:AvailableForSaleSecuritiesDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Available-for-Sale Investments - Summary of Available-for-Sale Securities Held (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail", "shortName": "Available-for-Sale Investments - Summary of Available-for-Sale Securities Held (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "sybx:AvailableForSaleSecuritiesDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "U_sybxInvestment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Available-for-Sale Investments - Additional Information (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsAdditionalInformationDetail", "shortName": "Available-for-Sale Investments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "U_sybxInvestment", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "sybx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "sybx:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Prepaid Expenses and Other Current Assets (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail", "shortName": "Prepaid Expenses and Other Current Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "sybx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "sybx:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Property and Equipment, Net - Additional Information (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "shortName": "Property and Equipment, Net - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail", "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail", "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "sybx:NumberOfVotesEntitledToEachShareOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "U_sybxVote", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Common Stock - Additional Information (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "shortName": "Common Stock - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "sybx:NumberOfVotesEntitledToEachShareOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "U_sybxVote", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "sybx:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Common Stock - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail", "shortName": "Common Stock - Schedule of Shares of Common Stock Reserved for Future Issuance (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "sybx:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Consolidated Statements of Stockholders' Equity", "role": "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Additional Information (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "shortName": "Equity-based Compensation and Equity Incentive Plans - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_srtTitleOfIndividualAxis_sybxEmployeesAndNonemployeesMember_us-gaapPlanNameAxis_sybxLongTermIncentivePlan2015And2017Member_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail", "shortName": "Equity-based Compensation and Equity Incentive Plans - Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_srtTitleOfIndividualAxis_sybxEmployeesAndNonemployeesMember_us-gaapPlanNameAxis_sybxLongTermIncentivePlan2015And2017Member_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_us-gaapPlanNameAxis_sybxLongTermIncentivePlan2015And2017Member_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail", "shortName": "Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_us-gaapPlanNameAxis_sybxLongTermIncentivePlan2015And2017Member_20200101_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "INF", "first": true, "lang": null, "name": "sybx:ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Parenthetical) (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanParentheticalDetail", "shortName": "Equity-based Compensation and Equity Incentive Plans - Schedule of Stock Option Activity Under 2015 and 2017 Plan (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "INF", "first": true, "lang": null, "name": "sybx:ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Restricted Common Stock Activity (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail", "shortName": "Equity-based Compensation and Equity Incentive Plans - Schedule of Restricted Common Stock Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_us-gaapAwardTypeAxis_us-gaapRestrictedStockMember_20200101_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail", "shortName": "Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses by Award Type (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail", "shortName": "Equity-based Compensation and Equity Incentive Plans - Schedule of Equity-based Compensation Expenses by Award Type (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Collaboration Agreements - Additional Information (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "shortName": "Collaboration Agreements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_us-gaapTypeOfArrangementAxis_sybxGinkgoBioworksIncMember_20190601_20190630", "decimals": "-5", "lang": null, "name": "sybx:PrepaymentToRelatedPartyForCollaborationAgreement", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201001_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail", "shortName": "Net Loss per Share - Schedule of Computation of Basic and Diluted Net Loss per Share (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sybxUnvestedRestrictedStockAwardsMember_20200101_20201231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Net Loss per Share - Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail", "shortName": "Net Loss per Share - Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_sybxUnvestedRestrictedStockAwardsMember_20200101_20201231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Income Taxes - Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail", "shortName": "Income Taxes - Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail", "shortName": "Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Income Taxes - Schedule of Valuation Allowance - (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfValuationAllowanceDetail", "shortName": "Income Taxes - Schedule of Valuation Allowance - (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20170701_20170731", "decimals": "INF", "first": true, "lang": null, "name": "sybx:RentableSpaceUnderLeaseAgreement", "reportCount": 1, "unique": true, "unitRef": "U_utrsqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Leases - Additional Information (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "shortName": "Leases - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20170701_20170731", "decimals": "INF", "first": true, "lang": null, "name": "sybx:RentableSpaceUnderLeaseAgreement", "reportCount": 1, "unique": true, "unitRef": "U_utrsqft", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Leases - Components of Lease Cost for Operating Leases (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail", "shortName": "Leases - Components of Lease Cost for Operating Leases (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "sybx:LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Leases - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateForOperatingLeasesDetail", "shortName": "Leases - Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "sybx:LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "sybx:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Leases - Summary of Maturity of Lease Liabilities for Operating Leases (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail", "shortName": "Leases - Summary of Maturity of Lease Liabilities for Operating Leases (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "sybx:LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Employee Benefits - Additional Information (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetail", "shortName": "Employee Benefits - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesIssued", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Related-Party Transactions - Additional Information (Detail)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "shortName": "Related-Party Transactions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_sybxGinkgoBioworksIncMember_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - Nature of Business", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNatureOfBusiness", "shortName": "Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200401_20200630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Selected Quarterly Data (unaudited) (Details)", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedDetails", "shortName": "Selected Quarterly Data (unaudited) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20201001_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingExpenses", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Fair Value of Financial Instruments", "role": "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sybx-10k_20201231.htm", "contextRef": "C_0001527599_20200101_20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 51, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r529", "r530", "r531" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated By Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r529", "r530", "r531" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_MaximumMember": { "auth_ref": [ "r255", "r257", "r420", "r421", "r422", "r423", "r424", "r425", "r444", "r488", "r489" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r255", "r257", "r420", "r421", "r422", "r423", "r424", "r425", "r444", "r488", "r489" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r244", "r255", "r257", "r420", "r421", "r422", "r423", "r424", "r425", "r444", "r488", "r489" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r244", "r255", "r257", "r420", "r421", "r422", "r423", "r424", "r425", "r444", "r488", "r489" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r155", "r409" ], "lang": { "en-us": { "role": { "label": "Title Of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail" ], "xbrltype": "domainItemType" }, "sybx_AbbVieAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Abb Vie agreement.", "label": "Abb Vie Agreement [Member]", "terseLabel": "Abb Vie Agreement" } } }, "localname": "AbbVieAgreementMember", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "sybx_AccessAndUseOfSpaceUnderAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Access and Use of space under agreement.", "label": "Access And Use Of Space Under Agreement", "terseLabel": "Access and use of space under agreement" } } }, "localname": "AccessAndUseOfSpaceUnderAgreement", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "areaItemType" }, "sybx_AccruedResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 10030.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development, current.", "label": "Accrued Research And Development Current", "terseLabel": "Research and development" } } }, "localname": "AccruedResearchAndDevelopmentCurrent", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "sybx_AgreementExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement expiration date.", "label": "Agreement Expiration Date", "terseLabel": "Agreement expiration date" } } }, "localname": "AgreementExpirationDate", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "sybx_AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Anticipated completion period for research and development projects.", "label": "Anticipated Completion Of Research And Development Projects Period", "terseLabel": "Collaboration in research and development" } } }, "localname": "AnticipatedCompletionOfResearchAndDevelopmentProjectsPeriod", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "sybx_AssetsAcquiredUnderOperatingLeaseObligation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets acquired under operating lease obligation.", "label": "Assets Acquired Under Operating Lease Obligation", "terseLabel": "Assets acquired under operating lease obligation" } } }, "localname": "AssetsAcquiredUnderOperatingLeaseObligation", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sybx_AtTheMarketMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "at the market.", "label": "At The Market [Member]", "terseLabel": "ATM" } } }, "localname": "AtTheMarketMember", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "sybx_AtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At-the-market offering,", "label": "At The Market Offering [Member]", "terseLabel": "At-the-market Offering" } } }, "localname": "AtTheMarketOfferingMember", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "sybx_AvailableForSaleSecuritiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available for sale securities disclosure.", "label": "Available For Sale Securities Disclosure [Text Block]", "terseLabel": "Available-for-Sale Investments" } } }, "localname": "AvailableForSaleSecuritiesDisclosureTextBlock", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestments" ], "xbrltype": "textBlockItemType" }, "sybx_AzzurGroupLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Azzur Group Limited Liability Company.", "label": "Azzur Group Limited Liability Company [Member]", "terseLabel": "Azzur Group, LLC" } } }, "localname": "AzzurGroupLimitedLiabilityCompanyMember", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "sybx_ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right exercise price of warrants paid at closing of offering.", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Paid At Closing Of Offering", "terseLabel": "Warrants exercise price per share paid at closing of offering" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsPaidAtClosingOfOffering", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "sybx_ComputerAndOfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer and office equipment.", "label": "Computer And Office Equipment [Member]", "terseLabel": "Computer and Office Equipment" } } }, "localname": "ComputerAndOfficeEquipmentMember", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "sybx_CowenAndCompanyLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cowen and company LLC.", "label": "Cowen And Company L L C [Member]", "terseLabel": "Cowen and Company, LLC" } } }, "localname": "CowenAndCompanyLLCMember", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "sybx_CurrentPrePaidResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Current Pre-Paid Research and Development.", "label": "Current Pre Paid Research And Development", "verboseLabel": "Current Pre-Paid Research and Development" } } }, "localname": "CurrentPrePaidResearchAndDevelopment", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "sybx_DeferredTaxAssetsLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 10110.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets lease liabilities.", "label": "Deferred Tax Assets Lease Liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "DeferredTaxAssetsLeaseLiabilities", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "sybx_DeferredTaxAssetsOtherLongTermLiabilities": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 10100.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets other long-term liabilities.", "label": "Deferred Tax Assets Other Long Term Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "DeferredTaxAssetsOtherLongTermLiabilities", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "sybx_DeferredTaxLiabilitiesRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 10050.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities, right of use assets.", "label": "Deferred Tax Liabilities Right Of Use Assets", "negatedLabel": "Right of use assets" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAssets", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "sybx_EmployeesAndNonemployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees and nonemployees.", "label": "Employees And Nonemployees [Member]", "terseLabel": "Employees and Nonemployees" } } }, "localname": "EmployeesAndNonemployeesMember", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail" ], "xbrltype": "domainItemType" }, "sybx_EstimatedExpensesToBeIncurredInAccessAndUseOfSpaceUnderAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated expenses to be incurred in access and use of space under agreement.", "label": "Estimated Expenses To Be Incurred In Access And Use Of Space Under Agreement", "terseLabel": "Estimated expenses to be incurred" } } }, "localname": "EstimatedExpensesToBeIncurredInAccessAndUseOfSpaceUnderAgreement", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "sybx_FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents net transfers in and out of assets and liabilities measured at fair value on a recurring basis using Level 1, Level 2 and Level 3 inputs.", "label": "Fair Value Asset Liability Transfers Between Level1 Level2 And Level3 Amount", "terseLabel": "Transfers of assets and liabilities between Level 1, Level 2, or Level 3" } } }, "localname": "FairValueAssetLiabilityTransfersBetweenLevel1Level2AndLevel3Amount", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "sybx_FairValueAssetMeasuredOnRecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair Value Asset Measured On Recurring Basis [Line Items]", "label": "Fair Value Asset Measured On Recurring Basis [Line Items]", "terseLabel": "Fair Value Asset Measured On Recurring Basis [Line Items]" } } }, "localname": "FairValueAssetMeasuredOnRecurringBasisLineItems", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "sybx_FairValueAssetMeasuredOnRecurringBasisTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair Value Asset Measured On Recurring Basis [Table]", "label": "Fair Value Asset Measured On Recurring Basis [Table]", "terseLabel": "Fair Value Asset Measured On Recurring Basis [Table]" } } }, "localname": "FairValueAssetMeasuredOnRecurringBasisTable", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "sybx_GinkgoBioworksIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ginkgo Bioworks, Inc.", "label": "Ginkgo Bioworks Inc [Member]", "terseLabel": "Ginkgo Bioworks, Inc.", "verboseLabel": "Ginkgo Collaboration" } } }, "localname": "GinkgoBioworksIncMember", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "sybx_IbdcoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IBDCo [Member]", "label": "Ibdco [Member]", "terseLabel": "Ibdco" } } }, "localname": "IbdcoMember", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "sybx_IncomeTaxDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax disclosure.", "label": "Income Tax Disclosure [Line Items]", "terseLabel": "Income Tax Disclosure [Line Items]" } } }, "localname": "IncomeTaxDisclosureLineItems", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "sybx_IncomeTaxDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax disclosure.", "label": "Income Tax Disclosure [Table]", "terseLabel": "Income Tax Disclosure [Table]" } } }, "localname": "IncomeTaxDisclosureTable", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "sybx_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase Decrease in Operating Lease Liability.", "label": "Increase Decrease In Operating Lease Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sybx_IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in prepaid research and development net of current portion.", "label": "Increase Decrease In Prepaid Research And Development Net Of Current Portion", "terseLabel": "Prepaid research and development, net of current portion" } } }, "localname": "IncreaseDecreaseInPrepaidResearchAndDevelopmentNetOfCurrentPortion", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sybx_IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance costs included in accounts payable and accrued expenses.", "label": "Issuance Costs Included In Accounts Payable And Accrued Expenses", "terseLabel": "Issuance costs included in accounts payable and accrued expenses" } } }, "localname": "IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sybx_LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, operating and finance lease, liability, maturity.", "label": "Lessee Operating And Finance Lease Liability Maturity Table [Text Block]", "terseLabel": "Summary of Maturity of Lease Liabilities for Operating Leases" } } }, "localname": "LesseeOperatingAndFinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "sybx_LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee weighted average remaining lease term and weighted average discount rate.", "label": "Lessee Weighted Average Remaining Lease Term And Weighted Average Discount Rate Table [Text Block]", "terseLabel": "Summary of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases" } } }, "localname": "LesseeWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "sybx_LongTermIncentivePlan2015And2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long term incentive plan 2015 and 2017.", "label": "Long Term Incentive Plan2015 And2017 [Member]", "terseLabel": "2015 and 2017 Plan" } } }, "localname": "LongTermIncentivePlan2015And2017Member", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansTables" ], "xbrltype": "domainItemType" }, "sybx_LongTermIncentivePlan2015Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Incentive Plan 2015.", "label": "Long Term Incentive Plan2015 [Member]", "terseLabel": "Plan 2015" } } }, "localname": "LongTermIncentivePlan2015Member", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "sybx_MasterContractServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Master contract services agreement.", "label": "Master Contract Services Agreement [Member]", "terseLabel": "Master Services Agreement" } } }, "localname": "MasterContractServicesAgreementMember", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "sybx_NewAccountingPronouncementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New accounting pronouncements.", "label": "New Accounting Pronouncements Policy [Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyTextBlock", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "sybx_NonCurrentPrePaidResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non Current Pre-Paid Research and Development", "label": "Non Current Pre Paid Research And Development", "terseLabel": "Non Current Pre-Paid Research and Development" } } }, "localname": "NonCurrentPrePaidResearchAndDevelopment", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "sybx_NoncashFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noncash financing items.", "label": "Noncash Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of non-cash financing activities:" } } }, "localname": "NoncashFinancingItemsAbstract", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "sybx_NoncashInvestingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noncash investing items.", "label": "Noncash Investing Items [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing activities:" } } }, "localname": "NoncashInvestingItemsAbstract", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "sybx_NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash purchase of property, plant and equipment in accounts payable and accrued liabilities adjustments.", "label": "Noncash Purchase Of Property Plant And Equipment In Accounts Payable And Accrued Liabilities Adjustments", "terseLabel": "Property and equipment purchases included in accounts payable and accrued expenses" } } }, "localname": "NoncashPurchaseOfPropertyPlantAndEquipmentInAccountsPayableAndAccruedLiabilitiesAdjustments", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sybx_NumberOfVotesEntitledToEachShareOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of votes entitled to each share of common stock.", "label": "Number Of Votes Entitled To Each Share Of Common Stock", "terseLabel": "Number of votes entitled to each share of common stock" } } }, "localname": "NumberOfVotesEntitledToEachShareOfCommonStock", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "sybx_OperatingAndVariableLeaseCost": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating and variable lease cost.", "label": "Operating And Variable Lease Cost", "totalLabel": "Operating and variable lease cost" } } }, "localname": "OperatingAndVariableLeaseCost", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "sybx_OperatingLeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease cost.", "label": "Operating Lease Cost [Abstract]", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseCostAbstract", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail" ], "xbrltype": "stringItemType" }, "sybx_OperatingLeasesRentExpenseAnnualRentalPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating leases rent expense annual rental payments.", "label": "Operating Leases Rent Expense Annual Rental Payments", "terseLabel": "Operating lease annual rent" } } }, "localname": "OperatingLeasesRentExpenseAnnualRentalPayments", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "sybx_OperatingLossCarryforwardsExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards expiration year.", "label": "Operating Loss Carryforwards Expiration Year", "terseLabel": "Net operating loss carryforwards expiration year" } } }, "localname": "OperatingLossCarryforwardsExpirationYear", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "sybx_OperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards not subject to expiration.", "label": "Operating Loss Carryforwards Not Subject To Expiration", "terseLabel": "Net operating loss carryforwards not subject to expiration" } } }, "localname": "OperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "sybx_OperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards subject to expiration.", "label": "Operating Loss Carryforwards Subject To Expiration", "terseLabel": "Net operating loss carryforwards subject to expiration" } } }, "localname": "OperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "sybx_OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other than temporary impairment losses investments number debt securities available for sale.", "label": "Other Than Temporary Impairment Losses Investments Number Debt Securities Available For Sale", "terseLabel": "Number of securities with other than temporary impairment" } } }, "localname": "OtherThanTemporaryImpairmentLossesInvestmentsNumberDebtSecuritiesAvailableForSale", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "sybx_PreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pre-Funded Warrants.", "label": "Pre Funded Warrants [Member]", "terseLabel": "Pre-Funded Warrants", "verboseLabel": "Common Stock Issuable Under Pre-Funded Warrants" } } }, "localname": "PreFundedWarrantsMember", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "sybx_PrepaidExpensesAndOtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid expenses and other current assets.", "label": "Prepaid Expenses And Other Current Assets [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "sybx_PrepaidResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10020.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid research and development, current.", "label": "Prepaid Research And Development Current", "terseLabel": "Prepaid research and development" } } }, "localname": "PrepaidResearchAndDevelopmentCurrent", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "sybx_PrepaidResearchAndDevelopmentExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid research and development expenses.", "label": "Prepaid Research And Development Expenses", "terseLabel": "Prepaid research and development expenses" } } }, "localname": "PrepaidResearchAndDevelopmentExpenses", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "sybx_PrepaidResearchAndDevelopmentNoncurrent": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid research and development noncurrent.", "label": "Prepaid Research And Development Noncurrent", "terseLabel": "Prepaid research and development, net of current portion" } } }, "localname": "PrepaidResearchAndDevelopmentNoncurrent", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "sybx_PrepaymentToRelatedPartyForCollaborationAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Prepayment to related party for collaboration agreement.", "label": "Prepayment To Related Party For Collaboration Agreement", "terseLabel": "Prepayment to related party for collaboration agreement", "verboseLabel": "Prepayment to related party for collaboration agreement" } } }, "localname": "PrepaymentToRelatedPartyForCollaborationAgreement", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "sybx_ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from employee stock purchases and exercise of stock options.", "label": "Proceeds From Employee Stock Purchases And Exercise Of Stock Options", "terseLabel": "Proceeds from employee stock purchases and exercise of stock options" } } }, "localname": "ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptions", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sybx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock and pre funded warrants.", "label": "Proceeds From Issuance Of Common Stock And Pre Funded Warrants", "terseLabel": "Proceeds, net of issuance costs, from issuance of common stock and pre-funded warrants" } } }, "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "sybx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recently adopted accounting pronouncements.", "label": "Recently Adopted Accounting Pronouncements Policy [Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "sybx_ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reduction in carrying amount of operating lease right-of-use asset.", "label": "Reduction In Carrying Amount Of Operating Lease Right Of Use Asset", "terseLabel": "Reduction in carrying amount of operating lease right of use asset" } } }, "localname": "ReductionInCarryingAmountOfOperatingLeaseRightOfUseAsset", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sybx_RelatedPartyTransactionCollaborationAgreementInitialTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related party transaction collaboration agreement, initial term.", "label": "Related Party Transaction Collaboration Agreement Initial Term", "terseLabel": "Related party transaction collaboration agreement, initial term", "verboseLabel": "Related party transaction collaboration agreement, initial term" } } }, "localname": "RelatedPartyTransactionCollaborationAgreementInitialTerm", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "sybx_RentableSpaceUnderLeaseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rentable Space Under Lease Agreement", "label": "Rentable Space Under Lease Agreement", "terseLabel": "Laboratory and office space to be leased" } } }, "localname": "RentableSpaceUnderLeaseAgreement", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "areaItemType" }, "sybx_SaleOfCommonStockAndPrefundedWarrantPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of common stock and prefunded warrant price per share.", "label": "Sale Of Common Stock And Prefunded Warrant Price Per Share", "terseLabel": "Sale of stock, price per share" } } }, "localname": "SaleOfCommonStockAndPrefundedWarrantPricePerShare", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "sybx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of prepaid expenses and other current assets.", "label": "Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]", "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets" } } }, "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "sybx_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Schedule Of Property Plant And Equipment Useful Life Table [Text Block]", "terseLabel": "Schedule of Useful Life of Property and Equipment" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "sybx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of shares of common stock reserved for future issuance.", "label": "Schedule Of Shares Of Common Stock Reserved For Future Issuance Table [Text Block]", "terseLabel": "Schedule of Shares of Common Stock Reserved for Future Issuance" } } }, "localname": "ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockTables" ], "xbrltype": "textBlockItemType" }, "sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options forfeitures and expirations in period intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value", "terseLabel": "Cancelled/Forfeited, Aggregate Intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "monetaryItemType" }, "sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options grants in period intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value", "terseLabel": "Granted, Aggregate Intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "monetaryItemType" }, "sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, options outstanding, weighted average exercise price, and additional disclosures.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price And Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceAndAdditionalDisclosuresAbstract", "nsuri": "http://www.synlogictx.com/20201231", "xbrltype": "stringItemType" }, "sybx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award percentage of shares outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Shares Outstanding", "terseLabel": "Percentage of shares outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfSharesOutstanding", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "sybx_ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation by share based arrangement award, options available for aggregate intrinsic value.", "label": "Share Based Compensation By Share Based Arrangement Award Options Available For Aggregate Intrinsic Value", "terseLabel": "Number of options in money" } } }, "localname": "ShareBasedCompensationByShareBasedArrangementAwardOptionsAvailableForAggregateIntrinsicValue", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanParentheticalDetail" ], "xbrltype": "sharesItemType" }, "sybx_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "sybx_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "sybx_TenantImprovementInvestmentObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount the lessee agrees to invest into a tenant improvement of a leased property.", "label": "Tenant Improvement Investment Obligation", "terseLabel": "Tenant improvement investment" } } }, "localname": "TenantImprovementInvestmentObligation", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "sybx_TermOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of agreement.", "label": "Term Of Agreement", "terseLabel": "Term of agreement" } } }, "localname": "TermOfAgreement", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "sybx_USTreasuryAndGovernmentLongTermDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "US treasury and government long-term debt securities.", "label": "U S Treasury And Government Long Term Debt Securities [Member]", "terseLabel": "U.S. Government Agency Securities and Treasuries" } } }, "localname": "USTreasuryAndGovernmentLongTermDebtSecuritiesMember", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "sybx_UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unbeneficial percentage of ownership after exercise of common stock outstanding effect to issuance.", "label": "Unbeneficial Percentage Of Ownership After Exercise Of Common Stock Outstanding Effect To Issuance", "terseLabel": "Unbeneficial percentage of ownership after exercise of common stock outstanding effect to issuance" } } }, "localname": "UnbeneficialPercentageOfOwnershipAfterExerciseOfCommonStockOutstandingEffectToIssuance", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "sybx_UnvestedRestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested Restricted Stock Awards [Member]", "label": "Unvested Restricted Stock Awards [Member]", "terseLabel": "Unvested Restricted Common Stock Awards" } } }, "localname": "UnvestedRestrictedStockAwardsMember", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "sybx_WarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants exercised.", "label": "Warrants Exercised", "terseLabel": "Warrants exercised" } } }, "localname": "WarrantsExercised", "nsuri": "http://www.synlogictx.com/20201231", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201813Member": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-13 Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.", "label": "Accounting Standards Update201813 [Member]", "terseLabel": "ASU 2018-13" } } }, "localname": "AccountingStandardsUpdate201813Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201815Member": { "auth_ref": [ "r196", "r197" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-15 Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force).", "label": "Accounting Standards Update201815 [Member]", "terseLabel": "ASU 2018-15" } } }, "localname": "AccountingStandardsUpdate201815Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201818Member": { "auth_ref": [ "r347", "r348" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.", "label": "Accounting Standards Update201818 [Member]", "terseLabel": "ASU 2018-18" } } }, "localname": "AccountingStandardsUpdate201818Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201912Member": { "auth_ref": [ "r329", "r330", "r331", "r332" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.", "label": "Accounting Standards Update201912 [Member]", "terseLabel": "ASU 2019-12" } } }, "localname": "AccountingStandardsUpdate201912Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r82" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion Amortization Of Discounts And Premiums Investments", "negatedLabel": "Accretion/amortization of investment securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r10", "r11", "r41" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 10020.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r37", "r201" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r28", "r52", "r53", "r54", "r479", "r497", "r501" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r51", "r54", "r55", "r95", "r96", "r97", "r356", "r492", "r493" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalCashAndCashEquivalentRelatedText": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An element designated to encapsulate any additional information related to cash and cash equivalents not otherwise addressed by the existing taxonomy. Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Additional Cash And Cash Equivalent Related Text", "terseLabel": "Cash equivalents maturity" } } }, "localname": "AdditionalCashAndCashEquivalentRelatedText", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r26" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r95", "r96", "r97", "r295", "r296", "r297" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r99", "r100", "r101", "r102", "r173", "r174", "r175", "r176", "r178", "r179", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r329", "r330", "r331", "r332", "r446", "r447", "r448", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments For New Accounting Pronouncements [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r259", "r261", "r301", "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Equity-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r213", "r218", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments To Additional Paid In Capital Warrant Issued", "terseLabel": "Proceeds from issuance of pre-funded common stock warrants, net of issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r261", "r288", "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Equity-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Potentially Common Shares Excluded from Calculation of Net Loss Per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r91", "r136", "r145", "r150", "r169", "r351", "r357", "r374", "r462", "r477" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r8", "r49", "r91", "r169", "r351", "r357", "r374" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r367" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r162" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail": { "order": 10010.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Gross unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r163" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail": { "order": 10020.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r160", "r185" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Amortized Cost Basis", "totalLabel": "Amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r157", "r161", "r185", "r465" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail": { "order": 10030.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Securities Debt Securities", "verboseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r159", "r185" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10250.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Available For Sale Securities Debt Securities Current", "terseLabel": "Short-term marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r159", "r185" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Available For Sale Securities Debt Securities Noncurrent", "terseLabel": "Long-term marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r262", "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r254", "r256" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r254", "r256", "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_Cash": { "auth_ref": [ "r34", "r503", "r504" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r34", "r83" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 }, "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10240.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash And Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail": { "order": 10010.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents Fair Value Disclosure", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r16", "r84", "r87" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash And Cash Equivalents Policy [Text Block]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r16", "r84", "r87", "r461" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash Cash Equivalents And Short Term Investments", "terseLabel": "Cash, cash equivalents, and short-term marketable securities" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r77", "r83", "r86" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r77", "r376" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCollateralForBorrowedSecurities": { "auth_ref": [ "r466", "r484" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage.", "label": "Cash Collateral For Borrowed Securities", "terseLabel": "Restricted cash included in other long-term assets" } } }, "localname": "CashCollateralForBorrowedSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents At Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r98", "r170", "r171", "r172", "r173", "r174", "r291", "r292", "r293", "r329", "r362", "r375", "r387", "r446", "r447", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change In Accounting Principle Accounting Standards Update Adopted", "terseLabel": "Change in accounting principle, accounting standards update, adopted [true false]" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r105", "r170", "r171", "r172", "r173", "r174", "r291", "r292", "r293", "r329", "r362", "r375", "r387", "r446", "r447", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in CCYY-MM-DD format.", "label": "Change In Accounting Principle Accounting Standards Update Adoption Date", "terseLabel": "Change in accounting principle, accounting standards update, adoption date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r99", "r110", "r177", "r298", "r333" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect", "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect [true false]" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r226", "r260" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class Of Warrant Or Right [Axis]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class Of Warrant Or Right [Domain]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1", "terseLabel": "Warrants exercise price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights", "terseLabel": "Warrants to purchase shares of common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r344", "r345", "r349" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r44", "r210", "r467", "r483" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 14)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r207", "r208", "r209", "r211" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Total Shares of Common Stock Reserved for Future Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common Stock $0.001 Par Value" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r25", "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r25" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, $0.001 par value 250,000,000 shares authorized as of December 31, 2020 and December 31, 2019. 38,183,273 shares issued and outstanding as of December 31, 2020 and 32,266,814 shares issued and outstanding as of December 31, 2019." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r242", "r243", "r258", "r303" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation And Employee Benefit Plans [Text Block]", "terseLabel": "Employee Benefits" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEmployeeBenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Compensation And Retirement Disclosure [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r57", "r59", "r60", "r65", "r470", "r486" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income Net Of Tax [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r125", "r475" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r87", "r353" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation Policy [Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction In Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r228", "r229", "r240" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract With Customer Liability Current", "terseLabel": "Deferred revenue", "verboseLabel": "Current deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r245", "r253", "r502" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions", "terseLabel": "Number of investments in unrealized loss position, more than twelve months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale [Table]", "terseLabel": "Debt Securities Available For Sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r166", "r186", "r191" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities Available For Sale Unrealized Loss Position", "terseLabel": "Aggregate fair value of securities in unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r167", "r187" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Unrealized Loss Position Number Of Positions", "terseLabel": "Number of investments in unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r22", "r23", "r318", "r463", "r476" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 10020.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Income Tax Liabilities", "negatedTotalLabel": "Gross deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 10130.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets Goodwill And Intangible Assets", "terseLabel": "Amortizable intangibles" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r319" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 10010.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Gross", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r321" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets Liabilities Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r326", "r327" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 10060.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r326", "r327" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 10140.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 10090.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Deferred Tax Assets Property Plant And Equipment", "terseLabel": "Property and equipment" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r324", "r326", "r327" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 10070.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets Tax Credit Carryforwards", "terseLabel": "Tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r326", "r327" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 10120.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost", "terseLabel": "Equity compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r326", "r327" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 10080.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r320" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 10030.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets Valuation Allowance", "negatedLabel": "Valuation allowance", "negatedPeriodEndLabel": "Balance at end of year", "negatedPeriodStartLabel": "Balance at beginning of year", "verboseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities Net [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r326", "r327" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 10040.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities Property Plant And Equipment", "negatedLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTemporaryDifferencesBetweenBasisOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan Employer Matching Contribution Percent", "terseLabel": "Maximum matching contributions as a percentage of eligible compensation" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match", "terseLabel": "Eligible employees to contribute to 401(k) plan" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan Maximum Annual Contributions Per Employee Percent", "terseLabel": "Employee contribution" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r81", "r199" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Equity-based Compensation and Equity Incentive Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r262", "r290" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Text Block]", "terseLabel": "Schedule of Equity-based Compensation Expenses by Award Type" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r225" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends Common Stock Cash", "terseLabel": "Cash dividends" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per share - basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedDetails", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r87", "r114", "r115" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "localname": "EarningsPerShareReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r114", "r115", "r116", "r117" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r310" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Continuing Operations", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r310", "r336" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": { "order": 10010.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "U.S. federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r310", "r336" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": { "order": 10060.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Net change in valuation allowance, Tax Rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r310", "r336" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": { "order": 10030.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Other", "terseLabel": "Other permanent differences, Tax Rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r310", "r336" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": { "order": 10050.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation Other Adjustments", "terseLabel": "Other items, Tax Rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r310", "r336" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": { "order": 10020.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes", "terseLabel": "State income taxes, net of federal benefit, Tax Rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "auth_ref": [ "r310", "r336" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail": { "order": 10040.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation Tax Credits", "terseLabel": "Tax credits, Tax Rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryFederalIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 10010.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Payroll related" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Employee unrecognized compensation cost, period of recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r289" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options", "terseLabel": "Employee unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "ESPP", "verboseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options", "verboseLabel": "Options To Purchase Common Stock" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Laboratory Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r95", "r96", "r97", "r100", "r107", "r109", "r120", "r176", "r218", "r225", "r295", "r296", "r297", "r331", "r332", "r377", "r378", "r379", "r380", "r381", "r382", "r492", "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r368", "r417", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r367", "r368", "r369", "r370", "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r245", "r246", "r251", "r253", "r368", "r417" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r245", "r246", "r251", "r253", "r368", "r418" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r368", "r419" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement Policy Policy [Text Block]", "terseLabel": "Fair Value" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r417", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r389" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease Liability Current", "terseLabel": "Finance lease obligations" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r389" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease Liability Noncurrent", "terseLabel": "Finance lease obligations, net of current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r390", "r398" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease Principal Payments", "negatedLabel": "Payments on finance lease obligations" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r164", "r165", "r180", "r181", "r182", "r183", "r184", "r188", "r189", "r190", "r191", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r67" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10110.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative Expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority Name [Axis]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority Name [Domain]", "terseLabel": "Income Tax Authority, Name" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r311", "r316", "r323", "r334", "r337", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationDescription": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.", "label": "Income Tax Examination Description", "terseLabel": "Income tax examination description" } } }, "localname": "IncomeTaxExaminationDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": { "auth_ref": [ "r305", "r313" ], "lang": { "en-us": { "role": { "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.", "label": "Income Tax Examination Likelihood Of Unfavorable Settlement", "terseLabel": "Description of tax benefit likely to be realized upon settlement" } } }, "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination Penalties And Interest Accrued", "terseLabel": "Interest or penalties accrued" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r92", "r108", "r109", "r135", "r309", "r335", "r338", "r487" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "verboseLabel": "Income tax benefits for the net operating losses" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r61", "r87", "r307", "r308", "r316", "r317", "r322", "r328", "r521" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r80" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase Decrease In Accounts Payable And Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r80" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Contract With Customer Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase Decrease In Other Noncurrent Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r80" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase Decrease In Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r80" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r62", "r134", "r384", "r385", "r471" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10060.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r75", "r78", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service I R S [Member]", "terseLabel": "Federal" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentIncomeNonoperating": { "auth_ref": [ "r68" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10050.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.", "label": "Investment Income Nonoperating", "terseLabel": "Interest and investment income" } } }, "localname": "InvestmentIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments Debt And Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r367" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail": { "order": 10020.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments Fair Value Disclosure", "terseLabel": "Short-term investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease Cost Table [Text Block]", "terseLabel": "Components of Lease Cost for Operating Leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases Of Lessee Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee Lease Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee Lease Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee Operating Lease Existence Of Option To Extend", "terseLabel": "Lessee, operating lease, existence of option to extend" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to terminate operating lease.", "label": "Lessee Operating Lease Existence Of Option To Terminate", "verboseLabel": "Lessee, operating lease, existence of option to terminate" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r402" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r402" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": { "order": 10080.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r402" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": { "order": 10030.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r402" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": { "order": 10070.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r402" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": { "order": 10060.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r402" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": { "order": 10050.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r402" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": { "order": 10040.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r402" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail2": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "terseLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee Operating Lease Option To Extend", "terseLabel": "Lessee, operating lease, option to extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Renewal Term", "terseLabel": "Renewal term of lease" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Term Of Contract", "terseLabel": "Term of lease" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter Of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r31", "r91", "r169", "r374", "r464", "r481" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r42", "r91", "r169", "r352", "r357", "r358", "r374" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r13", "r14", "r15", "r20", "r21", "r91", "r169", "r352", "r357", "r358", "r374" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line Of Credit Facility Maximum Borrowing Capacity", "terseLabel": "Letter of credit" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r468" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail": { "order": 10030.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities Policy", "terseLabel": "Available-for-Sale Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r77" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r77" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r77", "r79", "r82" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r56", "r58", "r64", "r82", "r91", "r99", "r103", "r104", "r105", "r106", "r108", "r109", "r111", "r136", "r144", "r146", "r149", "r151", "r169", "r374", "r469", "r485" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedDetails", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income Loss Available To Common Stockholders Diluted [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r68" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10040.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income Expense", "totalLabel": "Other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income Expense [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity Table [Text Block]", "terseLabel": "Schedule of Restricted Common Stock Activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number Of Operating Segments", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10090.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Operating expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedDetails", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r136", "r144", "r146", "r149", "r151" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10030.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "terseLabel": "Loss from operations", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedDetails", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r395", "r403" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail": { "order": 10010.0, "parentTag": "sybx_OperatingAndVariableLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities Payments Due [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r389" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail2": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r389" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": { "order": 10010.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Lease liability - operating lease", "verboseLabel": "Current lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r389" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail": { "order": 10020.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Lease liability - operating lease, net of current portion", "verboseLabel": "Long-term lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfMaturityOfLeaseLiabilitiesForOperatingLeasesDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r391", "r398" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Cash paid included in operating cash flows" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r388" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Right of use asset - operating lease" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r400", "r403" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Operating Lease, Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateForOperatingLeasesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r399", "r403" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Operating Lease, Weighted average remaining lease term (years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateForOperatingLeasesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r324" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "auth_ref": [ "r214", "r363", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "Information by type of options indexed to an issuer's equity.", "label": "Option Indexed To Issuers Equity Equity [Axis]", "terseLabel": "Option Indexed to Issuer's Equity" } } }, "localname": "OptionIndexedToIssuersEquityEquityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed To Issuers Equity Type [Domain]", "terseLabel": "Option Indexed to Issuer's Equity, Type" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r361" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r12", "r41" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 10040.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10040.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10230.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r50", "r52" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax", "terseLabel": "Net unrealized (loss) gain on marketable securities", "verboseLabel": "Unrealized gain (loss) on securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r69" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10070.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "terseLabel": "Other expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r4", "r7", "r194" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10030.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense Current", "terseLabel": "Other prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables And Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r70", "r72", "r158" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments To Acquire Available For Sale Securities Debt", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r73" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r262", "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansTables" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r32", "r33" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10260.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r7", "r193", "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense Current", "terseLabel": "Current pre-paid research and development" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseNoncurrent": { "auth_ref": [ "r38" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.", "label": "Prepaid Expense Noncurrent", "terseLabel": "Non-current pre-paid research and development" } } }, "localname": "PrepaidExpenseNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r5", "r7", "r192", "r194" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10010.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r74" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from sale of common stock, net of issuance costs", "verboseLabel": "Proceeds from issuance/sale of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r74" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds From Issuance Of Warrants", "terseLabel": "Proceeds from sale of pre-funded warrants, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r70", "r71", "r158" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities", "terseLabel": "Proceeds from redemption of marketable securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds From Sale And Maturity Of Marketable Securities", "terseLabel": "Proceeds from maturity of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r56", "r58", "r76", "r91", "r99", "r108", "r109", "r136", "r144", "r146", "r149", "r151", "r169", "r350", "r354", "r355", "r359", "r360", "r374", "r472" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r37", "r202" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r206", "r522", "r523", "r524" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r87", "r198" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property Plant And Equipment Estimated Useful Lives", "terseLabel": "Useful life" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r36", "r200" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentImpairment": { "auth_ref": [ "r87", "r204" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.", "label": "Property Plant And Equipment Impairment", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "PropertyPlantAndEquipmentImpairment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r18", "r202", "r482" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r35", "r87", "r202", "r522", "r523" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Policy [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r17", "r202" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Schedule of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r17", "r200" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "terseLabel": "Useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" ], "xbrltype": "durationItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Selected Quarterly Data (Unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r252", "r406", "r407" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r252", "r406", "r410", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r404", "r405", "r407", "r411", "r412" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r304", "r525" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10100.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r87", "r304" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research And Development Expense Policy", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research [Member]", "terseLabel": "Research and Development." } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r9", "r19", "r86", "r520" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Common Stock", "verboseLabel": "Restricted Stock Awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r27", "r225", "r298", "r480", "r496", "r501" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r95", "r96", "r97", "r100", "r107", "r109", "r176", "r295", "r296", "r297", "r331", "r332", "r492", "r494" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r88", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r241" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue From Contract With Customer Policy [Text Block]", "terseLabel": "Revenue recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePracticalExpedientIncrementalCostOfObtainingContract": { "auth_ref": [ "r195", "r239" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether practical expedient was elected to recognize incremental cost of obtaining contract as expense when incurred if amortization period would have been one year or less.", "label": "Revenue Practical Expedient Incremental Cost Of Obtaining Contract", "terseLabel": "Revenue, practical expedient, incremental cost of obtaining contract [true/false]" } } }, "localname": "RevenuePracticalExpedientIncrementalCostOfObtainingContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_RevenuePracticalExpedientRemainingPerformanceObligationDescription": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Description of consideration that is not included in transaction price and not allocated to remaining performance obligation. Includes, but is not limited to, variable consideration that is constrained.", "label": "Revenue Practical Expedient Remaining Performance Obligation Description", "terseLabel": "Revenue, practical expedient, remaining performance obligation, description" } } }, "localname": "RevenuePracticalExpedientRemainingPerformanceObligationDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r63", "r91", "r132", "r133", "r143", "r147", "r148", "r152", "r153", "r154", "r169", "r374", "r472" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10080.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue", "verboseLabel": "Recognition of revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedDetails", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Schedule of Potentially Common Shares Excluded from Calculation of Net Loss Per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Available For Sale Securities [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]", "terseLabel": "Summary of Available-for-Sale Securities Held" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]", "terseLabel": "Schedule of Temporary Differences Between Basis of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Reconciliation of Statutory Federal Income Tax Rate to Company's Effective Income Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r261", "r287", "r300" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r261", "r287", "r300" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Schedule of Equity-based Compensation Expenses" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]", "terseLabel": "Schedule of Company's Classified Assets Measured at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r37", "r202" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLifeOfPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Schedule Of Quarterly Financial Information Table [Text Block]", "terseLabel": "Selected Quarterly Data (unaudited)" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyDataUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r93", "r408", "r410" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r16", "r86", "r461", "r478" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Schedule Of Restricted Cash And Cash Equivalents [Text Block]", "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r262", "r290" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r266", "r276", "r279" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Schedule of Weighted Average Assumption Used Black-Scholes Option-pricing Model for Stock Options Issued to Employees and Non-employees" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r45", "r89", "r121", "r122", "r215", "r216", "r217", "r219", "r220", "r221", "r222", "r223", "r224", "r225" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r87", "r137", "r138", "r139", "r140", "r141", "r142", "r153" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting Policy Policy [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r80" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Equity-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Discount rate from fair value on offering date that participants pay for shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date", "terseLabel": "Percentage of discount for employees under ESPP" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Forfeited, Number of shares/units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited, Grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Granted", "verboseLabel": "Granted, Number of shares/units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Granted, Grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Ending balance, Number of unvested shares/units", "periodStartLabel": "Beginning balance, Number of unvested shares/units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance, Unvested Grant date fair value", "periodStartLabel": "Beginning balance, Unvested Grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "negatedLabel": "Vested, Number of shares/units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value", "terseLabel": "Total fair value of awards vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value", "terseLabel": "Vested, Grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Weighted-average, risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Number of options, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Weighted-average price, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value", "terseLabel": "Exercised, Aggregate Intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Cancelled/Forfeited, Number of options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "verboseLabel": "Granted, Number of options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value per share of options granted to employees" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "periodEndLabel": "Ending balance, Aggregate Intrinsic value", "periodStartLabel": "Beginning balance, Aggregate Intrinsic" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r268", "r290" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Outstanding Ending balance, Number of options", "periodStartLabel": "Outstanding Beginning balance, Number of options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Ending balance, Weighted-average price", "periodStartLabel": "Beginning balance, Weighted-average price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic value, Vested or expected to vest at December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number", "terseLabel": "Number of options, Vested or expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price", "terseLabel": "Weighted-average price Vested or expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r260", "r263" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Exercised, Weighted-average price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Cancelled/Forfeited, Weighted-average price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Granted, Weighted-average price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r87", "r262", "r264" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share Based Compensation Option And Incentive Plans Policy", "terseLabel": "Equity-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r282", "r299" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfWeightedAverageAssumptionUsedBlackScholesOptionPricingModelForStockOptionsIssuedToEmployeesAndNonEmployeesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1", "terseLabel": "Aggregate Intrinsic value, Exercisable at December 31, 2020" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Weighted average remaining contractual term, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Outstanding, weighted average remaining contractual term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1", "terseLabel": "Weighted average remaining contractual term, Vested or expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent", "terseLabel": "Purchase price as a percentage of fair value under ESPP" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r396", "r403" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail": { "order": 10020.0, "parentTag": "sybx_OperatingAndVariableLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short Term Lease Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State And Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r47", "r95", "r96", "r97", "r100", "r107", "r109", "r120", "r176", "r218", "r225", "r295", "r296", "r297", "r331", "r332", "r377", "r378", "r379", "r380", "r381", "r382", "r492", "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansTables", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r95", "r96", "r97", "r120", "r445" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfRestrictedCommonStockActivityDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansTables", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Stock Compensation Plan [Member]", "terseLabel": "Potential Shares Issuable Under ESPP" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyCommonSharesExcludedFromCalculationOfNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r24", "r25", "r218", "r225" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under employee stock purchase plan, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r24", "r25", "r218", "r225" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "positiveLabel": "Number of shares sold", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs, Shares", "verboseLabel": "Sale of common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r24", "r25", "r218", "r225" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period Shares Restricted Stock Award Forfeited", "negatedLabel": "Cancellation of restricted stock" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r218", "r225" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period Shares Restricted Stock Award Gross", "terseLabel": "Issuance of restricted stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r24", "r25", "r218", "r225", "r270" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Exercised, Number of options", "terseLabel": "Exercise of options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfStockOptionActivityUnder2015And2017PlanDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r24", "r25", "r218", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period Value Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r24", "r25", "r218", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r24", "r25", "r218", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period Value Restricted Stock Award Gross", "terseLabel": "Issuance of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r47", "r218", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r25", "r29", "r30", "r91", "r156", "r169", "r374" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r90", "r225", "r227" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Common Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r383", "r413" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r383", "r413" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r383", "r413" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCommonStockScheduleOfSharesOfCommonStockReservedForFutureIssuanceDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureEquityBasedCompensationAndEquityIncentivePlansScheduleOfEquityBasedCompensationExpensesByAwardTypeDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.", "label": "Summary Of Valuation Allowance [Text Block]", "terseLabel": "Schedule of Valuation Allowance" } } }, "localname": "SummaryOfValuationAllowanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TangibleAssetImpairmentCharges": { "auth_ref": [ "r0", "r203" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.", "label": "Tangible Asset Impairment Charges", "terseLabel": "Impairment charge" } } }, "localname": "TangibleAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r324" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward Amount", "terseLabel": "Tax credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Text Block [Abstract]" } } }, "localname": "TextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r164", "r165", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfCompanySClassifiedAssetsMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r99", "r100", "r101", "r102", "r173", "r174", "r175", "r176", "r178", "r179", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r329", "r330", "r331", "r332", "r446", "r447", "r448", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type Of Adoption [Member]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetail", "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r245", "r473" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "U S Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureAvailableForSaleInvestmentsSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r306", "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r123", "r124", "r126", "r127", "r128", "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r321" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance Deferred Tax Asset Change In Amount", "negatedLabel": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfValuationAllowanceDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r397", "r403" ], "calculation": { "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail": { "order": 10030.0, "parentTag": "sybx_OperatingAndVariableLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureLeasesComponentsOfLeaseCostForOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted-average common stock outstanding - basic and diluted", "verboseLabel": "Weighted-average common shares outstanding - basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail", "http://www.synlogictx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Shares Outstanding [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.synlogictx.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31010-122693" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL51790836-203054" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r206": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130569-203045" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r242": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r258": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65877542&loc=d3e27249-109313" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r341": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420" }, "r349": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r361": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90193-114008" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90198-114008" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519491&loc=d3e90476-114009" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117817908&loc=SL117819236-161440" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r386": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r412": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.1)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r526": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r527": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r528": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r529": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r530": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r531": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r532": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r533": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r534": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" } }, "version": "2.1" } ZIP 96 0001564590-21-015256-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-015256-xbrl.zip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`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�NY4-CA'V? M)SW)__B8Q0"'1XJ8^=;M=X"EC"]L?$V*\$'D,3B@/W>"9DO.W35>B1"U0NVZ M]V%21&70]+N>D9X.-;\"-JX+C? 20"0R:FR($0%DV.)B#@&BV$R8* 5+ZIVK M#EDD^[>BSAT"7%UV]_J<53%CB^^>]WQ<\/OY$;,0RWD=H^/-"= J8/@B9FN MFY\1XQ#P')&#]H7+@*?0)1SM M3)^@;*YT,PD,M:&=97J\1MHMDG\'@G(%W1X#I+!94>&Q>>#OJ=?0Y=U\R>7& M%5%-UKQ6CQ)"15YNMZ#JF)Z683 ":CX$J,# 0HBN B !&J_KFLGD>G.;G_YN M:V1=F.,QO0X,1K2(H&=_3%^BQU3V@E\C@;ZVQ<;XQ&_>I>-3MSL62,.1@;'7 M*FLE%83A#M;'_67@*P%N[4U 1]6C9V.1)"N%,>MN5#-1%IA(\^RE9'QPC(CKPHAL;5_:V')RG7O3S&',\EY>BUAO8 M-R!CJ9-&&-Y]'R8F8D+JMP.&I%]RYKM@>BSM?C'!P+**[!Q9],327B9-)Z?< M)S7R: F%_EO#'/UY"31;B"39(T^M")])FI5=S!8C1YQ_;WMK MRKV8M0"U&+N7@SL:TGIN7&;_ M.N5*'6"1K9.24MX$0SC/;6#SA37$J^!Q6&V1B)/1XT$G5*CC$#>[M4F$+S M@*D;-?]3V=T_Y\W/,)ADJ +3,3,N26 DDWK#H#8L9^O,DV3,,OVBMTZ4."?OG&/*U>-W3HQ3H"(H7JU7'I M]9WH"T0.-P;$$(>HG#1E>@W\G/$LE.^F4&+ETV*%$)J^H-[WH:7MG6>I "WG MV*X60 2R%$@L)+W;7:&(.Y(C\/J,[JL_5G%";3$5R^H!^]\^<6;5:>"QK _G MN1ZC.B4%#=C.S(G-76D,^@Y?B%T*:*CF,U;J+=#HD;NC%,$HR>A3WL]GTB@2 M-\%_K8]\TXQ)])W;!ET.OJ=+\,1^67\LMI8A\8?\@_^4;BCK&0T"(56@UL7!RJ/50_2K',Z^_'H]2;4KC3$_-0497+"'%!"9 M:U:]W=X8#^T GN[+6;4Q:0E?F7;"AY*Z0K.R."U"604.?J*%3MGKO(R;@N<= M FXUR)!OLA".0WK-!CK,C3.$#GP,ZSQ]!Y;'%I]EAF]SC?YS(;0M%R[=4,<%H).Z#U@N[H;2, M'NG5D:I!J/(6)-*TBX#6UQ5A#")(-]"1S 5@]NZ.5&DW!@>9-R1Q,"!0UGUP MB%5.XM6>=N43PR6_;W,:X/8QC!,0TCL\&H.C*!#@(0=L. MLI/>[IG4/N6X8FR4KG=%#Y\ 9GU9E!5.G\R]4C.!MI) M^6VQE%BP9N^J8\[KXCL)6AXHE6&SSV:-62[7JBHA95NZOEFKT&(H"3)#$F03 MOMW;=*0\:/9M"IH(56^S-:"\\2P4NTJ)^1G_2U^+IC8V4>]YD"BU]PKHX.HR M]V6@=5[P](0-N":@R3?M>AUG1ZZ&5JHZ[4$]\ "^Q]E[?' M?(^EW4 &S$EK"HX@P@X!E?VT,WOV%'_4,S0GZ!&*WZ5N9S'&ES,BS\YJXGE5 MW;/D1[$?AZT^0*0Q)R6LATP]1NN'\@>^!*2#.=HK-Y_K'FUTN?_" M[#./'43[0>(FV+DDG9_$:<)R8?%=],@RJ RR-D XU;G?H629%J;Q(=4(M*M MQ[.'5=U>A_'ENA#SM5O(X\Y9[_@!8.9<*>5Y]3%MATN;K<@"&]M7#A3&RJ8=HJ<^0%L05(DN#XR+C'Z$]6:),A\(;XR_\6'KH0?GQ?8 MA]*^#H^DND@&V5>DN':/[]V^DAF^HMO\7],6Z)O,:")Y".A1A@L> M!%B.7% MW:8"U%OFSXE&5&ZL$?' ,10>V1QS%G:3"@K_/JRP1A@\!)1YS"A/KNQ)\&Q9 MB@)_BL>DCUVL%64#NL),*;FSH'?"''5_F]S;,_H&UJ95:QNHLN7/Y?%\\V'6 MT=:O9P6=,V1FR<@-\QU$,L.:O$%+XD?2$86'@)RN/_$Y6@W\H-GOT%)V0=KS M0T"OI]DA8-YU%7Z:,08JSR4>(43$'&>BD#!Z<;ZME>K:Z,RX>B+U(>260MVS M6'#?Y5,L&:\>"OH@)5XY\3;3W.AY\&.,7T/+NS/\VE[T&(FBLJH,]'@21/A9 M9!YBYZSNY#_03K]JZR&@C1F#'BLN",8G=BRW2;%&[-:=J+=E8 MCRIW'7^M\A]/\-_37/[3AJ38/V>[Y!P-!3\$4:1010KTP TIR+EA]0<&TO=A^$&(M8):_2BU<]07M-!\( MT/7%WO7!'S)FXIC_X%\NY]W$PAC&]OP.\"1\CY%\5UF8@[?<\/_TH?_ZD9KR MYTA\5+^^1&-1TMX *H01H):4%KQ D0BH1:\[W^2FE1FAI9X= BX",Q,69RIY MD)5O:;HA7&,KV.9B0M@.:S1ACL"*=7-VVGE'1-M]@[@^*1I1C%J/=*)F=]+3&L>=)6SGFLSL.^*.FT*:UPRWM3PH6+K[9B M*K[/^:%&/#=UKS(=YML QA2"W]D-A5MEG/0A_%E;/ 3$Q'#21(?POQ]C]G0' M>;H@I?M*AC#L@@*-!S+'1D]\69\]A M6 M>W;N=O)\Q>W(OI KZX'.!OV:J!FB/_X8,GS#0YP,C::9^+IY77+\/K'*Y>0I M$/ON O5*V+A.^F3:)R-!R *4)L1"E2W^'DI:VLTC5<5638#-\2:NMX?C>9YH M[P;%V-?R<<3_+HLNDB$&0)6C[ 9,2S+GQ ;M\L7V3*SE7L%S.[TD;*4#GQ>: MNM^14]M/=7\^5/_J>7\_@B+)1E1 4#49TS-<<"U*1+L_AT>36/1$.P0+D>U8 M6R\_UM;5OO#:B"-M:7TICY>N?U1,4("A&XA:KF:MNYG]( MG;'8!ZT.;_[MA239 @J!'FEBIR 9)Q5)0_CJ4 3>+0!B]=N7'6:*.N$N;S?+9$!'L;U"I9"*VJBC=PKU>KD;:M\R]XM?;.S#1+%3KF-05/C.D.3]"#S MV#N!FB606>P[;9=9A2-6%&<"6SLO62W_*,']CI" D.ZQ"P#]8PV:9V]]?621 M/"%D7UB 2HLSC3>:Z4?/Y&^;>IB:% 8BVI[!MLB2G2EL:\'4NY,T>_)&^/-M M1"B"6]:Q&EMY^L8C'BWH1UG"Y1/C,4<\BOFZF5A#*$W$>Q;2M"S0&(+.L5E- M>YQB6VWCKP3WG>_<_F9@M>*UZ[II M"1YZPK"'WNQ/>#;KJAM\>1V+LMB:4E F:LDD4?3)_LU( 1J7XQP*$%!N-%*T M3AS !?.9&=>8AL_GQ08\U&Q[Z%SLR[O8HY0KR2^C\NK,9U?]._++'WA,S>[_ M*[H!Z6:"YP>(:(82:>;]2]!X(=XBI:21?'*UNW%DO2+XWF;OG3(#KHB$H+U M[X,>V&!=HWTX6VK*\.<7M%)TPZ"[S#@4FFKCX<3H I;FA$8P]9"C/Q3*QV"' MR;BSS*X7>^;A5J9/#'F,I]HE"-@&*ZY[ M28VC]7?ZKW;T\MKLU=G(,3P=-LSOHMD$Q3GM4T<8$?/1" *D=8,%YD#JIUV& MGE$!5UL7M_N?(=;$\8LD5)9*$=! N.( MEENJ,6QM!8;:-N!WL.!OJ/!OHP*J]J3FDQ$#C%(6Y7M=]5AQO;[@*G!O+#09 M6C']&5TM2>.[AF*FF(UATZ,V6XKJ=I9*US[D^**W%<,/EG[=5EO: M5T5_-\N#\=PG ME=>X*"(6J!@:D'H9UU(88-@>9[LJK(BF6J;ZXB\&R[W4!+Y<_&.LLBS75Y3W MR&)(S#60J:*A9@2#!\1U/.2V>[.7+^8-5X]*'MHX5? MCHW5,&UWKR6MPLZQ8R^N2^I"2,K&]%2X) P\2).A\E9C+@9#;4;<.TM)<+<( MMU3HV66"OEL]N+I-]F3>PW,(3/NIK\%+* 42&*,PKMSI(.1YZN_YJ?WF2F1Q M-8&M;>.,D5M>1:Y8GX^;W].JNL<8N?(NL9;XXEKG)/,Q!%ET&)48.+O?'/EGYE+5RJEU*;B7'3\RSQZ[^51C>=R M.Q%C&,*O*AR*"'8A\\UB/FJWG\60S?'$1D9BF3Q@7'6D*)FB;#?T+:.O,SMNZB][/%S!>O/3U4I>?7! M;,Z^H0U]20DU$%-!P36*Q-Y79L MQ"#*%=80SZ>]R)+M"D3[.WUPS^T &XWJJVOU3Y!(?<\[=''43^C)>R W!8K" M1F3397O%V@$X*T7NI;T82DIH.WR@1J>\;F5OYDI3FGLLRMGANS@3%M=4;[GV MDI^U:<&V'X5"-S=-H6+KAP#68)K6W]Z7ZOX^.!N9_Y[;\\]RRD5D<^%Z3W.( M)3_K*]._@S\TN2C.X/$]QD?P.P0IBL2#5^]\O6D[F42)J0!FFWT-:"\;5=.P,285V:K%EOF0%&8S:-1W&K=P9FJV/GQ,Y]R+I_)Z[ *\W)\&NA@QS%G;2* MV6#-N$;BC"A6S7ODBJN*/]W]7DW]V!8/\==Q+RS+8&7!'< < I_&?/KH@TO" M__=:HWL?8-RS&T==-K(IHJVO/&+$;)T&*R@0>@=K0$+$N? M![**6;CTSV=L;]((_VJ'^G\0 +GC%8@);V1I#O127547$*ONJ6=R@7DKYX[7 MU<4OO -7L08F*:N3.E\OC43SZCT^TD,Y0;I(0!(5R+:W*I M;=NY]%)YN$NV1Y@ 5W(:"8#Z4\XXT?(W&8UBSWS=HR@"WS5H"FHEA5=:S25U M3%]1PS]!?WGR<:BNA?\I>_*ZU69GDW.8QMMH<.A"5+H13*8Z=5,W/G13H+;J M\N9@FG\P+2GY-[P5^F.I%30F,QN,; 6'J#4%3WZ3)$N@M1_:N6)37PPV:8G, M7_8^&]"MZ4B4G0@R2]M%B=++0<\]/QP"2IU;+Z+"@6=*X ,O]B-N_,9_XHBZ MMR1H\'K;= 29B6-PG#$*2<]H/5I8SR.J5< M)R9H$W\:,E\V0)?-\6A&^C+:,:=,5L'U=-MT7TS36;65>J*L# MF'\#?8L6@*O #.C?="56$.<9,I00$V.;D:*,"UEVM-B\?0M# %RB M$N0"QAD30HGV9,?[E!:RLXU;\0URE3R7?ZZWR^1['_J/@S2 MKI./O3%HJDNZOQ6'[4D\\O8=\W9*MG_B!SEF]<-O MA4M2M5=0W)DH&'?/^,D$MI:4K! *,^].QW9*/\B-_CYWP<#G\P-<^OQD8EBM M0_ADGD,%S45PF-6&RVI!3_A<]1[Y&]9ZR M+:,5_4Q3I";L)U"E$*TN7H> 8T&DC'PR7W.2\(712G X,T8)A+SQO2B;R.6C M#%XX1@HUW?U!FBN"#IHS1 ME-#PRYZ"A@6&>?)Y*I2W'!\'3&U[.,I?9T4^SN!C,XN2/!Y75SGT"GTMMJ5) M@'Q<__/<58L7VU)UPT*J&@_R):5LNKM-O+,GW#>+M62 ^<*:]&I9T%,414JMV_]X<>^\!N;0ZT.Q5H93FV!$B:#8362X9 M@GCB2;GUS[T]>TM!2: M)_VKKB[-E/Z=(>4*Y&<:*N(OO*?3[G.G>LH M&].4E/BVL!6YW"/GXK;K5Y6WY4I13C?MF!]+$[(R'-.^UMZYN9"6YXWS&K*V M379-&*D:IIHS3A<.5Y[F:T-7G"_-<3F=9V_C\NK4Z"A'VF1=25XO'X!..+JM MX[I$U*>^A$\? @31SAL78!*CAX#9!('JT+4=(B=A=-4FFB/134QFR_C=\ZP% M?NU8*(#1 ZV&$A6HO$UUAX!R3-37@9BP8WFCVD2UBS'J75NPAL#P":\ET%UG M[6W>%8?+3"V?0+3H:YM_FP[PMZ5T.(I__^8FWCCLAJ]7G;J8;\!_]LD3[JY< M\V-F5OD/ROPK*UT*1>NU2?T?%75%'I?W:+SB_6;V,H?-+,>J1_C7V7L])_LM M?/UV'9R[9^>?/!@5",G*@;85+*MOV4S9=HE5UU5_RH[5T#Q5Q"[R;M+G_J#: M!AYEQWCG9?X]2PR>1+G@?@AX]T+[NN(A0-EGZQ#@I5&X9:C]N-$ L]M-__JR M?SQN;O=Z&1DF,WNML,W7*YL9:=OM'_QM4(ROCM[Q_, 0JL.>7WV0K%H8=9ZM_IQAD?W'R;OF\(63]?>\ZPT4 MWT = N);FRZ0$Z,D0V&/\+U"MN#DSWV.^=;9I"Z+=U)79O-; -$:HJI;"K2S M((9I*FF)3G<\!(#5*W^^.K'FT#@>@-BU;8N,B$ >6$7226Y>78_U/EP MH:'NWU/, />MISC4 "SQOX_86_ <:4>T*?\]@MGV9+ S[^A>_U\\!LU9?N41 M^GWB#TX-^;:\# ,47QS;QK59E7/D1Q_.SM(W[PCK_[7G6\)M22]G6 M*\>"1^^MRRAT9IS[30O&GX8T,R3*;-/5;8:<2X?ELA><0JQ^>F2_XGT,$EAI M)CAP\9_L7:N@0RRV; 1KUK2]K#0'@LVANC'S_8+T*%W=/^A*OK7J66B,%N_* MSR91TD+#7BIB(0%7TOLEINY>V:5#@%^C&EJ#J0PAT]*C(&>N,! _:#8)RKV> M(N2&[X^05P6=NJEKB-O.3]>+TV8^P"G6MF%[YU+5 \W^5W_Z7I2VSN5<@%W+ MG=(QIR9'0SXFRK#P@\)+!:@#_3!]2BFI'R\CV7QK*AK=C&)I((+G M>>O3PIJ>(H]4\\-'Y]3OGOH8[A2G<;_PO%TT^F[ =H!;&^[)S#E?\-'>8N@S M2W.CIRD>GZIMWI@=>5;[A7:#V]HB(\W?#S]WN5%?8RY$YI2DK&C_IDUVW MH*Y!,<%VAND85--?[QY=KEFIG6WN-DTIOBAY/GUB0+6@S*::XG_JN9.-?&3) M<$)18K&.T,2 0CO#E<'+Z(56\'7&G)\.D,1C6]-M#O:,ZP)4DR7>VTZX/(^J M9&"]I*R*WV:<2!AF@>;,D&X@(Z'LZ,<*..!]>CS,A6K\K$EBI$G,Y-3],Z"#<*YCW>ESGD7"XHV2HMD?$Y?SV0NR9A6./$.<$R%+ M1!"@1ZQ6+.O>KAPU8;M?&7+=9!+48,HA31M\FW6R]O$+Q3YXO:DY03NG6N6; M>*:Q;0EQ]]6?)N=YD@^>-B!^?(FOT--8MSO0WWFG4\]#'_[B;W4;P@D5,5/& M1Y1B_G''KM,C*TZK\:O8RZ][?K31'G)5QV;(U=36Z*MUBFTIGO]Y]5'IIY"3B$:H2Q1:#X-G6V$8(()[JWPG4<38MCZJ M;%^>Y>NGHT=0AF3,6Y@"^6*K3=)KFFE6F[?R#7B]4!J\8M&S9]MKR"5/7#=EF$OE'07 M/>%I1?_6(.KL3@XE=$80P,(!K4"*D2/I$/!>]J9M .1VW"@+;W'OK'Z1"%.5P[18K##A$6>T%'= M\_!V!]"@MN+L#-?*":>Y#1QWNRW?G:'Q5.=QE6_RYP_(_>S-GUF_77R7!?$# M2:7?A>CP/C.2@F:"L_X@;R6LOUC8SY;"!\K037NQ7_P7V@ MC\8Z%DST^3[N4I#+3+:YS7$JSY=-)K;KEY),!\(-/)X*(4^79C,&@,LU^<<&W2]K8U](RF(S ->KKV$>!; MN)"AK];D76Q*566!?64? Q4HJ60_=6\_T,FG^_&+XX CUUD:4.=5FPH_-DJ^ MK!CQJ)OR_9%@P:L2\&,E=M4NV#/*:8(! M^0V%3#H>) ,4,.0YNX)SR/Y9YQGN_BBXV]./1ZT[7FY^ZH/SAU16K?,W"< ? M)85BZ I@6--9FAQIMYRTT?I*SD("* MWI>WSS25Z"([5$FNU(8(C>0*6^O+5&WL+0>O)<1(#E>(C?P*P5+F([A_):+DUO, MR9V8DAW"V>P77IR\_=%8UFL)%DH1-?16*SSK,^=,%"+-S:Z_R>W-@TZZIF ^ M9MLB3E#\VU:2M*++E6,^V^JG\0)"7+Y\S((FCT-2_D2?KZ\D[$SH=U!U89S8)G&;RC1<97&69.C+U)S87\5Y/SH:/WMU)(O%05JEOTI* M:C2K]C)^(D\R9-V$KS30\T$NO>RR,*^2Y5ZGG(![OTAV. KHCKB8VMF?/(%; MW9?#)-..ST>0175A;./$Q1IHV911[-9$G+7%0-=]"XR<@'>QO-4AH"T0+5J08S40 MRJ25H9L[:S JT[A#F,#U[4VJ/.Q2'<4E5Y^I;@?(,,\*JHDZ9OIT:66-L3[5 M[IS#]>C!18[R9^)GBS[6*LE(73(2#F)24S[Z.UU1V.E!FBG5$N9/TFEW$*-$ M=@;SF9'/9V^ZJ>&"[D#=?YI<&)>=+RJA]JKQ\#KX;"F\:^"B6B-:[!"N,:=@ MWEB$[>P623V?9*,6*G[6 ML.R.LFX2K-Y(NKY)?)YRD-:9[9U6IB'@MY11[K)2["8G-(IU02HG#26Z?]%V M-]Z\>5NB.&A]MWS& *3ZMQ$&FPI\O)PR0UA\1^4+N DQSZ$8J(PT//C4!"/> M><8$R=P([)4+53H>F@L&($N01S_N$- \\V-OK9\ BIE6]8VMH/IPAGT/.;)S M^L9U2W:^L6I9Q ?>5+8+J 4,0:&=BX=F17E73+M+[LP77R\GG#8+-GQ0%QNF MU*\28NB!P#EN"T*RFO>-VQ]GJ&7N/C)VE)429K%X$Y_B*Y*TL^F$1#^H8M< M[H1;]5#54MPHTZEG_02,G_M.EAA[C;O]'.[/#%Y'08]N4B$,K"GM 1D=,E=/ M K>9G\_*HY==_3VU(FM47H4+0"0+6 J^OGRDZ6!IMYP0L\9'LL5XKVHEA23. MM:D+BTP?3"5$7IUW&P MKV(WF'O_6GD?7K:<_UXJY@;N3[QM23'<>-$59DZ/0#NAHAEB0PR)@%P\/)V) MJ\0_QTZZ-%W]_33H]+W+#?FVO99&_,%''M?HR(Q:^$5"WL';D&7^88< I_2+ M5@.^4][]7;5U$XXY%/\'38PNJS==&1U^O7I79 M@MU%!W9]7^ M#VZH=/YC945-6S^I%#2Q,S;' ,$'%IM-,2^"BR9*U$>4Q86C7C; X54QXDU) ZX9M4YUO MFTY95R_0CKZBL_^-G:'3H11Y-EH.D)!+ARV# M#IS+4'\*_L7%_R$=T_2?TC'_M[)L>PC@:+H0L#5GV"XDB?=O4SAMYWJP6QU0 MA?- N@DOQAF ,J-S8DX>D018 $\$&'<(ZY -D+-HUC_^6M^+"^S%J])SQSL= M;,/2\*;75XQ4Z4?^CC0$S7YNNDA_RP"BVH%AYZOJ0COD7@UYE,*BR_1S;HR! M'*L]TAYZ?@K>%81]=6[N+U_3-?Y0/^J)CT&HS\?XB'9[\7?*)+@<(QM7QVTY M_YW"4<[4@\<4%L:)+5*V<;YX23&9VZ[:G( \:Y#]@7]23FZKIS4TOUGIZN04 MC\)(F\XRKQ_V$GEU#MT&'J_&^^63_0F8CXY#+X/ESVTJ"W9K(UM.&8_,^[46 M1"^E 6[3;O*&MS^]D&N6Y?T9N9WT!SZ3X*245-;R\.N$NUAFR81'KWZA>S*B MDHMXC52_>X=BF >#4@H+]M7\"LM^_9+EWUAGWQ<)"RH7IO,X10,DT"R' +<- MW!(!24PBO]T@5+<7-I=&_?Y3=U<6EJXUY&?)(]3OYU$T+OGC(JC:F=A&EMF= MH]0J1,-LQ1*UA"*Z^4)@UP0[,G]4RPWONGPY)D_A%SGRX21;&,LJU"1Q@=R* MR4!PT[31/YEAB@8DI7*U:!R+P>@;\ZL63IF#UW)G]E.V]?1Y('GP^?^F@?]+ M@>\C6K@/ 0O\:$[$S"AH>RL(:@'I09-N'0+V#3S;D'L[,73M:>R(!2F@?R__ M +F %$9T>R4? K 'Z .[4,D[OJK_X.I7__]H&/./IC&U3#WI?"8L2@]!>(#? M(TB60);E*+70W3R:'/G&],Q"H!STLB:G[O[59)[S> =V0_(I>&A D,,@S/3K M."7I!CIZ!7._,GJQ+]_U/5+\7<*!IC3-X6?"0;/(&6%4 M"O CE&7'^F5E98.8B5>.;%<OK"J(2PU:-!M7?#W!O&#!ZE+WVPER_A7IZ& MF_X.B=I:"!(RY0[7;''!9IP-*F68NE*#C )5\+6B7VO)-:'(?.T.%AW;3?=B M,LS"OH. =KN[H]/R[5M#?#,>H\!4HAU)+=.A ?7ZUV$ ./DBN)$@+'= M:*6.[OG$F5LD]$=N@P;L?99TQ0WRHNW$G8Z[J?Q&[%J;N=VMG9'DLU&0)]-5 MU:O?5@CB-CQ.TJZ;QL8SV\,4S.XV91=-NJ_#;4G_S(VG+W0B';T\$7G/&/QN M%WN)OB3R7.GYP@*^=MS)49@0.N]'ST([(]\CN/ 49'% &$S= M$^52)I&.GSD>$(>U)"?6>D1W70Z^<<6QDM3QCJ'1Q5C?B-#D21P MGQH63_Q'=X6OPM(D9 B-"Q_ F'(C^;?*UWF^?^D+_F*4?[?#UO+SD427_J3T M-K?CCV?$X#@D.\(9/,&Q&TN*(:I2=1A=N]73)]P0%$.B9X,>H1!T_-FT\DC[ M5VMZBJ:%<\,'@VV?.:JK; MWH7CBPJ"B(B @!"EJC11BA2)%41$E%Z$B @($5!J@) H5;J"@( 0Z9U([T2D M1)ITD%!"0I.>4$(@A1O>4^ZYYYS?=\[XQOWK_I$Q0AAK[;GF\\RV]UYK3J9X M;59K#U%>=G%%)*[/CJJ7Z10[^Z^4#%CL;5L=[Z5(:--.BY$S(PA;\,O,0DZL MF6DN]LY2_JAW8G51,A[+1U]OZ IOC=4,>?+YORT;T'CSN6#V,KW00$"%Y?/. M-BJ66<]2))T30DM>H(5 $"H=V-9T>57OSW43:CU0YSW^-?2)=)2/BK>G M_VC'B\3GL!XJ%-YJ@A2!21.X!"E"W_9*A%+G* M"\7A9;+?PL:ZWUJ8*FB]"2:@Y2M=@YD>:N4Q51NFPC0L!$V%@B;BS(;.)STG M@L)RS<1*B?3NQR:_H>*8J!6BB?I6 M0/($/76UX2H>?=I1DW-$0YWPKN$V,$Q.UDRB#F"R9K(1,N]^PLQ-1>,>QX7= M4"V=SYV1(R*-GT42G95XK]7(K"S_=8ISYWZ5[*O6K6UFO@NO7R-=MR4\H MMNDPVS46; MCZ6,%&Y@&,>4F$FV*T7B"V4#2)'"A56PN J7H/T=IW'O0,^K!V4K_.6[U+Q)$_4KSS8.9$X:9L"+Z>TV"C\[JM M:?6]IXU\)?T]KUE81>^Q9.;%!:L+G3T^>L(Q<>9R3=+]#*]!2W-%EDWG(<[-#PH?GM@Q[%XVV^\<,E7Z_5(P\(,>J6#N#[3M5BW5K2S)Q6V)="P MSDD9;"F/<#;4A>,EL+=;<9C#X:1["HU"+'R*\M')H&B&Z"^*-+X] =N()"OZ MEM26R#09J7DVD!(J'ER>%!_TQXL<_3%4?])"*:X)I;+SRS&G C'":$SZ#5_F MYDLKW!L?K-.TT8]&5^2NQ!$F;1_1R[.1;6"N-4&L/!=ELUF$US[F_EW.>^6!:YHX:P_J:>^A*R/RQ.75^8YDBQ)7::#V*FKI0/)(SJ.-]?TJU5SE+^_@(_ MA:EZ'L^M;2(%.,7IZFA]KF\[3G11;;AX\-:U9F/> M+K%[X\O[8(6 @M;11)H6/84A2#M-U,.U-JI/Y96E60?D/E0N]5BO3JBN+L$[C4]C/<=T* M1@O2@V6F4\NZUCOE^@,+BY('9V@"\:RK-XF9S6HEA>[%S"3+L/AYD).(:%UY M*2FXLOO4/B!W8ES/KNGZS=M?RN_4OCVO_[XH?-R(ECF(MI.G7 *NH$D\TU;( MF*;+C*&T0P.>*9.V)C^3\BGA YU+',9#]*J/UE>)<@"QS,DV5&2 7*]?V MO:I0T#?],7>"0T2%94_GX+=%G4$LCB-TGQ12C52D6R5)&;[NL M'2OO9*$LJKY,>8]\RE)/A_QPW>]E2=<^H *Q.C?\FFJF8[A,OX]7W-J+R& +*2$=$Y8Y?:S83"*-5YHP M^AU]&F8[L.J!"X$?Z5M][K?*KS,J%C)C-& W($)2DI9U@X;8F5X$QKYOO_/) M8&9!>BGM.CV1F>*AL3$$^W02NRL'Q74Z!:R3!:3HS)!.[^T#WCUR+.]20GUP M23..2M>$_9ZM&(^U-SF1%4Y&'8>W 8_SM$;,]$;ZCI23Y%NY"W95IJ[564;H MWE(3LM)4TI4VQ."B3S**(,.9IO+?VN43KB1:+I%-*Y&R*4W5M7,FN3&8SL<- MF2()_:[9Z^O.SHK:G;BO,0'%&MK$#&8:8(L,\-H A2FF2C-XY)GEVDD-%8F< M"'KZB31G.=>7'HNW)L"]EW0N_1C/"->RE[UZ:IK^F"H);P6S@9XCN+0=\!>5 MKKM;\#W&ZA-B3N&N3RY6Z]>!E(MI451=RM5O=?*K#E1I2K6AOS?>JA4;73IM7!>WHGEIP!Q05Y4L M<I07&%RR5M>:(A@WV0V$LNI3ASM?6.A0]70F(XNZ-('/BT=*Y$ ME$161(S:-VG>VE@5 ;9:'KFY(^*_V+,3GDG;##M9;S0B=\!WJ. ;^4DVOPG" M@DW+E:/)2Z-^3O[@F=3;;8+@8/E*X%&H"S.RX4/]2Q)?^Y$]Z\Y%8N;CGP:5 MW!"WO?;SZ#V:+Z7:SY-J!I^<$J0':K"00(R3"-:E,J?W2VE")(>06<'<(*[X M!=TLS((]5FLS8[/([NWXCU/ BZW/Q;S!/.CI8E %;A5,['I$3P(]!W)2HJEM ML= 6!O>J+:$WF";KJSBN)^>8N()%)IU23.#Y^%V7![-A?RN2[0QUE*Q #X?Q M4J5@A_H87$N&9I1"P\%Y%0MDV+I'F=20*T>(BNR"[E76PW*7*4*F+YX\:_RL M8??^MP7ONT1NM'M6#VS&]@2UH.@?( M7MEC:<"6+^Z]ZM75^CLCOX:1ZW\NX"QGWA M;"&_E0WB+YB]7TQ%BO/R10NRKM?J>/K2,^FG&P]X";&Z]]K)]7X2\(5O0*(E M%^7BV7T LX#BFSI%\2]ZHM*".#RA \'_*C-6$DKC@Y"MJ>&K,1KOVK4&5J1G M8HY#(=8DY+NM?0 K5/=>S9"2G@%974^S?>#*QA,]L(O3J^EHAO(+ _$!Z38B3K>A>KQ2\WF' M29]$A#L,<^TSBH4\7??J05*9P1B'W1;#.N)-NQ]I&T4>.N4;U&NBM*4$>/KT,?@=X35O*33, M)&]M=AQQE?Q24R2-+^A%LX6"COQ[0XK?;NEU?>TE ABP\!_WPWYHC6 MP6V](X=&JG',K*2S.D23/TDUU$O@ 2EP'_!@RA%Z5@F;]L7T=^[#@ 8D68(> M7X'[A28[$M$KNQ!GML;^E>KEQ,OM_*L604B-C3B:N9NQSL*SO-\ E%G)YW'> MXUJR!8C#IR+]^1)WUV@_8;F<,LK<:LBSXW';ON-S9>P7,AK*!_Y_WX5)0U!D M8P(U; J8]-6'7P0OPD\/E3R-G;F_,5]=^J&_-,N<)> HU[G1+85[737;*/?S M/[-CG\U9W4XF.8U6K:JO4$7D?)@I[TN\[=W>A-YD,EK7TG."\0B$MZ90&4'. M!P=P,.M7DB+B>R-IA\Z&Q3 XF)9"@.RA?S5]? F^O[=.>><)^BV,F 83N>+W M 8_R]P&].SN(9M!'+HIID^8^(%W(C"G;2S1-#TA$P?SW ;>4#W9X#0+C)@QV>!V) :5O$/P=T, > \%:4?0 CZ* / MTQ$WIEQ*]*?M$8L/F;(@6N\P+WUC>1_PQS[@#7#I-&B!N@_XAIA&=BS0I-' M?4!?6!%BN@3,D(RAF,)!3,%X#@1[PA0,8>;'/Q 5L:A-NW,?N74"392G'&)\ M:6$@T#16QC%:&N)[/6D?0&=+QC#8YYBK?[$/"/:>V0?L<2O%T'B9(;UU=#NT MU/_"OQ&#$[3+V <0F3G[AL\^@'V=F;%MB4* %&EF. [+9/#B8O8!O^^,@(BF M\OL 'O"(2-M6YK.]Q_L [E.Y=!84C8,!0.0Q2S3D^C[@T$%!(X4DEAQT![HE M>:"4VC^58OVG4OX$*_9/I=BL@._[BJ[^3POZO _X+U84\X\KTN1G'-D' $!# M9Q"].\R5'>1.2J/U=DO3;?Y?DOU%M_+]7 M+2]3M8QUIF(A_XUB3?Z=8CWV 0M4*IK)$=1_Y(BYY;]R)-WP )FU UPDT?^* MR[^0U8YI,##=\TF5")$P!)DKX.IFF!6)R3EG3%HX?M? MYPQES@EBSDD$TKB1C&.\N7",R)G F75,E(@0*ERP,9]ZO:@S5BI4=H)K\ORL M?WHHUSF-/QY#)\#K:R]86$Z;?I\7"!&[TG:_T<$'5"L7YG6/&GF"E2O1QE8K MO SLYX_+CR)Q8:;X*5;3J?H$_B@EI?*!K0B5VH::2V9!C_N-W+H?_I'787_N M>*PTL8O!+DNUIWG0:QD7E/J(\,8&Y0HGKHU<42S%+:6=)/JV_01=N"IR:B5?T?<^T. M[Y3-^3:B^ABVH6]HKQ#S#X9!1*L#G>GN ]BDHM"_]8;1?_D!/!B:"*1M@CMC MY$"[\^AX7\1X&4._E5[.D$SD80+6M@\(!.\#SB$4F(8: !UG!$U:,A$;^(O; M.S;CNL?CZ4KCUSW@XM;O#YAJN@7#R.@3FG)3PYDYN0NS[ E8_),-ATG5]&-UU0R.[#\=J,<&D^9ID-W'?ULO MU0O<00FEZ2E+,X(C]@%'T8P;#.:$^#](S0+@HTXXBMQ?J'T2Q$PB^A(+$=-5 M3**B/Y:1M@ZGS,ZAA"B@ D*?Y"[?')TP3W ;LLNZ',FI + M ]J26,)19/_]/#&7Y'=GT3L](D;@S0[F?(CQ6*::0 3'4O"6#)BBM _88-WD M8FH7&(WXKF/<(H(%]U=T,') MX3EMB+Y2Q/3H/N 'L!OTSR.!Q+>4!490H^5?@XX27\UO=C(8"J+ M"0&LGUXK/TN[S9!,X?U'[)@N\I]&,[%CG4'NG=IVI?']Z4>V2'-WF9I.9.SF M_UTR=+4=#?D.T3KX#/W;#$UD>I)9KGFN?U)-#.4&S9UY,>OBO\4MY-\G^+N M_Q,10/\\&(1G(?72C_E6_RV2PO[WVOXFX+_EPE,F%_Z/H2_^&5/4XF9G!,-' MGKZI_?_%A<#_S(7>OW)!530"M/0_"H3X3_(LL?PW\B#^HSQY7/_$3="_P>V@ MD#K3X7 MYX@@ZL6$>JFE1HYLMF,Q2<=)'SU_EOIJW9Q]=1.5?S'=B_CFT.)#%'LEV-G" ML+)DG-H[1Z,J^HQXAW6?]?&OU.E-V)F;CXM'V?E9CY:A;?[Z;*1[X_N_V7_ M^I?G*GG_^#3EC_O_^-8?,_Z#F(LNZ:(M"?[O[[]9B@:-.@O)C80OC=PPZ'\:&WU$]J._VV]":.SH-I M/#,8:T4FD.8,;#*&=@I)#AAVD22ZABNQ#C&.49*7]"<[RT%\#=4=\V=+^@<\ M; (D.,$YM3]VG6/UU>E^+LDQHH9^IY3 M"]]P1 LM8NYW+E8S^ CP%$V5P!66;!V79^D(%Z9X>WN($G/B\JH_X;#)!:TJ M$X!OHD4I<3Y1E^L[4#\O:O+37M/+E>8HQ=2G$,:%$&4$JW(X@/T:&^ M.]_&HU[]HFBWF0"Q^X 3<%FHI'J'DBO0Q42A#9&/@87G?>@XI?$@.D0^3<+D M0LM*F6#_7I'C;?/KV7/9 U:"?ML02^3YM/[$D52=1=ZZS=_C2\G]'GIF5 3C M&),81_A;Q'\SSI%V@J:5]_0C/2!C4H,T&X?CCQ-CC\U%7U7J M/C]L?^@AONJ1V55N$(W7E<&A1ZPGGQ@H:>*%22MK7J3D*SZ5BYM?J^SG#;DS M:H>(.2,-./_II%G!C'<[CGC?E2+.W]Z+5;E%Q*U*49UH]TC>H3 >_*0,,-17 MN*E1-G5]+$G7Y_=TH)USP)F7V %/_"M+9AJ Y9KV7EDE%I*K2#FY1;"').T8 MS3.+*G]LWB<=:?PYW!T2'?,NZL0K:AUS08BM<==SI'Q+5R+ KJR&B]2M@I[GA1 M+S-I^&8,G.3PKD;K/A=O0%1=3;'SXEY(\L_OKKPYPUO.]75 _,A]9@5Z1 MIUZ"CS0)UO4UJ<).]BGEYP3'"AM8RLN1)]_A8PFB<7(GKITXU,[%N\M*PI$K MZ)7[@*=TH18P47\=6[+\W=N:;W"-_=>8H_=Y*?1 L67G(&'H@13WXL:5S!_A M&3X98<.[;CW4]!RG.OOJ;,ME->5TSN'4N3H]B*?SN5C53,_C)477[,X%L$T' M@H_1F"5$@"!,AIZ%AL2[I&A6^#!40L0MMZ30B_21:9-MC(7>=7Z;5[::1/1-&6K6N-DOK M_9XF$+Q'V9!(ZH?,>)(N=D M:D3GX-,,6->/^V5$VCRKCL6>.V10N&7:ZAH%YH"?,K=V G'3G!VR6G)?J/@. M;R4^N!'R_=>79*]SKPJ>WU O?7E!_"S<@3$))MX!AX !36QW"< QUA9FV&DP MS],F]%S2Y0HF.?7X9(,[Q<%JEA58]DQMH:,?ZX)^L CP]OY&"J%?H*+W 54. M(3 QIGE=(HHD$KWQN,C* T&=/7L,@*7+_8['^']52,2GV+QYTCUZZNBUU-GQ MODLFE5>*1&P,S#Y?UYHI=!S3O9,:VSCNM'ZWKSW!,?+;]VN^6P,)84K>PE8E MDT4)DYX@DR8^Z#*#S[NEF)\@^H(_^8GO? KOBAK\2[I#B.KI*\< U.** -/2 M:ZM61]Q\D>VH8 O^-DZN:6:2'26300*%*8Y'T/GOKWC*=*_-% MZ8]"@+KWLR2$W*V*@:C%B8\7A(\<=@BXD%&F=+YAT(.N!9)Z]#7$@['2'P(L M?J1YA&@HW(OGE-D'3&B"&)*5+UBO7QI:DLW2E] LO;2X)_*3Y=FTW^M&O["X !/+YQ;@LE00*O&N-Q)V!FQ-$62@49 M[C$Y>I9+!Q%1]+37]3?:[FKR'&>*TVW+3K+V#!3K3BO<$QEA]N@ M6,U1M=XJ>R<97+X/8)87E">)35>("8WX]GZ8[C28[\D++#EVT.>-%(_YI-A3 M'N&VHO?=5XYR7-FL?CT')O<2T6]!3N.(,9Z9PPEU7FB"3FXM46GHY1W?[,2/ M95IL(*]'RY[' ._U&IR;4XV@J-5RZFTH@BQ$+Z-=I1I'>2D37:J%?;P0X:5E-B%B*O"*J^_I!K+8 M.+)6,/="=3?J18<@.AGC;DYC;;I%.7 \7IY[?]!#Z+F+FFG"7U?<*JVD8.D2X([ & MV ,.QA$?[@/&I,G,"CX@EZ9528]%.Y+[:%P9B\LHC$J(LY<51P?N>:D9W_<( M:+9S^U--JT5!U'F,'XD5+T7CVR0XK.*F06R,H;3C=233EDDN@E)(K:*(<(A M@\IQSE=-MF'"IW1,%!V5,:\3;[[_\L?5;:XHT/1[!0H+@]UPFFL\A?Q@Z"5, M/J<$)4W3(DZXGSD/36;5BAWCOD]X$@R-YG]]0N'G]EE/,;G<$6?L;W'=EG$,0ST+,Z<':YPO M@1TC :.W0/R4AWHFSI:W2;?,&G-*KP^W)-1$[X%2)<]-%Q%NM<*R;QBCLO/K MP=3A74,F8""F+GJ@71@2M)YLQ?SN,BEL:-"WY9<2(P@=UT_5^.5LH^YB^."6 M]\,?*'Q M#2NK!K+6#HTOAL'AF,/H-;'(72FD7H"&"Z& #\HL*"FM)A1H@T;VJ_X[DX+K ML==%,:HNK/CBN=7Y?!_E[#RKCM>O7U_5?:TXP.%",>ZZ:SY%@^,3$U MJ>/M\VI 3RPQ0>=,N3I/;&M:5MKVMC;MU"CCF#L)Q&"7)3W6&B_FQZ]%>*") M\=#"E=F2&YQD=1C>VONPMZB2\PI79_$>F94E@?C38G:RN"AKQW5O#/C15J$V ME-N>_:)5HQAO&7AD9=N5(M&[ J9:(YIO-AVA).+U>D;"T1P>WIL-H$+*J(Y? MJ6V15M>YZL%488E@<9;G5/,,MEV%<@+Z&<(.B9UI\5TKAU!E:!84+_1Q3SG.B'9VU!O4%R5B""$,<: M+D(R*(C;Y9;.(/WR&/8"5AE,H?K9_@ARYQKSQ\JO:>#::+$E> M.\GEI3WU82"!4VYZW,E"MH]:S9?(L7EG^NU2T5$!R49\\+M!/X M790G58:+4U&7V^8U)?3?"](!Z9?*DJQE8Y*6O< ML5HP:-3-G!/9@I_&<9%D*=IV;/\>"GL[#"=#\J#[P M@3U6&O/$ MR7T 7T'9^AE/>-EX'Y%9<+'7!B<2%Z_[W??GS_+>5FP XSD0W..[?4=T\T9W MW!!^]#@&%*565U%;6AL[L'8E5NN7GNCZ/B M5I";;5"I!I]L7HGA[+:H%JS5G?X.(9OX>B./?VVN^X\?YC]T#K;M _^V+=S MR%/B7YX?J*D)/M=/UC8&KIY]+ SW1C1WPL^/TE2H0E"YG1;LY%Q0+TEY4@2B MGA.6A"A'10\8!6C=F,$RRQY^EIEI9QZ#:I+CJ8G@*9S?1-*2:): M@_9UQ+24F7OR]N$ZSTP_\5:]K] T7!!]=+-]L -5LP^89E:N9^#B?QXW?P)+ M>TDR'DIV#6NXB8]A7U+[.")4W(N\/AFG_L6 77I-ML*#,YP,(:Z7Y]^]E3VL MXS:9D^QM,;;6,*B1K'IP:HUQ)]^K&*4X/26798><;OH?_">K)Y+,]HZ>IBUD MPUE1S:YCWC?I 2L(QU2FMW4L<$3S$8A[3M+3GV#@L^7^]0B:+YOH:XWGI$U@ M_>=J 52?ZU@+F1E#/TQS442[054Q&/XX$Q)?1/H3R[$G4W)"QC7\]C\[YKX) M3(K=$0X5/^JB(YDKW%)YF121K0GIBNU17"-7[EB_N.Q#U[B#+3PBI)VVF%,\ M0A[;O;JF&]'E9\CXX'X6L=T?L ]0BU4]];CI(N_'K4ONX _ 4F9AN$.0HO&" M\$Z,,6"U_*KLS$4T7J:Q-O%FO\../-VYN"I)A M*A@4151_=7U:/F!G'R"X'2, $Z*DON;,4MZ;"*5S>"RR_"@P*W*[,= ^%_<" MBCOB=O1LV5F-;+73A?G& =Y1R7K% ][#Q;X>; MF[[[S%CQZG2U9+)TSX*=< M)^4Y1'=/,". &C^87E<1C+W(DO?Q5IZ!KIA MQ^.814B15/V6E!KX2\3X"\ENX\M0L? 2>,)6"RY<6]YUD-C*=)= MY^F"D#DX><]ZM++.$=[(U6]7$^'5J^3M,5Z7A5K8(:N3^#&-W@SVZT3M&5#K M.O^2$Y*79J7RSMEC$"&?4-7CYWF"/2XJY]YSK$+46WU?^E$FZ:;A8PCAII-F M%"[R _HG>9P^*;$-L@FA%SN?UXUXH?$+;Q2,GDO1$4]YD&IL7!K@S?E:0\4D M6BU!D$>O1WFR*-.A> ?;C>%J/;W\=(D@=?2CH([+G$>QU.=ARKM[*J+]P3>MRC MP,'-;I:L\7EGSEO/2GIL3%K=%YF>L81K;$7L]'UY*NS.+J@271C3;(J93 M!;57U(DA73/H%AP6B-E+2"=P"?C'$C &PZ6'+\JX/_#R@8H= 9S=0M6!IE-P MQ ?HHXQ.;$(B]>9O9LB'00C2ZR>AFJ=K!C5NPLK&[RX4&5X]QZ)Z^*E[W_"S M*Y]YSQY^?:EQMR1VSFG58FEG\[BF0T1Q3(*(D7.7/>Z*E[X#!%*%^05R#!)& M7:EV$:]$PTQ,H2CPAVSN$96^I; MNBNF\@=V].4Y!:S*4?=OJ^"7B&8)D#UH3 7OV@8^#;M-3]X'N- -";.+>,K6 MJJ5>78/YL\$1QY%[\S.9/"Z=UZM-:KJCT[B.%M[/=&Z[/Q&-S;;S&\^/YE'+ MCVA74\@IRIJ!V_D+C8R@;Z^SUH0HCXL7Y Z^RA4/$UW3YF0LHMJ!X^LM0"ZX M+!,M5Y@.$3F#6Y7*@ZD2GTP)?TV>L=#GEHB\?+_.2":BSH0[:A6C$>N$68', M"""8884BC0@".G@TM"[@>FZ< M.)._]&V948P[6E"07..._3E2N>I?XL H=2.D2G&J[LI[^DV-5J)LR<_"+Z 2 M-=_'_O,MN=S)["S]>MT_]U6=>/AQR;F?R]J0F*F9\>Y*2>% 2#G9NJIH?O$2[>PKVS%K0? M:@)2PCZUDD<+KISS,7(QLSLG;:MN)OWF/OO!@73BH;334I;TG(;S^8P>=(5S M5K)*>V](2I&&518.$ ?&\+ U80LGJVWL6,ZI'K_VX:[_RAA'@/0FAL%..NA, M24'Z$U* E(M2*]RGL>#VF,.K2*/2@=5 E;"B_EOQ+_9T+VDIKY[;+9U3/2\] MT;4\T-:W%WU^S)H81[WB#XRCB>2&?7I<&(3:QK*OC7PV-:I#*5&0+DX6SB&5 MN;W93E67)["3M_J?C#_1$E&UM0DQ,6PV.'98A W%3C']2S\(4R)59Y@A "T0 M IZ!J8.Y[Q93N)JM)?L)=3'?35E>QTJ; Z4ZIKRU@N"_^1[=NY:#:%8_>"T9 MS(&8_@(ZG$YYBQ>8&:3IY*Q6DQ*#G]LN+*I\#JAQL9#$F@,_1Y\0,-?N._S\ MZ2C2Y:M-,0L MC#+8:YDJNDY)I/(_P<&<*"Q'=L*;^.>R:W/.'PK7%P 8Y M%I5.1"EJ)8ID2IZB[&;0CE#T<];KAB1/.5D$(9<\NB1L%JSN(^H*?#WM+V5* M!",,D=P-QM.(/Z"L9J3$UL:'/[M:L-8I2NV5GGFV/Z+''B5Q+ 34N__9- F] MPL6DIC<]@1G@],?U"7)(8B)9H:&:&-.ZSG>G23CNNW(3O/R/8+/,M\Y)WRL, M=),:WHT]<+YZ:!X0#KK=41.CC+'SM!6$#08,6(C37>MUK50T.:[A:;FL288N ML*]Q(VI5C2IEKGKZ_>!(M,A!0QR*:.B*$A[,!;Z9[Y3L$GA<325DRVQM".>T M ]88(0@@L+8 M794]RYIK.G@IL?BGPKIBSNIFHYL'KUT=@=#+F^086%SE?#YB!G5T.4U@D*9R MU=&:GVA=Z=)OY=BW)N#X#.3E<^\$I9=X0>8T3Q_L!25F!D&17&]V/<'H !_5 ML'V-WP>$^;8FP*4IM039H]OX^O+4#'F;#)]W-SD.&^S&R9_KD52[.(EAY'VO M8C^["9_*='/9T;EN19>O6_+4#L_5%E!B0]D"+B8-131PN"IJ*UH&/"(\#075!5^/NER3Z%]I9,W M(I.SX>T':TL6=^X\*ANB+;4%/TC,[GID?64']N9L8X@'#NL^1+[ MW%O$>+MNK\-9_SQT^H\%T"4?4Z#6(:21V_3LN&%&]#UAA>( . M4[Q-('8DUI:P "2WQ=CBJLM[MH7WK'<2S"1@BC:T+P#L*\03-M:\$H?V?"909S9X$PMW]+&73%G\T./=%MX7-K= I.Q:?ZK M=B\]>.]A)[,JG!91*OXNMH9B41? 1U0>FJ*AC8;E^AV6NL!3--U]0.#;?< S MZ?500RMTNI:/U'/K,R6\M8M@"T87 M\C2YC&FAZ_YW93MIY5M5>U M $ALW@>4QI#;,&%"9&NBNA._1?.PG+PX<993)M'!Z[F,J91ZBO3.0U_3!=3J M5>8J!RFZ!/E5<]8PQM&#=S2XP:%UL]ZFC'-?$R;MG"_]UA6PM%020GB*-@1[ M.W1N_.CZHT#N\Y7C3_R3/^=;6E9D(V1ER+^28WN_NI&C%0K]I"5G7*^[-.H7 MH*T MN9 7A+MEU,_Z"Q,S9U1:P)' 8XKH* 27ABVD$.IJ-'ADK@3E@NF"OE$/^]$9 M?S[P(B#?@.VP::?F<2;'!1@M<';*?-.Y4HJ4K<\TFG('.\K@;C38\,L#/U8I MZZP^(>[V_'D 6$(@[+S1\X0NH/0 >OJMM;2K"'3F6_+.ZN-"+(UG1'QX74.( MN'YSR%5VIM]5SJJIJ^G*G&3T)/B?S;QH&F]]MV[36LKAB M/.KHNE$(WORC[FG?JTY]'P_;!24LUX]S3MX[B4,TWT+;<;)@NHB;[8@SBL)\ M]D1A9 2HHM+9:81#NZS6R^BN]WN^N$/@%V>SPK7J?N<.\<9)S1[G_?C*;YV' MF875(LM60.6G<4=@'(3)FPT/FBZ&FE>2=+IGCP5FK@%(M0C:5U.QF,[9'6N(5+TV6..F\?>G\JVK3%=2-^- MP&NW(<:E&>S9)%P[D@_ML"J):=D'<*XU784Z60%;^1]5C$X)U0S8Q*^N1WUU M+C_VC"TNX-=1LR$[XRAX.51HNO<[+F3-C@AZLS6ID/QS9#AY8/C1F>*,%^EG MSG*6ULO=8'5L_M&FCD9Z\JL<^:#/523LN+BZBPF%^U*PL>3C;JNRABE;X=W=E0-&:.R M$ZI](?F[ML1R,C/9"(AD3" JH_.I=^#C:M&)#AD4!X)6?#9$A*5NP)KS:FNR M75")M=FTC#'!."E9):Y;SC[NN/(TXPVC&_T5^"UF#'FGCKCV%A^E;E@5:/"A M044Y/;M]5,TDS:5MRT3D==?]]Y-)$E$I\T^^+#R5FO!BGX?+P.PHSL3;W["C MK:YA\ NA^@,T4)9N@5.935:LM!EC*T#\R"\'EC=N]X0A2-Z4F5)R[I$NX5.1 MQ@G)LOQ@BBU,V?1MU[K!PXWA6IW)Y<)=8>7N?0 O3]?LK4&?E^-&J7E7,+_\ M1E,97>A*E6;T.'!Z+@;#]593TOGV[2&)!,[!VW/Z$ T'KN.EGS]-O'KE6RA] M/.1P,_4JS&&D2>JW!280+BI;C([6X"E4CIOA$#)+5KSRMHFCIC],5.B3H&I< M[%'R@]BH&&4SWZ'=VAD74_NTY6&X0^[9NX*?2^26[B\6(ZT$P"VX"@X8@OYY MAC)'E?TXE!NW4[7W$/72)EGG7(KS2.H5A:-3"[,)\I\(JEX)$U\"=P]V 470 M@]>:A)>K0$1CY"]WZJT6G::AIE$"77FDM044NGW^O(Z.=A&-87XWC-"!P(JZ9& M@Z->Q0H2$C7EX3?KANW?O9NU%YH0_6J&= ?](D[Q")]]Z1 8A9<=Q_9J\U%+ MDN$./UZ?D#XB(Q1RR21Y3':MTL!:/[^%<7 ##,.EJ9P?"3O0X%81?")5UUNMN M\OL:::5X0[@S\MNED[ .]KS#+F(#"!?T>"">?X6'*$>=D6^3WDZ8@=S&KW.U M7"G^6>I3+7W\*?FW%?&6O)04@#;(3(93Z"&:\C0'2JDG$U=C)JY!9E9/H-36 MX[W$A1:+#W12^+2P\+[T]VFNKV^%?!]7RXY\7."=?T8R5OAT M\$8X;MMNMDXDA)]3]]A=@YRBQ&WO^;8LF_I&6=ZW?3;0^N]\4V+5FS:MWH]C M)CMB&@_(HV'ZV/%V$__>!?U'S_WD;ZQ\9K; M@+\WA,K*6[K_+[MX/3QWV_8!K,IG&6U-[$R9DM-=]P$YRWMTX>ARFN[T^C'H MSQ[%?< 9*%A_N'@FL3N:\WZG:C_XL O[])M7]WJ?\%CMVBO847X_$YPO;T1! M:#]E,*S;M+._W2V3+,B-319 (487B*@%ID@)5[>@#]/,FNAIMD.5*:@3CGM! M/860T9V32JT)I!\_G_I$ZB6(K]I=4F9>WFG9J')- )A9H"\^'EQ;( M\=X8EGT%6)%>T;6TA B]6"DJG@DY8VL4[I2KBOHSP5EFOG M'RD1C\]\FR82:>23V8G5<2GVBB^!\] \#CJR4SCP,32>Q&D$[?15O%0+=%UN M!5]11TG-QNE?'R[)*7NH43L;K6TCR/\'OQ$VZ'[#'\= V;B3&E+$>@8[DU:' MTQN(B2O;PFGQ.924[Z]40CW&H2,7MGIN_;PW']TV#(V4(;)9L@CIB)T+@.>( M/TNR=VP>X=[5/-OUJ$Q$FY@;3SMO0X_$@SE^. M7CFWYL/TX]OZHHWG%'KA@# MA;"SE-?%CKAC\--+%U_G0T--RL?FY9%G-UTNF3^>WQ"-OK;#Q['Y%7@96 @^ M"6>%G:%4BE^A/:;HX='R2U#T5C6@2J8/)Z+'2JF%=H"YR#^ M1&8NCBQ'^''*]5C1;'=,=05/MF\+W-_?L 0^7,?4#&4Q37GPU4 MA2GU1"1YPEEL^D)--(X<1RQ)R782M*JC)>X4NCL+W6&]T2.NW&V)6L]:K$FF M9Y'DW]+X9^Z&R)^A:.L.)XQ%6);DYF)>B4H)2#<^//9M<='0B0E@2:6?70%$ M4W!P;:UB%)<[866>%6M1#51\^>VCQ@E38=;L,R?$]J($C8;D?V2E3D6O*F57 ME.N$J)\SZQRV7^CJGH'(&LTJV015. MR785]CI\D_;1>*D-3(^X$RG^%?JR^=7(H])[A_*@4LW)3;6NA"C+[Q9V([GV M7RR<^/FX&X@ G4/BTK4^4NG">H[!+,D+#%S^=KB2CPN>+W5RL-Y[J\Y+F=$2 MV#*<-6>GG%5<5V:R76X*TMA"4E3YR6(UE!M-\L,T5<(/#3.93?G F<';:[68 M"]ZM&5'X>=1>\,'U"82"GRO%M;DB^+JL.!FNN4^TGOFZ7,4 W-RJ; ML'OPX-*SI8MN5FT2D*IB[\*12=Z8GV"*Z@?T#$>#)&+I"[,@RTI4VDG\EM#[ MC5EP?49T%^8B%A4]*PGZK!3==B_'7$K+]SVO8M>S:<^]]N(CW3.J%&JD PXU M:U"'?\LZKSZUM#0SN39SXP-&,-CHT64 RY<_:I9M&ZO ^IQ=1.5U_W67-!/U M"].-:9HY8BDS.A;C%G38&IP/WM^D2H]H8&%:U!=*5S%C$G3"DXL'>CUKHWB+ MKG91Y&Z#\D@PL\[2/G1['\ /C]_AHIV*(<-L:*U(>N<0NN299X+\"!";<-;DK7GC[[ZAH992B4VM?^-//N=YV\O$60]YU*IRG3BF-6 M);Q6,2G57LJ1GHMMVODT3:)(+>HF(WN5"[DZ_B2BL5+ _T3@_'C8A?M MFF>?$GT-$[GOY_ O#43,SCZN)$/L*Y:'/6]%WQ2$HHORY5R\I<<]=O2M4X&W M#^Y0?]*,_'_[#O7IZ&-GVF1/']I-9%+S')-O,)H+_5.3D@[S3R85 ^S'*JO# M9<9[*?'$M9XGS01= WQ.TGEP4^O3CI/-ZK ?^P#HY7W /?@W(/$15P 3T4?R M@:]H]RC.L"K?MN0BZPO$XM;:NOXUG]TS3UVCOMZ_=_2,[V4[X*.9ZWIP%T3S M3<1T$DY0\P@-7,>\6 PS9,G:J8%B9(US2>@6JK%K&;3@%'[N(CO>0HO:RW?# MK;ZOZ(O+SE=*N&KV&7RIW*"%EFOUO:ZN\M]0I:_;9=B!5IOXZ>V/IH29A4E/ MS;V,)COFK%Z(YH<,+L;4%&_- +X(4MPQ(>C;Y MX?/16VR>UL?V7IR-#-]X;6;Q2^UGJME82L)<#*J2UOZW?^.+]Q7T 6&H2 MF(0FODK[0#6%^=)3B[9ZQVQ6&_2(.S>'2S(IF3;XE,S7>7?]7#H-5 D/O[;> MM+^98(KM_G)!J9VY/.8RB0]28@[][J+ZP%[V/0\U&UJ=#<0S$OU<*XMES7AC M:2&SB@7WI1YHF==.*>PIY,,[<5RF,\_!%<"WKMM 9F9#>('&2];T2=R;)DDT M/"UH1G 4BO]BG?MX)$E-^NU[/ZXP0>WP[?70.G+@]'7X=:DGC?TN7_JWS<]/ M57F[\L@8\C+.11N7XGC79,C9&ME/+V3S2A45.SC4>>%&2PFZXKF&BM"]:K?H M_DFKEZ.NFR!UA",'.!!-?!1#D0&]A1^C7:4X9$WI$$VFE\&GFL[?=BFK33B4 MXB\;,_'!8*;K.*IF;2KST%F5CB95IN9OZ1+KR;O#&IY4>WB_)C %+QL3-C.L M83R3"GEL:;Z=4KL)]2@]9BMF=2_KZDKGN]F),PK&J &N7[UD$)@B@5F)*3"W ML&U'GM8P+RBJ&RF&L#B8CLB)*XQKF8?,5;W[89[E6I<&RSK^ :Q$$R?Q!S+D M&,/64O1BFJFGAMBRJ22M#V^*2\0?E''0=$SJ0&S[>93+'TX[D3)R%[ M,A1F\G*XD1[3=!7^,Z'I KU"@VV=,%>9MF-!T@Z=A5:><5U?FZV+Q>(Z#S\X MTC-X]_3+F/JY,^*;)$0KFJ+L @Q&1=KRNP@]/ W]/+T4_E#[)=!C^.@M(GC48H 8\B3U'6 M&3P71 C/ _;L_3BNRKC$2F>7%2:(5]D)=*[RK@ /(Z87Y=_N#5HR;:9":F61 M(,_5$%FHG(Y/^5'))M9KHO#CV:M,5%=CXR%4-XYR(2>0>A>*)">30C%W-&1?I;H2#?- .6$03!)6? M[DFWI_W\C)0=T"FP,T$LLRK=U:G(E?:$>P0R+W 9Z* MR).63Q1HW!VH>12#O99TJ8N02#LM3PBIS_K(Z!V$W?"P4K[6-.M%YLY.%MT# MG%L%:\0#ME%\,8?PI#/0(6,[?O$4/2G[X=6Z7^1+I,:7FJ*//(8^6NKD#*^. MVB.>4A-'$E]MH^9ZR7^07-OTS\"'02?@',VDW/9DS4 "%[_9+Z<$!I!D-QDA M9)ITY^T# \Y<^Q7N@=I4;3*67F'KL]5&1S5=%/),^G@+=U))M(956&/%5&A: M;6IL,,HS0]]H)*IRDJR6>/8Q^5)67J.E9?$PTFZ"453(RG1HGJ'R>7TTLGS MM:K/$WP$'6<=!5)DNMUTMGL\#8D;3W -J!WY341ZEV$,.C:460!/PW.WEDE< M#/9-)LM&*,]C5<)!$-RQ'WT+,+4'<4Y7X!R0LT$,XPT'3 Q%38@,(3:VM<=1 MK].X22H1)6+/2I>6!*G[V]"@Z5.)3>[IN\39S@^-COG3=! M2RFCR>P#>+I:7YC&A1T1Z#S5!.DB"$#:F\(OGW'/O.>>>^^[[ MC?'N&^/]L<;(2-9>:V?OM;[Y?6O-N2:0;9)--TRV:4Q9WMBR'=YTM[!X8-U2 M>'Q?QH(T_H1E#EV0LM@&/L88BM%#4^XH7JLW 0=J/+D'$VHPJ) MX6N$MDFX@B/_Y*?P-.T6-2D):W.NNH/^]L-HWSO9?)77!^:4EF4FAA>&AYL^))JJ]RW!0:D8?AU3>9AUCL^R Y$LEX$ Y@@ M+;EI'2/)W^XF[H&.N:H:\1??\K]L:YS_,DI/O+LPWCA!-:J>^^4JI&8/1!?8 M U%=&.E[H,=V,B35M94[[;)?HVYXWLTV!0V,2@ M*H.2Z#^A/);G4RWT\@\W+/_SC.=6\$O]Y)]FM"']/:]XYEZO5P MS@I@Z^4L'DK[G#70U5+O2L\Z2A$I<%GWG9NO><-[B8.6E\K&A9%CO-T#.>Z! M"*I4+"4,QC37GG#6YY/*LIOT;U[QA*DV3!O?E /S$)&/0"IR+5D MFC*J:UI]%.<4NP<2[Z8TM$O()[!1.$=;ZS7L 6A+1Z]/.X[@].9 TER/J%G\ M +L>G#^$6T/-\%G,RN(792@:,;M5_ :%VVIWSHI MV+(*PUU+YN&#-#9F'Y2;;ODG4O@@T$TYXL&R MQTS?DO'>\^3F J$6D$BT,C M+D_TG"*>Y :^-?)]J97G*^PPM<$.I,(HB>&7-OA=+&KZ""LJGI.VK856G6Y/ MHU:$K[Z\SM8QIE4$TEN12P4"R=ZVY)IXI-%301-8&N[FV&C1G,YBUVP.("<%,6L5?ZUL=1 MHT53CO//^666K'N_Q7:N@?^L8.]G4987]"-_PJ:1FB*+\3^AU8VW"A] >1 R M)IFHB4)#_+[RSH03 5\-/D<\.(B8D3K@$.OM^AGPG2.Y[FJHS MX$].HHZZE29[X)Z9P[B>B;%;O1'PCDS.D-<'*^2+.-AVJ(H8/Z+FTA2&UV(Z M'%L@ M#V:B"_Q%_]TNWF=Q3[^5JMYH_8Y.O>ZQJ?Y;')OZ@ L9?M M?&;LX%CZ20^2FM;2:\?Z>+2?S YN7'G14J!&1=7$Q8_+0,HMPD)<;FP5W(X] M5D7AEGBB:_ L=,?+<0/].0CW&N3_A5]ZN*3[=:N-74O_UTCN$D+.O\Y5?S9H M!13TMZ.3C6X.O?IK_CLE$B8&)4!&)S8JD>>L5"$$^W.!Y;F[9C]A6X_#/GNH M[Z+,+S9WEJ8U0NB7[=YAH)/IV?/U7 TUV;OK: H']W[II4=1SEEU(]JA5QX*U? M09?L_9?;?/ND^8]^J3SYM2YQ![T*1>@XE.5)K@B8O>^2GW0M52P>X%8=8+4C M8U,FD9?_O47-XYWO6M$)J<%2C[7*)>Q@P?05;L=0J8&##M_[#L:O?^K MK6A^?6K!?==S%7-=X"=81F1%OD9R7L#][YK\? M+'W\WY,#*I'*8IA\Y,0V&!=289@YR"@D_0IDO)R_RHU>^A3]:'K\KT]GB_5X ME.;&>M?SR&#F H:A:J KL?A'60[^'!B0F085G-9+^,>.!E\^'P>02 MD,;_(ECROSQ^\G\B_<(_%+@L6YY&# AP9G*RE,:!9^29=;DY6308K N[RO8UT3L.>.,H^_;<:'U-GN M_Q*G\TB_2CJRH_T;US5IBD'_MCWL!P*(JR\1Z3WVW%4QL)VNN&T'P4S[]AOS M4,BXXZ/A M1DV/GFEV:KB@)!0ET*%T^+X#G-GQ1X&CQ^'4!3(2)0WP4T2F ^=O,=X1,_52 M>$S;@X6/ZYJ2&BFGW*^,1Q\XW/[H3L$@=2BM$):;LVODCDF^U.+T"@X;OV/* MKY&_FU]A'UG5*>:58W"*W4+HD62)O^E+FA#R +GT)1%]& %N.;8D 2&7Q4E1 MM"0@ T/R50L?KH:?QCQU\DHR6BB3!(LYOY>5*+_F7[EZ.U\@FX"CJ^Z.;9V] MF6_>35;JS:8 M.KQ/1S3U;%IRS&68(Q;QT^R @AN7EJH-GBYEL].UR<6C//>2/_'&E[44W3.T M;Y^S?-.V.SO^7! MJ>?J!@B"I>[,V@+VS_)R(;,36I'8!#F$X"#YK0V3DUN9AX%.$BR&(!'*HBP" M@+-13(_A^9]2CLJMMFT'%&BYJ=(O@JTDCLAM73'[K-K?@7%)@IY_F+SC%C]A MZHMQG"%@;1F?]T#.'O$.$FCWLO&NNP-:I]UU)!!@JV'E#3Y7S)-PB^GM>_N' M;]QHGJP(WG?GA/N36:B!W+[+97AL?#B;AUR;EUB'7#ZP\-C10^W[1B[V]X M;_7;"5,[%Z62&S<#+".!4"8/B[6P;P#7H' %[JFYGRQBAT"1]J,W4I-P<-G2 M;UK667WQKVW++F&6O1-JN!Z^KGJV1D]W*$ELAX:@R;I@0B#U.K!(G"'(X"'" MC4>8$#+JO3+7:NSI!O^.X9,JUW[0\?[VJF!\'@(3@IZ=]IB8(25D!I'MSMB66']?LW^M];U]&B/Z#4Q)^O*M$KD7\W M:,%SMO>[K;^SSH.R]/.<+4UNK[P,B%LLXC@#2&W0>8V)F!B/2U PZBM3 -LX M(%GSVAUI=&Q8."RDNKKK_8JZ?C->"G*=N@=*3$')BGA$:%TC\@BX75XUHG0D M2XU4K]9ANY2;*NN2E\4$%:\''7@XLE4O4 -I*] R_A K->A^2;VD*O/;C$L2 M8B&ZF)J595.<.E'1J6B0$-$XJ>^7]B GH"KO8X#,(Y\?Q=5]6Q=V=6PC7K_3 MUU N*5VC3TW'41RB?O,D-CE,7"&BVQQX'E/KT9%(^/MI!)=5346-U?N(>397 M$=N#9B"V3ES4,[9>MD+^1=PG_9P@FC:3@). WL\,T(_H<+N'O ($BF%\391N MGCT_H' M9FU=,O'MFYW3V&R@@IS8BA.JM%.X1E%N'Y(TH*BDEUI-6G\5,/Q9 M7)I3FY@$_M;.>>%G0FOJU1_%FCGD\.@^RI> M3VH$[8&>-;I.*5YXJBLE@9C+)@^$#?K%8UVFH'65/9'/,2-\Q+P\=+(%G P; MHJ!9U&NM@<(VMQB"E*-(SHI9A)+\6L&"-HC09D7[R:@'=6>)[D_F7S#&/H1E M[($JHS>L_YR>1N>MH=HSBK:U9>;V0'B/4)O1V*H-MJ4*Z<1()+3@G'SQ&9T' M-H:H*R>."YRAM9D]]/(ZS+\U*R3$9W')F_O.$5-KVQ2J2^7:CJ6=*JT;_@BP MZ3%UI8_4^[JN.CN/.LY!0:A6J"CJ$N TT80361AD'J&?K*FY.$;G F!>U1N> MHEZ='U?,0A9^=L[P8X<>^+_<5=A6;5$(A7(R]R..]!(3F\M RRC1OF?;IT:- M!]PL9(5^@IZ MOY_HH<%D4%JNN.,TG3^0]I_W^IZ35OC@XG@\[-&!J>EH&1QJ8_@EMPY8(30C MS<*F>F2J$6M0HADU&'@!Y&4UV@*M7J0+""'@^,^HKS-D6");)\5VCOU=_;"M M4=CD,D$L[WGJV^1H.T4CT;#'NHIJS3:;=8W>+#ZN]B?KF(,=PF_6/36(#*&B M:AGMB]';:E,^)@'LW%*W"=\&^[;8'K=..LB:/!N[1QAA;LPG1 M(=C^8((FK6#8)Y'/]7JR:UK6$<]S1+TQ\"EESAA_KHSD)0.>D&]?UN[DW\KE M[8=N*._*!V:8M\TI0?UX$%>*"<-[H'!HKSN^]X\?" :0+-X#\3!/0R9N47]3 MGM-O ,2"*7G2E+WQXMCC_>KW!#X(%@0ZVJW%S[XMQ M.2#&&A!E]OH*PE'X.]37=K^E^\]'GX^6R.+E,. P3DK[Y>$[8S%C@;]YC?^[ MSS^F%;FI*X22)[_&1;G1QY[C?428/V%_)=O^4\,E?R*RIMK^&I%E^:C(ET^=8E5T<%RG%[!U+Q6>+W$_YRXRL'+ZCTM!L<;M9_^PK?"? KG^ M@PCNXJG?*#_0W"S@3WS.5,6TUJ<45RL"P9E0@^I?I=)3\/W(V)<9[IU4=FQ" M&1C8W0/)A) 5F V(Q#V0X8-L3@?R-,&!(8IIZZ6?W@/1-*#$+Y6XWZK0: S MHC14GXU*,XX0=&N@"WK+''+7<(+^XO/:[6 Y*T*]9TM\:A"5VXA;>\31'S_BO+17^V6S#_D<; @\/-#\VOFQU>7N/ATU:"8JB*Y)MFQ1 M. 1L0XFUR#-S00H=R8B<7IC@73MC*E?*$6[XPCOH2ICU9IZN2KSU04Q#1DH)L!3E M5Y S;W[?_R'UV\#^"AE&3'\P1;VOD!CS)>L9K-6UT^.4]Q$1HY5%85UW M3JDCJ6;--A=YE9'R##H^:#IZLCQ=ER8WYEKB:GVU__EGG:8F.O%'K[:M%BE8 M*Y(8&;&1SPAAGJ6[C!#E_.>6E<5-_(+F:X[:*P'8U&OR07&XUQY1]/ M7UD?,E<]*#4;Z!2L\V4OJQ)*^K:\1Y\' T;5,,B=K?#T!],"M7'N@XU<^=O+3=R!/(B;;\K^?F'.1 M^: -CZ2PQEH@Q4 ?R"]"VC%2L9<4PC8:K_JM_K9CO$D;(=U=[+8_,IADRIF< MQ#)29AQZI-[GT_P %TT"Z"5NA'IL:\;K0(ZL>+4R"I'.B)VVQ0?D_=EKV?N& M,I*,=E-;9BH3HXO1]ZQ1QZ[1=!#U%6;#]!3\$&\(_%9K;S)3V%?>*\ M<"" 8ZV[8 E73L=4\ +UPNG6#N.J#[PZ)6/K.S/_L86>^7=<5Q#F"=Y5A M^UA_4'$>MUEF6FHYBVXMPH2A#]&AY)Z-V\;CETQ4-"T;$A1CS]S<>9[DN9NV M4L#60M>C>2W;L.."WD'&::1KHV-E4J'K M/B\F(-0J5;FG6WXA)=\UF@NY.' M[J]%FO[):K@'^ER6+9L-QNR!B-BMOYO:M]&M0HM[(,#CBQPS'D?R^QNZ!+!P!/TW'/F]/P;$0C>FZ,;U M/5".!Y"Y!PJ;89'UNP_W0) 2E#J*@#[(["+/M#$EF%VLWV+]6/+$8YS9O^ R ML]F;W."1^BO W<'F=T^CZMP,/2NU"4I+0V]-B8,"7[,@'@QK,#;$^*;\!73% M,L\,#2V;_N.BR7_R[3K3.9)N:EH)6ODW.?POK_I?:/;_L;01_UP2#!U?VYRY M:6W]]%NK.C\9MY[#$NNRC$P='<0'CP1(A5^4 I:;;I8 JQP'DIMW(T9L@]7\ MW4@/QXS$.GDE'Z:<[-&C%5.Z3PBK*_>'=3SX=$=]J;.=">XL2=M6][324E$4 MJWJ/6?@BL43/@=3 Z/P*S,/1A:U$#""[V&2-DD'LNXQWH]QJ^A29=FS0IV/X MD"G'U.O[#[RN0*_31*E_CM.-1'V%5J-"!8K(DG,JJ4&(21B1MAQ>FN\^U6IK M''V()2*OG%SKP+YH_%PY)"]5CJTV(K[D[.0N$+:&/0 ?L&S? U59TH]Z4X\S MX)^"F0\89,IC)M4QC MFPA*)D+:86!F/XIG< \T-W.#(NEO4Y,$GIJZ%'O2+0=T>'YE?^&RC03['B@T M3(V8VHG/OB/P)28N7;/];XBB:I!_<@-GN%FI45.^'= MZO>/FUN%BQ.#_4_LYU M_J4&4WE_96<@*T]C"ZY/3DKZF3DZJQ$C6QQ_O;XZ.F>56N18ZN*[D[*J=2OJ M?,G(U>/73G6*$D-$DZX:W!JVOAUWE,=R4$N<:,)[);E50S5BS>W9P$Y7%N1WR]F0YN,W[KV/FROAB_AS% H;V_ZX M/KL[?@*S7K"\2^ECYU.(U_PC.\HF#*@P1N:S<65(/*;2( RI(7F7D4*SB5TW M1]?M3SX7.7XT;5>4Q$$7NTB#KM3'98$9"T5;TW MY==<_O[CL"H_XF9C*U^9:7I-H'70SRZ*VD7A#QQ7;>!.M*VG!1A-'&1=IOG0K,BE_D-YY?XM$>2HUJCSD-> M:Q*U'[_!=N\7[78] C+0]GC25DN_IT.WMF"GO$,//F+JC\?S; Z&;*YMX\'& MNI/S.*=5S"'@SNV2G?9$B9;R#P.^"Z#9-B$? A89YET%4M_N'9=A'KI(MB6. MQA(!!NTQL'$3F*%HP,NJIERS9-_.#]Y/5[=[86C575/^YO-6&SQ8;D->X3I+ M+1^JS!0UJ:FHJC%[86M[63)!67S_QV#0[SL5#57.MFH9+O56AF?- B>LH=8> MFQ;7!KXYGHWY<-XT-S7HU!>!&57?:W"XAS/GA*UN.5YDW6K.[&-.W[Z^VT,W M[:&%:T_^2X^7>[QILMG<,$&$Z4R;RO3#^W]9ZSZM08-XS-O[^, ]';VHJ9Y" M/^(_?1M>XX\FS1RV1<2,?K\R/Z6/JT\>':.ASX)^N9XU+H+'YNQ(K%69XK?NS@41S NK1XLN8 MK8__ =+]@X7E@_^(W_GY4Q]N#?[LV]_/:O-6+_G2?3O_)B^EM1U[A56#B0^0\- M'_^';D>@E%TPP]=AT6SHWS_JBBO_DV;Z[PH/3^TBVU3QE=U@N6*84XD4$D;!,WE^ ML^S&0[KST )%(I/%F)MM60B,ZT*(Y?O1LT'>@PZ'%Y M(DE=0?YD3=*U==RSURS[8 "Q+*A(V,?7O'74+\_HM_09JDL]ZK=2X\8B;)TH9C8!(>]<&5@U^*MK]WL5HW ML-?E-@T69 $6R>,XC[S#:,>W]89!CMQ/CT@3M7*7D*;?JU^D4\QM6,AV" =W MB!M$NS#'(60+CRC"[TEOGVS L:>JPN'A+YF+(5LU-@R5COZ1U"2- >94>RMP M,4QKCA_]Y<,>Z"BSK=48&'C%>+B^<_HE>;'9 U#-81[&D-/O1+9AI0"[CXA? MMR/T9 B-\%(3'U[5(ML.\9 M!OM"0J[Q69X9D0#^=U+39]^*AH_-.TWZ)5?@L((H!L_L5NT]_*X7]FE*P+;*[2 M*BO_2S3AES8P_T?/2A93)GCY9'/\=QCTK_#G;^5?N6P>>/7WW2HGTE%7]D!V MJ;M#RO_QN8_#Y%^%;_S?*'H]:JSGU4IQ#EM'7G/[ D[]R_K1GV6AHIZ?Z^[G M9 *-"^*\_GK^#\O.]1ZV 2)&O^N63^E#_63*:#(3NV8A+1&4C8BM5=NB M=X43$_Z6(=5N+U[ ONGU\B^_)N+(9O$<=RF0-2K!.;(27G)YCN;5S>QU=A_ M]G4G5^FI253N6['$'4<*$KM,+M*=2=U*QIC;52XECMA&0^1LE(1Y>M17W2:, MKG^1!#<0.NL15?\D#1],M\U?H99_1-4R$5O8&RU!P M[1XAU2*)8>[*\N>G-Y?@QQCQ/R*D)YQT4]DX^ M$9\F&/'L<*6=#FFEBWF,JE(B7NL;LZ@@H#_ QM\S&=*TQ;?O"^T&:DA'@,S1 MBCE:UIH8K<&=)3=P^> @:IAO0-+_8RFW_X]@4X.;TPV]/'2COE/DLG!WI LI M7J?7G"*!<1]Y.GE7RL1/\VI>%3/5?G"W?5PW2FD<.YL*:OCKV730(AZ[P?$*FM3'% DG(2*5TX M8P68POU&3WZJ<)&IL8B820IV3I2/5%MDB^OCZ"<8Q-&E2^"C3,$!+6-'GT*7 M0&AE\;UZB[31I]\VS+SJQ)5&*CQ0EY"2@\B[V'U#.M)+3U=-3G74WTW+-=:A M=@Q--)Q,T!H9VT1HP(&95<;26Q:-!VUUE$JHQ3F\;;Q#8[-K/DWRG#O>> MY+BL>X*WH70-%*0ZAXY!\S!%N;PI;'@;BWCJAU-CKI:=QU+%?2.T0B:WA!>* M5[.TR+"(1A7L10I';.6$]NEKE3MI_0M5?#UD]^OMBK3L+>8.0U"L^5 M"%)?LFK137AVJ!)5[PW<. NH^N9Q'V:LY\3M';#T/.*KWZ!N50*)QW'3K MG#_!,FO(8_?SX?7Q*].V7>+Q(TG]TY?C/7%=CV_7B>[#VV>]VK*U6%%U2]2?,;#7#D]=^'2D8T[JP5:;%*&?* _A97,MCK?NS@>D( M#\C=JBJ_VF!#K&W*5/-&TT)#8B3Z")V7/'NG MPKT6'MZ=9;)_E"D";4.!-@EM=7.TUJ3ESI!?6C=8CTU4)BGR[!+U3@12NT$! MD2',"\B+0(C?Z6@B.,I&IZC ID7BYTBK68(U;[8,)PQ$R0H>@8;HG )P#@!N M3H%]M8Q(R5LZ-;2\!QK__2*)I;H JD1& IQ8 W47V M2ZE/"0[7/L1J%KJ-.]:V-["/M=TG!\RI98.-JH!=LOZ.6?G .>8Y 7/-(4I MP"*T;4[#(V8J7(EUFI^S_239T@B4Q$0M?O*J@5T@'G7VT\ Y@I[(I*N@\?&* MC!?9Y3]F)3BT1 ?)KM=_IK1Z09PRT0[Y0$P@?0^GZHP$7;YQG[V*:(*4_SW M+_M6FO62:C5.B"E!-Z;@@ZL4>!$*QI5IVC;?>MHF&5G$R..-=O@IK3V0MT1P ML"_Z@(XV',V'?IPH@3C;ZS"X#>9Y7)VB]-A/X&R<$*MSR$6C:478P!Y[H#6'4YCJ'5.D1W1_W%O,0JFO>V1,8@BC) M,NH9)/QW33@=^M%J7"79&9VO77V[[/OM9W9MJ01P5^,1N7 &IO*+-Q&-UQ9L MP7#1I0OA:6AJU7>;9""]"?.H<>"D4^L-!0[Y6NYX?+ZHWA,0N!K^-G;.LD5F M)(>\ACY>:8%+-G?3T+PTE./"0\BX)*K70S8\&/ <_J$L8P_TT"&4((>\ :3/ MH861T#U0= S]:F.R 7:HV/!1;(^?]]ZP(HO?N#M2O:<4)8/H#+JH:\ M$X^2?%Q_9[N/?;K7;"@GQN# K'BQ]W-$YYQR"4F!%_!N$9%B2E%,&USR7:A% M]:3-3:)CP@53=NLHL230M@P_!=R!BV2J#:"4D 8UE%),$0/3+JA7:1L+W5]: M.OI)+"Q"^$UB1?W^G.?JPE+WG/NA+I#P+-5J1KJ.Z#(\9U7BS&"C4H%U-\GD MDHWBE)W-V:#1*"6QC_2PAW.%6D[!.L_).!;QS5+!U0PTGJ3(7!TJ+5TG!,)M MQ:^K2R4I2RD=Y% [:QYW+] M= _*%6)OJZ:5._,$,&?S9&K+&JJ6.-R\S)FII);VZ[$ZO^E?A;/ 3RD:'!QM"E*B]TTX=?>)Q MJ2%(PSA=^#Y63_S7@0[!-\3#/IPN?)4%\N\6&

+PD\SF8/P%G6MEDD,I+N L_N=B[H M]LM+5ZVKUW'_;OC4:GW.LV.J-0\4R'Q)*2(>P9'JM+C>(V_T_:QZ,_ZZ\XB1V(\C^NI%$F> 0O)HTPX+UNP5*3^3\Z:"XDO;OVS_OG8RQ(L[ MW2JT\JC_:Q? M+5/YP9U@+4^\+K@*Z0S8NE&XJ&MDK6E9\MWZE%".L)\\0\G6%83HUZ76 E?B MZSK-^;(:'K--E.C(TM6Q0ULE(H-X$=MI> K:M;_D&LD_]=.Z_,+5NJ[281E) M+3:+REY1!-1F=*/Q3"XBJV/UUJ!*IGZ+:)Y+24W0U,H12^V*D49;Z@@0I!") MA0#H.876=459#Y2(ZX7I"8)M:=,3O3LITDU-9OLSGA%*MHIF/O5&*/S4$5_! MB-)ACP5M@?#B[B([5:ATW8,34L?WB; M/^%&N[:]W=+.%_CF[$^G$]P5(&VC_9_ ^(WG^^?,*CUB4>+'72[LUB=5EQRE M*?[@KNG&2RF4G_ Y82E."WA,P$=!'X'Y742.)'L'^:F.(=-MU42,((+4M:OG. MKHQP+Q_+JD9H>E!4W2%BEM-KJL3YZ2'E[YG:">(;0TB0K<#;,DC MMH$>4="C6T$"MJ5NI*&J0T07=L]:]A/K'(5+,% R.?%#5/^I]X-:NW^F#9M55W CV:&F&C? U5"FACP M#AM8U#FW6RU^(R(7L0G\5M0OG^Z&&S@U<81N\O9WEB92H\G\^6U0 L=LK4/D MCJ"]^)TZ>)=U9>K1"8-RX>,/)Z+(NKNVXA=C0-0QE"S@P&H67 43H9^C.,46 MRV?F-4<0E0^J=&GH6YTKS=V%]U7[:) P[Q+RRW7H]7!?H-V?+A/]D'*\>:)01#-M6&19XW.52=/]D MK0/PIL%;8FK&+RM3/1M D=.W/\'-+G?K&_SAGL3,Y=*X!'V1<7O/C0K,>0IIE-N,"Y]2...SBHG801 M0T";C]I.(?#M-JA4\:F6"4)G@9V4\;G\]V<>*.+[O*U=* VSOY:X2&U ^KL] MT*-.U!/'(6AESJ;]#W37B5V"[9C([BHU"[A%4M\#.6V$H\$V>(O1^*PO^5<* ME%Q^RAP]-&[TFJ\\T?5%OM1L0M4:5!CJ#&$#>F<%ZLBA+=,B%8/W:T/R!Q^4 MASRP*CO*G@![Y3/Y\?#/W(2M?9,.B(GFWW[1YY#B:%*@D(_;==5DV.##^IO: MWV2EW_)JO@$=ECH"4BZ >3N<9K;$ST$3T+P>.MIT@\\/4UN8D&IR3]: L^+D MJ3U0KO':U,2TN:;ET/2)6FQEGT)IY1SL#9\D)0CD^\\3E.U#>$*"/72": MTCJ[$:UEP63OTY%9LJQO>[)"<"LM%.VN\ZZ['-IY5RSD:W.WYQZ(%PK?B(!R M,2\M0SF05PJM]4?[*E9L7A&*;^+SQ-/[G6[M&!>:UTF>#%G FO<5HTX"10YD M<$QDJ ^/YNUR(/J)CPG8 /"M5B%HH5V>I#0;.V2$E6>.JYH$X#[1X M:YT68GQHY*+XM6$XSU7O705*"U0OR=>5CZ;-PXN!\CW022[H;]),3YT& MZ,RM#7/S_.ELCO[_O%ILF84:A(IZH)WW0!$FE/U=K;%%1HQW!S]5),WB&[Y+ M/3P*EA2_J"L1>0WA$8YV58CV1?-70B*A(EBNLHAW%->OTY#&2 OCS.\?P:DG M[-F\LC^#2%] M-=@K7]LSX_G%R>! 15# 8'F'W((F>B)P[L*0UD6^/5!%+@H6+^]-?)W8=FPW ME?=>T%KAO^ZMJZ\V;>AP,@=WLI3[M5P4VL&'RB*W%?9_[RJ9F+C+>*=R MP.G;L2%ZW,7>)Q(($)4G1[V=_]==A^J=M@GH$6ND(T5AC4E%@\LV!(2VWVR' M)2VHC5,/VYSL&?#2.&)@KV]'>T*_"0RS#"L@T$N.OUSX:_]7// M%V^M[IE&<7L@53FMWLD[E!<.\E>,Z;D23]!@5%" M\PA_;UKH_+$.72?Q?6I-,@D17P+;50,8D1$;94CY''R!JQGA*U5%Z>ZA%)(9 M[JR@U@F9.&HV#^>S>P>;^'_!UB0IT+G$>(.H4Y215Z-I-T2ZQY*MZD<.?+;Y MWG#1M7Q;EAUUOUT'/1%*%M.[:?;>(>H8\']EZNA M#MK,T1D^'4W$E;F:X&?0?8^[J:(E5P2>XDL.65JE_I@Z4$3G;+R?H#?YF&W9 M-0&>;FOV88&D1L/S.W!PI3!"!70HFW SY4D3HN M=.>U?CQ(TVZZS2!@ITI5552/L[/#,QFY=!-/F6"F^ I4%,O7X@,O$[/I(/A\ MJ.\2?]7^YES('$>WJ*XF8G7(C*/_'D]MN^>,");/@7Z7/%\:_P&I/T)7TLY< MF6P-?/_]X_>FHVP_D%T]3P\MEL+C 3S-$+'8ZB!X#LM!%P#N8F4I;"XX@DC2 MI"N7&T_QP2A0@V?M');C>VVG% >2G5'@HQ#C.ZU:QY+5$ZWRLPTAXML54[L# MW%(1)F-F^VX)+QE>VNI8-0.:6L?TT:S5SH'M,\K#1V8:Q^NO MQAO6),"'8NI-!AK--P#L9=LX;@[%]O]BL7O/_10 M5ZIRC O^_H6O6B-YR004&*'>S?]V3FZ#=SE+ (LC.X4*Y'^\=A@NK@-_MQ\F M\^@\XN:&_3X6\]D%4BDU>(+I%TABLIG2OS6=_4GSS;?6W.&/D[ M;T,7A>?$^C@&&@0'7F5PIY$QXZ/4]T =37>%,CV&%*CY3)ZJSO-T+EIU*Y83 MFN+U.C1WTGI75C2.9[JCG'D!-8&5!:"DJW(.3^"">[VP!%;3/_A:%Q;)? M4& MB>((:!.*'?"!1"MHW4N]W&V:+?^M4^2=J94;P>]'DCZ?1)5@LP(AT8IU M023R*=*?S*C,#&RZI0$7,2>HS6N\NBC\._QF#[DO2"FU[^<@;MF\DP=]T#58';>WGI MIJ-(+C)X-@XE54$NS:ZV62CT+\[[&+WC]BQ.U2Y7)0#S@O+U*T?]:Z$F?KY4 ME1T=P6^N.O3LL_P*FJV2]!Q+TZ;[ [(,>?$!9;&WW..I0,H&_I-'Z M<=D[ZH'BZ>&#SJ()BH:T+\W98%3B3TX?A .+J_N1IM,I<^; 83)F]@LNJHI+ M7$)TNS;=RO;9[7L-L3]!(*Z#0D^2@I0L=228 ]B+ )[LV&8O24YL]9!L9QF\ MI%8S,F,DM[S8^[SJA72AIH-1<^IW X[O6^NYHS_W>]#-7;[LA&V144Z*JK"1 MY+UOK4/'')107W''L&> 5>JMD2IHK :;:YJ6S?GW([^[1RIMYFXWOS'B"OG5 MQL<34I'A)6=)],.7[4<>8T0\@\182!Q)&\$_>>$2P.W7K=FI.?7MG=:HL/J] M'B,Q[F"U_<$Z,;H7!S+8U?8W0IHA50;MVIHD5"AYE!H"G-(ZRY2;O,0U86*C MF:MXL/>UK$/M%,=PI% G'^HD"S %+J&CIY58HG]N-AQ;BX0XI=:D5L O\PLP MK?P>%"O:9APT]W[^F&W)]0=*D:Y)$6S; QU6B* K4^1ND8M)RP_=C*^;/7S$ MV83OA)R96AV[I<.&M R=0[>X04@^U2E/<)7K74:/'T[-&Q;?"583%KX5FO Z MFF: ZE.B@P>WM%5;F>#4-HD3%)T\JCB74<+L5>GDN!3O'=US.; M9D+MA0$P>:67V!N^6%L;,95E5/JS?.'N]?6ZS.I@I;$ $(=34M+J?W35RTN7\:X?44GY>N,G+3LKDQW>K7.4]1K5*:IM)<:SB>V]X7 B M3L#&Q=FL_/F,N6ULX%?O!''4@E64_AI*LG\E%NJ4Y\'>_>S^P+:1\KRUZ$XZ MFY&0>;/1@8?<[$*=7Z785CXF-0;.X==-',D.+=."];'Z-?4LO):"?QB?=MU/ M(!PKMS%R>AO!SQN0\%9]]JD+I@*S;H:ZU$W"'(&+G,]T*T98PN^*0V[1[F1. MWBAF 6K3U]VGB*^]97S[UEY9?M,PH//)D.Q&0[4T*8Y6#,Q<%3FAL(3G/,W" M[K'FN?8QITL$H8([*TW[OWT#7PY2HKY@% [.UL0^@T3\9G_]80INLZ5H6@%/ M^U1141&BJ-7YD!#P^AY(6"K@Q2&.\IOVCK3SJ/X43*5EV+;\=;=3XM#;__R*;QW\X@9/1@.R7DN&-M941:OE7NT:]1Z$B2:T+[O!I M64FM8[H2PF26/;"GS/>V)8+I, !/28+Q&1"++%C4)J"]. M)TD?O3OD/I/1S<)T>99-:)\1-<56*,2<6YNU@Z[13' O^3P7?5%/UGKUXD:S M^W4EH!0#JBL%54*Y[A$WPZYSUHAHYVU6;FOB'/1\\AHB"J1_%A^Q[_8S+=D. M]6^ ']5L$*E !KLCO4T\3RO2]A%UQ0(]ZK/;IQT1RZ]#\+:-U=(."G5+HI7Z JQ4:UJ MX;CP'0?RFWRZ;2YAE:K$3-\LF%O8U=GXXHH0I+J7D_'1.B=74"=&!&^64Q@= MM-ACAQ._QA45G5[+2(*4";4'A 56;\J%,/*PJITT;:0\AG09>.3C%+$II-,Q MFJ6K.2$\55[/XM]=ZWN@^V4B=Y>JT9R-URC4WS0B%1-0<25;)2U6JZ#LRP-_ M/5K=1IP?R#/Q,B,/ZMS5FV C$,D1J67'""U$^-TQ7E=<77MO-3QT;W^=N)ID MV0W'M*TV=_5+*Z!-2!RT@G^G8R:"*=Z/O#]G^(.B&OG0-DJY\U+MCPC_VE\' M4M8W7P7ER V&- NSCS9!QDDT(D]$A&*] W8C M8#3[N(&>P4 ,B#(3 JEPCD,=0LS9UE4 &373_,,;Y\_O@3[]&!Q^:#1_[XJP MHA$A.^$"^"[GO#ON?J*(K8M-:BOD,!+9.(AD*[*OW+&',+\;I"D[ E+I$W6G&'9Q 3[:EN'A^6/^V.)I\S.7GUJS A.WGT4Y$]/T4B MF;0' EL!^7H9W8X%A+SVW&YA(.P9*ZM;1X#VNP59?9.GZ!LQ*#$$:WVE!:CH-GT$$^TS)@G(^8"84QF+1.Q? .;AQ 8$7;\>3>6(/C',I8Q[N^COSYBY&;=8IKST MJG"G@&T!3!C9(>Z$H!_S*.!M_/"V92#@H]N!=A_D;[&:E%2+9N9MMX\&;T?C MCH7?7=?T0C4S^;+V0,V0XXV/YKBZ&%>N4?3+3L3>'BJY<6O%8B7)/Y5=Q_"( M]"SW[ ]N$C:KKJJJ(?9;0U7"G1[?KR$10?Z%*J47JX.AJO3[GOEP#*<\DQ,I MS/)2ZTW'4-2F%4E:ICH,H34"I ME:JJD1N JB*.&E5.C!>;KTB[?91*,,S=?:@_5L=1G_ %_%$^\_U=98)-Q^=/ MK8;E\6T!O.9F'*^9O3,57S::&0HV;H%V PI5\O!]"P-()7B^P8'[AH<.R')Q M9\QF[%<#)9F6K?63S6$L DU4QK0:5D7+<@[X56"GT8:K^@4%)V:E/4,CQ2^9WUH-DM=K4>6 M;12.WP,Y0\<;.B @Y)W22S,RMM#'T\_C?756H92J>2/ZB^+#Y+#+;X0X MU)O*[KT/UF*!I#,@K+JV2V:N-@M*G+(S*E5.C]VHE,>EUGSGVG24^3!=MV%_ MA00&9,JBMK6A[5E"@U@%0G,ND&RED7":O.4U%BMR++%46::A.EPBD,3Y'AJ6ZP[]K#@OA*> M.D>?!?W8UH=N'9-;VBXX;IU],_1+E)DVF"@!4265CA?LGYPH&]L#S;4G]W1X MC26_]1Y#8K>7*\TX>C&'T0]ZCP'0.=-T2B+>X?C:MF:)Q)F1X4LX<.N#'9-3 MBH*UCRD+8A=7DTP5/5\\\]D#C<-(*M$4)1O*8E-9PG&$Q4S;3I%?Z7*2BXM7 M_%.AE)>JQYZW)1EP+&C-_7&8W[=0LP?:KZ ,(6@: +N>I+"I/,"G0ATJOGW$(Z7>;"; IZ3"4')R42E#"-%E0>KWM9,NC?.W_SSQV:N M9(R^[]>%R "X9C1O(XOO'SQ .0?E8IXT(@8N-7)Q%Q6*:[M+OKUB6QC^NK9Y M4E1;3\]^G*:-ZO6%L#4>*W@L.'TRW7IHNV'90WG=YO:8N].+>[/>P1RF1ITR M6(Z<4W'.?"L@BD((]/-B/!:,U*$(ML3.Q')]1*#-!G_*;QD[#5[U>##(,;VF MU[7HZYGAK-;A&H@>9]/#,5ZOH9TPO$",$:ZB5;NTPHT='S'7XV]^QQQF,F_8 M>R)+'[&D!:',T^_0K@&XV8ODIA"D0CYA,O[6>GI\;R:?N=LFE>?-KXN9>+7U M+&V18"UHD\/GU$0'DGTL16ZNMZ.PT4XU?!A'E*BPTW:;B[E\<:$S$3O%S#YN M>M'6 EIQ8P3-IW,*>4WGG+Z#^./WS?*H;^C^BX*IC=4;Z:-"_*N'!PH1Z6T: ML# DU)^4Z>7-DX!QW1$T+WY4K1]CE0$RFGW&4K,7:5I(Z?19AQ9M!6(8X=L* MSX?BT/58<(K4E"1TJA-_UZ=XAJ! #8R=RTK/F79!R=7VL<8!S\IEFMZ(/.FX M_W'*BV^&D_FN.RLY92=^6M-MR3M1J.-&E,0FJE_:2!;A24V*"K5ZK<(NC&?S MK-J!BV=U#]S9 T5@%6N!\%D[I0X_E#"V_\>0?%C)!U>CZL?JDMQ0[L0'&F8< M671>1IK6E5E?B.YW?Y,_2&@)Q7 ?ED +E M9B]W2HCF"*9L&;[U;% R_C/YH^%7K>)G;$\[?1S1(60E;]\"TO_GYA(*J# MI'UX55<"1NFB6@WJJ"-X6S7<%@H%,DN!^XY!*K]MA7Z^FRJW,/S_VCOW<*C6 MMH$O6Z+$Y'R*J105DE**8<)&LAFE(L?=MLLQXVQB&)%#R!3)CAC'G,UVG'*: M M9QJLD_9[UVEY8!6(0^1?>LBQ\IX%E' -,]LMH?-DK;TMQ',4L37<6L[:K<;0 M]H0UU]&6C78'S8(,QE/X=5YX[! S>J)6R+:LSV>!7RU_"\4C@:Z!0NX'X9C>""GK5-\<*+PR7T.+,#::GU0_E]. MOI-E5,!\,E"R8VT8I)-_0K]Z:C977,O3.;YK<8U/#(^'5NX7#A^;W./1[S]E M-EBCD8;*,4K\D:)UUR'OZD\J)U,^EQH+875B>>"1:9!'+,!>VI8%-!#+':+J M1!TWPI.JQ.BR"KE'4S+GXIQ%'U'W6SS\;2IH\MQP\!+V_#*!C$[$E!E$,L\0 MHBN:!FO@$SG1!G&:%[6E2Q_;\U5XO=2HH]IR!7Y(IPF]&!%[)I8J17:+SVFO M!%^C5UV]9]*O\7M-35V2?@XLS#:I,46HPN]Z M,4\Q=+'X'.P)7^/:JX)-24N4D FCL&[?.[0JY:>-S@C^""?I\'0/7S?>_,B' MN0\9J_I=U=Z&24D*,A\J]H$_7SZX;7.LVY8)'^1,B5Q'A MMGL'8%!.P_RA&:K@+*4PX+?VDA)K95>D.-!=%<'"L8G2^VFDB&AEMF4!M MY'->EVJ4=!TJ>]7W^X/H'>EP'S.@(#5'7-XG*#9_L5!"2X!^.&E\>=DNW!;J M5"'*;9I0;L%KL]L3UE"F',(Q#0-;V8CA *MXIA ^@KF=0HA"EB,XYM0(.\9= MYC0>A=DD&"0(%]?N3GT^(0%O2.I@/#S0BVU&RJ /TES&VSYXD6HK'^\N>^3R M\5GX"*F?.U8"89\XX^X[G5JQ^JB:M,#;N.&=I!:Y:F6LTWGM;A&R*,YQ]%,A M#SS!@+2TD^90K^X\,R)$_AR;>"/BL,O3=UDJ^!Y3C@U3[@:Q)+\FJ,#5D: 6 MT;J]_8EF9#=\H3,V7_'>X_D) L3Q>:?)^A[*V^.?F_SQ\V'C>,&@;HSP2216 MLL_&P"$39=NE3P@WV*]6NZQK_4SZ],T1VOU A=E#-0JDWWP>UQB*112:7WB& M;7O6+]JQK5>>>I7R+)9[VT24;P0)RT?[I;5\E \5U((@Q.DL<=W+UXEI*1 Q MW8XH M#T;TH55+0GY MJATNMS;OM\9\%(0_;]94^.1BPZM?TINH4])[,[WD'+VB-(K+0L=>2H>V_D$^ ]N&NYA5/U%]4SG#__(G)V\DBL2R/< M84&WT1PG@.88Q_.BR@S+!CYKC,/T5)FGXSZN6&*9EEEK[;AJ=XXCA?ZW8YY( M;E:];FXS+L,B^@HG"(2P'W2WJ82=Z_*T3 RY*Z/(]A&$:!!#?J5BS+?(0,"GS8I]ASN MO&SSL#06 5#S(,%TB%:$6-A3\HVX#>NC,GPGRV?NU;CNV/=(LUJ[%79[)%@+ MD;CF1^ZBG^PDD)5J[,?#R8N98\2%>Q<_5,S^E$@X3](]S["+K^8F$D0^$=E_ M>M[M8KN7D:2Z-O#9L#BIZV)5!2%N7*>]1)9>$/_6@;/;P[:-_4_J"/[*$3EU MKL2U>*MUOMS !-B*J-?44O,"<7Y:> '2,,0=KJB?2"KB[T)4\'BOM214ML2X8T5.Y6KY&8E=E 'IC )9C2&)*+)CE@!.5" MZ1KUD!Y06_D3R]-.$SD*/![6R@&TPB,.F"=JB,OB3!EKMEM/-IXO] M6?)MSZ+&##]Z;38$'[,Z&&!&O$:\8RO0$W0:;?)FGH^:0L*)6#MMV#W&R!Z^ M4]ZZ^0*Q)+53ZT8K/M=[B=]14H_QL2![QM=WT#)4P>Z#U5"&H6=;RE-]SJ/Z M)B>>_-KKE"I)7KOKY1.0X7C*U\O.>-K.R,7Y047[$_KBI1\66B'W* M]@O]Y.OA MO'W<2"/L.%?C =RAA?YY93\:&JRX<;<.M:JHWG]X_ MC7\5#.G-)'<%HWG'*JLPW"AEPU[+-6/JO:=.)5;K"UWMF\)NL%03_V[N!G7] M@C'L3DMMM 9)W1RP7D +N2T4&@(2SP_MC[K(7 @#%+.]T%;J?.X MILM$5\C@>.+" FDT?*/E[DDC31DJ:5@KW>7IJ*H/ZV<-'(W67^2=:Y]J_?G#_MP;=&.;^ 9;Z61;;-,) MQU,W\QJ0D[JY%?D2O8KQOQO>>^F)D&B1'PB6(B'YG.KXR9W))"7Q*N M"S^6BB*/'N!Y;M^VYU"KILL48L@P2&8.6CF%OZ-UC*Y;TTT_$3#6)*:C>;5H M7RI"Y76+0@A@%K,2?#ZW(]#79+OQ+>A=S(V/%(<%&%&BQE &F^NH1++/1F2. M6JUW'$AN?"D/,V!$MU0)T718Q:-=0@:Y:+%\FQ_:A^Q M>W#&VT#S\MG($!5JV>TGE_%OS4AAY78Q@1FY:(\BR4<9/ME<@QFGTE,K!TJ !?V9Z M,:V A C1.D4+6=(F^SYWF$;EN]SJJ+EHR],?F>U!O:2RZ*XF]%9@-9CF0)ZM M.0=S'@%Z3$KA'Y49"9 AXM+B!Q909$V!AJ%/3/"IK")$:9XME\KN3\U_5E!- ME=LH"(%,G84J,9L>!7'V$5WPD0-VNV"7/8H<36=\/68WPII(SX[F[[\88D;M M$1=L13ZSI5KUHC!$8%[&2OK4=C_7 M'\X<-^#<\UEB$Z=+AH?"5#R1,#62M#(B(#Y_SSO_G05^ MY!Q24'J^S9S?*+^J!%YYXEV@WU$LIZ'G\\YWXL76O_+OT#S$.6TW%-KH_S"( MFP8G(851>-,>NDCQP7+;H_V%BY*:K9,_7CYPW]OLD3S,(]5W4!M/W\_ ?4:^ M$VJRE:09CL\5N>CU,=\$[JJLVQ\W_;HJ2J[Q6FC@RY97IW_V]'HR6&='O=<'/L2L1.$GD%*H%?:ROT TO*X'K9MG,?1)R'*8EFA1XKOY MHZCK,O+FQ$>),2&<&PU^R1&WJTZ*YMR[T=! A*QJ\)Q$K._4O9[5(&A#-EC2 MR15T[Z"6]6^\V;3CFQ'U/T)SZ],IBS:QJ*GHFZC0NR-/]>4@R+QM M#9Y)-T MKC'EH3EM,F2^@2*X:4U.S4ZSMD:5OO'1KZX@/)3]+?M#]SEK?9Y/:O9UW/O& M,1&B+$"P&.Z(%:1%-UD.$4(_Y^'+%:QL#'O%KIJ=5# MSFE@ 3_0! \KT07&:N4-8F]\4/6_DBQ2]0I\(V7*SUV4#X&)23JKY-Q9?5'U M4OZ*W>\&T;U>.(TIQK09&[^;6V/SE$L2_BX30*DUJD]-O+>U1=WH-$J^RV]I MOFRNB/#TQ_DOY$MK&/>5!_!XU\K52UE9H1I]U]8H/!/W#/0N P!W6E[N_[8] M&/_JB6:8:.CR[C(64*Q$GXLO+AMOH=]19 %ST1CUR9GORP[_IRX[_"K\D?=W,%)17G^QB!J#[+^V<1 M_M-//?_'=UCYJX3$5,2\TNEB/B.L%)M4=7U[*_ZK/0Z^E9G9_K>S_SBZ;M:W MV'=XENK(X?@G,?[3A]/_@_T(_N*A_@Q40[V8C-SS<$?EBU"EG?1/)K<*,;3+ MZA$,KG060+P1?$;]TN:;-RR@/J\?/J,$86RJ0L+4@\\P!R.8C"1@:J:X@"EB M"V;5ML LA1K0C]3J,D-^9P&CVX//6"KDLX P\UQ,]Q7HYE@/"]B)-V4!:85P MZLLT_BM9QO5[[+P=07$\'$WLIX/E%R 9P$S2F*@Q;\\[82T M>M5UFGT0<468[1:<=-6.!72;@-1@FI[W*+F0?9T\A$%V!#VZC@&A3X/NGMW3 M(=*'J2]E*WH">I7)%$E@ 8QM)!90QP=XJ9H;@SZ_9@',$'=V1+"T*^8L8%4H M@DE3Y6COZUL<-/B']"=:DB.WL0NGB6S-'T1ZP:!7UK)5VVVIKEAB;!O_HOG2 MY)P-E*[@,KJQHXD%H"4OTY#^.?"A"QAVV(<4,D%(KP 0\A!Q*=Z KI ,YM,# M\R4!TX>*L4R1#E!3!JC)&$HN1F)F#HHQP-[KDXPJ.,UG&27Y$4Z7L3,:N[ MV1HX0O60F/H=?J Y'M <&*__=-+%*]WD@V-G-M$8:BM8L2%@+CC(PX[63%$7 M37N1!4QO?&74'*6S (.MPFG((,!)W-4L #?S5245L\* L@N'/^H]"[@CL\3$ M9'XIMU"P\].U"NI/VZ7NZ5.$_[O27GR(V^W6NBV2>WHW,?5B;/,E;/-8F@X[ MUQH[6MN51"I \S:C="8[LF"=YV5;?LNV?%9\MC?%BG=L.$UE[>T7E'V#\)7U M+129*/#4'?5I)D;V"TJ$-8@RN87BKV#/W#V'6Z=CMZJ0M!=H^<&6XRHS15B: M;C%F>OFKWSY==.87MULR*N$D_N>@\5=_M'50W:S@*GJ?^W:^<;"N)3(%I+#K M= 2;7D\$O"-Y[K70F?)@1A!(?X*)$6+[_$#/!;QQ9#U TW>_.";P#-3=N%4/ M?KU@R0+(D>\Q76R%6-J/;O!I"AST6$+X"I&^7PVZ0L-16S/_0X8>IAQ^DULG MG**O-4"DMF:#25008'-X/2%083-4+[%F#^:?@LF6)X+3$P:U\R,#(P,3(S,2YH=&WL MO6EWXLB6*/KYO;7>?]!SW[J=N1Z0X-G.JKR+])!%'T_7.*NZWA>O0 I QT*B M--BF?OW=>\>@$ @,'K# .JN[TH"&B!U['G_]7X\#S[+N>1BY@?_;1J-6W["X M;P>.Z_=^VTCB;G5_XW]]^W_^[U__WVK5.CYM75A-.W;O^;$;V5X0)2'_U#[_ M;+5\S_6Y]=_?K\^LX\!.!MR/K:K5C^/AX9"+ M5:VJ!Q^%G.$/UC&+N47_.[0VZYN-:GVKNKES4]\\W-DYK._4MK<.M@ZV]_^_ M>OVP7C<>\(?8@&7\[]#:J=5KC=K.7L.X\(K9=ZS'K=:Q<>'N%MO:LKN- [9E M;V_QG4YWI]/8WN'=O<[6 :MOFBL-AJ/0[?5CZY/]F98(^_5][GE\9)VZ/O-M MEWE66^VT J"Q:U;3\ZQKO"VRKGG$PWONU.13^S&< )R"'QT^=D+/_6W#@!I^ M4PO"WI?->GWK"T PAA?P#>-Z)[W!O'CWB_A171J-.H^9)T\]X1Q[@UYE[KVE!6Y=L[E/G/M*/\&^@GW ML)>]A3_:_?P[\)>\=R2#?+1PXO +;OD+7,%#U]8W $X^?4_@5\?N<[A;C6(G M?W'RQYSUX2] \;-OE1?DWS[UMIS+[20,@4>-\N]1O^;=&"1^'$Z[3_R8<]LC M\+:[#"P?M@B2C8.#@R_TJZ: .)Q*OP=?X%=UX<0CLY2./W=8I"G=C8+MS<;> M+-X@KM!KCMR\%<.EC2__?7[6MOM\P*KC#,5]G/:&!G(?Y/'(XM/+X_SKTTN_ MQ"'SHVX0#HC!XY-VJO7-ZN:N\9 JG$&6.>HY^^DI33\?9+ ;Q&DY<_#? M 8\9B:8J_SMQ[W_;. K\&+'S!JABP[+%I]\V8OX8?Z&[K2]X7^S&'H<_D)=6 M&_6[6\4T:W 1_/Y%7?#K%_4J%!D7/T!J^"!B8QY:]RB4-FL[2GAU F?T[5?' MO;>B>.3QWS8<-QIZ;(04S''5_]>O[N,A/HZ'^$E\=!V'^_21/L.U%X*.+1<( M\/2VCO\#R/AL@(_D[F$3)+*#4OG48SVYQ\?XFG=A]WAY8V=S;^?@@+94;]0; M>F\;W[K,B_BO7S+O>>K=V^:[E4)P"CH#\Z[@VL YA>^BQ=9Q^M>"B]@S%W'B MP^F,CF 9(?-:OL,?_\5'BRT@_77!A>R;"SDB_B2!\1=GX8GOH-JSV%JJU<8F M(/]""]EJU-5"I$ ^/.-1Q/GED(= 5G[OC //.7ET(R FU]V+X=(;#?!R2-\ MX2RVPCA,%L.:K<;F^/*N^3WW$WX5,E Z 5PGCT/NN ]4*I"CCC%O*,@BF&E MG9BY/FP!:1DO?_/%[HXO]JC/_!YO^4V;1 FLY2IT01T<>CS]J@W\UF&A$_T< M.G#H32<8QGP69.73F\Z_DRC&'4>G07C!'\RW!#[\:1,\HB:- MS7,^Z/#P95#8?PTHM ; U>')<,#=+I]Y=@4'Q\%J(\5^8^L5H+#96!.D>"5P M3+"U54.*G=> PO;:(,6K@&-GU9%B_S6@L+"J%U-]>NA[ \LD!LA;._5? M%EORYH0:]'HJ96.OOD=+Q3^>!]'-"?UDSN7=\)#@/5LM?XT53DB'O!7B\R]@F42; M:(N?!7X/[P5B@?>[]QRO0 =!TW<0'IHR&P<2]U'=(QCM_[5_WM@\7A!.$TBU M9G":X!$ I^WSS>U%X32A#;\43G_P"$'C.V@(VO#G38!?+0Z^Q@J [V#"6G\I M^$X>>6B[$4J+8L)I[QGDN+L]H5EF>>>TK6K&.FN3F<5M/F-Q$R+]51=G,+(G M%W=*7I3 MQ+?%0_[>2N]QC_;QQN&PVIOTF()!@-7*$QPBH@DL$:0F"Y_RHDG M@TJ1>^B[WF\;*" WOJEEJB4]=YU;K[5."<>YUDE?&BY87';(NQRC#CR26T$' M_F%$7G9XGT5!@D.,NORV$;D#T&8WY'?]$)=#+F7M3GZ,'/4S"^TP0+_PW*&" M!:(5\P8A [9_:1P&-NX@$44)&$*"HIJ'DK@T^D]I9+2?>I&3HY;^9WZTG7P MZZX+>BLMBN>&#XY:_\IZ;<=O5F_ZDO,J^:8AN:O'7@_2)HS1:?M-18OJ#?60 M]+?L/5RX><4=TGF;_26[&//%ZCL)Q Q@D4H(JC]OZ8L()4 T!L0!L),DY-_D M$ND2]5#U6^9-^-2YSZ]!CL#B'YL(=\7?5&9!8U\_6_[RXB,P&%7^"<@+#N&* MUSL $#1;]=4Z *":W>I6_74.8"9L5H2G9&"3X0]O!ANE/:P0;!H'KPF;7,*= MP48=]QXV,[8X? CI6RP.U X7)OLLX4\\SGC5,?<#;QRRY=HM,F MF_%-GY^S\(['E]TN+-CO3<^47%NL6E1[660%T\"_\0WA?SCU ):O?;]W3MD2 ME*Z2)I:BO)7T\2[T\:&QNL2C=_=RK ,:%=K=L798])2+Y.-@5 %\)>N'70OX M5SX0IA7+T;)V6#?5.?-Q4*PH\:2UP*=\36O-,>C=XTE+*H=Y765IS9&B #I2 ML1%D(7UGW9&E6&I.H1%GALJRYEA2C'C2F)N7KL'YME]JK^-X M=!1RD,>GS'8]V)S)3\YX'//PLBNN6 -N,KG5E(7D;7:]&7 M'.OUL(G:[/4#SVD-AF%P+YK^?EC,F@&-CX=E1F\@U!S:8F=3NGJ1;B$O40]] M85LO[6I>PJ2#U^:-8\]YX/.1R$D^37Q'F0#*K\'< M\ _F)?S[Z%PH=0B%TY#_G>"DR8P+1%UJ7!A=5H2> M9AQP#DE-'G%)Y!^6R+=*(E]W(I_/GBV)_*V(_+5I2E[;\N^YL"S&_>.8_(LS M@S#/$S:Q!J2X;(Q;8&F3QY#-PIXXB ^#[,^42)MO*Y$^-O4\6XC,YV4O2;HD MZ>4KF25)?TR]L"3I@JFDIZ[/? 1D"U8?)GAIE@S#81"RF!_S3MS&1[BQR]>A M6F+*QDTQK0.PKKUNO#[&_ ML8F)2:0_VS& M^TM&L J,X-U"-B4C^*"V:,D("LD(WBW04S*"#VJGEHS@;1G!A\\"+!TOZV55 MK@DN?EP;\,,3R!M;6Q^=0%;>-OKP!%+6-)0VPQH32/$*8U>X/V&Q:GQ6$_V7 MVT3Q_6OFWMQ"*>GIO?,W2BOIHQ/YFRN1)9&_-Y&7BNS[$GEAZH!6EQ17+-R2 M9G(6H.3FW9"]F'Z_CTT]']==6)+TVGHJ2Y+^F'IA2=(%4TE?6-.SPN18O)J> MTC);'V6UI*OBT-7'U: _/+&O1&%L2>Q%(/:5UZW7A]@+FY*_PI2Z6H;>JF2_ MKYH\7,%ZN+6@N8^K@I:,H)",8 7KX3XV(UAY];1D!"N@-*\)E97VUEK4PZT% M+I:9GA^60-Z\'NYC$\C*VT8?GD#*5.;29EAC OE(??\+GZZSY%KALE?N&X0$ MUQLI?K93ET:S!PP5P/+Q\&->**PWJGRDS-C"BXXEJ]5E-LDJB(Y"(<4"HF.- M\:.HHN-U427Q78$G/RF8EG+/L3,="+-+1$[2J]2CU<^9]^&S9[U,0G(TZU7J MFL5>]!0!7(4! "@>77D N:;O8'WO$/?S?30N(?5/:Z NS;'M%/_'-K[>&M*+ M$&)UF> J(<1R1>0\"($,"E3*81+S$"ZY['9=FW\X?D%L^BDPE-QC3F19GH2@F8#Z@Y<=NH^XE_KX+592.I,AT')4^9!DS5G*,5#D\)RDS,P MG7@_\)S68!B":4LAM(_&3F8 H>0GWVO =MZ1X2Q\ M"@#I,#YF,?^&J\=SJ.MS2'_+WL-]1]XQ3N3JE[/XX?IWO>"[&SP$X5W4\NUL5EX[AEL0@9%.XA&Z @*?CS4]Q3AM MX+?CP+XS.$1]EPX9_]BJKR*KF!^2TE$R!99/<(H%5C3S-+)Q\\QY+(=7F50" MW*J^NQ"5B#NVZBM%)25ZOXL@S"#*&^E,41A?,[\GO<%A?,X>W4$RR++'(X]% MT67W3Q8" ./+\-KM]6.--5_5&$<-F;R'%2KKYF'2SDC*K ML)3Y=K1'+4OBDWL^66$]]O.+Z;:AZ+91W]K<*>EV5>G6A$8.^J3!]UP$>@>J M;BQ,U7#Y5G5SI\C^EU66?Q_2/_$4&EP.16Z=PQ^Y=JP!7LP0O+FH\!&0 --V+]@@ MK=%4[9];OHV+O^=X!9SYCNGW:TB_WZIB@KEK*2V>V/?[N+X64SC&,YK?5N%X M-OM89\/[W?G(*AFBS\R%+O'O+?#O]6(4!*"FNO>NDS!/ MBV!U>!$8WA< 6?4QB__S2VYX#/RSMPXD@.Z]7,!)*3X;=*]' HLH$!GPES10 M#!I8826VI(&UTZ5?@L>KAKXK@C[O5G[^ K%>HL(']G2?&"A M,QZ7O>91'+IVS)VULX\S^TWMT=P=E_KXB[!E#1A-L;%EK7A+B21OH90L5S]= M4)B4![[J6N@S_>QK(!E6)K. %[7( M>2[JEQB_\,M7I+!LN9WV2OPK1-N\53O^4O*6$:;VTD(@II')X^V MEX E>AH& S%6F,(BE]T3%OJNWXNN>-CNLY!_'^4_0"/03_^>1S%WQC*D- 2NR< Y2E2"PF?J^!F/V@^%UTT?V6^/U!0K9OB=@%#.5]9([]0<+) M'PRC2QX]I%/ IP NT&.PAK'DT@OB] PHEGPZ/Y'PACTVD[@? #A'NJA87Q'S MT&?>-;_G?@)0#^]=F[>NVVO@1IB^^Q2=GMC_>CL67@,]5E<$KR!Z++?>;Q) M67$&?*OI.YB/Z_T7\.K(<>TQ-6U]4&-<",W<>XD6,]%BOT2+Y:#%_JH)DS50 M@E=&JJRV'KL8RUE+O"H@[UEMG%J47ZG(+'L\"KGCQD%[MZ1J8 M5%/W.EE;^MJY2BO#6(MCS2W")#\@,K\M2WU'JBHX(AN#5I,XC/[NQE/&K,*O MA_BS>M@+AZQBH[CZG@@M[B_G0Z8XWEZ@K!$_#.AJ#S1LQ MY]DS$=\/\9[S#NA%:;9=__\DX0_PB 9GKD#-^;.FM#9L=2=8ERTD'W5?!S9?THL_+[Y@+#RT4OG.;A MV'&J!,/Y#O0=0JC["X=0]Y=B4!4 )]<3L%KE?I6Y[ZNLJB]I6GO!%>36%>2QS\KS7 Z/!7ANOVM/@A<# M=C$>NZ1*?X+GG@+LZO%8!-."7M6#)?'8QH'DL>^52?52P"[(8U\GY?O7+^[C M8Z/ &3)'(NN /UG4P M8+[X[8%C'Z%#/P@'S),WXXO5-_3T&*V4+GP!W_I<7'7/0A?LQ4-+7KCQ+?[U MR_#;:BZ].[[T3A#"D:BE'P=)Q^/69FUS!Q8V9([C^CWU8R/=US-WNO'M?_Y' M8[?^=7P1=!/SW)Y_B+.%>&@^=2OWM7GOD7#J!)YCOGAW'A@_%Z _+UHW)\=6 M^Z9Y<]*VYM[88@!\CXVU3XY^7K=N6K"KYL6Q=?+?1[\W+WZ<6$>7Y^>M=KMU M>;'DW=;?GUN_@N" BRZ2 0@=FV3T*,VW=4"15^2V;XH/G\Y9>">V<.GSSXH\09=0.Q& 1_!\157MUYBA M/!,G\-L&((S-/0_.S0; Z\_R(.AS5BS:@>>Q8<0/U1]?K0?7B?O C0 ,X@VD MS\2.=4_O!@0(AOHQXN+MVL[V+U\?^F[,J_ANW/I#R(8;BRD1^5"7<&[S7L"M MGRVK/1K C[F,\[E@GTH,RUW%-#ZPM9G'!YJ^GV 6VC (XX7X@84K8?%O&RXL M#;1UV&7@=9CG!7$G>$02.MC;WOTZP3%2=O#KE]C)08K7..WG >]I@M1'M/&M M>7'QLWEF79]<75[?6%<_K]L_FQORVFKL?'(^6Y>G MULWO)Y:A,FAUH7ET S_+6PZVMBT-(/A/B/]!"OVF#()EZ81OJDR=:(L]#BV+%TABS+Q>$K,K-.A GV;"0^=+"%,-S;=]@(%\/]C6_'W!9Q MFZU&9<:RMO*6=4K[^@N>= K?1(M)6_QKDG;&/R_3/GA37 :64C-I!18(76R\ZNKDNG5Y M;)U>7YZ+"]_KO[C)]WKW!Y#BV%+?C3"CP3IU@3T#^8"\E-LW>3$07CX'Z?TOZ_RD[!59_&&S8PE*]+A\)WBE8O)5_AUJ%P\LCLF"!H!5TKA9S%(BL:49>_A##,P\;/V6/ M+^9F70>%YER;C4G.A=5@(:C!U%2(2K^.X*%Q.#H*G.?;OZ0:1_BT81CRQ!["%%]..RX-_^<%O3A[\#7MLR<"WF"SX',UG<[?:V-_>WK2>V\J'(D"K2"T@KC/0^O?1ODE2,M7T **NW?7 MY$0$@K#'?/>:CA/BK!?QSYGK\\9B,FZK MWK"^N[[/1U8['A=SM1F>_,T<0W%R-9L+6HN)"P)BN[ZYN -_3L1HK"-B[$T] MBB/X\S*\"1[\Q0[BB TZH>OT)K3961BQ/W49)/@OPRM0ET$0+NA".&^.+\): M!>Y8,!PYF'HX5P'8,M[_[PX7-HJ^@=&UG4NK;\;_5UFSD?!&Q] P!#IPA\RS M^".WJ3DN?-W%LNA2&31 !EAI(5KF:7OO$R-X4_*UK.<% CY-CQ)F(@$H#IHA M9XM3^FYC;YS./TMU;^JK,PX9:KASU8?-/\<4WZXWJ@<'>SLO=2"_OC__3?'A M4^I _I__L;_9V/L:63'W^!#A:/D$R(H%K,1+T#%I,3A;@*NDES> R!P>VG'3 M8+L8<9TL;D5THGQD#O6, FC!'W_<6#!%62Y-C8_=3ZC!,!\GJ8='Q;G MH'*<^\5PCD^FEFQMU;:V?_DJET2@B2@D4J_M[0QC2QV_E0V;S+R&Q-_,*T2 M)/>29,E-V[L43B+,[MOV3A.>T:N1WE2[WA2(2,Y(/*0RD,JY"%= MR. P?[3[V"S) K'PT'>!M%+9\6P;JCS*91[E5-VWD3&WI7HP:FQVB)6R0I;OH-!?FYU1I;=Y_:=!N<'#[X5 M<1;!)QP5TMNL[RO]BX#S@<6UJ;KKIDQW;2S($ M_U_\4CZ8^<>K<)RO&J$:.^8N(ASUG.="TC)Q;T)T#R7PC(MH1CB\"X MF-9Q$4SQS[X$'KL*'A-9L@9>;ZX37OM!#-_\G;C(@8'Q=K%:(*1RGBB/(^N* ME""4%2FI?_'#('4C)_WSC\!+_)B%5/L0+EA76"+SHLC\T.>4UY?%Z$/K4T.& MBOK DQ&9'8MYGL9H$]4[7%X 3WX*NPWNK;1AQ'C\F4JM'/C5[]&EPY#;G#QC MC4WQ/"I?C:Q/\%#8KA4E=A^LZ #3\2W1C AN9/$X=3ZP:)(TZ6:YF\\@>'S' M^K1I;+D#NC5X+!1]&(JGDXV M.95"1TD8PGI$ 2$:H#&+%ZW*);;Q=N3S4G@@<;\>4_LXQ&PA/@,J#]PX!@K@ M'J!T&/CP ,\;6?R>AR.+!O9@9]Y[;AVSF(EJMS$J3Y]A"K0)+>V:]Q*/I6R@ M7;VQ/N&?>U\WMS9K6I<#J0D<8$C%-,N@>[%\30R;]:_3UD<_ M-[ZJRYZ\8/KZU(4HCN7%4]:JKI1F(O"*3G53:1FF:E%[O9JWS=4)MC<.:EOC M66:OZFY=/D&=(?8)X!L8)KX@-)L[=%JO[:X9;&;6'TP"8&>GMK^]9!#D]MMX M51!(T3$G#!JU^GIBP8*XL%FO[:P9')HE>W@1>]BL-=:?.4S+T/@0LG2Z:R&G M+I<<<4= 3;T@'+TP;DD/)'*TY0,IA)FGQ\X9"B_I]^.(]]WIMN3X$:1 >ZK/ M5:D6?!"UH(UFIP"#MCS%1VE3EASFXVH(TR5BCB>/,.E[$KD^CQ;SL3^[KVRI MN- QG>1[@PI&N:7$GDE1VY,4I<[U!QVK'/"ZG#Z8Q5(,%F?%RQ'4"Z^KH)2V M',DUHZW&4VF7JQ%_[,X((V!QXYR),QB9I'@D&'V801,'5A*)$ 0L1K3+CG5W M7!7LPR @OLL;X^.BQT M(@O;@+G.M'3)K4_LPJB\K]?%.%Z.M/IP^ MRI P\*S@'M:2(D4:?$H B*$^^NWZME'MV69AA\%CJY>/'A]1JLJGQH[UL];& M^3![F[M8&OH9-Y[N4B;A=CR0>@;J==UP(.+40W@WPXL 6RGST:$5L\1Q8[FN MFK4 &OD_:S.-/IJ,Y,4+BY?!039C(@U8]68 M_L]Z/4!,Q-P!U8;(TC3 -UM4K458M6;!X5)*'R49=#'U#6Z)%%J&F2ZY\.5_ M)3ZWMNH5"T^Y0M=XF!+7D6:RY;#1Y,V:JP^""'D?YN=[(R'=.6H%@!T!B(:_ M$^JZ6Z&DGO\AL?0T%+/$@8.[ N]^WKI1L U/_-D^WC"Q-Z?-T15QZ%,O8$_F MX."44B!5VP4@1K]M5(&MXO +>-SNQK>M_9J>9:%6)'$4CM1S<9H8[B?![708 MJB8HWP ,MA=$*!F&@-P$__^Q6:MOI<6!>%T&K-/SE58XEZU)Z'/.0KMO-?9I MHPT$#^S_ ?\SX[!IYB2!*LJ<=DYO+5&02?68;;KA,HE)&80#F'W\C?H6HD]Z M_*V+T^QH%3\9.$$L+P"$.*CL[NQ5]K<;$V@ASC6'B#0=F"0XJW"T8@7I!BC' M91KKWLRVD5)#)Z*TSRYWOH]@ZP!LW^8W (?O'KQ],8[.@2"&F!P6)GS.NK_" M=_8YOCSZ>7YR<=/&/NB7UU>7UTT<\_C]+^OZY/3D^N3BZ&25"0]E03< H?N M3,A1>$%YEH!X\!=18=#]C#UJ+-? %Y0+H<(85+4#,>M(/TWWV;WO,Y4V3[NHOL$.S%:B?D[ ZT%N VA\Q[ (AN6%]>_O:G9]+,&G#[ M#J]\@ZI.X\WUMV2^-Y12"71PA%((^-+[@7.Y29ZU^K[.\YQHC=S(ZTL^OPKUN.+1J^7>&*"I[U-/"@']B0#9L#:^CY-Q#X["LNL?H@&W']<-:]O;EMC MLSOH26"YRB$'XE%P:G"MU=(N,#9/F'29IR;8WS+8VGQC"#\D?YO:8&@J@!J'X.7O".P4YZ/8+]MW.I4M6_J MKQD\_;W9R]MSC\)0Q6;)E K"E)HE5UHB5[HY.;]M-&^O6^U_W9XVCVXNK]L; MWZ[=Z,XZ978'EV>4SQPX]M//^1@^]QSQVK'K-NE6([P4I>KY%S%X%R;)>-: M,N/:O+VZOKPZN;YIG0"CN@J#(0\Q]EQRIB)01LF9WI\S65LE4UHR4]JZ/3OY MT3Q#UG1TR.35\*UE4(4BD9%'OSZ)D0\623RV93VW? MGKT0**1.+Q6F6Y4IAN] M(SM_G=SWUZ?_&BU;ZZ;%S=M"HY=7MR> M_.^?8"N)PF(LJLJ9ABZ'8Y[\G;CQJ )7>%2YU4YKK*QS[ 41BGHI,=7(NDI" MN\\B43TI[C4JJTHSK B$N5MF#!2$,>Z6C'')C''WMGUR=G)T]JZ:%X< MM9IGM\?-FR;.:90]CDYU^QF< %+RK"+03,FSBL*S]DJ>M62>M0?*W$7SQPEE M-9&[^V>[W0(M#KX]^ZO=:M^>HC(WT8,+_=^)J%Q'#:WI,V\4N:29I2SN*/ = MT;<-K[GF4>*)G@"70RZ\ *765@@*W-TI.6!!.&"9A[YT%MB\_=\_P8!MW31O M6G^,_VU\^]_8XL/%AGGWG+@9?.&IST8PT&IV@B26,]!P^R6#6S*#V[\]NKQH7YZUCIM9V[0-7.Y$YK.G6EM;M402SK=V M,AQZ])F%H])J+0Q%E1RM*!SMH.1H2^9H![='OS[F^O*L+9+ICT5V*G;)"P-/*&V44N^4 MV:E%H9B28Q6&8WV40NHY$P&7S;V^WUY>@]9V>GE]WKQI75[,ER5X21,56FFW MX*=3!4ONMCSNMK_.W&UNX!JWQZWK$^J9=WORWR='/RE3X;1U='*- M.?C75Y<;WX[=D%,?O8IU\LCMA-(4+KM=UU8Y]4=J8(KU ^CR_.KDHBW]1"DCPXF3W(^D(ZCD6>]/,R7/*@S/ M*OOM+9UG;=ZV@65=MV[^NKW\\P+4L-];5[>@CMTT6Q>WWT\N3DZQ H@*%4?6 MY8,/.EC?'=)H*SD'[SOW.2AGF&P@?B<=+ M1>*6L&6M%NQ[B!,O2U.U( 17,KS",+RR4^#2&=[V[=5UZ^*H==4\PXS3RY\7 M-ZV+'[>G)R=M4 BO_V@=8?=EU[?=(>AU1G;I*9>#@-L\O'?M,DFK&-2TWMQL M;N 7+Z2^9BQL)6"^_GRG3&,H>AK#'PMG,?Q1)C&420QE$L/[LYJ5LIW*'H)+ MMYUV;D_^^_?6]]9-.Z\>^;9]]#L&_/INQXVCBI53G&RU[3YW$J\TGHI!3OOU MDIV]-SNS&F73OR7/5F[L;GP[A9^L1KWZ+ZN=#&#MHY(C%8$B]O.&*W^)6Z6!8S8\E8?F*QN;PSRDRUO%&*(LR4?BRNWT M0[6?(>OQ:B?D[*[*NK"=0^8]L%&T87UY.:3?9X_%1Y7%%F'Z,A8%ZW-A>'IY M_6?S^KAZ=GGYK];%#RMMK;,07(D>S#UMUW:V?YGJ,5PZJMSTWY$0"3Q;1$AQH[>->M/;@W8';>BQ.[/>MHP"2-LT&;% 3P9KF==;O59V E" M:Q@&]RXVJJ3.D_CK5>C>8^)SVCO<.H-_>N14@FTA%*RF'>/UC8.#'5I90!6H M7>[P$/:><4ME3V?C6V3T)"=OE.6Q!]A-T_/,18LG B#\S+=="V KK("1T\GE/M $4Z!5Q F"$/XLCMH/!D(6H=YB@K5DW=/&,LW!] MVTL<7K$Z24QG[@>QY;D#%Q,EXJ!B7LNP[^"A9#:@W"CD%.P4]36A^Y'^8P%A M "+_ME'?L&SN>8"E-KQ;?Y9*)'U6FBK=@5JJQX81/U1_?+6$>MFHUZ5V.=/H M$Q<+KO;0AXU4\=W(BAY"-IRJG=+Z9W+.W7DUR"RUSLW[/(Z)=E4)J;LGU]TC4<$OD\8513*>+]MR9C$Q.[F?#TB#W"< MW:\ZN#$5B=:7?C+0FW+"4^)#>? ?E]GR&E(>$MOF$4GB( FM$)@T"U$*@A;@ M@(3Q@B$Y('D7MAQ'__,_=@Y2NB8[<\+*+/EQX?"IY, M4$%CK@<,&6P:4.IAW150KB/9J#9,YPO8'MR$]E,,F_;($"5>#K<["1AV8 PY MKH-&0Z\"]P8^+08F"$8M77X.=N4-.NC50I]'R'N)Q^(@ M'%ELB Z[DFFO(=*53+MDVB737@6F/>8"(4;7D8^,@-O%?2ONNZ%C#5F(<8Z2 M(:\D0I4,N63()4->!88\[O>8HE%+]S1> M.,'J@=GBO\:TC)3C5Y'CCXS;>5AR_]7$WI+[E]R_Y/ZKP/VI32/HXDH* M:.Z?*NB# 0^Q0,+]1V0Q80>->[?4S5<6NTKN7'+GDCNO G?&M$8?5>L'C%7: MP(Y)O\8!P$I3CX!'XM^E.WN-,*SDT"6'+CGT*G#HD-]S/^%6C_L\I"YSG9$5 M,8]K#W?)E-<$J4JF7#+EDBFO E/F Q[VL)4G)>QA1W=2EP-1+Y-.G(^YW:>* M&4KH,Q*P2Q:]FBA6LNB219A58M*AC1 >&C#H"IV;^R$*>B(\%?FRDAMSS MBN6Y-O?4Q,/ MRU7.#E.M=OUNR*(X3"C%3B;MQ3BFT[.B413S0 M: UY& 6^SSUBQ5W=CA@_#=(I?<"V<9>D:$LVC4^(DJ%HE69$&LU.(O@4W77* MZB;$\R=S^F3#$3$5"Q[+?>+A";TC&%)HDQ*WK6'2\5Q;-)[R1R0I\*926JP: MMI?2HI06I;0HO+0@1_>4+I85V<8/G>)Q/XBXY;D1YJ# .N"N*P:"H56Q1/_N M9DTU&[R&IUFG# K5LG82L;6<]<2\&[G3;]F:TR71]KHJ;T M0Q4-P4/>];@M)+^=A"%*^WN7/\B2JI!'V!(3Y;>4^IBI%%/O2)3I<)?\?B8: M:GU$]1L%78 4$8RN"]M1-%J] W'@2Q05?Q/25K(8:_8[%0@HXC88M+%9 AB, M"\/J+]BU[+I3R;PSP)_[V(Y3AGT"JX-!'Z!E6*4WLARWV^4$C6X8#"BH)#!ZQ0K--=-*U2&*7J:R(%KW MZ62# $-?LK$KO!L+]F;3O.R;.Y/PZ4"X%_$'[/\Z!][5K!\N()*$QQ@[PFZP MHD$K]1,=>J GX,(2!+[G"H#[<\#RY-'FPQ@USI#_G;BA. .//50PQ,>B*!E@ MRU(K &54-M<%P"9#A\I9L+/>O8O=4I]J@XJ-0!!#0LXB; *%-&*Y75#0'S(: M=P=X.#($=L]=A7A2DG9C3)KAH@/R;B_FZ!J&;<(2[ M &%\E; .^T^B.!Q5Z),*'D@KI,]EJKLX)HEH0#T1%[V'4^$'Q\ZPTPN^N5>XBMLL MBK/;KL@EIZT=8>61"\?&@. Y$*PC@R#X7-?O$Z?RL!ERY]^274\R3,E"4@9N MNZ&=# "/X=*(>,T4GB)OH:*NS#U2>HC:7B)YXYAJUD_?HR8->( /2$F2+>)* MD7H35BV39]@+[@%)R7ZFUYKK MB !3 8 3%&_HMBLXBZ#Q86<13#VW%PX&T.^/X.U>U6;#:.'-/[G3#D2O]R:G]/M.-1>%)P'JMCAL, M^PPNLGD22RV%7*Z@>=B)U$=0T0%]R$9Y-9KH(@V:3GODPS5PO_7=#> ?T/JW M]S>_"AF(*%";N"3]C1:6%K:0U(:K*5\:S8?&WM<(E9]AZ'+*IW;"I#=C/6 . MQ @/L DICR_S9AH)@7=X<$?(>E3?B$H".;5=4+E! MAN[SKDN>\X%KAT&'2TM,&GNH-CE@@]SCU 0#*B>TK(K(/?L2=.=>@*%=:5Z* Z@HV A]&JQ/ MTEU!A3/]_WS&;FNSCWOH#F&9/E=&:C0+<%TYTB(&E2)6Z)GN'A9-_OS(T.JO M^MP?>:#D!7X"9&-]NOK7S\^TEQ,4U'#7[R,XW>"1>?@[S70A6D+[I).XGB.0 M"/7,+KPEH$8'H! "1E?)B -#D@MOBSL8)'Z*A&"FR$D:Z\%>9)A(:,YH:WT/ MP%9">!R#<2W\%K1O^"FR79KE O!ESCV>R\CJX.5@'B/1P4T/?9?^Z.*!96LJ MT'L!"(*6%AIK,SE"IB<0W1BCK0'WZ=/+A)M(D4]C8@*OE;%A/EC01!=]AF3P MVV)!-AMPP<80$V5R<1"ZHECO*@RZ\!P$Q7\Q/)6C $NK!6#@G,"L&%EG2?J M6$DHF^T.7PGJ+[2L8IKR3_.+3.-1\X%M;]++UK M_TF]RZ"Z=]E?EF_-V,ON(EMY'P:"A#3 ?C# "U"H.9,%K2AWVG]=?&_L-O:1 M)D& :=DZLL0,)M0?\B0 L/0*RGED4AEI@%B I"%8#3R4X70CB]FNHWS-((T( MTLP#U@!BZ!, 'N2#;2<#;/G+(^6DZP3.2$2OA1<67XQZ#4HHAW=Q*$,6?>G0 P([!R2"R M;H[-!A!GE1Z_.!CAEOH[ 34$C@4.<+.^6:_-#L+#\D6Y2Y "C"$$NM%IR_@HR%6>!NC2Y &FR&_ZL,56NY#\CJX_S[$"E M!FT8KZ"/? 2YN4:B"=DC<*AGU$33[U$,CPZ;-[;D"6P#KM M7MP2R#'7Z8EPF 3^Y*YHD*"\@*Q/>.@@"#7Q5&6[N+%TLBH9Z& G(K/!N ': M!A.HDSDV#6***0^P43\?YT[W7"@0TQ!S)H&N@%0Q-04&VA#1 ?%DL0 %/8F6 MTK]A Q Q&@H<-$4$(]\;.;&X1AQVJ.:G$C^&8X<#TO2?,DO"RU? \*WDA)"^0F@./'L#@29P=N&RH" M=J3[!^\"VJU(%=V-%*G+)L CS5"ZH!%$>MXKJ,S=D84=@#'6YBK?UD=/-<85RU0H^H%443W\E ,<]4G9R26 M.%C[' 8)!F71I6 8+MAZV3@B&0(7'3YQG.R=Z_A\))V0%?4Q H.5')4#*8KP M-I\/^[!VYME@?D6N$ DAES-CY4P59-7*JIL,C:X628'*<5 M3"W+#,TIM8:1M>:25X7XZ/Y^?9,8]:0%TPP-GX1M%^WC]&\H=$'!^3#*T:'2Y(Z,[2!-W3'$-?4/?''\$) Z'QV*1*>F%)7HVQZ2 M/]?FPN7G8&;4#,U&N!9 /X43)GAA?H"-?0D&PR#$)609R#W\/W(TWL[1T1_&>%?\FJE?N,KE&YL$#T=MU\!$:3B6.1QS8EA MN?X]9J*)Q$?@GT^$W="Y"HH6*&F\H@VVP,^-OI$N5]'93L"9T4J@)-$\Q:HB MS0WI(E5/)"F8^(X26C]:(-! I#<(W:+,2$/>;1AJ3APM^N1>"$=:2C/5(JB M$9B>]^A YVGUY]FMJRX]G'.4(ZU1V$RM'Z2-)41$>O3>?OG\6>IVU/FH$MY M>%-)PU3]"G6?HZG8I$D:6)/?_&0VXD6"+CC9DM" ['WR=(YFZW:/4 MO.R [DY9DXD=*Q<"1M&HI.U>Y(;C 56GJ$>XE9I@A.*_0+YQ$ -F:0,5KJ8< MX@'G,3T*T]G=+F9C8_B>"SD9&@]V !]8*#T!I*1BCJ9PJ& $$G0-/X';9:T; MXB:N8Z9C%G<$UD& "0/_<.E+SZ&;%QK&Q8K&M2@6+I(M2--=::O_4H;R5YLO M:,<.YC:8_L&,8)@A"-"H11--$[:-9*K*%2;26@(PO$>"+I(!I:Z 3LO]>S<, M?!E[1X4>Z8ZRK1%EN"Q,-48F$W'1 TC!U[09S4H[ ?+EF5"(1I*H20*Q/KD5,(2&CJQF!)V.AF MJ@$T7%4"=.%&D4<2)HK<2#D7Y/%2?OW(%MRQVCR_J@A?E%RY3&*RVK$[$'-9 M\9L6ZA9=4"M\ZP<'#*@(J4#(GA?INFE=_% )4\)&S'R%-MD( :H3O< PTR4; MZ=!O&>@ 2G.K DO'8"4"$,Q/T"#4'@&B(^D/$.BDLO?)L3[;EJ=#F[ #=7!= M1-_D^5 ZW&@P!#N59<3EC0YPZ<>/A51LP5/_P7R[9, ZUJ<;CE9NZ/[]F;K MP$9?^3$ MZ-",Q 0?MF;KZ(%$6_+19B-E(/%X+-.0=,J1' EG4+/ASL$X G(W!4E!=9*X MB;>W'.@8JSBM#!MA1 B[>[)!2[=H4-:&B\B%S"BI#E2 M>U*-)PPZ"7!<4%"DKQMI!IAGK%\JRU)%TB]LFF#K*5M9RV!!!KV1TD?2!2'K M[5!.34YJH\I0G!HUR_LV/TQ*Q6938@J@=WS7UAZ+R7I&34 2K1I@;APBFYE^ MB[E*G:R.YP4B;V):KO%8K^PT\Y@P0'MO2>MQ0N5L3D ]C#794:,32GUFE ?& M9 6>VB5P4YEV9)$X,S-N>A0&?5_G3JM-BVQLFXO.MK@-8&Q11L;^ M'")[2[=, ,$"1Q(Y '0K1'*/S"V)8E<1LWFP8"E/;1(?(]S[5+9,F(6KAEME M/(&A'SJ2;6"Z"9YUAI]D*$(Z^I5N"T^JH#D-2!*+C79$EC\F+_6$[B>C =F) MH9BI]#A4VK*FHQI6O(L'Y0YQ%IZ&+]?V)M;BBZ)RBXT< . M#3>9"2[AAO!2#B>ZF_H(HQA&81R8?BK).2AGGQX1]=VASKR3@@>-*%2\T&V M7Z-&Q(V9(-*S)7MJDW$: M0AVPCR[+#K#!!YU8^,J%GA-GL;GLLW '/2L*[=\V>MV[_M8V&PW=OSN4(MJH M_7O8V[" T>)&-X!MQ_A/IG_3[L[!\/%K7ZQG\Z !'Y"X7A\_7P7S)TGWV8]] MMR,S][-;V]W[Y0F"VOC6I$%_RH..2$[IY0K3I=XL_-BDP7$6^F;&W&Q9HJQ M&>\F!1EU "FQ4EF:RL$C](+\G9!)2Z\'&B-E_D'Y(Y5"+L0^Z15&Z54$/X'L MI6(KDX!]6"S8 ;,*[2B&3J4!TK0PC IIX(N42C"X>W%?L07=RS3F;""UH?@A M".^,XJ]H?"NH'2LU6)95 @P&J-@\Z555H!?YG/="2\RZ.E#GQGHJM%(F]>-H M*LN:7=*S7Z @ C+HMC2H7E93_.XRS[!8 UE8*\+Y2#D+CL?JME4JL,S3G>:AUP^L/=5O82II;'S+ M3T9[23G+N*]Z78M75K\XN"P(67)!2&ML3V(7,G-:[4)TKIMQ(%.V.>\A:2CD MYT;F+OU)\*3+$1+2!+L;&34(5WT^R5W 3"2"3/\U3N9)A M&8P\8H(W3*N)$:JQC"&)\%>F4S*Z.>>H:A'1R+$59@YJ2G&+"'Z8J]/ >[+P M1>9GH9;M2&>=PX7W4$?JT&G/[G0S//H,DMP,16;8]MO%28HA72F9>6JJ=BTG M)OZT(%W1U/&UR)G4FR7KML-E KP,/TQ1&BJ*H:M,^,J2$MO5D4P<'C&,,NW] M8Z6];Y?N\,);QO.DO;_]*HXH]>@%^>#SM^5;PFY(1RS4BF32:TY28Z&662G4 M:I1;6?A1 7*^CJW*=B5&)U82QRHRFVG9]"HM%PNN>:)'\912!D4N3U5E)RN? M>T6GP3U/!9U;.0QT+FSK>D*,K$FTS"9$8'%@-Z^\R9GD(I5!_QE9$4 M%N6U!='V79HY.):WJ,?9J'G RAJ:#(2 YD0EQQDS%%>@>Q#IMR@-,^.VF$A1 M-A,5WS2Y+\\9L*34OE?)['MM7]I[T/VYF>KQATKUD([-K"R^4LEVG9%UEO:Z M;.NDDB,SK2EZVO/[I 2=S2[$N %57J]"B_"MAPZ0*;DN@I8I35\G!,F3-W+& M;#84AI;LL$=A>_F8.9.Q1'K0M#R:A=-F7L%!^ZKQ[?? U9,TN6HJ_+)'ER:T M91.^]-TZLTNT7E7CRU3"F_Z9NB!D6S5.)H 9*92BD$0EB\U3YO=\\+_).;\S M6VK+Z7!:'5%%7J)>%H]"V..$$L"]SS.9> C^4\/->*208O1LY42T*5+BF!NS M1[-)@!G\HR*\@!P5Y&V7'E!JRT_*"#4<-!RB(G\UJ_.HT0BR$Z\C^RSKTD69 M4X#E!".9\N<;E0,BW2+"QGO!>,;BD+)S876??IQ??887<^97PP $.TU*0UKY M$STQJ&%EFH9.C]J-):S,$<1[@100Y21ZT; QX91.O>$ ":R:=$377"QDD/W8 MK&"8CLI0C#K2G5K(%R2SM6R:"RXT$4!IC_@[>:T1AL)M316^O"OJ5+&,0AU+ M;JFO]6":U435'].E*&%7 M=$;/VEY&T1WLLHJU8D&/8Y/ CBB49BKU6[?83B(NHT_8P]0L;Q:&"_><)Q*$ M.B.%H3*UV05[Z%X5^(GR"7_,:SS6Z5=H2C)'7R*FA]D2V/6TUTT\V?MDI>]IC=GJ_@ZG7+/DMI!W?!L6'YQ$:, MC#'99%ZV.C"P1$(+L\D2%B@2(]YP&4DG$/>,YSL^,Q5?9>K&J;@LA5 M@ /=$(6_.;,L;YW&Y(U\ZVF\K".GQNYYN4/3#)B73=8T7E#L'A5(]J<(_,,9 M>L.*YYWB'F5:M%FF.;'?I^>K2/\;]D/()?9\0J=8=57&;9%<5(=T&ASGHE6$ M'L-TS,H86U!35Q8:GZ*&LZ1+TL"2[)$XR]0I*M2\G;0#.3U%E."K\FHQZU39 MC@9C) W*'!D3 +$GWA.K)RF0^&!]RBQ]-!9(4ALA?Z-.$KM1:IU33Z61I9B2 M60P$(&P6(H"3.)U#(]N[H@,]IAL$K$0W'^"VLN2,)-^P.)3K\X#%XE/5.)CNF5N)MZ5YT MA@)VA.!J@DTZ$L 453JGSA'R#?59M!.5-B_/=-UB_SME[+^,_<^U"C-8D#LY M*^V&=Y)5X"Z 4U^EG/J[,G>QNYODC84**(]SI4(M+J-P+*[)S=([GKGX'')= M8#]3D"//PSMF*6D\2GO"N1%U<';2L*:P261<()##5%&!]T:BO1.**6S3(BA!J;2+M=:AK4\1><=H,A;%'Z30R-E N M@T#K57"M.]2MZV_H)3C#EV7$HBC0)R\4-GT&.TYK(DW9S4J/?!DW@F M&TZ]?DSO7>CMYY39AW 9G.<(N H"2ZT=DH?5]D%.3;],!JG.&F$IIML%G!',Q>D;T(^.^'6@WA(UQ=0,\6O$5XRI5S$54 M5TW.IQ1\ZM.66DHB&$L$AV;W5;",VV[$J;>+*@.@-V=&@"<^^LK%JG,VE"92 M$TNLC#<&)Y/'QJ"NL$NTSP84_Z&8964^E6X:P*+NI0N4N8/L6N7 .^7Q]$8Z MBH3/88,@02<8=JW1P1P-NB<#,(+?"T^Q["1J&Q[BU_3)I*&[9VF^TX;LO@^W M:@-.H2EN/YW/L2U#H60R2 :2,1)M#Y]622YG9L\ BPW3/H=4 M9CC6CUFI0DH%UEHO,BJ<.,85GU5M-I.AKE+#Y@4BG(TF.=M+' M4IJ?Y;46#!?UA#2!;THU77SX+O+@M MBB&BO,.&'@IV-'03" 2.%_O"2FSR@TPW"5G7)(8[6I]PI34A'7LUJVVX- M=)9Z8^^S5:]7K 9U(MO\NO]9"& T3((.(9NC.[Z'%%FE]!E8# EU6HZ>N.>* MX$=(G3>?:G:*.:+YA4B?)+1HD6K%H.;6G@8<%H4>6G\$<$.C4;%:N'EK>V\' MYQ.S9.]@;^=S)HCW/'S3;=O06(U 36$.$=$8BKE8OHP]4$5C.]2&:91@+">. M4IDMX.$=AG5IRI$@YYAFY\"AYQIFN::@M'3'J^M#-4'>3_3$,"/_A;.8Q@[! MU\]#T"#LB0)?F>-SAXI\/-:74&U+-294K/ PJUD!-JM7"K'L\2X*$?@I)C6V M0_W4?]NH;Y I@?E30.GZ\Q!W)C_+YX@[JA1,'T;\4/WQU1)RL%&O_R+?$-)_ M'#>A ,QX3F7FU_[Y>OP/!B;#C/; 3' QS QC2U@M;_I#XWEVH@IWZR M) [FEUT>Q\AE5<+I<"XQF:^@_OHE=IZ$CY#4[P^?&9K!?X[M^3]?!,P9SM_9 M.I[#;9E4(E[X7;. JKF1]]K4[+S#)U^/B ,&\^Y7@[RG(-"Z4DX&=E-.-Q<3 M\J$_/O-W^@G-T)#''Z)$WM.G/7[GN!!43LML_'B _2!\BD6'7'@'R*L0Q6H" MM'+6ZCYAVD&$QCV 1Z3:"A53O424Y# 9>J1H*?;9)[^K(_0@&GBG$D5MX3P MH1M[HLM0(&?;J:0:$)L^FOY93V22S<8@!(;_A/@?E$;P+PBL4FX5D/I*N57* MK5)NK93.<11X=VA^W#-7Y!&CR5$,:2GS@J5!;^&4 M*I&[K%*L,=%QT/%4KQ LVA<1^J&>?Y63YBRJH ;D7U'91X, ;Z1YPH>EPH(F$Q:X2P:B/X1LD'5YSTY8"E-59.I![(0SZ5F]ECB]L \K_):YO(+K669 M>"O3RC(YM&:7]X64DA5+!OVT^=GZKL9EX/;'\J70F7TDTB#G2$IYJG0I[AMU M2R*<&V.:\OAP.$(>7;NCDAAMG=^E-,6G2VZ[)FI MI)'0$5P_POQF6:BI%C56G*;+:U41&&JW6).-::1]3.^( OQ;90]&%82LS 'U MF&B>"NJ&D0CZS'"YG)RF/$&ZEX6H?1=;XH_8A2+*VU.4YHJJ >UI52I1L^M' M:F2A3'_$E!0Y_U*5B.LFT^,=#40ZIO70YZIE&:;(A^(+D1$J4R\PJL5$=R(\ M[)G9GX=6X[/J3ZB?/7YY)&KH/9'C-+T@45;EB=D4;@QL%0'X[")%X0O" &22>AB8=1'#FV, \>2 M1/C-#=/\7&0BDJ>+RL 1L&#LJ)PAK:?)2EZ*-/@TOU$I:TQU$L:DX\FFS+JP M4;:7P5K%V&Q';Z;8*!ZF"MFS/(P*+"K6'6C&U7[P('L@YE6/ZR8NFN (.A(CB2MZCPL:O'A#D0G$-7M27*H_(/AQW.KOI M%%0U%0V7^RVEN,#Y!LQT1NLZ@ F:GJC&OFW>-G.=):<)<'(UH_ M#W.NJ"ZQG(8MB?8,HJFXTHJ,,@\I\)%C4>6)(=M$X0&54LE^+'P\^,\FUR'( MH((I;3BE0E69*.TH+8O R@XES0#IL6)!7)%ITX(5RZ2+8']TV8,D$E-]J3\;OI_ZDFJQ]B.%JF<&6"VVD&1\Q0U8K$:I)K"G M>%3Q.QV-SSBF:F;VK+"VE\2T M:26E9$(*_$JCD=-1O\0V0Z6$I4G/Z&(-PCDR1(T+U7 MA*G:>.L&T3WX#0B/%"2/TH+=3A*G35\GH*L"TJ\U*^^=BJ.F]Z+Y'37&*Q.J M35E]]I-4J NN^-]Y:C9=!("50214)OKQDEC.>> PT=EK11SK17$ M.M8+33FK$)X_TJ/K;H)',)D/9SC0IS[DI^^Y=UPJD9G&1SHY:^9 Y,FV4=+' M+U/"W?RDR71FO"-$QFK(?>CN(M-!Q;IB7BH&_7X8:C M5;J8M/U"(UZ-/AJ9JBW15X))OY3H,JQ;)"*GIB_$X2! MTG[D<9#'0[=?-*K/S7X,??2BHC%!NU!=RX:!:@N"34U&J6L1ER4.W1^#O&H0 M*V91Z.K2&<>'2T^3\U'5JV2P,@J\1+C( MFF-M0&I;% 6>0F(&68Z<:CI.=7 M33.4^#8^S$.Y'Z_Z/%O7&?6#!UJ%$U@T:4+T #?GL8H;)FH,TQ?38+@G7BPG MLTFG*7G/N&II %9OA)NE@>NI+]35UJQL4B-S+0&!17X-O-XHQ4/S5?FB](CU M]*Z\H,_0 ]?96W/T3V?4"LI M%C#1DE0Z8]]MT5/:L^H)9>D$LT -44LGZ5((/M5&4M@$JRT()S'6# M*6?_Y"Q ,[9)<]!$>PO3Q1P'.&4YHG:K57&-5LK70^3O%$&>%5?>-PJ165K* M^U+>E_)^#@>/'EA(,8O4)_\L5\\Y=A?*9D^(P7B/(GHX[(\B-1)-N0\&V!40 MA)'1/5-'GDD8]B,\8 /C6(OH[YO#!J0T#.;U%I[:D;?^T%T9F M:HTU!YWI\])9BQG!3*#2,2D1J2;7"KU=!&7QTK'Q)J M,Q2(;$:DVH_H6J <"!/NK,F%3CE?F[+ER#/X@$-YI%_FE9-?5R9V=B7=4F<4 MA3>U[V/AY:)9NO4H)0$KAQ5BQ.^23D MQS3225,F.GD/>.%P2.\)WR MCO*I2@=R%@*9+EZJ,XD>:T!IPRH6@/8+9<7CP!J5V--+1Y.+;J@BHRD%4F>D M$OG,!%/=PP4;4U?$'&X;2\35P='2\8V);XN6=I05;.RXZR6/L/#X@K#2!GE.MADG1K=(&>D,:MVJ#+US)@%RWQ*.1T-9?QTF$F6$J%UFJ%%5L> MASV1N:K2IU3AC.P(K[//BNYKFR]\]#I.@KD1>TX.5W^[>-E\&Y[74_3:9/]L MI]'KK^2=O%A%1L@GG"4@TH21WA8C3("]HJ6I.H1KTSSMOZOR/[2>BB.'!T,O M&)G9))4TJS:G+?A$Y^IDH-/9GUQPMGV5*K*5D8W)#L0@##!X4H$%VPP;&T^( MBVR]PO/>7S%3*:1?)2VDHL02Y/1V")Q<2@HYUK.BBQEE,8:8X'4!>!8192R9%N,I^W(G@E_N6==:RG3IO)ZK4GL**E9CJR!;@TZ@+(Q\<;=U:I;KN*_3K%)%OB?:+%0F;\59?2//"E M0EE!8Y7>/#7V-+X%*8&5&D"S?M,IYND\W8#\Z4&HW<*.V;/!YB'*#M%1HH+/ M$&Q3N,%QGSQ4)5S*&RSZ&8^A=*N*%M\@1A+KKJ/(31P-E7HNA@]*# M$$K?CZB,UY U52 Y'5C*P]2U,,3A(D^*E/F)0'Y$D7-X4*OO_5(@KV.*Z*BR MX]P7$*D4/QUK?($:O/(&Z3IL])*K+"Y#>Z. ZU/#' .R'U"Q*G MG[KV'2R^A0_5 ;N#*TDEPX:VHM&%41;NSO(O*41WY[ HX!IX7!@H+157,=]- M]_H>,^E:] _0^B)]3&&(5-*Q()M#F&J0(0F->C=9,273>VGX M\I]BN++9B@+U06+^.DM'"PI'["NSRXI0=_![DW/#(E+_E.CA(6%!3A(Q[U>F MF5,7&QDX$<-2*K"9**ZFH1?1PC<9RI;Q8]&3#Z(IG>>Y\'(B;&..P8HUAV_W*$_,(\ATKD*HGJ0BC>/N_SJV& H_M0YJ2Z7O.??X"X?H!*,ZQ89V='HN(M?0PF MPX-2 _O@8L)DEIRI29HKXFFB5YMT9E7[ 1)1]FILIN+^G;@2[D"!1/4#73\H MFJ4Y@ W8DS [1E"KD2*W)^N^DXVVX*PQNW[R]^EJ[X)Y(%,3YR8;G.-KO]O<9I"E"L+AIKO!782 MJ8ITO,.?S//+=)?+)A!,FT.MX0>O$#781F8P* 7"8"+#4\\\I[2WPW0PO&AO M1_!!)[[NT:('OX^/.--3:#Z>];ZOWTYK%(,[T,9@XJ*,*LC8)#<70[6%"IFGH8\*C!Z^!#%)7U0WRL'\#R64C554HF;)+ MFT[,E$FJDEIFMUH0:*B=&XE-"3S"'1?Q] #(@2'E?2);OVF%:Y),E>2>!3"# MO1G'E(*C(O-W.ZA-B#G7#&V,;H*-?9DO1OQYU$8:E6+5$2!*D''A#0K\$9X, MX;'@A2E+,$P?,U%W=B8R';5N:B#"BZD2J XV!MD5*TL 6Q90KS'5D6"NNTY0 MWX/W_CX":P>;%"1B5L>[IR>N=B;K?IG)NO1,UOQ7SFJJ^E[J&G6%$6DJ9,4D MV;ZH,;?[OI#\IMHQ1_=+C,@C=9L>7"65*F:D9T)F5;+]*"D.@$I%2*Q<>&9, M#S6:4[KEB9_62$N=8TB*_3_(-H6&19DNV"((5]MSF(UJ[333!-=1X8^&;DH69+MHVXCZCT<-A2- M@F6>PD3)=@HDZ73AJJEZIMURJF+D5X^GR\E(>2^6FYE2#:[%(B;2*C^1D* 1 MF3T3Q3-:KS*ZJE/,4HF&C.C4X!+OIX[IA:AVF/G*HMG5+:F*7DG!?VA= @>X M=^$-5!.J*/)84N1J&Z5IYB(SLJ5R=.5LBB+&DI_45R6/2<@2E66J,TJ%#4:2E'BIED.^GPM?GR*@\PQQ42TN$^A25AT% S0 M/XDP=UPT8XW$++72M*=&Q6SHGK%XU:A1D3DJ<:0+>&@G89AV4!,K,?B17*1Q M#(MIJ87RLUWCIM>-Y*^4=4282!9S#KU[S+[39K5*_-"]\F35N:LF[ZH'_"-L MJL& .J,'-B(+?J5K$D6]GMO#H;?H%B*G,Y"OQ'V!.;I2/!+L@_B-=# Q/?1E MD,02JQ=G3:F*A>88>4EZ0!L9DU.F7$\+,8J^!BH#G$O[K)^QSY _#3/@IH>F M#,J "[7@4=Q1)&T2Y\K6F?>=1*AL%-"A/#W*.<9>8F&6*.4GK+(]F;IR5M,M - QP1_(*T1;MBL MURD,I#%&GOE/GYQ9[5C/@39NZKHB^\QJR)MY,$S%UTF"Y7-P&3Q#D)NK'7OP MJ('KHW?*3;UCT<#8ERHZ !I9Y6B)]L\@IT)Z7W'^#3MP18:B=G1..J92QIER M3-FS5+$2[&@Z['-_Y*%C&D-(_9$#S L^PP,^735__TS^,)D01CTY3?7-+'TG MM.R(5A["/2V2R(F32-5/V*K2Q1:,,1E22&033WY/7E?@U37K2*H;:E\ 4;!I M36>:Z]\'WKW4=] N5RU:04C%H2P)UUJ7V4@6787F_JM=+)U4MZ<9^Z)B4/(, MJ?\@VWT(A$%[3R?@J/1WH0.-^?P.URHO:XTZ$Y4]/,N>7F5/KY7JZ36U$]6_ MDGOF_PJ,>_+Z_9U?OF*:1+4O0-G8!*9XCYT%,*U'' @=%O"#O6T\U63XS?H4 M,?3XHFZ/"AW)1[L/+P55[S.Z.D5H*V7^.@8L<[=E/(><% B>828^]= /A+.1 MK':05T*S!,F;YIE1&G )X%E8QRKM7SE^R1#G9*!_5Y 020I 5,AN29M)HO" M=4NI5$JE4BH5FG**)Y6NF#?R_W'_?J%@NCE70FG(>WB28 Y5AW\/_Q&"2.1: M(;.N6'#!B,K!*D: 3D[!^)0U^1CZZEQ6]49H7:&!W#S[G,TMPO"@&LB0+]XR MQ@YS$B_6,FY. ;2J'J5C'@TQJ!!R]'IRWY$FH"PD1*'LN5U>]0*1;**2TA&> MPK-7$5U!74H-+1->\^-K@2B8(['54@\U>VG$@L]3W")5.611;-R&&$LQ;X-+F,'0]2F=_ M.\_BVV;JI5R<,[M#GAT-^R .H[!Q'8*3AGI;,4XP:IYR_4-"$:,-!G5&8 MP_].*+52D:)DDN)R2:=D9LD*<#L0'8.MF .PR,[KN,KP^_3]]^W/P B1Q'!K M73EV.&TI^:?LH$G/),>J&XD E:A1^")S^H:9D1+P6$IQ]@+[#F4U[@M A=#I M\-D 2B-%T42HZ)-;X[6*"$5EA/W 99]5CQ-JE4(!HDSDAURXEL,&8#_6K/E< MS7)$.8^$P*%14/A$"@W2@>4N99+P5SN7\*#,)5P-:3^O=;6$W)LT7!,DH2AT M1)I+>QOJX,9# +]3764F;J(9'!$A%?!3W-#UNPQ[8V&_">KQ"ZJ>Y_1!(1 , M-:V&!W+L\BB6>NL]\C?!2RGE4<[S-::\2^:IHN\RR0;G;U-DG_7\('+'TM1D M?K^XG@2"5GFQD\=@"'@CFOQB'LUCS/T(&+4.P2MVDNJOV 3+#0?4LTFPUI$< MP]>E1#KJ((G5"9233A!+;\:&%]A[GZ9[1U%"4]'EFSK<"QXL)EJ348J.!_Q( M](+N\#Z[=\GAARD/J%SI6"E6#0XP3=(+,$R,%3/84",>B?Z=5*%&!:*JH30P MT@#E39IOP.U_^(!5A%P-G""L*" .9 ?]B+O_8-_.FM4$?, N61360HQ!3V(' M;1"LAPTY:%I^+#O*JWS4 9-3'XFK U.F67YO'XT'>SM$G56P 1^?R!@!D!I@B25^6MBLA)(!LE S;V M 0_=-*.M<;!;QVP%.EQ9X"$U.%_P \QNR!@G5,\DBGUZ1,O;=2,15A(V:C.Q M.%3!1RY49B\^J^E),Q:S>P9"-R%_05X>0YP346WL5G;2' 9/#%_7."Y:Q]!0 M)_E\1^.B?-3.6 8%<$W/>< I"BN.*T<*1I6<"+CLS8<$"H1RC]JX2/NC6D N MQULIUT&D57-@;^R.5\;;$N8I_PA[4'7Q&R,P+@OGVV($@$X@[ )KS"07S8BR MRS+@BAY#FLV7RK,FNHG71:8C._VJWH/HJ #6^'OPP*D]GD 5TYU"F6H!F*09 MQ*<,:E%1)UPM"E :>N)KTJZ5LDMKC:2#1-D%N?X=D>]@0SI?3PQE$-V4P=:BQLRX<)F?D3J!Z&5&3R<% RI-:3CF3.5!0#:PKU=%7=,3&)1'837.J&Y/OB>O1NA5P7&L&)]X%U MP:B%YXJ3^7(#F-:#[ LK!NB1:T:QB M&A]$RZH)FTK\5S,OL>+GQWVI+3SP2.V&M\ZP!1VJPG&88>VJGPOV#G3TEO8[9TY6>&=2=04S[,F51.!8Z23PF\BE1.-.R 5>NV(U, M"*.0PNI3]Q4;>6\:"+):JN"^@EUM511(4P9%*;#""*N1\L) E@@#?<(@4$4, M&"=K;R(>-';D<*P:5U6G8.U22_LM(K_1#$;B"3J;B:7(!,UL^"BK_=%H&FF; MY'$6=,1AAJ_#4)JJN%O:AL"L'J=5^%)PH73)[$C%9@8XQ$TOQNABK9])'1-@ MTTR^07K[E-6%HS_!HI-M4@P?(!IQWRG+_GOP") )?=DIA:5-?7T&AJK''MW( M2O-VMQ#A*O62>(RIFT(NI!D!IM MRAN#$*9#)4*06A^6^TB4&W.5L(Y8ONCS,QXU%%X=I=F;:"U@:184QJ<$UH3T8G148 MP#[QC#BY7$H(],V411$L4TCDL.#C!\2K)2-,N]1+<$76/* M)!)2H8LOK$/RC#VQ;E'N,Z.SN*U6CI)"05XH0)GR,'H.6IZ373!$B-,(7V8R MM:E2)9;/SA3'Y8Q?HUM5$8S6D:3O\,HP[$A["37.IP/:-!*L#9BDT0[J*,6J.[#L:+'!?9-%GU9LW4O%'L=-RL M09;>!64E>"#13GIWQ@@PPOJH&IEQ_9S^,#/2#";?:\R;)4]-.,KD%H@1 [E* MSUBI6=Y41'?Z_+^55]);OCP'!+4Z'NJYAQ9-3]A&LJ5VZN%B&>L3U.>,Y@S M0T5>,#BI!J;Y%^G QB>1FK:@4-K&W@<#*JIV'>O3S5%31W==LNM]]6(YOT$' MP&$)?73-$.T (,:6S!8W1] @!H ME-8&Y(+=F@VJP"YHLJ/U1#<&1:\8;<;B/3+BA4"1&5"([17KK&KX,1V.'\C& M.6LVCS]KUZ@J.9^,TC-?C113!R9_KTCR&8Y"L-9C-)NN/J-:[P!G<-%$ 42R M_P][[[K.K5III^L5UQKRE76XB?3R=??O8%^X:>_?G+SS^='.&33YX,[/#]3MN? MG1[R]H_>IMD)]OY]+*N=(.#?8U07;?FHQA,%ES*H_*IL[2Y^TE\[_I$+]6%+ M'&?U IG]8G8W>:UR^>]F7_\N4WNIJG>'BHZ?R]104#\D^34E)-A'[O)166^? M'O_Q^,G[G]CKA!KT,*P-6*K!S.BYN"E2P?>S=7F"_"V*[EHM8;NCQQ;N" 82 M&Z^M"[4;^ /[K<3_Z\FV=L:%3L4\B/=.Q/JF-=9YC(RJPY(4 ML+A9*G2]:>PTEUW9QH1]M[V<;3=%738D3/UKXL?E3&")C>4O- N8O57L'%M$ M=EB-*ZMA_D&R)M\(R?K'[_0[Q),JH?=]2S[2!J%AC0LDJ,;EEB#C[;JIQ_RC MS$+R>SC\F)G4;AMM/\1I/+F_6_5Q],=7]ZM*'H??%V%JUVT M8@'>(EZ1",JXL,D-KN\Q\\(1PH==,M<:K)>9:4YW)IXR]_'$%[I>%MVJB(:_ MNYGIVDJ)0#BBWDEWO"O1G.;HR*7TGH7\K>LX>5.\95#_JH3-/C4J(BQKSE+J M1TTOPV6[,.AO7\+CGVTB?MF 6WI)7(*?30_2=98\BWG$??0#W6D2"!>)L8 ( M_X_>;[AG%^_;_/P&[JT)&W?LF6W0R2I=%&ZFW+:VE'0E<'P)_L:B-S4JP"R)9LYN&:@OA M#DE?L*?O,3&/VIKMN$#VFI&A@?"5H!J@I #;8.\D%18&]NK-I(FVQ$'(2/YV9GU_J" MS>\D@"?YC9Z*=O"Y+!X59/P- WR9FGG8VG:OJ#AM*]<*6!'9'W.U@"FNX?'M^_+ZI%IN[\.YW8U.6 M?6<"3[-Y@JD4\CI73&>";G)$&Q;E4Z7 AVHP2Z3-?_HI:1W#ZT0@Q"CEZ_/G M[)7DC 2Y %CV3Y[";_@K3Q4_CZ?; _33KX8/8,,5'O!,SW]!<8[*I*WT?&K6 MQ^PYTC.LHD'HK%2W.%FR(^N KO=T(_AB$9G;-9;CZ;NST]^(ESD[4[S,LV]^ MMG7F&0E#+^YBDA!E3W< D K:4 ;!_>Q[.>&8B2=I!08#C=-I3<.4J>)P"FJ4 M6LEUNPFJ;\/6B2P P0H.P5?A_C6+X_#_D?F7XTS::<\OT7/%GV8 0V XLZ,\ M38>8&\'>0NJ]1DFT#5:&SY;#VIAK4T5):;])72GO,DV,&N M#H6;W3?V30M_VDUB>'C$&T6F,GRV:.?"28E8,IZ-KIKUVXEV]9;$D8VU6 ') MJDV] '0-+L&&Q1142P(_?L_=G\;F2LT\>TLP>H*U$Z;*RNW^F^1"HO-KM=EZ M**?:2*M2I4)2>X6@CDKQA. JA84X>O[9/LMH(AC/R>2EP0XT*1)3O/ M6EUD5:91329R.ZRK_+//P^>. MSR9'Z!H#P289.?STB\D1=X,GR#]MF(S9,SEP/F'I6;?1>C<7'^H'^;) %2[E M[A %CU\*;PR#@O&" [F(,!UWA-:?MZQ51V<0W8O,&/-'D!XXSUO6H0QZAB4/ M+@TIH3")^1BU8N]+M]?-LDRB(+M\ZYUC\ ^^O2X-U9==].'P])H#%T@7@C(D M7OJA)I\*Q"SH;88W%5W4OT)2EH,WUFR4C6A*4P_B)]GJGB^78Y9#6:LO:,@# M&CKTZSQ'@<&+JC;&;SIKA<0@"KOTPH )QWK1%JN]KPL*V_/?@)8%(^U//2-M M'22$X,S,6DM=F&+ B&=#3/2^>9@\=EWN6$,_\)MC-ZVS3WL:.[M.]UG!GWQU M]D0^M8"TS^/SF5-[],7DW>2W&X6G8A2*D#T[50[=: M+12=.G$WU7ER'J<%[W8%')Q_>3)YX3Q)@W;*JYQ'QP(]]MNVFHQ?X5"JGK0G MO,^CG#K\QW3,O62P[XL_=QZA84O0)S*Y3^)[$2^1V_=!2_[>DG[?[>JLIC2_ MYOW[;%BA81HNLX\9&/%0S;X=&F\7L;%FS.%4FK >AX5T([( MG)C_EVTU9U&?R*91AU/M- T+]0!V[[V[Q0!2E((H?-8&?8<5Z.P 4DDY3[.< MU7V"8-#EM2_,8\WU_4MSRQ+V#1O11(_:*NE\#U8?=PP^ZKMJQ=8[]A4*VO#@ MIW\74?M4_6^ SX0^*E_'D=I"VNSJ-" M0\5LWZ,:U:MJ67:;IB9\Z0&)U<_OOT>_N]GS4A1<1OVZ+=2".KIZ=/ M3W>D(I_VVHSGN;2!PK O\;,P@H.<-C"*%%&_OJLOD.D_/B,T+$CVZ@,M#@D< MWJO@'7@ #&19AVBI8QS $UA/B[REM\/VNI]'OQ[)@(90DR_&&J7NKXSU#(._ M?6J/#C.0345*? R8DC>#HQ7P92[XLPUKD=?Y V03IT"2,H)'L,1$">JK(\97*_74HB0A'%A+])*UNPV@8 M,:NWU;PN.:]@-J%P_[+W@5BCGPUN\F+W.K.[2VUL?UF5R#0XZ[6ZTV'8,S3S MU-_K0(3FP[J_K,- EHC-%> +.]+/4"M-M$BRJ9],]9-\(JG%E$$L_"Q(;WOT ML!0U+&3JJOK;.B7_[M?D320X0L\9-O:,M(JIV9CA(JZ'E\HZ ,4F5]*DQY]^ M;6[:W7?+E!.#T-2\Y=]Z]-URAZT_*8O*;"#2%I+!I[%O8J["@VFM"HE*R, $ MY7C/M1=C/\X%23',V(9I72[+5:+'Y/C"\N>,%W8%8U2%&<;L]CSK-1*+[?!D M"*RK'QVBU=;'#K\(!%X&I1Z/\31VY'L;CB:7[Q*'A=78W;:]*END (D;DB]V M=_4\#!7?O".(8U%=MI&@+_CB51&)/+-I[+=>R7LEIM;EJBA82\AS9J-RF1V!+'CM#FK+Y-]@")L MR/0)-V70<@&X!4Z#:)F:>S7*8?(E2DU(4*)VXSER.F M_ ^2K?9#13!7V0S*=34O5TEG:8+&9T>?_NF+AXQX-!CS]/0_'*W0R-@S9#L0 M;Z*EPS<_ZWW3JKX5@)?/*.:74@+ZKBR0V-80][.FVQ33<'*IO2;/(9C>L#)X MB0 V_(T/S,D^NKOS/_[ 3[%4(A*_#'N0Z%/$D)*X,"52/$5MN#S%4LD7PFN1 M9\!M"Q]"L2@#P&KP)!X_5' VR%P(>P1%+; _]^_?Q;,BN62XE=I!$]>GPPO MJ^-)&UY;49T^WA^.

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end

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�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ྒ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�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